
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="939BE807DB0F4BC500005579A08ADEB0.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="frontonco" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC9465159/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465159/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Frontiers in Oncology" /><meta name="citation_title" content="Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy" /><meta name="citation_author" content="Charleen M. L. Chan Wah Hak" /><meta name="citation_author_institution" content="1 Translational Immunotherapy Team, The Institute of Cancer Research, London, United Kingdom" /><meta name="citation_author" content="Antonio Rullan" /><meta name="citation_author_institution" content="2 Targeted Therapy Team, The Institute of Cancer Research, London, United Kingdom" /><meta name="citation_author" content="Emmanuel C. Patin" /><meta name="citation_author_institution" content="2 Targeted Therapy Team, The Institute of Cancer Research, London, United Kingdom" /><meta name="citation_author" content="Malin Pedersen" /><meta name="citation_author_institution" content="2 Targeted Therapy Team, The Institute of Cancer Research, London, United Kingdom" /><meta name="citation_author" content="Alan A. Melcher" /><meta name="citation_author_institution" content="1 Translational Immunotherapy Team, The Institute of Cancer Research, London, United Kingdom" /><meta name="citation_author" content="Kevin J. Harrington" /><meta name="citation_author_institution" content="2 Targeted Therapy Team, The Institute of Cancer Research, London, United Kingdom" /><meta name="citation_publication_date" content="2022" /><meta name="citation_volume" content="12" /><meta name="citation_doi" content="10.3389/fonc.2022.971959" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC9465159/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC9465159/" /><meta name="citation_pmid" content="36106115" /><meta name="DC.Title" content="Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Frontiers Media SA" /><meta name="DC.Contributor" content="Charleen M. L. Chan Wah Hak" /><meta name="DC.Contributor" content="Antonio Rullan" /><meta name="DC.Contributor" content="Emmanuel C. Patin" /><meta name="DC.Contributor" content="Malin Pedersen" /><meta name="DC.Contributor" content="Alan A. Melcher" /><meta name="DC.Contributor" content="Kevin J. Harrington" /><meta name="DC.Date" content="2022" /><meta name="DC.Identifier" content="10.3389/fonc.2022.971959" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy" /><meta property="og:type" content="article" /><meta property="og:description" content="Radiotherapy is one of the most effective and frequently used treatments for a wide range of cancers. In addition to its direct anti-cancer cytotoxic effects, ionising radiation can augment the anti-tumour immune response by triggering pro-inflammatory ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465159/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9465159/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=%22Front%20Oncol%22[journal]" class="navlink">Front Oncol</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC9465159
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC9465159/pdf/fonc-12-971959.pdf" class="int-view">PDF (2.5M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/9465159/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/9465159/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="9465159" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9465159%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="LYlIQ5dV3TRlH4zixQgWtD8KSzD5GCdsYwbJfYbxf9MdKDSrv11i91y5mv3v6JNS">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9465159%2F&amp;text=Enhancing%20anti-tumour%20innate%20immunity%20by%20targeting%20the%20DNA%20damage%20response%20and%20pattern%20recognition%20receptors%20in%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9465159%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465159/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC9465159/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/36106115/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC9465159/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/36106115/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC9465159/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/9465159/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=%22Front%20Oncol%22[journal]" class="navlink">Front Oncol</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC9465159
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-frontonco.gif" alt="Logo of frontonco" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="http://www.frontiersin.org/oncology" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Front Oncol.</span> 2022; 12: 971959. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2022 Aug 29. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.3389%2Ffonc.2022.971959" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.3389/fonc.2022.971959</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC9465159</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36106115">36106115</a></div></div></div><h1 class="content-title">Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Chan%20Wah%20Hak%20CM%5BAuthor%5D" class="affpopup" co-rid="_co_idm140317300278288" co-class="co-affbox">Charleen M. L. Chan Wah Hak</a>,<sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>
1
,</sup><sup>
*
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Rullan%20A%5BAuthor%5D" class="affpopup" co-rid="_co_idm140317300274480" co-class="co-affbox">Antonio Rullan</a>,<sup>
2
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Patin%20EC%5BAuthor%5D" class="affpopup" co-rid="_co_idm140317345236864" co-class="co-affbox">Emmanuel C. Patin</a>,<sup>
2
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Pedersen%20M%5BAuthor%5D" class="affpopup" co-rid="_co_idm140317345234720" co-class="co-affbox">Malin Pedersen</a>,<sup>
2
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Melcher%20AA%5BAuthor%5D" class="affpopup" co-rid="_co_idm140317345232288" co-class="co-affbox">Alan A. Melcher</a>,<sup>
1
</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Harrington%20KJ%5BAuthor%5D" class="affpopup" co-rid="_co_idm140317345230176" co-class="co-affbox">Kevin J. Harrington</a><sup>
2
</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140317300278288"><h3 class="no_margin">Charleen M. L. Chan Wah Hak</h3><p>
<sup>1</sup>
Translational Immunotherapy Team, The Institute of Cancer Research, London, United Kingdom
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Chan%20Wah%20Hak%20CM%5BAuthor%5D">Charleen M. L. Chan Wah Hak</a></div></div><div id="_co_idm140317300274480"><h3 class="no_margin">Antonio Rullan</h3><p>
<sup>2</sup>
Targeted Therapy Team, The Institute of Cancer Research, London, United Kingdom
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Rullan%20A%5BAuthor%5D">Antonio Rullan</a></div></div><div id="_co_idm140317345236864"><h3 class="no_margin">Emmanuel C. Patin</h3><p>
<sup>2</sup>
Targeted Therapy Team, The Institute of Cancer Research, London, United Kingdom
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Patin%20EC%5BAuthor%5D">Emmanuel C. Patin</a></div></div><div id="_co_idm140317345234720"><h3 class="no_margin">Malin Pedersen</h3><p>
<sup>2</sup>
Targeted Therapy Team, The Institute of Cancer Research, London, United Kingdom
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Pedersen%20M%5BAuthor%5D">Malin Pedersen</a></div></div><div id="_co_idm140317345232288"><h3 class="no_margin">Alan A. Melcher</h3><p>
<sup>1</sup>
Translational Immunotherapy Team, The Institute of Cancer Research, London, United Kingdom
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Melcher%20AA%5BAuthor%5D">Alan A. Melcher</a></div></div><div id="_co_idm140317345230176"><h3 class="no_margin">Kevin J. Harrington</h3><p>
<sup>2</sup>
Targeted Therapy Team, The Institute of Cancer Research, London, United Kingdom
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Harrington%20KJ%5BAuthor%5D">Kevin J. Harrington</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm140317346086608_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140317346086608_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140317346086608_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm140317346086608_ai" style="display:none"><div class="fm-affl" id="aff1">
<sup>1</sup>
Translational Immunotherapy Team, The Institute of Cancer Research, London, United Kingdom
</div><div class="fm-affl" id="aff2">
<sup>2</sup>
Targeted Therapy Team, The Institute of Cancer Research, London, United Kingdom
</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><div id="fn-a.h.b.g.a">Edited by: Qiang Zhang, University of Michigan, United States</div><div id="fn-a.h.b.g.b">Reviewed by: Michael Orth, LMU Munich University Hospital, Germany; Alexandros G. Georgakilas, National Technical University of Athens, Greece</div><div id="fn001">*Correspondence: Charleen M. L. Chan Wah Hak, <a href="mailto:dev@null" data-email="ku.ca.rci@nahc.neelrahc" class="oemail">ku.ca.rci@nahc.neelrahc</a>
</div><div id="fn002">This article was submitted to Radiation Oncology, a section of the journal Frontiers in Oncology</div></div><div class="fm-article-notes hide half_rhythm" id="idm140317346086608_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2022 Jun 17; Accepted 2022 Aug 1.</div></div><div class="permissions half_rhythm hide" id="idm140317346086608_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a>  &#x000a9; 2022 Chan Wah Hak, Rullan, Patin, Pedersen, Melcher and Harrington</div><div class="license half_rhythm">This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="abstract-a.h.b.n" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.h.b.ntitle">Abstract</h2><!--article-meta--><div><p class="p p-first-last">Radiotherapy is one of the most effective and frequently used treatments for a wide range of cancers. In addition to its direct anti-cancer cytotoxic effects, ionising radiation can augment the anti-tumour immune response by triggering pro-inflammatory signals, DNA damage-induced immunogenic cell death and innate immune activation. Anti-tumour innate immunity can result from recruitment and stimulation of dendritic cells (DCs) which leads to tumour-specific adaptive T-cell priming and immunostimulatory cell infiltration. Conversely, radiotherapy can also induce immunosuppressive and anti-inflammatory mediators that can confer radioresistance. Targeting the DNA damage response (DDR) concomitantly with radiotherapy is an attractive strategy for overcoming radioresistance, both by enhancing the radiosensitivity of tumour relative to normal tissues, and tipping the scales in favour of an immunostimulatory tumour microenvironment. This two-pronged approach exploits genomic instability to circumvent immune evasion, targeting both hallmarks of cancer. In this review, we describe targetable DDR proteins (PARP (poly[ADP-ribose] polymerase); ATM/ATR (ataxia&#x02013;telangiectasia mutated and Rad3-related), DNA-PKcs (DNA-dependent protein kinase, catalytic subunit) and Wee1 (Wee1-like protein kinase) and their potential intersections with druggable immunomodulatory signalling pathways, including nucleic acid-sensing mechanisms (Toll-like receptors (TLR); cyclic GMP&#x02013;AMP synthase (cGAS)&#x02013;stimulator of interferon genes (STING) and retinoic acid-inducible gene-I (RIG-I)-like receptors), and how these might be exploited to enhance radiation therapy. We summarise current preclinical advances, recent and ongoing clinical trials and the challenges of therapeutic combinations with existing treatments such as immune checkpoint inhibitors.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">DNA damage, innate immunity, radiotherapy, immunotherapy, combination therapy, cancer therapy</span></div></div><div id="s1" class="tsec sec"><h2 class="head no_bottom_margin" id="s1title">1 Introduction</h2><p class="p p-first">Radiotherapy continues to be one of the most effective treatments for a wide range of cancers since its discovery over a century ago. Approximately half of cancer patients receive radiotherapy at some point in their cancer treatment (<a href="#B1" rid="B1" class=" bibr popnode">1</a>), whether in the curative or palliative settings.</p><p>Radiotherapy exploits ionising radiation to cause cell death or senescence <em>via</em> DNA damage. Broadly, necrotic or apoptotic cell death occurs depending on cell type, radiotherapy dose and fractionation schedule (<a href="#B2" rid="B2" class=" bibr popnode">2</a>). Cancer cells that evade apoptosis and continue to divide with accumulated DNA damage can die <em>via</em> mitotic catastrophe. Also, excess autophagy can force the cell into apoptotic or necrotic cell death (<a href="#B3" rid="B3" class=" bibr popnode">3</a>, <a href="#B4" rid="B4" class=" bibr popnode">4</a>). Classically, the response of tumours to conventional fractionated radiotherapy is governed by the principles of the 4 &#x0201c;R&#x0201d;s of radiobiology: <em>repair</em> of sublethal DNA damage after exposure to ionising radiation, <em>redistribution</em> of cells in the cell cycle whereby cells in the G2/M-phase are most radiosensitive and are preferentially killed in comparison to the more radioresistant late S-phase, <em>repopulation</em> of tumour cells and r<em>eoxygenation</em> of previously hypoxic tumour areas (<a href="#B5" rid="B5" class=" bibr popnode">5</a>). A 5<sup>th</sup> &#x0201c;R&#x0201d; of intrinsic <em>radiosensitivity</em> has also postulated by Steel, after observing the varying survival curves of different tumour cell lines following irradiation, which is thought to be independent of their DNA repair capacity (<a href="#B6" rid="B6" class=" bibr popnode">6</a>). Combining agents that can target DNA damage repair pathways, as one of the 4 &#x0201c;R&#x0201d;s, with radiotherapy holds considerable potential to enhance therapeutic outcomes.</p><p class="p p-last">In addition to direct cell killing, radiotherapy can induce immunogenic cell death (ICD) and modulate the immune tumour microenvironment to lead to anti-tumour innate immune activation (<a href="#B7" rid="B7" class=" bibr popnode">7</a>). Due to these immunostimulatory effects, there is increased interest in radiotherapy as a promising combinatorial agent with other immuno-oncology agents such as DNA-damage response (DDR)-targeting agents (<a href="#B8" rid="B8" class=" bibr popnode">8</a>). This two-pronged approach exploits two hallmarks of cancer, namely genomic instability and evasion of immune surveillance (<a href="#B9" rid="B9" class=" bibr popnode">9</a>, <a href="#B10" rid="B10" class=" bibr popnode">10</a>). The DDR sensing and signalling pathway are the collective mechanisms evolved by cells to combat the threat of DNA damage, namely the detection of DNA lesions, signalling of their presence and promotion of DNA repair (<a href="#B11" rid="B11" class=" bibr popnode">11</a>). Promising DDR druggable targets include those within DNA repair pathways and cell cycle checkpoints, as well as damage-associated molecular pattern (DAMP)-sensing receptors which can amplify the DDR-induced immune response when combined with radiotherapy.</p></div><div id="s2" class="tsec sec"><h2 class="head no_bottom_margin" id="s2title">2 Radiotherapy and the anti-tumour immune response</h2><p class="p p-first">Radiotherapy has both immunostimulatory and immunosuppressive effects. The difference in the ability of radiotherapy to initiate pro-immunostimulatory effects and turn immunogenically &#x0201c;cold&#x0201d; (low T-cell infiltrated) tumours &#x0201c;hot&#x0201d; (high T-cell infiltrated) may account for the enhanced response to radiotherapy of some pre-clinical models and clinical cancer histotypes.</p><div id="s2_1" class="sec"><h3 id="s2_1title">2.1 Immunostimulatory effects mediated by radiotherapy</h3><div id="s2_1_1" class="sec sec-first"><p></p><h4 id="s2_1_1title" class="inline">2.1.1 Immunogenic cell death  </h4><p class="p p-first">As a defence against microbial infection, the innate immune system has evolved pattern-recognition receptors (PRRs) that detect microbial pathogenic molecules known as pathogen-associated molecular patterns (PAMPs). However, these pathways do not exclusively sense foreign molecules. Immune activation can also occur in the absence of microbial infection, instead being triggered by inflammatory signals released from stressed or dying cells collectively known as damage-associated molecular patterns (DAMPs) (<a href="#B12" rid="B12" class=" bibr popnode">12</a>). Radiotherapy-induced cellular stress and ICD can stimulate an immune response through the generation of DAMPs (<a href="#B13" rid="B13" class=" bibr popnode">13</a>) detected by their cognate pattern recognition receptors (PRRs) (<a href="#B14" rid="B14" class=" bibr popnode">14</a>). ICD has been defined as the chronic exposure of DAMPs in the tumour environment (TME), which can induce an innate and adaptive anti-tumour immune response in the host (<a href="#B15" rid="B15" class=" bibr popnode">15</a>).</p><p class="p p-last">A characteristic DAMP induced by ICD is the secretion of adenosine triphosphate (ATP) from dying cancer cells into the extracellular space. Extracellular ATP functions as a &#x0201c;find-me&#x0201d; chemoattractant signal for the recruitment and activation of dendritic cells (DCs) (<a href="#B15" rid="B15" class=" bibr popnode">15</a>&#x02013;<a href="#B17" rid="B17" class=" bibr popnode">17</a>). High-mobility group box-1 (HMGB1), secreted from the nucleus during ICD, binds to Toll-like receptor (TLR-4) and is critical for activating DCs and facilitating antigen processing and presentation to T cells (<a href="#B18" rid="B18" class=" bibr popnode">18</a>). Translocation of calreticulin to the cell surface on dying cells provides an &#x0201c;eat-me&#x0201d; signal to antigen-presenting cells (APCs) and results in their phagocytosing target cells (<a href="#B19" rid="B19" class=" bibr popnode">19</a>). In the context of cancer, ICD leads to release of tumour-associated antigens (TAA) and subsequent priming of a cancer-specific immune response. Another characteristic of ICD is the expression of heat shock proteins (HSP) HSP70 and HSP90 on dying cell membranes that drives cross-presentation of tumour-derived antigens on major histocompatibility complex class I (MHC-I) (<a href="#B15" rid="B15" class=" bibr popnode">15</a>).</p></div><div id="s2_1_2" class="sec"><p></p><h4 id="s2_1_2title" class="inline">2.1.2 Secretion of pro-inflammatory mediators </h4><p class="p p-first">Radiotherapy-induced DNA damage can function as a viral mimic through the accumulation of cytosolic DNA or RNA in irradiated cells (<a href="#B20" rid="B20" class=" bibr popnode">20</a>). Cytosolic DNA and RNA activate cyclic GMP-AMP synthase (cGAS)/stimulator of interferon (IFN) genes (STING) and retinoic acid-inducible gene I (RIG-I)/mitochondrial antiviral-signalling protein (MAVS) pathways, respectively (<a href="#B21" rid="B21" class=" bibr popnode">21</a>). These pathways activate complex downstream signalling <em>via</em> interferon regulatory factor 3 (IRF3)/TANK-binding kinase 1 (TBK1) and nuclear factor kappa B (NF-&#x003ba;B) that results in production of Type I IFN and other inflammatory cytokines (e.g. interleukin (IL)-1, tumour necrosis Factor (TNF)-&#x003b1;) (<a href="#B20" rid="B20" class=" bibr popnode">20</a>).</p><p class="p p-last">Radiotherapy is a form of ionising radiation that hydrolyses water and forms reactive molecules, such as reactive oxygen species (ROS) and nitric oxide species (NOS), which can directly alter DNA, cellular components, and molecules in the extracellular matrix (ECM) (<a href="#B22" rid="B22" class=" bibr popnode">22</a>). ROS and NOS can be derived both from these direct ionisation events or activated immune cells, and work with other DAMPs to accelerate lymphocyte and DC recruitment. These activated immune cells generate pro-inflammatory cytokines (e.g. TNF-&#x003b1;, IL-1&#x003b2;, IL-6, IL-12) (<a href="#B14" rid="B14" class=" bibr popnode">14</a>, <a href="#B23" rid="B23" class=" bibr popnode">23</a>, <a href="#B24" rid="B24" class=" bibr popnode">24</a>), chemokines and growth factors leading to a sustained inflammatory response (<a href="#B22" rid="B22" class=" bibr popnode">22</a>, <a href="#B25" rid="B25" class=" bibr popnode">25</a>).</p></div><div id="s2_1_3" class="sec sec-last"><p></p><h4 id="s2_1_3title" class="inline">2.1.3 Immune cell recruitment and tumour-specific T-cell activation </h4><p class="p p-first-last">Recent data suggest that radiation can enhance cancer cell antigenicity through upregulation of genes involved in DNA damage repair and cellular stress responses (<a href="#B20" rid="B20" class=" bibr popnode">20</a>). Immune cell recruitment is subsequently increased <em>via</em> expression of adhesion molecules (e.g. intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and E-selectin) (<a href="#B26" rid="B26" class=" bibr popnode">26</a>) and chemokines (e.g. chemokine (C-X-C motif) ligand 16 (CXCL16)) (<a href="#B27" rid="B27" class=" bibr popnode">27</a>). Within the appropriate inflammatory environment, DCs take up antigens in peripheral tissues and mature and migrate to draining lymph nodes, where they induce activation of na&#x000ef;ve T-cells and differentiation into effector T-cells (<a href="#B28" rid="B28" class=" bibr popnode">28</a>). Radiotherapy-induced ICD, as discussed above, increases tumour-associated antigen presentation that can lead to specific tumour-associated antigen T-cell priming, expansion of tumour reactive CD8+ T cells and infiltration into the tumour microenvironment (TME) (<a href="#B29" rid="B29" class=" bibr popnode">29</a>). In summary, inflammatory DAMP signalling generates a favourable environment for activated DCs to process and cross-present tumour-derived antigens from irradiated cells as a &#x0201c;tumour vaccine&#x0201d;, to na&#x000ef;ve T cells. These T cells subsequently can be primed and sustain a systemic tumour-specific immune response. The T-cell receptor (TCR) repertoire is also known to be shaped following radiotherapy, including when used in conjunction with immune checkpoint inhibitors (ICI) (<a href="#B30" rid="B30" class=" bibr popnode">30</a>&#x02013;<a href="#B32" rid="B32" class=" bibr popnode">32</a>).</p></div></div><div id="s2_2" class="sec sec-last"><h3 id="s2_2title">2.2 Immunosuppressive mechanisms triggered by radiotherapy</h3><div id="s2_2_1" class="sec sec-first"><p></p><h4 id="s2_2_1title" class="inline">2.2.1 Immunosuppressive cells within the tumour microenvironment </h4><p class="p p-first">Whilst pro-inflammatory signalling can lead to a positive anti-tumour effect, cancer cells adapt to survive with mechanisms such as hypoxia resistance and unrestricted proliferation that can result in a state of chronic inflammation and evasion of immune surveillance (<a href="#B33" rid="B33" class=" bibr popnode">33</a>&#x02013;<a href="#B35" rid="B35" class=" bibr popnode">35</a>). Evasion of immune recognition or immune escape (<a href="#B36" rid="B36" class=" bibr popnode">36</a>) is now a recognised hallmark of cancer (<a href="#B9" rid="B9" class=" bibr popnode">9</a>) and this inclination towards pro-tumour growth is mediated by changes in cytokine signalling (TNF-&#x003b1;, IL-1&#x003b2;, IL-6, IL-10 and TGF-&#x003b2;) (<a href="#B37" rid="B37" class=" bibr popnode">37</a>, <a href="#B38" rid="B38" class=" bibr popnode">38</a>) and recruitment of TME-immunosuppressive immune cells such as tumour-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs) (<a href="#B39" rid="B39" class=" bibr popnode">39</a>) and regulatory T cells (Tregs) (<a href="#B40" rid="B40" class=" bibr popnode">40</a>, <a href="#B41" rid="B41" class=" bibr popnode">41</a>).</p><p>PD-L1 (programmed death-ligand 1) expression is found to be elevated on tumour cells following irradiation due to interferon gamma (IFN-&#x003b3;) release from tumour-infiltrating lymphocytes (TILs) (<a href="#B42" rid="B42" class=" bibr popnode">42</a>) and TILs have increased expression of PD-1 (programmed death-1) following ex-vivo irradiation (<a href="#B43" rid="B43" class=" bibr popnode">43</a>). A recent publication found that irradiation of colorectal cancer cells triggered an ATR-mediated DNA repair signalling pathway to upregulate CD47 and PD-L1, through engagement of signal-regulator protein &#x003b1; (SIRP&#x003b1;) and PD-1, respectively, to limit tumour-associated cross-presentation and suppression of innate immune activation (<a href="#B44" rid="B44" class=" bibr popnode">44</a>).</p><p>Recruited MDSCs and TAMs can suppress T-cell function through antagonistic cytokine signals (<a href="#B45" rid="B45" class=" bibr popnode">45</a>). Supporting data includes that from a phase I/II clinical trial testing the combination of radiotherapy and a primed DC vaccine in which non-responders had significantly higher baseline tumour levels of MDSCs (<a href="#B46" rid="B46" class=" bibr popnode">46</a>).</p><p>Tregs are relatively more radioresistant than other lymphocyte subsets and radiotherapy may increase the infiltration by phenotypically and functionally suppressive Tregs within the TME (<a href="#B40" rid="B40" class=" bibr popnode">40</a>, <a href="#B41" rid="B41" class=" bibr popnode">41</a>, <a href="#B47" rid="B47" class=" bibr popnode">47</a>). In several pre-clinical mouse models (B16/F10, RENCA and MC38), Tregs in irradiated tumours expressed higher levels of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), 4-1BB (CD137, tumour necrosis factor receptor superfamily 9) and Helios compared with Tregs in non-irradiated tumours (<a href="#B47" rid="B47" class=" bibr popnode">47</a>).</p><p>Cancer-associated fibroblasts (CAFs) can be the predominant component of the stroma in the TME and facilitate stroma-mediated radioprotection through multiple mechanisms. Following radiotherapy, CAFs can survive through formation of integrin-mediated attachments (<a href="#B48" rid="B48" class=" bibr popnode">48</a>) and radioprotective integrin &#x003b2;-1 signalling (<a href="#B49" rid="B49" class=" bibr popnode">49</a>). CAFs can promote an oxygen-rich, immunosuppressive and pro-inflammatory TME (<a href="#B50" rid="B50" class=" bibr popnode">50</a>&#x02013;<a href="#B52" rid="B52" class=" bibr popnode">52</a>) resulting in increased tumour growth, invasion and metastasis (<a href="#B53" rid="B53" class=" bibr popnode">53</a>).</p><p class="p p-last">Conversion of ATP to adenosine by CD39 and/or CD73 is a mechanism by which tumour cells can escape immune-surveillance by limiting the functionality of multiple potentially protective immune infiltrates, while enhancing the activity of immunosuppressive cell-types (<a href="#B54" rid="B54" class=" bibr popnode">54</a>). CD39 and/or CD73 (over)expression has been found on the surface of tumour cells (<a href="#B55" rid="B55" class=" bibr popnode">55</a>), CAFs (<a href="#B56" rid="B56" class=" bibr popnode">56</a>) MDSCs (<a href="#B57" rid="B57" class=" bibr popnode">57</a>), TAMs (<a href="#B58" rid="B58" class=" bibr popnode">58</a>), Tregs and exhausted conventional CD4+ and CD8+ T cells (<a href="#B59" rid="B59" class=" bibr popnode">59</a>&#x02013;<a href="#B61" rid="B61" class=" bibr popnode">61</a>).</p></div><div id="s2_2_2" class="sec sec-last"><p></p><h4 id="s2_2_2title" class="inline">2.2.2 Tumour repopulation </h4><p class="p p-first">One of the 4 &#x0201c;R&#x0201d;s of radiobiology is repopulation (<a href="#B5" rid="B5" class=" bibr popnode">5</a>), and tumour repopulation during radiotherapy and chemotherapy is an important cause of treatment failure (<a href="#B62" rid="B62" class=" bibr popnode">62</a>). Some tumours exhibit accelerated tumour repopulation following irradiation by paracrine caspase 3-dependent prostaglandin E<sub>2</sub> (PGE2)-mediated signalling (<a href="#B63" rid="B63" class=" bibr popnode">63</a>). Tumour repopulation may also be driven by a small number of cancer stem cells (CSC) which promote tumour growth following an insult, such as radiotherapy (<a href="#B64" rid="B64" class=" bibr popnode">64</a>). Rapid proliferation of cancer cells is generally accepted as a prerequisite for most conventional chemotherapies and radiotherapy to be effective, and any senescent and/or quiescent tumour cells, such as CSCs, may be treatment-resistant (<a href="#B64" rid="B64" class=" bibr popnode">64</a>). The CSC response to therapy may underpin why macroscopic tumour response to (chemo)radiation is not a robust predictor for clinical outcome, since small numbers of these relatively resistant and less immunogenic CSCs may survive to repopulate the tumour (<a href="#B64" rid="B64" class=" bibr popnode">64</a>). However, <em>in vitro</em> pre-clinical data from human breast cancer cell lines (MCF-7 and T47D) have shown that radiotherapy can recruit CSC cells from a quiescent state into the cell cycle (<a href="#B65" rid="B65" class=" bibr popnode">65</a>) and a CSC-druggable target in combination with radiotherapy would be useful.</p><p class="p p-last">As we have seen, radiotherapy can trigger key events leading to potent anti-tumour immune responses <em>via</em> production of immunostimulatory cytokines, DC recruitment, and T-cell recruitment and activation. However, these are negatively balanced by the potential for concurrent triggering of immunosuppressive cells within the TME and accelerated tumour cell repopulation. Targeting the DNA-damage response pathway (DDR) is an attractive approach to tip the scales towards maintaining positive immune anti-tumour states, which can be characterised as &#x02018;pro-immunogenic&#x02019; and &#x02018;pro-inflammatory&#x02019;.</p></div></div></div><div id="s3" class="tsec sec"><h2 class="head no_bottom_margin" id="s3title">3 Targeting the DNA-damage response pathway</h2><p class="p p-first">Radiotherapy causes cell damage, stress and death through induction of DNA lesions in the form of crosslinking, single-strand breaks (SSBs) and, most significantly, double-strand breaks (DSBs) (<a href="#B66" rid="B66" class=" bibr popnode">66</a>). These processes induce a plethora of intracellular signalling pathways involved in detecting and repairing DNA damage. Targeting both DNA damage repair and DDR&#x02019;s downstream cytosolic nucleic acid sensing pathways with small molecules in combination with radiotherapy can lead to increased immune activation and anti-tumour efficacy of these treatments (<a href="/pmc/articles/PMC9465159/figure/f1/" target="figure" class="fig-table-link figpopup" rid-figpopup="f1" rid-ob="ob-f1" co-legend-rid="lgnd_f1"><span>
<strong>Figure 1</strong>
</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="f1" co-legend-rid="lgnd_f1"><a href="/pmc/articles/PMC9465159/figure/f1/" target="figure" rid-figpopup="f1" rid-ob="ob-f1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140317300188816"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9465159_fonc-12-971959-g001.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is fonc-12-971959-g001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC9465159/bin/fonc-12-971959-g001.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140317300188816"><a target="object" rel="noopener" href="/pmc/articles/PMC9465159/figure/f1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_f1"><div><a class="figpopup" href="/pmc/articles/PMC9465159/figure/f1/" target="figure" rid-figpopup="f1" rid-ob="ob-f1">Figure&#x000a0;1</a></div><!--caption a7--><div class="caption"><p>Druggable targets of the DNA damage response (DDR) pathway currently tested in clinical trials. Radiotherapy induces DNA damage and cell death. Nucleic acid sensing pathways detect cytoplasmic DNA and RNA to stimulate downstream pathways. Cytoplasmic DNA activates the Cyclic GMP&#x02013;AMP synthase (cGAS) to produce cyclic GMP&#x02013;AMP (cGAMP) that activates the stimulator of interferon genes (STING) pathway, leading to type I interferon (IFN) production. Radiotherapy-induced type I interferon (IFN) can induce RNA sensor activation through RNA polymerase III conversion of DNA to double-stranded RNA (dsRNA), radiotherapy-induced small non-coding RNA (sncRNA) or STAT1-induced dsRNA synthesis from endogenous retroviral elements (ERVs). These activate (RIG-I)-like receptors (RLRs), melanoma differentiation-associated protein 5 (MDA5) and retinoic acid-inducible gene-I (RIG-I), which also drives pro-inflammatory signalling through type I IFN and pro-inflammatory cytokine production. Toll-like receptors (TLRs) can recognise damage-associated molecular patterns (DAMPs) of single-stranded RNA (ssRNA), dsRNA or unmethylated CpG DNA in intracellular compartments such as endosomes, to lead to activation of nuclear factor-&#x003ba;B (NF-&#x003ba;B), mitogen-activated protein kinase (MAPKs) and interferon regulatory factors (IRFs). DNA damage repair mechanisms of single- (SSB) and double-strand breaks (DSB) are often upregulated by cancer cells to avoid cell cycle arrest or death. Inhibitors of DNA damage repair components, such as ataxia telangiectasia- mutated (ATM), ataxia telangiectasia and Rad3-related protein (ATR), DNA-dependent protein kinase, catalytic subunit (DNA-PKcs), poly(ADP- ribose) polymerase 1 (PARP-1) and Wee1 (Wee1-like protein kinase) function to propel the cell through the cell cycle, despite the presence of unrepaired damage, leading to accumulation of cytosolic DNA. This leads to cross-talk with the nucleic acid sensing pathway <em>via</em> activation of the cGAS-STING pathway and dsRNA stress pathway <em>via</em> promotion of ERV expression. These two pathways, through positive and negative cross-talk, shape the radiotherapy-induced DDR response that feeds into anti-tumour immune effects, including recruitment of tumour-infiltrating CD8+ T-cells, natural killer (NK) cells and CD11b+ innate immune cells, such as macrophages and neutrophils. Maturation and activation of dendritic cells (DCs) is increased, including DC cross-presentation of tumour-associated antigens to naive T-cells, which can become activated leading to T-cell-mediated cytotoxic-killing of cancer cells. Furthermore, the immunosuppressive effects of myeloid-derived suppressor cells (MDSCs) and regulatory T-cells (Tregs) can be reversed and macrophages can be repolarised from M2 to an M1 pro-inflammatory phenotype. Chk, checkpoint kinase; IKKi, inducible I&#x003ba;B kinase; IL, interleukin; IRAK, Interleukin 1 Receptor-Associated Kinase; MAVS, mitochondrial anti-viral-signalling protein; MyD88, Myeloid differentiation primary response 88; TBK, TANK-binding kinase 1; TNF&#x003b1;, tumour necrosis factor alpha; TRAF3, TNF Receptor-Associated Factor 3. Created with BioRender.com.</p></div></div></div><div id="s3_1" class="sec"><h3 id="s3_1title">3.1 DNA damage repair pathways</h3><p class="p p-first">Radiotherapy induces double-strand breaks (DSBs) in cancer cell DNA, which results in genomic instability, cell cycle arrest, apoptosis or death <em>via</em> mitotic catastrophe (<a href="#B66" rid="B66" class=" bibr popnode">66</a>). In response to radiotherapy, cancer cells can respond to exploit individualised DNA damage repair mechanisms for survival (<a href="#B67" rid="B67" class=" bibr popnode">67</a>). Three primary DNA repair pathways have evolved to process DSB repair and maintain genomic integrity: homologous recombination, non-homologous end-joining (NHEJ) and alternative end-joining (<a href="#B68" rid="B68" class=" bibr popnode">68</a>). Upregulation of these pathways is a mechanism by which cancer cells may acquire radioresistance and, accordingly, radiosensitisation strategies which inhibit radiation-induced DNA damage repair are expected to provide increased cancer control (<a href="#B66" rid="B66" class=" bibr popnode">66</a>). When DNA repair is inhibited in cancer cells, this leads to accumulation of DNA damage, cellular stress and cell death which subsequently increases the likelihood of these cells triggering innate immune pathways and being recognised by anti-tumour immune surveillance.</p><div id="s3_1_1" class="sec"><p></p><h4 id="s3_1_1title" class="inline">3.1.1 ATM and ATR inhibitors </h4><p class="p p-first">ATM and ATR are both key mediators of the DSB signalling response that induce cell cycle arrest to facilitate DNA repair (<a href="#B69" rid="B69" class=" bibr popnode">69</a>). In addition, conditions that activate ATM and ATR as part of DDR may also participate in regulating the innate immune system and alert it to potentially &#x02018;dangerous&#x02019; tumour cells (<a href="#B70" rid="B70" class=" bibr popnode">70</a>).</p><p>In response to DSB, the MRE11-RAD50-Nibrin (NBS1) (MRN) complex assembles at DSB sites to act as a DNA damage sensor that activates and recruits ATM to DSB sites (<a href="#B71" rid="B71" class=" bibr popnode">71</a>). Briefly, when a cell triggers the DDR, ATM initiates a massive signalling cascade with the phosphorylation of hundreds of substrates, including p53 and checkpoint kinase 2 (Chk2). Activated p53 transactivates the expression of p21<sup>Cip1/kip1</sup>, which inhibits Cyclin Dependent Kinase (CDK) 2 and CDK4/6 to induce G1/S arrest (<a href="#B66" rid="B66" class=" bibr popnode">66</a>). Chk2 in turn phosphorylates and inactivates Cell Division Cycle 25 (CDC25C), maintaining the inhibitory phosphorylation of CDK1 by Wee1-like protein kinase (Wee1) and Myelin Transcription Factor 1 (Myt1) to induce G2/M cell cycle arrest or apoptosis (<a href="#B66" rid="B66" class=" bibr popnode">66</a>, <a href="#B72" rid="B72" class=" bibr popnode">72</a>). Inhibition of the ATM/Chk2 axis can lead to replication stress and accumulation of cytosolic DNA that subsequently activates the cGAS-STING-mediated innate immune response (<a href="#B73" rid="B73" class=" bibr popnode">73</a>).</p><p>ATM was recognised as the defective gene in the inheritable human disorder, ataxia-telangiectasia (A-T) (<a href="#B74" rid="B74" class=" bibr popnode">74</a>), and these patients have characteristic features including genomic instability and profound radiosensitivity (<a href="#B75" rid="B75" class=" bibr popnode">75</a>). Deficiency of ATM-mediated signalling reactions causes sensitisation of cells to radiation (<a href="#B76" rid="B76" class=" bibr popnode">76</a>), which has sparked interest in ATM as a therapeutic target for cancer treatment (<a href="#B69" rid="B69" class=" bibr popnode">69</a>). Inhibition of ATM and ATR have the potential to improve radiotherapy outcomes as they are both key mediators of the DDR (<a href="#B69" rid="B69" class=" bibr popnode">69</a>). Indeed, ATM inhibitors such as caffeine (<a href="#B77" rid="B77" class=" bibr popnode">77</a>), wortmannin (<a href="#B78" rid="B78" class=" bibr popnode">78</a>), CP-466722 (<a href="#B79" rid="B79" class=" bibr popnode">79</a>), KU-55933 (<a href="#B80" rid="B80" class=" bibr popnode">80</a>), KU-60019 (<a href="#B81" rid="B81" class=" bibr popnode">81</a>) and KU-59403 (<a href="#B82" rid="B82" class=" bibr popnode">82</a>) increase cell radiosensitivity (<a href="#B83" rid="B83" class=" bibr popnode">83</a>, <a href="#B84" rid="B84" class=" bibr popnode">84</a>), particularly in p53 low/deficient and phosphatidylinositol 3-kinase (PI3K) highly-expressing cells (<a href="#B77" rid="B77" class=" bibr popnode">77</a>, <a href="#B85" rid="B85" class=" bibr popnode">85</a>). In a preclinical study <em>in vivo</em> with KU60019 and radiotherapy, combination treatment enhanced TBK1 activity, type I IFN production, antigen presentation and increased CD8+ TILs; moreover, complete responders had established immunological memory (<a href="#B86" rid="B86" class=" bibr popnode">86</a>) (<a href="/pmc/articles/PMC9465159/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>
<strong>Table&#x000a0;1</strong>
</span></a>). The ATM inhibitor (AZD1390) and radiotherapy is being investigated in a phase I clinical trial in brain cancer (<a id="__tag_1115971779" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03423628" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03423628","term_id":"NCT03423628"}}</span>NCT03423628</a>). A dual ATM and DNA-PKc inhibitor (XRD-0394) and radiotherapy phase I trial is also recruiting (<a id="__tag_1115971814" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT05002140" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT05002140","term_id":"NCT05002140"}}</span>NCT05002140</a>) (<a href="/pmc/articles/PMC9465159/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>
<strong>Table&#x000a0;2</strong>
</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="T1"><h3>Table&#x000a0;1</h3><!--caption a7--><div class="caption"><p>Preclinical RT and DDR combination studies.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Target (drug), route</th><th valign="top" align="center" rowspan="1" colspan="1">Additional therapy</th><th valign="top" align="center" rowspan="1" colspan="1">Radiotherapy (RT)</th><th valign="top" align="center" rowspan="1" colspan="1">Murine tumour model</th><th valign="top" align="center" rowspan="1" colspan="1">Immunological effects</th><th valign="top" align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="top" colspan="6" align="left" rowspan="1">
<strong>DNA repair inhibitors</strong>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATR inhibitor (AZD6738, ceralasertib),<br />PO</td><td valign="top" align="left" rowspan="1" colspan="1">
<strong>-</strong>
</td><td valign="top" align="left" rowspan="1" colspan="1">2 Gy x 2</td><td valign="top" align="left" rowspan="1" colspan="1">CT26 (colorectal cancer)</td><td valign="top" align="left" rowspan="1" colspan="1">Combination treatment increased TIL CD8+ T cell infiltration, decreased TIL Treg cells, and promoted immunological memory. AZD6738 blocked radiation-induced PD-L1 upregulation to reduce number of TIL Tregs.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B87" rid="B87" class=" bibr popnode">87</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATR inhibitor (AZD6738, ceralasertib),<br />PO</td><td valign="top" align="left" rowspan="1" colspan="1">
<strong>-</strong>
</td><td valign="top" align="left" rowspan="1" colspan="1">2 Gy x 4</td><td valign="top" align="left" rowspan="1" colspan="1">TC-1 (HPV- transformed<br />lung epithelial cells)</td><td valign="top" align="left" rowspan="1" colspan="1">Combination treatment showed enhanced type I and type II IFN signature, increased PD- L1 expression, increased numbers of DCs, T cells and NK cells.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B88" rid="B88" class=" bibr popnode">88</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATR inhibitor (AZD6738, ceralasertib),<br />PO</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-PD-L1</td><td valign="top" align="left" rowspan="1" colspan="1">18 Gy in 3 fractions on days 1, 3, and 5</td><td valign="top" align="left" rowspan="1" colspan="1">Hepa 1&#x02013;6 cells (a C57/L murine liver cancer cell line) and H22 cells</td><td valign="top" align="left" rowspan="1" colspan="1">AZD6738 further increased RT-stimulated CD8+&#x000a0;T cell infiltration and activation and reverted the immunosuppressive effect of radiation on the number of Tregs in mice xenografts. Triple combination with anti-PD-L1 boosted the infiltration, cell proliferation, enhanced IFN-&#x003b3; production ability of TIL CD8+&#x000a0;T cells, decreased trend in number of TIL Tregs and exhausted T cells in mice xenografts. Triple therapy led to more long-lasting immunity with tumour rechallenge rejection.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B89" rid="B89" class=" bibr popnode">89</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATR inhibitor (AZD6738, ceralasertib),<br />PO</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-TIGIT, Anti-PD-1</td><td valign="top" align="left" rowspan="1" colspan="1">20 Gy in four 5 Gy fractions per day (MOC2); 24 Gy in three 8 Gy fractions per day over 5 days (SCC7)</td><td valign="top" align="left" rowspan="1" colspan="1">MOC2 and SCC7 HPV-negative murine oral squamous cell carcinoma cell lines</td><td valign="top" align="left" rowspan="1" colspan="1">ATRi enhanced radiotherapy-induced inflammation in the TME with NK cells playing a central role in maximizing treatment efficacy. Anti-tumour activity of NK cells can be further boosted with ICI targeting TIGIT and PD-1.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B90" rid="B90" class=" bibr popnode">90</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATM inhibitor<br />(KU60019),<br />PO</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-PD- L1</td><td valign="top" align="left" rowspan="1" colspan="1">8 Gy single fraction</td><td valign="top" align="left" rowspan="1" colspan="1">mT4 and KPC2 pancreatic cancer cell lines</td><td valign="top" align="left" rowspan="1" colspan="1">Combination treatment further enhanced TBK1 activity, type 1 IFN production, and antigen presentation. ATM inhibition also increased PD-L1 expression, increased intratumoural CD8<sup>+</sup>&#x000a0;T cells and established immune memory.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B86" rid="B86" class=" bibr popnode">86</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA-PK inhibitor (M3814, peposertib),<br />PO</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-PD-L1</td><td valign="top" align="left" rowspan="1" colspan="1">5 Gy or 8 Gy single fraction</td><td valign="top" align="left" rowspan="1" colspan="1">mT4 pancreatic cancer cell line</td><td valign="top" align="left" rowspan="1" colspan="1">Radiation with DNA-PK inhibition increased cytosolic dsDNA and tumoural type 1 IFN signalling in a cGAS- and STING-independent, but an RNA POL III, RIG-I, and MAVS-dependent manner. Triple combination with anti-PD-L1 potentiated anti-tumour immunity with a significant increase in the number of CD4+ , CD8+ , and Granzyme B+ cells compared to radiation alone or radiation with M3814.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B91" rid="B91" class=" bibr popnode">91</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<strong>Wee1 inhibitor</strong>
</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MK1775/AZD177, adavosertib,<br />PO</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-PD-1</td><td valign="top" align="left" rowspan="1" colspan="1">8 Gy single fraction</td><td valign="top" align="left" rowspan="1" colspan="1">MOC-1 murine oral squamous cell carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Triple combination treatment efficacy is CD8-dependent. Radiation alone reduced neutrophilic myeloid-derived suppressor cells and increased Treg tumour accumulation, unchanged with the addition of AZD1775. T-cells from tumour-draining lymph nodes (TDLNs) from mice treated with the triple therapy demonstrated the greatest activation and IFN&#x003b3; production upon exposure to MOC1 tumour antigen. Mice cured following triple agent treatment did not engraft tumours following rechallenge.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B92" rid="B92" class=" bibr popnode">92</a>)</td></tr><tr><td valign="top" colspan="6" align="left" rowspan="1">
<strong>STING agonists</strong>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Modified CDN derivative molecules,<br />IT injection</td><td valign="top" align="left" rowspan="1" colspan="1">
<strong>-</strong>
</td><td valign="top" align="left" rowspan="1" colspan="1">10 Gy single fraction</td><td valign="top" align="left" rowspan="1" colspan="1">Panc02 murine pancreatic adenocarcinoma cell line; SCC7 head and neck cancer model, MMTV-PyMT mammary carcinoma; 3LL lung adenocarcinoma model</td><td valign="top" align="left" rowspan="1" colspan="1">Combination treatment showed early T-cell-independent and TNF&#x003b1;-dependent haemorrhagic necrosis, followed by later CD8+ T-cell-dependent control of residual disease.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B93" rid="B93" class=" bibr popnode">93</a>)</td></tr><tr><td valign="top" colspan="6" align="left" rowspan="1">
<strong>Toll-like receptor agonists</strong>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Imiquimod,<br />topical</td><td valign="top" align="left" rowspan="1" colspan="1">Cyclophosphamide</td><td valign="top" align="left" rowspan="1" colspan="1">8 Gy x 3 consecutive days</td><td valign="top" align="left" rowspan="1" colspan="1">TSA mouse breast carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Increased tumour infiltration by CD11c+, CD4+ and CD8+ cells. Tumour control abolished by CD8+ depletion. Combination treatment led to abscopal effect, long-term tumour-free mice rejected rechallenge showing immunological memory.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B94" rid="B94" class=" bibr popnode">94</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Imiquimod,<br />topical</td><td valign="top" align="left" rowspan="1" colspan="1">
<strong>-</strong>
</td><td valign="top" align="left" rowspan="1" colspan="1">Whole-body RT 2 Gy single fraction</td><td valign="top" align="left" rowspan="1" colspan="1">B16-F10 and B16-F1 melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">Combination treatment led to enhanced cell death via autophagy. Autophagy accelerated via ROS-mediated MAPK and NF-&#x003ba;B signalling pathways. Combination increased number of CD8+ T cells and decreased numbers of Treg and MDSCs in the tumour lesions. Combination enhanced systemic anti-cancer immunity by increasing the abundance of T cell populations expressing IFN-&#x003b3; and TNF-&#x003b1;.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B95" rid="B95" class=" bibr popnode">95</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR7 agonist (R848),<br />IV</td><td valign="top" align="left" rowspan="1" colspan="1">
<strong>-</strong>
</td><td valign="top" align="left" rowspan="1" colspan="1">10 Gy single fraction</td><td valign="top" align="left" rowspan="1" colspan="1">B-cell lymphoma line A20, the T-cell lymphoma line EL4, and its ovalbumin-expressing derivative EG7&#x000a0;</td><td valign="top" align="left" rowspan="1" colspan="1">Combination treatment led to the longstanding clearance of tumour in T- and B-cell lymphoma-bearing mice. Combination therapy led to the expansion of tumour antigen-specific CD8+ T. Mice that achieved long-term clearance of tumour were protected from subsequent tumour rechallenge.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B96" rid="B96" class=" bibr popnode">96</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR7 agonist (DSR-6434),<br />IV</td><td valign="top" align="left" rowspan="1" colspan="1">
<strong>-</strong>
</td><td valign="top" align="left" rowspan="1" colspan="1">KHT and CT26 tumours received a single dose of 25 or 15 Gy, or 5 daily fractions of 2 Gy, respectively.</td><td valign="top" align="left" rowspan="1" colspan="1">CT26 colorectal or KHT fibrosarcoma tumours</td><td valign="top" align="left" rowspan="1" colspan="1">Combination led to induction of type 1 interferon and activation of T and B lymphocytes, NK and NKT cells. Combination treatment primed an anti-tumour CD8+ T cell response. Long-term surviving mice had significantly greater frequency of tumour antigen-specific CD8+ T cells.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B97" rid="B97" class=" bibr popnode">97</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR7-selective agonist<br />(DSR-29133),<br />IV</td><td valign="top" align="left" rowspan="1" colspan="1">
<strong>-</strong>
</td><td valign="top" align="left" rowspan="1" colspan="1">2 Gy x 5</td><td valign="top" align="left" rowspan="1" colspan="1">Syngeneic models of renal cancer (Renca), metastatic osteosarcoma (LM8) and colorectal cancer (CT26)</td><td valign="top" align="left" rowspan="1" colspan="1">Administration of DSR-29133 led to the induction of IFN&#x003b1;/&#x003b3;, IP-10, TNF&#x003b1;, IL-1Ra and IL-12p70.<br />Combined therapy resulted in curative responses in a high proportion of mice bearing established CT26 tumours which was dependent on the activity of CD8+ T-cells, but independent of CD4+ T-cells and NK/NKT cells. Long-term surviving mice treated with combination were protected from subsequent tumour rechallenge.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B98" rid="B98" class=" bibr popnode">98</a>) </td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR7/8 agonist (3M-011 (854A)),<br />IP injection</td><td valign="top" align="left" rowspan="1" colspan="1">
<strong>-</strong>
</td><td valign="top" align="left" rowspan="1" colspan="1">2 Gy x 5</td><td valign="top" align="left" rowspan="1" colspan="1">CT26 (murine colorectal carcinoma cell line) or Panc-02 (murine pancreatic carcinoma cell line)</td><td valign="top" align="left" rowspan="1" colspan="1">
<em>In vivo</em> depletion identified NK and CD8 T cells as the cell populations mediating the cytotoxic effects of treatment, while <em>in vivo</em> depletion of CD11c+ dendritic cells (DC) in CD11c-diphtheria toxin receptor (DTR) transgenic mice revealed DC as the pivotal immune hub in this setting.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B99" rid="B99" class=" bibr popnode">99</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR9 agonist<br />(CpG oligodeoxynucleotide 1826),<br />SC peritumoural or IT injection</td><td valign="top" align="left" rowspan="1" colspan="1">
<strong>-</strong>
</td><td valign="top" align="left" rowspan="1" colspan="1">Single dose (unspecified) or fractionated RT delivered in 1-9 Gy fractions twice daily, separated by 6-7 hours for 5 consecutive days for total dose of 10-90 Gy</td><td valign="top" align="left" rowspan="1" colspan="1">Murine immunogenic fibrosarcoma tumour</td><td valign="top" align="left" rowspan="1" colspan="1">Mice cured of their tumours by combined CpG oligodeoxynucleotide 1826 plus radiotherapy were highly resistant to SC tumour take or development of tumour nodules in the lung from IV injected tumour cells when rechallenged with fibrosarcoma cells 100 to 120 days after the treatment, suggesting the development of a memory response.<br />CpG oligodeoxynucleotide 1826 also increased the radioresponse of the non-immunogenic fibrosarcoma tumour by a factor of 1.41 and 1.73 when CpG oligodeoxynucleotide 1826 was given SC and IT, respectively.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B100" rid="B100" class=" bibr popnode">100</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR9 agonist<br />(CpG oligodeoxynucleotide 1826),<br />peritumoural injection</td><td valign="top" align="left" rowspan="1" colspan="1">
<strong>-</strong>
</td><td valign="top" align="left" rowspan="1" colspan="1">20 Gy single fraction</td><td valign="top" align="left" rowspan="1" colspan="1">Immunogenic sarcoma (FSa)</td><td valign="top" align="left" rowspan="1" colspan="1">The CpG ODN-induced enhancement of tumour radioresponse was diminished in tumour-bearing mice immunocompromised by sublethal whole-body radiation. Tumours treated with combination showed increased necrosis, heavy infiltration by host inflammatory cells (lymphocytes and granulocytes), and reduced tumour cell density.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B101" rid="B101" class=" bibr popnode">101</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR9 agonist<br />(CpG oligodeoxynucleotides), peritumoural injection</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">30 Gy in 10 fractions of 3 Gy over 12 days, or a single dose (2, 6 or 10 Gy)</td><td valign="top" align="left" rowspan="1" colspan="1">Rat glioma cell lines 9L and RG2</td><td valign="top" align="left" rowspan="1" colspan="1">Combination treatment efficacy was lost in nude mice compared to immunocompetent mice, underlining the role of immune cells in anti-tumour effects. Tumour infiltration by immune cells and expression within tumours of the CpG receptor, TLR9, were not modified by irradiation.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B102" rid="B102" class=" bibr popnode">102</a>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR9 agonist<br />CpG oligodeoxynucleotides,<br />SC injection</td><td valign="top" align="left" rowspan="1" colspan="1">
<strong>-</strong>
</td><td valign="top" align="left" rowspan="1" colspan="1">20 Gy single fraction</td><td valign="top" align="left" rowspan="1" colspan="1">Lewis lung carcinoma (3LL) cells</td><td valign="top" align="left" rowspan="1" colspan="1">TLR9 agonist alone expanded and activated B cells and plasmacytoid dendritic cells in wild-type mice and natural killer DCs (NKDCs) in B cell-deficient (B<em>&#x02212;/&#x02212;</em>) tumour-bearing mice. Combined treatment led to a strong tumour-specific humoral immune response with deposition of mouse IgG auto-antibodies in tumour tissue in wild-type mice whereas the number of tumour-infiltrating NKDCs increased in B<sup>&#x02212;/&#x02212;</sup>&#x000a0;mice. </td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B103" rid="B103" class=" bibr popnode">103</a>) </td></tr><tr><td valign="top" colspan="6" align="left" rowspan="1">
<strong>(RIG-I)-like receptor agonist (RLR)</strong>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">dsRNA mimic polyIC by polyethylenimine (PolyIC(PEI)),<br />IT cytoplasmic delivery</td><td valign="top" align="left" rowspan="1" colspan="1">Low-dose cyclophosphamide, TLR agonist (polyIC), decitabine</td><td valign="top" align="left" rowspan="1" colspan="1">Diffusing alpha-emitting radiation therapy (DaRT)<br />Intratumoural Ra-224-coated seeds</td><td valign="top" align="left" rowspan="1" colspan="1">4T1 triple-negative breast tumours<br />Squamous cell carcinoma (SCC) tumour model SQ2</td><td valign="top" align="left" rowspan="1" colspan="1">Splenocytes from PolyIC(PEI) and DaRT-treated mice, adoptively transferred to naive mice in combination with 4T1 tumour cells, delayed tumour development compared to na&#x000ef;ve splenocytes. Delay in tumour development on re-challenge was demonstrated.</td><td valign="top" align="left" rowspan="1" colspan="1"> (<a href="#B104" rid="B104" class=" bibr popnode">104</a>)</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140317346703360"><a target="object" rel="noopener" href="/pmc/articles/PMC9465159/table/T1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="fn-a.i.c.c.c.e.d.a"><p class="p p-first-last">IV, intravenous; SC, subcutaneous; IP, intraperitoneal; IT, intratumoural; PO, oral.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="T2"><h3>Table&#x000a0;2</h3><!--caption a7--><div class="caption"><p>Selected clinical trials investigating radiotherapy in combination with DDR inhibitor and/or other agents.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Target (drug) &#x00026; route</th><th valign="top" align="center" rowspan="1" colspan="1">Additional therapy</th><th valign="top" align="center" rowspan="1" colspan="1">Radiotherapy</th><th valign="top" align="center" rowspan="1" colspan="1">Phase</th><th valign="top" align="center" rowspan="1" colspan="1">Patient population</th><th valign="top" align="center" rowspan="1" colspan="1">n</th><th valign="top" align="center" rowspan="1" colspan="1">Response</th><th valign="top" align="center" rowspan="1" colspan="1">Toxicity</th><th valign="top" align="center" rowspan="1" colspan="1">NCT ID</th></tr></thead><tbody><tr><td valign="top" colspan="9" align="left" rowspan="1">
<strong>DNA repair inhibitors</strong>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATM kinase inhibitor<br />(AZD1390)</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">35 Gy over 2 weeks;<br />30 Gy over two weeks;<br />60 Gy over 6 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Brain cancer</td><td valign="top" align="left" rowspan="1" colspan="1">120</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971759" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03423628" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03423628","term_id":"NCT03423628"}}</span>NCT03423628</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATR inhibitor<br />(AZD6738)</td><td valign="top" align="left" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1">20 or 30 Gy</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Solid tumours</td><td valign="top" align="left" rowspan="1" colspan="1">46</td><td valign="top" align="left" rowspan="1" colspan="1">Active, not recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Active, not recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971758" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02223923" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02223923","term_id":"NCT02223923"}}</span>NCT02223923</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATR kinase inhibitor (BAY1895344)</td><td valign="top" align="left" rowspan="1" colspan="1">Pembrolizumab</td><td valign="top" align="left" rowspan="1" colspan="1">SBRT 3 fractions with 2-3 days between fractions</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Recurrent head and neck squamous cell carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">37</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971762" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04576091" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04576091","term_id":"NCT04576091"}}</span>NCT04576091</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATR inhibitor<br />(M6620)</td><td valign="top" align="left" rowspan="1" colspan="1">Cisplatin; capecitabine</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Oesophageal cancer and other solid cancers</td><td valign="top" align="left" rowspan="1" colspan="1">65</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971801" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03641547" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03641547","term_id":"NCT03641547"}}</span>NCT03641547</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA- PK inhibitor (M3814)</td><td valign="top" align="left" rowspan="1" colspan="1">Avelumab</td><td valign="top" align="left" rowspan="1" colspan="1">Hypofractionated in 5 fractions</td><td valign="top" align="left" rowspan="1" colspan="1">I/II</td><td valign="top" align="left" rowspan="1" colspan="1">Advanced<br />hepatobiliary<br />malignancies</td><td valign="top" align="left" rowspan="1" colspan="1">92</td><td valign="top" align="left" rowspan="1" colspan="1">Not yet recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Not yet recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971760" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04068194" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04068194","term_id":"NCT04068194"}}</span>NCT04068194</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA- PK inhibitor (M3814)</td><td valign="top" align="left" rowspan="1" colspan="1">Cisplatin</td><td valign="top" align="left" rowspan="1" colspan="1">3 Gy x 10; 2 Gy x 33-35</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Locally advanced tumours</td><td valign="top" align="left" rowspan="1" colspan="1">52</td><td valign="top" align="left" rowspan="1" colspan="1">Preliminary efficacy: in-field response (n=16): one patient had pCR, 4 PR, 7 SD, and 3 have not yet been evaluated. One patient was not evaluable.</td><td valign="top" align="left" rowspan="1" colspan="1">Dose-escalation results reported (n=16 patients enrolled). The most frequent AEs were fatigue in 12/16 and nausea 8/16. No patients discontinued due to DLTs. Four DLTs were reported: grade 3 mucositis lasting &#x0003e; 7 days in 3/16 and odynophagia in 1/16, all recovered without sequelae. One fatal suspected unexpected serious AE considered as radiation pneumonitis occurred.</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971788" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02516813" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02516813","term_id":"NCT02516813"}}</span>NCT02516813</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA- PK inhibitor (M3814)</td><td valign="top" align="left" rowspan="1" colspan="1">Capecitabine</td><td valign="top" align="left" rowspan="1" colspan="1">45&#x02013;50 Gy in 25&#x02013;28 fractions<br />over 5 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">Ib/II</td><td valign="top" align="left" rowspan="1" colspan="1">Rectal cancer</td><td valign="top" align="left" rowspan="1" colspan="1">165</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971806" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03770689" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03770689","term_id":"NCT03770689"}}</span>NCT03770689</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA- PK inhibitor (M3814)</td><td valign="top" align="left" rowspan="1" colspan="1">Avelumab</td><td valign="top" align="left" rowspan="1" colspan="1">30 Gy in 10 fractions over 2 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Various advanced<br />solid tumours</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971809" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03724890" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03724890","term_id":"NCT03724890"}}</span>NCT03724890</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA- PK inhibitor (M3814)</td><td valign="top" align="left" rowspan="1" colspan="1">Temozolomide</td><td valign="top" align="left" rowspan="1" colspan="1">60 Gy in 30 fractions over 6 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">MGMT promoter unmethylated glioblastoma or gliosarcoma</td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971786" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04555577" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04555577","term_id":"NCT04555577"}}</span>NCT04555577</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA- PK inhibitor (M3814)</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Advanced head and neck cancer</td><td valign="top" align="left" rowspan="1" colspan="1">42</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971803" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04533750" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04533750","term_id":"NCT04533750"}}</span>NCT04533750</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA-PK inhibitor<br />(XRD-0394)</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">20 Gy in 5 fractions over 1 week</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Various advanced<br />solid tumours</td><td valign="top" align="left" rowspan="1" colspan="1">38</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971805" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT05002140" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT05002140","term_id":"NCT05002140"}}</span>NCT05002140</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dual ATM and DNA-PK inhibitor<br />(XRD-0394)</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">20 Gy in 5 fractions over 1 week</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic, locally advanced, or recurrent cancer</td><td valign="top" align="left" rowspan="1" colspan="1">38</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971791" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT05002140" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT05002140","term_id":"NCT05002140"}}</span>NCT05002140</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PARP inhibitor (olaparib)</td><td valign="top" align="left" rowspan="1" colspan="1">Durvalumab; Tremelimumab</td><td valign="top" align="left" rowspan="1" colspan="1">30 Gy in<br />10 fractions over<br />2 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">I/II</td><td valign="top" align="left" rowspan="1" colspan="1">Extensive stage small cell lung cancer</td><td valign="top" align="left" rowspan="1" colspan="1">54</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971794" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03923270" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03923270","term_id":"NCT03923270"}}</span>NCT03923270</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PARP inhibitor (olaparib)</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Triple-negative breast cancer</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">Awaiting report</td><td valign="top" align="left" rowspan="1" colspan="1">2/24 (8.7%) patients experienced acute grade 3 dermatitis related to RT. Olaparib-related toxicity grade 3-4 haematological toxicity was lymphopenia in 11/24 (45.8%) patients.</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971811" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03109080" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03109080","term_id":"NCT03109080"}}</span>NCT03109080</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PARP inhibitor (olaparib)</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Unspecified standard radiotherapy treatment 5 days per week for 6 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">II</td><td valign="top" align="left" rowspan="1" colspan="1">Inflammatory breast cancer</td><td valign="top" align="left" rowspan="1" colspan="1">300</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971766" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03598257" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03598257","term_id":"NCT03598257"}}</span>NCT03598257</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PARP inhibitor (olaparib)</td><td valign="top" align="left" rowspan="1" colspan="1">Durvalumab; carboplatin; etoposide</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified consolidative thoracic radiotherapy &#x000a0;</td><td valign="top" align="left" rowspan="1" colspan="1">I/II</td><td valign="top" align="left" rowspan="1" colspan="1">Extensive-stage small cell lung cancer</td><td valign="top" align="left" rowspan="1" colspan="1">63</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971775" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04728230" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04728230","term_id":"NCT04728230"}}</span>NCT04728230</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PARP inhibitor (olaparib)</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">High-dose 70 Gy in 35 fractions; elective neck 54.25 Gy in 35 fractions</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Head and neck cancer</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">Active, not recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Active, not recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971792" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02229656" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02229656","term_id":"NCT02229656"}}</span>NCT02229656</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PARP inhibitor (olaparib)</td><td valign="top" align="left" rowspan="1" colspan="1">Temozolomide</td><td valign="top" align="left" rowspan="1" colspan="1">2 Gy per fraction given once daily five days per week over 6 weeks, for a total dose of 60 Gy</td><td valign="top" align="left" rowspan="1" colspan="1">I/IIa</td><td valign="top" align="left" rowspan="1" colspan="1">High-grade gliomas</td><td valign="top" align="left" rowspan="1" colspan="1">79</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971818" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03212742" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03212742","term_id":"NCT03212742"}}</span>NCT03212742</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PARP inhibitor (niraparib)</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Triple-negative breast cancer</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971761" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03945721" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03945721","term_id":"NCT03945721"}}</span>NCT03945721</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PARP inhibitor (niraparib)</td><td valign="top" align="left" rowspan="1" colspan="1">Dostarlimab</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">II</td><td valign="top" align="left" rowspan="1" colspan="1">Triple-negative breast cancer</td><td valign="top" align="left" rowspan="1" colspan="1">32</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971798" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04837209" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04837209","term_id":"NCT04837209"}}</span>NCT04837209</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PARP inhibitor<br />(veliparib)</td><td valign="top" align="left" rowspan="1" colspan="1">Temozolomide</td><td valign="top" align="left" rowspan="1" colspan="1">30 daily fractions of radiation therapy 5 days per week for 6-7 weeks&#x000a0;</td><td valign="top" align="left" rowspan="1" colspan="1">II</td><td valign="top" align="left" rowspan="1" colspan="1">Newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations</td><td valign="top" align="left" rowspan="1" colspan="1">115</td><td valign="top" align="left" rowspan="1" colspan="1">Active, not recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Active, not recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971819" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03581292" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03581292","term_id":"NCT03581292"}}</span>NCT03581292</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PARP inhibitor<br />(Veliparib)</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">50 Gy to the chest wall and regional lymph nodes plus a 10-Gy boost</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Inflammatory or loco-regionally recurrent breast cancer</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">15 disease control failures during the 3 years of follow-up. 13 died (all after recurrence)</td><td valign="top" align="left" rowspan="1" colspan="1">5 dose-limiting AEs occurred: 4 moist desquamation, 1 neutropenia. Crude Grade 3 toxicity was 10% at year 1, 16.7% at year 2, and 46.7% at year 3. At year 3, 6 of 15 surviving patients had severe fibrosis in the treatment field.</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971774" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT01477489" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT01477489","term_id":"NCT01477489"}}</span>NCT01477489</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PARP inhibitor<br />(Veliparib)</td><td valign="top" align="left" rowspan="1" colspan="1">Capecitabine&#x000a0;</td><td valign="top" align="left" rowspan="1" colspan="1">50&#x000b7;4 Gy in 1.8 Gy fractions daily, 5 consecutive days per week for 5&#x000b7;5 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">!b</td><td valign="top" align="left" rowspan="1" colspan="1">Locally advanced rectal cancer</td><td valign="top" align="left" rowspan="1" colspan="1">32</td><td valign="top" align="left" rowspan="1" colspan="1">Tumour downstaging at surgery was noted in 22 (71%) of 31 patients; nine (29%) of 31 patients achieved a pathological complete response.</td><td valign="top" align="left" rowspan="1" colspan="1">Common AEs included nausea in 17 patients (53%), diarrhoea in 16 (50%), and fatigue in 16 (50%). Grade 3 diarrhoea in three (9%) of 32 patients; no Grade 4 events.</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971769" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT01589419" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT01589419","term_id":"NCT01589419"}}</span>NCT01589419</a></td></tr><tr><td valign="top" colspan="9" align="left" rowspan="1">
<strong>Wee 1 inhibitor</strong>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adavosertib (AZD1775)</td><td valign="top" align="left" rowspan="1" colspan="1">Cisplatin</td><td valign="top" align="left" rowspan="1" colspan="1">IMRT 5 days a week, once daily, Monday to Friday, for 6 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Head and neck cancer</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971772" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03028766" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03028766","term_id":"NCT03028766"}}</span>NCT03028766</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adavosertib (AZD1775)</td><td valign="top" align="left" rowspan="1" colspan="1">Cisplatin</td><td valign="top" align="left" rowspan="1" colspan="1">45 Gy or greater</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Cervical, upper vaginal and uterine Cancers</td><td valign="top" align="left" rowspan="1" colspan="1">33</td><td valign="top" align="left" rowspan="1" colspan="1">Active, not recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Active, not recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971763" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03345784" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03345784","term_id":"NCT03345784"}}</span>NCT03345784</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adavosertib<br />(AZD1775)</td><td valign="top" align="left" rowspan="1" colspan="1">Cisplatin</td><td valign="top" align="left" rowspan="1" colspan="1">70 Gy at 2Gy per fraction, 35 fractions, Monday to Friday over 7 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Intermediate/high risk squamous cell carcinoma of head and neck</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971754" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02585973" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02585973","term_id":"NCT02585973"}}</span>NCT02585973</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adavosertib<br />(AZD1775)</td><td valign="top" align="left" rowspan="1" colspan="1">Gemcitabine</td><td valign="top" align="left" rowspan="1" colspan="1">52.5Gy in 25 fractions (2.1Gy/fraction), using intensity-modulated radiation therapy (IMRT) after chemotherapy</td><td valign="top" align="left" rowspan="1" colspan="1">I/II</td><td valign="top" align="left" rowspan="1" colspan="1">Unresectable adenocarcinoma of the pancreas</td><td valign="top" align="left" rowspan="1" colspan="1">34</td><td valign="top" align="left" rowspan="1" colspan="1">Median overall survival for all patients was 21.7 months (90% CI, 16.7 to 24.8 months) which was substantially higher than prior results combining gemcitabine with radiation therapy.</td><td valign="top" align="left" rowspan="1" colspan="1">8/34 patients (24%) experienced a dose-limiting toxicity, most commonly anorexia, nausea, or fatigue.&#x000a0;</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971797" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02037230" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02037230","term_id":"NCT02037230"}}</span>NCT02037230</a></td></tr><tr><td valign="top" colspan="9" align="left" rowspan="1">
<strong>Toll-like receptor agonists</strong>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR9 agonist (SD-101) intratumoural</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">4 Gy in 2 fractions<br />over 2 days</td><td valign="top" align="left" rowspan="1" colspan="1">I/II</td><td valign="top" align="left" rowspan="1" colspan="1">Untreated indolent lymphoma</td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="left" rowspan="1" colspan="1">26/29 (89.7%) patients had tumour reduction at treated site. 24 (82.8%) patients had tumour reduction at non-treated sites.</td><td valign="top" align="left" rowspan="1" colspan="1">Grade 1-2 drug-related AEs reported by all patients. Most common treatment-related side effect was a flu-like systemic reaction. 8/29 patients (27.6%) had grade 3 drug-related AEs. No drug-related grade 4 or serious AEs.</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971793" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02266147" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02266147","term_id":"NCT02266147"}}</span>NCT02266147</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR9 agonist (SD-101) intratumoural</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-OX40 (BMS-986178)</td><td valign="top" align="left" rowspan="1" colspan="1">Low-dose not specified over 2 fractions</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Low-grade B cell<br />non-Hodgkin<br />lymphoma</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971799" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03410901" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03410901","term_id":"NCT03410901"}}</span>NCT03410901</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR9 agonist (SD-101) intratumoural</td><td valign="top" align="left" rowspan="1" colspan="1">Epacadostat</td><td valign="top" align="left" rowspan="1" colspan="1">24 Gy in 8 fractions,<br />20 Gy in 5 fractions, 4 Gy in 2 fractions</td><td valign="top" align="left" rowspan="1" colspan="1">I/II</td><td valign="top" align="left" rowspan="1" colspan="1">Advanced<br />solid tumours</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">Early outcome reported for 7 patients refractory to prior therapy with anti-PD-L1 checkpoint inhibition. In these patients, disease control rate (DCR) and abscopal DCR was 86% (6/7) and 100% (7/7), response rate was 43% (3/7), and abscopal response rate was 29% (2/7) including 2 patients with long-term durable complete responses.&#x000a0;</td><td valign="top" align="left" rowspan="1" colspan="1">Awaiting report</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971780" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03322384" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03322384","term_id":"NCT03322384"}}</span>NCT03322384</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR9 agonist (SD-101) intratumoural</td><td valign="top" align="left" rowspan="1" colspan="1">Pembrolizumab; leuprolide acetate; abiraterone Acetate; prednisone</td><td valign="top" align="left" rowspan="1" colspan="1">35 Gy in 7 fractions</td><td valign="top" align="left" rowspan="1" colspan="1">II</td><td valign="top" align="left" rowspan="1" colspan="1">Oligometastatic<br />prostate cancer</td><td valign="top" align="left" rowspan="1" colspan="1">42</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971810" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03007732" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03007732","term_id":"NCT03007732"}}</span>NCT03007732</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR9 agonist (SD-101) intratumoural</td><td valign="top" align="left" rowspan="1" colspan="1">Ibrutinib</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">Ib/II</td><td valign="top" align="left" rowspan="1" colspan="1">Lymphoma</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">Early outcome reported for 13 patients treated with a median follow-up of 7.7 months. 6 of 12 evaluable patients had achieved a partial response (50% ORR) and 3 had achieved &#x0003e;50% reduction in distal tumour burden. Eight of 12 patients (66.7%) had experienced at least a 30% reduction in distal tumour burden.&#x000a0;</td><td valign="top" align="left" rowspan="1" colspan="1">AEs were consistent with known effects of ibrutinib and of CpG with no unexpected AEs to suggest synergistic toxicity. There were no grade 4 or 5 events. AEs led to ibrutinib dose reduction or discontinuation in 3 patients.</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971756" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02927964" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02927964","term_id":"NCT02927964"}}</span>NCT02927964</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR9 agonist (SD-101) intratumoural</td><td valign="top" align="left" rowspan="1" colspan="1">Nivolumab</td><td valign="top" align="left" rowspan="1" colspan="1">6-10 Gy per fraction to the injected lesion given on days 1, 3, 5, 8, and 10</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic<br />pancreatic<br />adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">Active, not recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Active, not recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971778" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04050085" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04050085","term_id":"NCT04050085"}}</span>NCT04050085</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CMP-001<br />intratumoural</td><td valign="top" align="left" rowspan="1" colspan="1">Nivolumab; ipilimumab</td><td valign="top" align="left" rowspan="1" colspan="1">Radiosurgery</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Colorectal cancer metastatic to liver</td><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971787" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03507699" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03507699","term_id":"NCT03507699"}}</span>NCT03507699</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SD-101<br />intratumoural</td><td valign="top" align="left" rowspan="1" colspan="1">Ipilimumab</td><td valign="top" align="left" rowspan="1" colspan="1">Low-dose radiation therapy to 1 site of disease</td><td valign="top" align="left" rowspan="1" colspan="1">I/II</td><td valign="top" align="left" rowspan="1" colspan="1">Recurrent low-grade B-cell lymphoma</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971800" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02254772" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02254772","term_id":"NCT02254772"}}</span>NCT02254772</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Imiquimod (topical)</td><td valign="top" align="left" rowspan="1" colspan="1">Cyclophosphamide</td><td valign="top" align="left" rowspan="1" colspan="1">30 Gy in 5 fractions</td><td valign="top" align="left" rowspan="1" colspan="1">I/II</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic<br />breast cancer</td><td valign="top" align="left" rowspan="1" colspan="1">31</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971765" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT01421017" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT01421017","term_id":"NCT01421017"}}</span>NCT01421017</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Poly(ICLC) intratumoural</td><td valign="top" align="left" rowspan="1" colspan="1">rhuFlt3L/CDX-301</td><td valign="top" align="left" rowspan="1" colspan="1">2 Gy x 2</td><td valign="top" align="left" rowspan="1" colspan="1">I/II</td><td valign="top" align="left" rowspan="1" colspan="1">Lymphoma</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">Partial or complete response of treated tumour in 8/11 (72.7%). Six (54.5%) had stable disease/minor regressions at non-treated sites and three (27.3%) showed significant distant disease regression.</td><td valign="top" align="left" rowspan="1" colspan="1">All AEs Grade 1 apart from 1 patient with G2 fever</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971784" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT01976585" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT01976585","term_id":"NCT01976585"}}</span>NCT01976585</a></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CpG- enriched TLR9<br />agonist (PF-3512676) intratumoural</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">4 Gy in 2 fractions<br />over 2 days</td><td valign="top" align="left" rowspan="1" colspan="1">I/II</td><td valign="top" align="left" rowspan="1" colspan="1">Mycosis fungoides</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">One (6.7%) patient with complete clinical response, distant site<br />clinical response<br />seen in 5 patients (33.3%).</td><td valign="top" align="left" rowspan="1" colspan="1">Mild injection site<br />reaction and mild<br />flu- like symptoms</td><td valign="top" align="left" rowspan="1" colspan="1"><a id="__tag_1115971768" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00185965" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00185965","term_id":"NCT00185965"}}</span>NCT00185965</a></td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140317303916544"><a target="object" rel="noopener" href="/pmc/articles/PMC9465159/table/T2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="fn-a.i.c.c.c.f.d.a"><p class="p p-first-last">AEs, Adverse effects; DLTs, Dose-limiting toxicities; NCT, National Clinical Trial; N/A, Not Applicable.</p></div></div></div><p>ATR is activated by single-stranded DNA (ssDNA) structures that may arise at resected DNA DSBs or stalled replication forks. ATR is recruited <em>via</em> interaction of ATR-interacting protein (ATRIP) with ssDNA-bound replication protein A (RPA) (<a href="#B105" rid="B105" class=" bibr popnode">105</a>). RPA-ssDNA complexes stimulate loading of the RAD9&#x02013;HUS1&#x02013;RAD1 (9&#x02013;1&#x02013;1) heterotrimer, that recruits DNA topoisomerase II binding protein 1 (TopBP1) which activates ATR (<a href="#B106" rid="B106" class=" bibr popnode">106</a>). Once ATR is activated, downstream targets, including checkpoint kinase 1 (Chk1), promote DNA repair (<a href="#B107" rid="B107" class=" bibr popnode">107</a>, <a href="#B108" rid="B108" class=" bibr popnode">108</a>), restart of stalled replication forks (<a href="#B109" rid="B109" class=" bibr popnode">109</a>) and intra-S and G2/M cell cycle arrest (<a href="#B110" rid="B110" class=" bibr popnode">110</a>, <a href="#B111" rid="B111" class=" bibr popnode">111</a>). In response to DNA damage, activation of the intra-S-phase cell cycle checkpoint slows progression of DNA replication to allow time for resolution (<a href="#B110" rid="B110" class=" bibr popnode">110</a>, <a href="#B111" rid="B111" class=" bibr popnode">111</a>). In addition, the ATR-dependent G2/M cell cycle checkpoint is activated through degradation of cell division cycle 25A (Cdc25A) (<a href="#B111" rid="B111" class=" bibr popnode">111</a>), and phosphorylation of Cdc25C phosphatase inhibits its ability to activate nuclear cell division cycle 2 (Cdc2) and, hence, mitosis entry (<a href="#B112" rid="B112" class=" bibr popnode">112</a>). Most cancer cells are defective in DNA damage-induced checkpoints through e.g. p53 pathway mutations, which leads to dependence on the intra-S-phase and G2/M checkpoints for cell survival (<a href="#B69" rid="B69" class=" bibr popnode">69</a>). Therefore, ATR inhibition will lead to accumulation of DNA damage, premature entry into mitosis, mitotic catastrophe and cell death (<a href="#B69" rid="B69" class=" bibr popnode">69</a>).</p><p>ATR inhibitors include schisandrin B (<a href="#B113" rid="B113" class=" bibr popnode">113</a>), NU6027 (<a href="#B114" rid="B114" class=" bibr popnode">114</a>), NVP-BEZ235 (<a href="#B115" rid="B115" class=" bibr popnode">115</a>), VE-821 (<a href="#B116" rid="B116" class=" bibr popnode">116</a>), VE-822 (<a href="#B117" rid="B117" class=" bibr popnode">117</a>), AZ20 (<a href="#B118" rid="B118" class=" bibr popnode">118</a>) and ceralasertib (AZD6738) (<a href="#B119" rid="B119" class=" bibr popnode">119</a>, <a href="#B120" rid="B120" class=" bibr popnode">120</a>). NVP-BEZ235 has been reported to induce marked radiosensitivity in Ras-overexpressing cancers (<a href="#B121" rid="B121" class=" bibr popnode">121</a>), and NU6027 has been shown to increase sensitivity to DNA-damaging agents in breast and ovarian cell lines (<a href="#B114" rid="B114" class=" bibr popnode">114</a>). VE-822 results in selective sensitisation of pancreatic tumours to radiation <em>in vivo</em> by increasing persistent DNA damage, decreasing cell cycle checkpoint maintenance and reducing homologous recombination repair (<a href="#B117" rid="B117" class=" bibr popnode">117</a>). <em>In vitro</em>, ATR inhibition downregulates radiotherapy-induced programmed death-ligand 1/2 (PD-L1/2) expression to sensitise cancer cells to T-cell killing, in addition to potentiating DNA damage (<a href="#B122" rid="B122" class=" bibr popnode">122</a>). Promising preclinical <em>in vivo</em> studies (<a href="/pmc/articles/PMC9465159/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>
<strong>Table&#x000a0;1</strong>
</span></a>) of the ATR inhibitor ceralasertib (AZD6738) in combination with radiotherapy have shown an enhanced type I/II interferon response and increased immune cell infiltrate (<a href="#B88" rid="B88" class=" bibr popnode">88</a>), increased RT-stimulated CD8+ T cell infiltration (<a href="#B87" rid="B87" class=" bibr popnode">87</a>, <a href="#B89" rid="B89" class=" bibr popnode">89</a>), NK-mediated anti-tumour immunity (<a href="#B90" rid="B90" class=" bibr popnode">90</a>), as well as reversal of the Treg immunosuppressive effect (<a href="#B87" rid="B87" class=" bibr popnode">87</a>, <a href="#B89" rid="B89" class=" bibr popnode">89</a>). In addition, further addition of ICI (i.e. anti-PD-1, anti-PD-L1, anti-TIGIT (T-cell immunoglobulin and ITIM domain)) to the ceralasertib (AZD6738) and radiotherapy combination further improved response and long-lasting immunity in a CD8+ (<a href="#B87" rid="B87" class=" bibr popnode">87</a>, <a href="#B89" rid="B89" class=" bibr popnode">89</a>) and NK-dependent manner (<a href="#B90" rid="B90" class=" bibr popnode">90</a>).</p><p>There are, to date, three early phase clinical studies investigating ATR inhibition and radiotherapy. PATRIOT, a phase I study of ceralasertib (AZD6738) in combination with palliative radiotherapy, has completed recruitment and is awaiting report (<a id="__tag_1115971813" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02223923" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02223923","term_id":"NCT02223923"}}</span>NCT02223923</a>). BAY1895344 in combination with radiotherapy and pembrolizumab in recurrent head and neck squamous cell carcinoma (HNSCC) (<a id="__tag_1115971817" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04576091" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04576091","term_id":"NCT04576091"}}</span>NCT04576091</a>) and M6620 with radiotherapy and chemotherapy in solid cancers (<a id="__tag_1115971789" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03641547" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03641547","term_id":"NCT03641547"}}</span>NCT03641547</a>) are ongoing studies (<a href="/pmc/articles/PMC9465159/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>
<strong>Table&#x000a0;2</strong>
</span></a>).</p><p class="p p-last">A downstream target of ATR, Chk1, has also been investigated as a potential therapeutic target, due to its ability to activate intra-S and G2/M cell cycle checkpoints and modulate the replication stress response (<a href="#B123" rid="B123" class=" bibr popnode">123</a>), particularly as a sensitiser to radiotherapy (<a href="#B124" rid="B124" class=" bibr popnode">124</a>). Chk1 inhibitors, to date, include UCN-01 (<a href="#B125" rid="B125" class=" bibr popnode">125</a>), LY2606368 (<a href="#B126" rid="B126" class=" bibr popnode">126</a>), PF-00477736 (<a href="#B127" rid="B127" class=" bibr popnode">127</a>), MK8776 (<a href="#B128" rid="B128" class=" bibr popnode">128</a>) and CCT244747 (<a href="#B129" rid="B129" class=" bibr popnode">129</a>), AZD7762 (<a href="#B130" rid="B130" class=" bibr popnode">130</a>) and LY2603618 (<a href="#B131" rid="B131" class=" bibr popnode">131</a>). Although there have been promising results in refractory acute myeloid leukaemia and advanced cancer with MK-8776 (<a href="#B132" rid="B132" class=" bibr popnode">132</a>, <a href="#B133" rid="B133" class=" bibr popnode">133</a>) and LY2606368 (<a href="#B134" rid="B134" class=" bibr popnode">134</a>), unfortunately severe adverse effects such as drug-related cardiac toxicity have also been reported during the clinical development of these drugs, e.g. AZD7762 (<a href="#B135" rid="B135" class=" bibr popnode">135</a>). Thus far, no clinical trials are investigating the combination of Chk1 inhibition and radiotherapy.</p></div><div id="s3_1_2" class="sec"><p></p><h4 id="s3_1_2title" class="inline">3.1.2 DNA-PKcs (DNA-dependent protein kinase, catalytic subunit) inhibitors </h4><p class="p p-first">DNA-PK is pivotal for the initiation of DNA repair following DSBs, which ultimately results in recruitment of proteins involved in DNA damage repair progressing and ligating the broken DNA ends most recognised <em>via</em> the NHEJ pathway (<a href="#B136" rid="B136" class=" bibr popnode">136</a>). Various cancer cell lines with reduced levels of DNA-PKcs show increased radiosensitivity compared to unirradiated controls (<a href="#B137" rid="B137" class=" bibr popnode">137</a>&#x02013;<a href="#B139" rid="B139" class=" bibr popnode">139</a>) due to defective DNA DSB repair, inhibition of phosphorylated protein kinase B (Akt) on Ser473 and reduction of radiotherapy-induced transcription factor hypoxia-inducible factor-1 &#x003b1; levels (HIF-1 &#x003b1;) (<a href="#B138" rid="B138" class=" bibr popnode">138</a>).</p><p>Given that DNA-PKcs is critical in radiotherapy-induced DDR, DNA-PKcs inhibition is an emerging therapeutic target for potentiating radiotherapy responses (<a href="#B140" rid="B140" class=" bibr popnode">140</a>, <a href="#B141" rid="B141" class=" bibr popnode">141</a>), and many agents have already been tested in clinical trials. Non-selective DNA-PKcs inhibitors include wortmannin, which also inhibits ATM (<a href="#B142" rid="B142" class=" bibr popnode">142</a>), and LY294002, which has a similar structure (<a href="#B143" rid="B143" class=" bibr popnode">143</a>, <a href="#B144" rid="B144" class=" bibr popnode">144</a>). More selective DNA-PKcs inhibitors include NU7026 (<a href="#B145" rid="B145" class=" bibr popnode">145</a>), NU7441 (<a href="#B146" rid="B146" class=" bibr popnode">146</a>), IC86621, IC87102, IC87361 (<a href="#B147" rid="B147" class=" bibr popnode">147</a>), vanillin (<a href="#B148" rid="B148" class=" bibr popnode">148</a>), OK-1035 (<a href="#B149" rid="B149" class=" bibr popnode">149</a>), SU11752 (<a href="#B150" rid="B150" class=" bibr popnode">150</a>), BVAN08 (<a href="#B151" rid="B151" class=" bibr popnode">151</a>), IC486241 (<a href="#B152" rid="B152" class=" bibr popnode">152</a>) and NK314 (<a href="#B153" rid="B153" class=" bibr popnode">153</a>). More recently, novel inhibitors have been discovered including M3814 (<a href="#B154" rid="B154" class=" bibr popnode">154</a>), AZD7648 (<a href="#B155" rid="B155" class=" bibr popnode">155</a>) and VX-984 (<a href="#B156" rid="B156" class=" bibr popnode">156</a>). Doxycycline was first approved by US Food and Drug Administration (FDA) in 1967 as a broad-spectrum antibiotic and has recently been recognised to function also as an DNA-PK inhibitor (<a href="#B157" rid="B157" class=" bibr popnode">157</a>). Mechanisms by which DNA-PKcs helps to sensitise to radiotherapy include prolongation of radiotherapy-induced G2/M phase arrest (<a href="#B158" rid="B158" class=" bibr popnode">158</a>) and reduced repair of radiotherapy-induced DSB (<a href="#B147" rid="B147" class=" bibr popnode">147</a>, <a href="#B150" rid="B150" class=" bibr popnode">150</a>, <a href="#B159" rid="B159" class=" bibr popnode">159</a>) leading to the induction of autophagic cell death and mitotic catastrophe (<a href="#B66" rid="B66" class=" bibr popnode">66</a>).</p><p>In terms of DNA-PKcs inhibition leading to stimulation of the innate immune system, a recent study showed that combining radiation with M3814-induced DNA-PK inhibition increased cytosolic dsDNA and tumour type I interferon signalling in a cGAS-STING-independent, but RNA Polymerase III-, RIG-I- and MAVS-dependent manner, in pancreatic cancer models (<a href="#B91" rid="B91" class=" bibr popnode">91</a>). Furthermore, radiotherapy and M3814 increased PD-L1 expression and sensitised to anti-PD-L1 treatment in poorly immunogenic pancreatic cancers (<a href="#B91" rid="B91" class=" bibr popnode">91</a>). DNA-PKcs itself also functions as a DNA sensor that activates innate immunity. It has been reported to function as a PRR by binding to cytoplasmic DNA and can trigger a type I IFN response in a STING/IRF-3/TBK1-dependent manner (<a href="#B160" rid="B160" class=" bibr popnode">160</a>) as well as a STING-independent manner <em>via</em> phosphorylation of heat shock protein HSPA8/heat shock cognate HSC70 (<a href="#B161" rid="B161" class=" bibr popnode">161</a>). It is still unclear whether pharmacological inhibition of DNA-PKcs kinase activity may dampen anti-tumour immunity in contrast to inhibition of other DDR kinases described such as ATM or ATR.</p><p class="p p-last">Clinical studies of DNA repair inhibitors, M3814 (<a id="__tag_1115971755" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04533750" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04533750","term_id":"NCT04533750"}}</span>NCT04533750</a>) and XRD-0394 (<a id="__tag_1115971808" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT05002140" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT05002140","term_id":"NCT05002140"}}</span>NCT05002140</a>), in combination with radiotherapy are recruiting. In addition, triple combination of M3814 with radiotherapy and chemotherapy (<a id="__tag_1115971757" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02516813" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02516813","term_id":"NCT02516813"}}</span>NCT02516813</a>, <a id="__tag_1115971782" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03770689" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03770689","term_id":"NCT03770689"}}</span>NCT03770689</a>, <a id="__tag_1115971776" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04555577" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04555577","term_id":"NCT04555577"}}</span>NCT04555577</a>) or anti-PD-L1 (<a id="__tag_1115971781" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04068194" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04068194","term_id":"NCT04068194"}}</span>NCT04068194</a>, <a id="__tag_1115971767" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03724890" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03724890","term_id":"NCT03724890"}}</span>NCT03724890</a>) are also awaiting report (<a href="/pmc/articles/PMC9465159/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>
<strong>Table&#x000a0;2</strong>
</span></a>).</p></div><div id="s3_1_3" class="sec"><p></p><h4 id="s3_1_3title" class="inline">3.1.3 PARP inhibitors </h4><p class="p p-first">PARP-1 has been the most extensively studied of the PARP superfamily and is a key regulator of DNA damage repair (<a href="#B162" rid="B162" class=" bibr popnode">162</a>, <a href="#B163" rid="B163" class=" bibr popnode">163</a>). In response to DNA damage, such as that induced by radiotherapy, an initial response is poly(ADP-ribosyl)ation (PARylation) of proteins including nuclear DDR proteins, such as DNA-PKcs, to provide a local signal of DNA damage (<a href="#B163" rid="B163" class=" bibr popnode">163</a>&#x02013;<a href="#B165" rid="B165" class=" bibr popnode">165</a>). Inhibitors of PARP generally function by inhibiting PARylation or suppressing PARP-1 release by &#x02018;trapping&#x02019;. PARP-1 inhibition has been reported to sensitise cancer cells to various forms of ionising radiation including conventional gamma irradiation (<a href="#B166" rid="B166" class=" bibr popnode">166</a>, <a href="#B167" rid="B167" class=" bibr popnode">167</a>), proton-beam irradiation (<a href="#B167" rid="B167" class=" bibr popnode">167</a>) and radionuclide therapy (<a href="#B168" rid="B168" class=" bibr popnode">168</a>, <a href="#B169" rid="B169" class=" bibr popnode">169</a>) (<a href="/pmc/articles/PMC9465159/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>
<strong>Table&#x000a0;2</strong>
</span></a>). Although SSBs are primary repaired by PARP-1, its inhibition may not be lethal due to other available repair pathways, such as homologous recombination. However, deficiency in BRCA1/2 functionality, which are key components in the HR pathway of DSB repair, leads to synthetic lethality and selective sensitivity to PARP inhibition (<a href="#B170" rid="B170" class=" bibr popnode">170</a>).</p><p>Beyond DNA repair, PARP-1 also plays an immunomodulatory role by regulating gene transcription of several immune cell types, modulating the stimulatory ability of DCs, and by directly affecting the differentiation and function of T and B cells (<a href="#B171" rid="B171" class=" bibr popnode">171</a>, <a href="#B172" rid="B172" class=" bibr popnode">172</a>). PARP-1 knockout mice show reduced T helper type 2 (Th2) differentiation responses (<a href="#B172" rid="B172" class=" bibr popnode">172</a>). PARP-1 is also involved in the differentiation of Foxp3+ regulatory T cells (Treg) and promotion of Treg cell apoptosis during inflammatory responses (<a href="#B172" rid="B172" class=" bibr popnode">172</a>). PARP inhibitors generate cytoplasmic chromatin fragments with micronuclei characteristics which activate cGAS-STING, downstream type I interferon signalling and chemokine ligand 5 (CCL5) secretion in excision repair cross-complementation group 1 (ERCC1)-defective non-small cell lung cancer (NSCLC) cells (<a href="#B173" rid="B173" class=" bibr popnode">173</a>). The capacity of PARP1 inhibitors to upregulate innate immune and inflammasome-like signalling events, such as cGAS-STING signalling, closely depends on their PARP1-trapping abilities (<a href="#B174" rid="B174" class=" bibr popnode">174</a>, <a href="#B175" rid="B175" class=" bibr popnode">175</a>). In the context of viral infection, activated DNA-PK has been reported to phosphorylate PARP1 leading to its cytoplasmic translocation (<a href="#B176" rid="B176" class=" bibr popnode">176</a>). Cytoplasmic PARP1 can then interact with and directly PARylate cGAS to inhibit its DNA-binding ability (<a href="#B176" rid="B176" class=" bibr popnode">176</a>). This has implications to how PARP inhibition, in the context of cancer-induced genome instability, can positively modulate the host anti-tumour immune response.</p><p>Early PARP-1 inhibitors were non-specific and non-selective, such as nicotinamide (<a href="#B177" rid="B177" class=" bibr popnode">177</a>), AG14361 (<a href="#B178" rid="B178" class=" bibr popnode">178</a>) and 4-amino-1,8-naphthalimide (<a href="#B179" rid="B179" class=" bibr popnode">179</a>). Newer PARP-1 inhibitors, such as olaparib and niraparib, are now used in routine clinical practice following approval by the FDA and European Union (<a href="#B180" rid="B180" class=" bibr popnode">180</a>, <a href="#B181" rid="B181" class=" bibr popnode">181</a>). They are licensed for use in patients with advanced BRCA-mutated ovarian cancer, metastatic-castration-resistant prostate cancer with BRCA1/2 or ATM mutation (<a href="#B182" rid="B182" class=" bibr popnode">182</a>), suspected germline HR repair gene mutated mCRPC who have progressed on enzalutamide or abiraterone (<a href="#B183" rid="B183" class=" bibr popnode">183</a>) and, most recently, recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer which has responded to first-line platinum chemotherapy (<a href="#B184" rid="B184" class=" bibr popnode">184</a>, <a href="#B185" rid="B185" class=" bibr popnode">185</a>).</p><p>Combining PARP-1 inhibition and radiotherapy has been supported by preclinical studies. Particularly in BRCA1-mutant cancers, PARP inhibition showed radiation hypersensitivity in lymphoblastoid cells (<a href="#B186" rid="B186" class=" bibr popnode">186</a>). In various models, PARP-1 inhibitors KJ-28d (<a href="#B187" rid="B187" class=" bibr popnode">187</a>), ABT-888 (<a href="#B188" rid="B188" class=" bibr popnode">188</a>) and the PARP-1/2 inhibitor MK-4827 (<a href="#B189" rid="B189" class=" bibr popnode">189</a>) increased cancer cell radiation sensitivity.</p><p class="p p-last">Many clinical trials are underway investigating the combination of PARP inhibitors and radiotherapy, with addition of chemotherapy and/or immunotherapy agents (<a href="/pmc/articles/PMC9465159/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>
<strong>Table&#x000a0;1</strong>
</span></a>). The mechanisms underlying radiosensitisation by PARP inhibitors are still not completely clear and, indeed, recent studies have revealed a wider immunological role for PARP-1 that could potentially be exploited through new therapeutic approaches (<a href="#B190" rid="B190" class=" bibr popnode">190</a>). For example, one study showed through multiomics profiling that macrophage-mediated immune suppression is a liability of PARP inhibition (<a href="#B191" rid="B191" class=" bibr popnode">191</a>). Following this evidence, the rationale for combining CSF-1R blocking antibodies with PARP inhibitors led to reprogramming of the TME and significantly enhanced innate and adaptive anti-tumour immunity, which was CD8+-mediated in BRCA-deficient tumours <em>in vivo</em> (<a href="#B191" rid="B191" class=" bibr popnode">191</a>).</p></div><div id="s3_1_4" class="sec sec-last"><p></p><h4 id="s3_1_4title" class="inline">3.1.4 Wee1-like protein kinase (Wee1) inhibitors </h4><p class="p p-first">Wee1 is a cell cycle checkpoint negative regulator at the G2/M transition. The process by which Wee1 activation leads to phosphorylation and inactivation of the cyclin B1/CDK1 complex blocking entry into mitosis is well described (<a href="#B192" rid="B192" class=" bibr popnode">192</a>).</p><p>Emerging studies have highlighted the role of Wee1 directly and indirectly in immune signalling (<a href="#B193" rid="B193" class=" bibr popnode">193</a>). For example, ineffective CDK-1-dependent nuclear laminin degradation abrogates apoptosis induction, leading to immune resistance in tumour cells (<a href="#B194" rid="B194" class=" bibr popnode">194</a>). Accordingly, Wee1 inhibition reconstitutes CDK1 activity to reverse resistance of these cancer cells to immune attack (<a href="#B194" rid="B194" class=" bibr popnode">194</a>). In various cancer models, Wee1 inhibition promotes accumulation of cytosolic dsDNA, leading to activation of the cGAS-STING pathway (<a href="/pmc/articles/PMC9465159/figure/f1/" target="figure" class="fig-table-link figpopup" rid-figpopup="f1" rid-ob="ob-f1" co-legend-rid="lgnd_f1"><span>
<strong>Figure 1</strong>
</span></a>), increased type I interferon target gene expression when delivered alone (<a href="#B195" rid="B195" class=" bibr popnode">195</a>), as well as in combination with ATR inhibitors (<a href="#B196" rid="B196" class=" bibr popnode">196</a>) or immune checkpoint blockade (<a href="#B197" rid="B197" class=" bibr popnode">197</a>). A STING-independent pathway by which Wee1 inhibition induces the interferon response has also been reported. In cGAS-STING-defective tumour models, Wee1 inhibition can upregulate immune signalling through the dsRNA anti-viral defence pathway by promoting expression of endogenous retroviral element (ERV) (<a href="#B198" rid="B198" class=" bibr popnode">198</a>). ERVs trigger dsRNA stress and the interferon response, resulting in the recruitment of anti-tumour T-cells, and increased expression of PD-L1 with sensitisation to anti-PD-L1 blockade in multiple cancer models (<a href="#B198" rid="B198" class=" bibr popnode">198</a>).</p><p>Wee1 inhibitors, some of which are concomitant CDK1 inhibitors, are promising as a combination partner with radiotherapy (<a href="#B199" rid="B199" class=" bibr popnode">199</a>). This combination has shown synergistic effects in various cancer models (<a href="#B200" rid="B200" class=" bibr popnode">200</a>&#x02013;<a href="#B202" rid="B202" class=" bibr popnode">202</a>). Wee1 inhibitors such as 681641 (<a href="#B203" rid="B203" class=" bibr popnode">203</a>), PD0166285 (<a href="#B204" rid="B204" class=" bibr popnode">204</a>) and adavosertib (MK1775/AZD1775) (<a href="#B92" rid="B92" class=" bibr popnode">92</a>, <a href="#B202" rid="B202" class=" bibr popnode">202</a>, <a href="#B205" rid="B205" class=" bibr popnode">205</a>) have been reported to increase the radiosensitivity of cancer cells. Cancer cells very frequently harbour G1 checkpoint deficiencies and Wee1 inhibitor-mediated prevention of DNA repair following radiotherapy may lead to premature entry into mitosis and, ultimately, cell death <em>via</em> mitotic catastrophe (<a href="#B206" rid="B206" class=" bibr popnode">206</a>). Other mechanisms include blocking radiotherapy-induced DNA damage repair (<a href="#B204" rid="B204" class=" bibr popnode">204</a>) by impairing DNA repair protein RAD51 homolog 1 (RAD51) focus formation (<a href="#B202" rid="B202" class=" bibr popnode">202</a>) and suppression of Sirt1 (silent mating type information regulation 2 homolog 1). Sirt1 interacts with and deacetylates HR-repair machinery proteins including Nibrin (NBS1) and RAD51, thus, Wee1-induced Sirt1 suppression impairs HR-repair activity (<a href="#B207" rid="B207" class=" bibr popnode">207</a>).</p><p class="p p-last">Several clinical trials are exploring the combination of Wee1 inhibition by adavosertib (MK1775/AZD1775) with radiotherapy and chemotherapy (<a id="__tag_1115971804" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03028766" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03028766","term_id":"NCT03028766"}}</span>NCT03028766</a>, <a id="__tag_1115971785" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03345784" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03345784","term_id":"NCT03345784"}}</span>NCT03345784</a>, <a id="__tag_1115971773" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02585973" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02585973","term_id":"NCT02585973"}}</span>NCT02585973</a>, <a id="__tag_1115971816" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02037230" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02037230","term_id":"NCT02037230"}}</span>NCT02037230</a>) (<a href="/pmc/articles/PMC9465159/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>
<strong>Table&#x000a0;2</strong>
</span></a>). The emerging immune-mediating effects of Wee1 inhibition provide a strong rationale for its combination with immune checkpoint inhibitors (<a href="#B198" rid="B198" class=" bibr popnode">198</a>).</p></div></div><div id="s3_2" class="sec sec-last"><h3 id="s3_2title">3.2 Cytosolic nucleic acid sensing pathways</h3><p class="p p-first">The ability to detect cytosolic nucleic acids by PRRs, arising from pathogens or disruption of cellular functions from genotoxic stress such as DNA damage, is part of the protective cellular response against infection or injury. These mechanisms are an evolutionary product of anti-microbial responses and can trigger an inflammatory signalling cascade and subsequent activation of the innate immune system. Targeting these nucleic acid sensing mechanisms has the potential to further amplify the DDR-induced anti-tumour innate immunity in conjunction with radiotherapy.</p><div id="s3_2_1" class="sec"><p></p><h4 id="s3_2_1title" class="inline">3.2.1 Direct DNA sensing </h4><div id="s3_2_1_1" class="sec sec-first-last"><p></p><h5 id="s3_2_1_1title" class="inline">3.2.1.1 STING agonists </h5><p class="p p-first">Stimulator of interferon genes (STING) is an endoplasmic reticulum adaptor that senses self and foreign cytoplasmic DNA, <em>via</em> cyclic GMP&#x02013;AMP synthase (cGAS), and is crucial for effective innate immune signalling (<a href="#B208" rid="B208" class=" bibr popnode">208</a>). Cytosolic DNA induces synthesis of the cyclic dinucleotide (CDN) cyclic GMP&#x02013;AMP (cGAMP) from ATP and GTP by a cyclase enzyme called cGAS. cGAMP directly binds to STING to cause its dimerization and activation (<a href="#B209" rid="B209" class=" bibr popnode">209</a>, <a href="#B210" rid="B210" class=" bibr popnode">210</a>), leading to activation of both NF-&#x003ba;B and IRF3 transcription pathways to induce expression of type I interferon, recruitment of immune cells, promotion of DC maturation and antigen-specific immune priming (<a href="#B211" rid="B211" class=" bibr popnode">211</a>).</p><p>The cGAS-STING pathway is essential for anti-tumour T cell responses (<a href="#B212" rid="B212" class=" bibr popnode">212</a>). One proposed mechanism is that CD8&#x003b1;<sup>+</sup>&#x000a0;DCs engulf apoptotic or necrotic tumour cells, and tumour cell-derived DNA triggers STING signalling in DCs (<a href="#B212" rid="B212" class=" bibr popnode">212</a>&#x02013;<a href="#B214" rid="B214" class=" bibr popnode">214</a>). The subsequent type I IFN production by these DCs facilitates antigen cross-presentation and T-cell priming independent of the TLR or RIG-I/MAVS pathways (<a href="#B212" rid="B212" class=" bibr popnode">212</a>). Recent studies have also suggested that STING signalling in the TME can suppress the immunosuppressive activity of MDSCs (<a href="#B215" rid="B215" class=" bibr popnode">215</a>, <a href="#B216" rid="B216" class=" bibr popnode">216</a>). STING signalling is critical for radiation-induced anti-tumour responses (<a href="#B214" rid="B214" class=" bibr popnode">214</a>) and, thus, it is an attractive potential treatment combination with radiotherapy. Preclinical data have shown that consideration needs to be given to radiotherapy dose per fraction as doses above 12-18 Gy induce the DNA exonuclease Trex1, which degrades the cytosolic DNA required to stimulate an effective STING-dependent type I IFN response (<a href="#B217" rid="B217" class=" bibr popnode">217</a>).</p><p>The first generation STING agonist, 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA), was originally developed as a vascular-disrupting agent (<a href="#B218" rid="B218" class=" bibr popnode">218</a>, <a href="#B219" rid="B219" class=" bibr popnode">219</a>) and its anti-tumour effect is based on vascular necrosis leading to tumour starvation and haemorrhagic necrosis (<a href="#B218" rid="B218" class=" bibr popnode">218</a>, <a href="#B220" rid="B220" class=" bibr popnode">220</a>). DMXAA has previously been shown to synergise with radiotherapy in mouse models in a hypoxia-preferential manner (<a href="#B221" rid="B221" class=" bibr popnode">221</a>). However, the TME was found to remain immunologically sterile and tumours eventually progressed with time without durable protective anti-tumour immunity (<a href="#B222" rid="B222" class=" bibr popnode">222</a>, <a href="#B223" rid="B223" class=" bibr popnode">223</a>). High local STING concentrations can lead to rapid T-cell apoptosis (<a href="#B224" rid="B224" class=" bibr popnode">224</a>) whereas low-dose administration can lead to &#x02018;vascular normalisation&#x02019; and favourably transform the TME to allow use of effective combinatorial anti-tumour immunotherapy (<a href="#B225" rid="B225" class=" bibr popnode">225</a>&#x02013;<a href="#B227" rid="B227" class=" bibr popnode">227</a>).</p><p class="p p-last">There are two categories of STING agonists in clinical development: synthetic cyclic dinucleotides (CDNs) or non-CDN small molecules (<a href="#B228" rid="B228" class=" bibr popnode">228</a>). These drugs are generally administered intratumourally due to their poor stability and bioavailability. This caveat limits their use to accessible tumours and recent efforts have been focused on development of STING agonists for systemic delivery (intravenously (<a href="#B228" rid="B228" class=" bibr popnode">228</a>), orally (<a href="#B229" rid="B229" class=" bibr popnode">229</a>, <a href="#B230" rid="B230" class=" bibr popnode">230</a>) and even as an inhalable nanoparticulate (<a href="#B231" rid="B231" class=" bibr popnode">231</a>)). In addition, novel STING antibody-drug conjugates show promising preclinical results (<a href="#B232" rid="B232" class=" bibr popnode">232</a>). There have only been a handful of preclinical studies investigating novel STING agonists with radiotherapy <em>in vivo</em> (<a href="/pmc/articles/PMC9465159/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>
<strong>Table&#x000a0;1</strong>
</span></a>). In mouse models, STING agonists synergise with radiotherapy to control local and distant disease and mediate rejection of tumour rechallenge (<a href="#B93" rid="B93" class=" bibr popnode">93</a>, <a href="#B231" rid="B231" class=" bibr popnode">231</a>) <em>via</em> early T-cell-independent and TNF-&#x003b1;-dependent haemorrhagic necrosis, followed by a later stage of CD8 T-cell-dependent control (<a href="#B93" rid="B93" class=" bibr popnode">93</a>). A number of clinical trials have looked into combining STING agonists with ICI or conventional chemotherapy (<a href="#B233" rid="B233" class=" bibr popnode">233</a>); however, at the time of this review no radiotherapy and STING agonist combination clinical trials are in progress.</p></div></div><div id="s3_2_2" class="sec sec-last"><p></p><h4 id="s3_2_2title" class="inline">3.2.2 Crosstalk with RNA sensors </h4><div id="s3_2_2_1" class="sec sec-first"><p></p><h5 id="s3_2_2_1title" class="inline">3.2.2.1 Toll-like receptor agonists </h5><p class="p p-first">Toll-like receptors (TLRs) are a form of PRR expressed on sentinel immune cells which activate innate defence systems by detecting PAMPs. Genotoxic stress and DNA damage are increasingly recognised to signal through TLRs and cause the upregulation of TLR expression (<a href="#B234" rid="B234" class=" bibr popnode">234</a>) <em>via</em> p53 (<a href="#B235" rid="B235" class=" bibr popnode">235</a>). TLR signalling leads to maturation of APCs such as DCs, which are key mediators of T-cell activation and subsequent adaptive immunity. There is growing preclinical evidence that TLR agonists in combination with radiotherapy may lead to enhanced anti-tumour immunity, particularly through the mechanism of enhanced DC-mediated T-cell priming following radiotherapy (<a href="#B236" rid="B236" class=" bibr popnode">236</a>). This occurs at various stages of this pathway; for example, TLR activation enhances type I IFN-signalling in many immune cells, modulates chemokine expression to enhance DC migration to lymphoid tissues (<a href="#B237" rid="B237" class=" bibr popnode">237</a>&#x02013;<a href="#B239" rid="B239" class=" bibr popnode">239</a>) and upregulates CD80 and CD86 co-stimulatory molecules on DCs, which bind to CD28 on na&#x000ef;ve T-cells for antigen/MHC-complex mediated TCR stimulation (<a href="#B240" rid="B240" class=" bibr popnode">240</a>). TLRs can also stimulate DC-mediated release of IL-6 to dampen Treg suppressive signalling (<a href="#B241" rid="B241" class=" bibr popnode">241</a>).</p><p>Given these observations, TLR agonists are seen as an attractive combination partner with radiotherapy. There have been numerous preclinical studies (<a href="/pmc/articles/PMC9465159/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>
<strong>Table&#x000a0;1</strong>
</span></a>) and early phase clinical trials (<a href="/pmc/articles/PMC9465159/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>
<strong>Table&#x000a0;2</strong>
</span></a>) of different TLR agonists, particularly of TLR3, TLR7/8 and TLR9, in combination with radiotherapy.</p><p>TLR3 senses dsRNA as a PAMP and polyinosinic-polycytidylic acid or poly (I:C) is a synthetic mimic of dsRNA which can stimulate TLR3-signalling pathways and lead to type I-IFN-dependent (<a href="#B242" rid="B242" class=" bibr popnode">242</a>, <a href="#B243" rid="B243" class=" bibr popnode">243</a>) DC antigen cross-priming <em>in vivo</em> (<a href="#B244" rid="B244" class=" bibr popnode">244</a>, <a href="#B245" rid="B245" class=" bibr popnode">245</a>). Poly(I:C) also has several immunostimulatory effects, including maturation and activation of DCs (<a href="#B246" rid="B246" class=" bibr popnode">246</a>&#x02013;<a href="#B248" rid="B248" class=" bibr popnode">248</a>), T-cell stimulation (<a href="#B249" rid="B249" class=" bibr popnode">249</a>, <a href="#B250" rid="B250" class=" bibr popnode">250</a>), enhanced cytotoxicity of Natural Killer (NK) cells (<a href="#B251" rid="B251" class=" bibr popnode">251</a>&#x02013;<a href="#B253" rid="B253" class=" bibr popnode">253</a>), reprogramming of MDSCs (<a href="#B254" rid="B254" class=" bibr popnode">254</a>) and repolarisation of macrophage populations from an M2 (classically activated macrophages) to M1 (alternatively activated macrophages) phenotype (<a href="#B255" rid="B255" class=" bibr popnode">255</a>) (<a href="/pmc/articles/PMC9465159/figure/f1/" target="figure" class="fig-table-link figpopup" rid-figpopup="f1" rid-ob="ob-f1" co-legend-rid="lgnd_f1"><span>
<strong>Figure&#x000a0;1</strong>
</span></a>). Pre-clinical studies exploring TLR3 agonists with radiotherapy in a radioresistant mouse model of lung cancer showed that poly(I:C) enhanced radiotherapy anti-tumour effects (<a href="#B256" rid="B256" class=" bibr popnode">256</a>). The results from initial clinical trials have been disappointing, likely due to the short half-life of poly(I:C) (<a href="#B257" rid="B257" class=" bibr popnode">257</a>). To address this, a degradation-resistant derivative polyinosinic-polycytidylic acid, and poly-L-lysine or poly(ICLC) was developed that has shown efficacy in clinical trials, although toxicity remains an issue (<a href="#B257" rid="B257" class=" bibr popnode">257</a>). Preclinical studies in a murine lymphoma model have investigated the Fms-like tyrosine kinase 3 (Flt3)-ligand with radiotherapy and poly(ICLC) (<a href="#B258" rid="B258" class=" bibr popnode">258</a>). Flt3-ligand is a cytokine which increases migration of DCs into the tumour and radiotherapy then stimulates maturation of DCs <em>via</em> ICD and HMGB-1 signalling for antigen uptake and processing (<a href="#B259" rid="B259" class=" bibr popnode">259</a>). This combination with the addition of poly(ICLC) further maximises DC maturation and activation (<a href="#B246" rid="B246" class=" bibr popnode">246</a>&#x02013;<a href="#B248" rid="B248" class=" bibr popnode">248</a>). There is a clinical study investigating intratumoral delivery of poly(ICLC) in combination with an in-situ vaccine rhuFlt3L/CDX-301 and radiotherapy which was well-tolerated and showed promising results (<a href="#B258" rid="B258" class=" bibr popnode">258</a>) (<a id="__tag_1115971802" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT01976585" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT01976585","term_id":"NCT01976585"}}</span>NCT01976585</a>) (<a href="/pmc/articles/PMC9465159/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>
<strong>Table&#x000a0;2</strong>
</span></a>). Two phase 2 studies in glioblastoma patients are also investigating the efficacy of poly(ICLC) in combination with radiotherapy (<a href="#B260" rid="B260" class=" bibr popnode">260</a>, <a href="#B261" rid="B261" class=" bibr popnode">261</a>).</p><p>TLR7 and TLR8 detect guanosine or uridine-rich single-stranded RNA and their activation can directly induce MDSCs to lose their immunosuppressive function and acquire an APC-like phenotype that can induce tumour-specific T-cell responses (<a href="#B262" rid="B262" class=" bibr popnode">262</a>), convert MDSCs to M1-like macrophages (<a href="#B263" rid="B263" class=" bibr popnode">263</a>), activate NK cells (<a href="#B264" rid="B264" class=" bibr popnode">264</a>&#x02013;<a href="#B267" rid="B267" class=" bibr popnode">267</a>) and revert Treg immunosuppressive effects (<a href="#B268" rid="B268" class=" bibr popnode">268</a>). The imidazoquinolines are synthetic agonists for TLR7/8 of which topical imiquimod is the most extensively studied as well as being currently licensed for the treatment of superficial basal cell carcinoma (<a href="#B269" rid="B269" class=" bibr popnode">269</a>). A preclinical study in breast cancer has investigated topical imiquimod in combination with radiotherapy and low-dose cyclophosphamide (<a href="#B94" rid="B94" class=" bibr popnode">94</a>), and found that this triple combination had synergistic anti-cancer effects at both irradiated and unirradiated (abscopal) sites. Long-term surviving mice were able to reject tumour rechallenge, likely due to the establishment of anti-tumour immunological memory (<a href="#B94" rid="B94" class=" bibr popnode">94</a>) (<a href="/pmc/articles/PMC9465159/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>
<strong>Table&#x000a0;1</strong>
</span></a>). A phase 2 clinical trial in metastatic breast cancer testing the efficacy of this triple therapy has finished recruiting (<a id="__tag_1115971795" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT01421017" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT01421017","term_id":"NCT01421017"}}</span>NCT01421017</a>) (<a href="/pmc/articles/PMC9465159/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>
<strong>Table&#x000a0;2</strong>
</span></a>). Synergistic effects of subcutaneous TLR7 agonist and radiotherapy have also been observed in a preclinical model of melanoma (<a href="#B95" rid="B95" class=" bibr popnode">95</a>) (<a href="/pmc/articles/PMC9465159/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>
<strong>Table&#x000a0;1</strong>
</span></a>). The efficacy of systemic delivery of the TLR7 agonists R848 (<a href="#B96" rid="B96" class=" bibr popnode">96</a>), DSR-6434 (<a href="#B97" rid="B97" class=" bibr popnode">97</a>), DSR-29133 (<a href="#B98" rid="B98" class=" bibr popnode">98</a>) and 3M-011 (<a href="#B99" rid="B99" class=" bibr popnode">99</a>), in combination with radiotherapy, has been explored in the treatment of several preclinical models of solid cancers. Dual therapy works synergistically to enhance tumour control, generate tumour-antigen-specific T-cells, suppress tumour growth (<a href="#B96" rid="B96" class=" bibr popnode">96</a>&#x02013;<a href="#B99" rid="B99" class=" bibr popnode">99</a>) after rechallenge in long-term surviving mice (<a href="#B97" rid="B97" class=" bibr popnode">97</a>) (<a href="#B98" rid="B98" class=" bibr popnode">98</a>) and reduce the formation of distant metastases (<a href="#B99" rid="B99" class=" bibr popnode">99</a>). Systemically-administered TLR7/8 agonists are not currently being investigated in a clinical setting; notably a phase I clinical trial investigating systemic TLR7 agonist ANA975 in chronic hepatitis C virus (<a href="#B270" rid="B270" class=" bibr popnode">270</a>) had to be withdrawn due to excessive toxicity in extended preclinical studies (<a href="#B271" rid="B271" class=" bibr popnode">271</a>), highlighting the need for caution when delivering systemic TLR7/8 agonists, especially in combination with radiotherapy (<a href="#B236" rid="B236" class=" bibr popnode">236</a>).</p><p class="p p-last">Finally, TLR9 is expressed on APCs and B-cells and senses unmethylated CpG oligonucleotides present in bacterial and viral DNA (<a href="#B272" rid="B272" class=" bibr popnode">272</a>&#x02013;<a href="#B274" rid="B274" class=" bibr popnode">274</a>). Again, TLR9 agonism can lead to activation and maturation of DCs, cytokine release from T helper type 1 (Th1) cells, differentiation of MDSC towards an M1 phenotype (<a href="#B275" rid="B275" class=" bibr popnode">275</a>&#x02013;<a href="#B279" rid="B279" class=" bibr popnode">279</a>) and inhibition of Treg immunosuppressive effects (<a href="#B280" rid="B280" class=" bibr popnode">280</a>). Several preclinical studies (<a href="#B281" rid="B281" class=" bibr popnode">281</a>&#x02013;<a href="#B284" rid="B284" class=" bibr popnode">284</a>) have shown that TLR9 agonists can lead to anti-tumour effects in an NK- and CD8 T-cell-dependent manner (<a href="#B285" rid="B285" class=" bibr popnode">285</a>). Preclinical studies showed enhanced tumour control in combination with radiotherapy in a model of murine fibrosarcoma and lung cancer (<a href="#B100" rid="B100" class=" bibr popnode">100</a>&#x02013;<a href="#B103" rid="B103" class=" bibr popnode">103</a>), and induction of immunological memory by mice rejecting tumour rechallenge (<a href="#B102" rid="B102" class=" bibr popnode">102</a>). The synergistic effects of radiotherapy and TLR9 agonists are dependent on a competent host immune system (<a href="#B102" rid="B102" class=" bibr popnode">102</a>). Early clinical studies, although in small patient numbers, have tested TRL9 agonists in combination with radiotherapy. CpG-enriched oligodeoxynucleotide delivered intratumorally in combination with radiotherapy, 4 Gy in two fractions, led to overall objective response rates of 27% in the non-treated lesions of patients with relapsed low-grade B cell lymphoma (<a href="#B286" rid="B286" class=" bibr popnode">286</a>).</p></div><div id="s3_2_2_2" class="sec sec-last"><p></p><h5 id="s3_2_2_2title" class="inline">3.2.2.2 (RIG-I)-like receptor (RLR) agonists </h5><p class="p p-first">RIG-I and melanoma differentiation-associated gene 5 (MDA5) are collectively (RIG-I)-like receptors (RLR) which detect cytosolic RNA and are a key PRR in anti-viral responses (<a href="#B287" rid="B287" class=" bibr popnode">287</a>). RIG-I preferentially binds to short (&#x0003e;10 bp) dsRNAs whereas MDA5 detects long accessible dsRNAs (&#x0003e;2 kbp) (<a href="#B288" rid="B288" class=" bibr popnode">288</a>, <a href="#B289" rid="B289" class=" bibr popnode">289</a>), and downstream signalling of either activates IRF3 and NF-&#x003ba;B pathways to induce type I IFN and other inflammatory cytokines. In the context of DNA damage, RIG-I interacts with X-ray repair cross complementing 4 (XRCC4) to impede formation of the XRCC4/LIG4 (DNA ligase 4)/XLF (XRCC4-like factor) at DSBs. High expression of RIG-I compromises DNA repair and sensitises cancer cells to irradiation treatment. In contrast, depletion of RIG-I renders cells resistant to irradiation <em>in vitro</em> and <em>in vivo</em> (<a href="#B290" rid="B290" class=" bibr popnode">290</a>).</p><p>In the anti-tumour response, there is increasing evidence that RLR activation in various cancer models by RNA ligands can induce cancer cell apoptosis in a type I IFN-dependent (<a href="#B291" rid="B291" class=" bibr popnode">291</a>), or -independent manner (<a href="#B292" rid="B292" class=" bibr popnode">292</a>, <a href="#B293" rid="B293" class=" bibr popnode">293</a>). RIG-I signalling can induce ICD of ovarian and pancreatic cancer cells <em>in vivo</em> by systemic activation of DCs, NK cells and CD8+ T cells (<a href="#B294" rid="B294" class=" bibr popnode">294</a>, <a href="#B295" rid="B295" class=" bibr popnode">295</a>). In a pancreatic cancer model, tumour-derived type I IFN activates DCs and CD8&#x003b1;<sup>+</sup> DCs engulf apoptotic tumour material and cross-present tumour-associated antigen to na&#x000ef;ve CD8+ T cells (<a href="#B296" rid="B296" class=" bibr popnode">296</a>). RIG-I may also inhibit tumour growth indirectly through regulation of tumour hypoxia (<a href="#B297" rid="B297" class=" bibr popnode">297</a>) and the gut microbiota (<a href="#B298" rid="B298" class=" bibr popnode">298</a>). The efficacy of anti-cancer treatments such as radiotherapy and many chemotherapy agents has also been shown to depend on the RLR pathway through endogenous non-coding RNAs, and depletion of RIG-I in human tumours confers treatment resistance (<a href="#B299" rid="B299" class=" bibr popnode">299</a>).</p><p>Harnessing the RLR-pathway through RLR agonists is an attractive therapeutic target and several RLR mimetics or agonists have been developed which have shown promise in preclinical studies. For example, a unique RIG-I agonist in the form of RNA stem-loop of 14 bp (SLR14), when delivered intratumorally, significantly inhibited B16 tumour growth locally and systemically in bilateral and tumour metastasis models, with cured mice developing immunological memory (<a href="#B300" rid="B300" class=" bibr popnode">300</a>). SLR14 was mainly taken up by CD11b+ myeloid cells in the TME leading to subsequent increase in the number of CD8+ T lymphocytes, NK cells, and CD11b+ cells in SLR14-treated tumours (<a href="#B300" rid="B300" class=" bibr popnode">300</a>). MK4621 (or RGT100), a synthetic RNA oligonucleotide RIG-I activator is currently in phase 1 clinical trials for the treatment of advanced/metastatic solid tumours (<a id="__tag_1115971753" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03739138" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03739138","term_id":"NCT03739138"}}</span>NCT03739138</a>).</p><p class="p p-last">Combining RLR agonists and radiotherapy is an attractive strategy to activate multiple DDR pathways <em>via</em> cytosolic RNA sensing and radiotherapy-induced cytosolic DNA/DNA damage detection. <em>In vitro</em>, an RLR agonist Poly(I:C)-HMW (High Molecular Weight)/LyoVec&#x02122; [Poly(I:C)-HMW] sensitised <em>in vitro</em> human lung cancer cells to Fas ligand (FasL)-induced apoptosis by radiotherapy (<a href="#B301" rid="B301" class=" bibr popnode">301</a>). <em>In vivo</em> intratumoral cytoplasmic delivery of the dsRNA mimic poly(I:C) by polyethylenimine (PEI), prior to diffusing alpha-emitting radiation therapy (DaRT), resulted in synergistic tumour and metastatic disease control. Furthermore, immunological memory was demonstrated, whereby splenocytes from treated mice adoptively transferred to na&#x000ef;ve tumour-bearing mice, resulted in delayed tumour development and protection from rechallenge (<a href="#B104" rid="B104" class=" bibr popnode">104</a>). Combining RLR-agonists and radiotherapy has not yet been translated into clinical practice and to the best of our knowledge there are no clinical trials investigating this combination.</p></div></div></div></div><div id="s4" class="tsec sec"><h2 class="head no_bottom_margin" id="s4title">4 Discussion</h2><p class="p p-first">We have discussed in detail the various druggable targets related to the DDR pathway, in particular agonists of the nucleic acid sensing pathways and inhibitors of DNA damage repair mechanisms. Next, this review will explore the clinical challenges and implications of combining radiotherapy with DDR-targeted agents.</p><div id="s4_1" class="sec"><h3 id="s4_1title">4.1 The role of conventional chemotherapy</h3><p class="p p-first-last">Conventional chemotherapy has historically been used in the backbone of radical chemoradiation (CRT) in many locally advanced tumours such as rectal, cervical and head and neck cancers. Chemotherapy agents traditionally used as radiosensitisers include platin salts (e.g. Cisplatin, Carboplatin) or fluoropyrimidines (e.g. 5-fluorouracil or its prodrug Capecitabine), which trigger cell death by instigating DNA damage (<a href="#B302" rid="B302" class=" bibr popnode">302</a>). Chemotherapy-induced cell death can lead to DNA leakage into the cytosol and trigger intrinsic STING pathway stimulation and activation of the immune system (<a href="#B303" rid="B303" class=" bibr popnode">303</a>). Some may argue that investigating novel DDR-pathway specific agents is redundant given that chemotherapy may exert its anti-cancer effects partly by stimulating the innate immune system (<a href="#B303" rid="B303" class=" bibr popnode">303</a>). However, it is recognised that chemotherapy (<a href="#B304" rid="B304" class=" bibr popnode">304</a>), radiotherapy (<a href="#B305" rid="B305" class=" bibr popnode">305</a>) or concomitant CRT (<a href="#B306" rid="B306" class=" bibr popnode">306</a>) in various cancers can result in lymphocyte depletion which can potentially negate a sustained effective anti-tumour response. Lymphocyte depletion post-treatment is a poor prognostic factor in patients who have undergone radiotherapy for Stage III lung cancer (<a href="#B305" rid="B305" class=" bibr popnode">305</a>) or CRT for newly diagnosed glioblastoma (<a href="#B306" rid="B306" class=" bibr popnode">306</a>). Furthermore, defects in DDR signalling may contribute to chemoresistance in some cancer types (<a href="#B303" rid="B303" class=" bibr popnode">303</a>) and, as such, development of specific DDR-targeting agents remains an important avenue for research.</p></div><div id="s4_2" class="sec"><h3 id="s4_2title">4.2 Maintaining anti-tumour immunity using ICIs</h3><p class="p p-first">The anti-tumour innate immunity initiated by radiotherapy and DDR inhibitors is likely to be complementary to the effect of immune checkpoint inhibitors (ICIs), which can sustain and maintain the adaptive arm of the anti-tumour immune response. For example, preclinical studies in lymphoma have shown that treatment with Flt3L, radiation and poly(ICLC) led to PD-L1 upregulation in both tumour cells and intratumoural DCs, and that the further addition of anti-PD-1 antibody led to improved local and systemic tumour control (<a href="#B258" rid="B258" class=" bibr popnode">258</a>). There is an increasing number of early phase clinical studies investigating the addition of ICI with radiotherapy and DDR-targeted agents, such as TLR agonists (<a id="__tag_1115971812" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03007732" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03007732","term_id":"NCT03007732"}}</span>NCT03007732</a>, <a id="__tag_1115971783" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04050085" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04050085","term_id":"NCT04050085"}}</span>NCT04050085</a>, <a id="__tag_1115971764" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03507699" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03507699","term_id":"NCT03507699"}}</span>NCT03507699</a>, <a id="__tag_1115971790" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02254772" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02254772","term_id":"NCT02254772"}}</span>NCT02254772</a>) and DNA-PK inhibitors (<a id="__tag_1115971815" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04068194" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04068194","term_id":"NCT04068194"}}</span>NCT04068194</a>, <a id="__tag_1115971770" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03724890" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03724890","term_id":"NCT03724890"}}</span>NCT03724890</a>, <a id="__tag_1115971771" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04576091" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04576091","term_id":"NCT04576091"}}</span>NCT04576091</a>, <a id="__tag_1115971777" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03923270" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03923270","term_id":"NCT03923270"}}</span>NCT03923270</a>).</p><p class="p p-last">Clinical response to ICIs is typically predicted by tumour mutational burden and neoantigen load (<a href="#B307" rid="B307" class=" bibr popnode">307</a>, <a href="#B308" rid="B308" class=" bibr popnode">308</a>). Preclinical data suggests that radiotherapy and DDR inhibitors may replicate the phenotype of high mutational and neoantigen burden and rationally direct therapeutic combinations with ICIs. However, the caveat is that radiotherapy-induced subclonal neoantigens may translate into poorer responses to ICI in some tumour types (<a href="#B307" rid="B307" class=" bibr popnode">307</a>). The combination of radiotherapy and anti-CTLA-4 increases the diversity of TIL TCR repertoire, leading to increased tumour control <em>in vivo</em>; however, these tumours remain dominated by a small number of high-frequency T-cell clones (<a href="#B30" rid="B30" class=" bibr popnode">30</a>, <a href="#B32" rid="B32" class=" bibr popnode">32</a>). It is still unknown whether it is more important to have an immune response against pre-existing tumour antigens or new radiotherapy-generated tumour antigens. As we await the results of the ongoing triple combination treatments (RT + DDR agents + ICI) in early phase clinical trials, further work is needed to investigate such combinations in the context of creation of subclonal neoantigens.</p></div><div id="s4_3" class="sec"><h3 id="s4_3title">4.3 Tumour-specific radiosensitisation and the safety profile of combination therapy</h3><p class="p p-first">A key principle of radiation oncology is that the dose delivered to the tumour is limited by the surrounding normal tissue organs-at-risk (OARs). Hence, strategies in designing clinical trials arguably should have some basis for a selective effect of any combination drug on the tumour (<a href="#B309" rid="B309" class=" bibr popnode">309</a>). Preclinical studies in mouse models, for example, show that M3814, a DNA-PK inhibitor given with radiotherapy, shows marked improvement in tumour control (<a href="#B310" rid="B310" class=" bibr popnode">310</a>). However, when translated into clinical practice, a clinical trial of M3814 with radiation (<a id="__tag_1115971796" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02516813" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02516813","term_id":"NCT02516813"}}</span>NCT02516813</a>) reported enhanced normal tissue reactions including dysphagia, prolonged stomatitis and radiation dermatitis (<a href="#B311" rid="B311" class=" bibr popnode">311</a>). Pre-clinical models are also severely limited in predicting long-term treatment toxicity in humans.</p><p class="p p-last">A further therapeutic challenge of using DDR pathway agents with radiotherapy is that there may be high variability in drug pharmacokinetics leading to varying degrees of radiosensitisation between tumour versus normal tissues, which makes it difficult to predict the therapeutic index for each individual patient (<a href="#B309" rid="B309" class=" bibr popnode">309</a>). Therefore, unless there is a clear mechanism for tumour-specific radiosensitisation, clinical trials combining DNA repair inhibitors and radiotherapy may be severely compromised by unacceptable toxicity. Potential solutions may be an intratumoural route of drug delivery, as taken by certain trials of TLR9 agonists and STING agonists (<a href="/pmc/articles/PMC9465159/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>
<strong>Table&#x000a0;2</strong>
</span></a>), or conditional drug activation, such as with a hypoxia-activated DNA-PK inhibitor (<a href="#B312" rid="B312" class=" bibr popnode">312</a>, <a href="#B313" rid="B313" class=" bibr popnode">313</a>). Increased knowledge of biomarkers and access to routine tumour profiling may guide the best selection of which DDR agent to use in a particular cancer subtype, for example PARP-inhibitors in BRCA-mutant or ATM/ATR inhibitors in p53-mutant tumours. Advances in radiotherapy delivery techniques using stereotactic techniques to irradiate tumour volumes highly selectively is a further way to reduce off-target combination effects of DDR-targeting agents. For example, a Phase I trial in recurrent head and neck squamous cell carcinoma investigating combining an ATR kinase inhibitor BAY1895344 with pembrolizumab and stereotactic body radiotherapy (SBRT) (<a id="__tag_1115971807" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT04576091" ref="reftype=extlink-clinical-trial&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT04576091","term_id":"NCT04576091"}}</span>NCT04576091</a>) represents one such promising approach.</p></div><div id="s4_4" class="sec sec-last"><h3 id="s4_4title">4.4 Radiotherapy planning, modality and scheduling with DDR delivery</h3><p class="p p-first">In some occasions, radiotherapy can result in the regression of disease outside of the irradiated field in the so-called abscopal effect, which is thought to be immune-mediated (<a href="#B314" rid="B314" class=" bibr popnode">314</a>). Inducing such systemic anti-tumour immune responses is likely highly dependent on radiotherapy dose and fractionation and these factors, therefore, need to be an important consideration in combination treatments with DDR agents and/or ICI (<a href="#B315" rid="B315" class=" bibr popnode">315</a>).</p><p>Irradiation of regional lymph nodes in cancer treatment is common practice either with high doses in macroscopic disease or prophylactic lower doses, if lymph nodes are deemed to be at risk of harbouring micrometastatic disease. This approach has recently become more controversial given that we know these lymphoid organs have an important role in DC-mediated T-cell priming, activation and subsequent tumour infiltration following radiotherapy (<a href="#B31" rid="B31" class=" bibr popnode">31</a>). Routine irradiation of regional lymph nodes may potentially deplete important immune cells and have a detrimental effect on the anti-tumour immune response (<a href="#B316" rid="B316" class=" bibr popnode">316</a>).</p><p>The biological effects of radiotherapy, such as DNA damage complexity, depend on radiation quality and degree of linear energy transfer (LET). High LET radiation (e.g. protons, carbon ions, <em>&#x003b1;</em>-particle-emitting radionuclides) can differentially affect cell fate (<a href="#B317" rid="B317" class=" bibr popnode">317</a>). For example, protons mainly induce apoptosis not necrosis which may reduce the leakage of nucleic acids into the cytoplasm to serve as danger signals, hence impacting on the innate immune response (<a href="#B317" rid="B317" class=" bibr popnode">317</a>). The effects of radiotherapy were previously thought to be mainly due to nuclear DNA damage and their repair mechanisms. However, the outcome of irradiation depends also on the activation and regulation of other organelles that determine cellular metabolism, survival and immunological responses such as the mitochondria (<a href="#B318" rid="B318" class=" bibr popnode">318</a>). Recent studies have shown that mitochondrial DNA DSBs activate a type I IFN response and mitochondrial RNA release into the cytoplasm triggers a RIG-I-MAVS-dependent immune response (<a href="#B319" rid="B319" class=" bibr popnode">319</a>, <a href="#B320" rid="B320" class=" bibr popnode">320</a>). Low-dose versus high-dose radiation, as well as radiation quality, can also have different effects on mitochondria-mediated innate and adaptive immune responses (<a href="#B318" rid="B318" class=" bibr popnode">318</a>). Interestingly, high LET particle radiotherapy which are more efficient in ROS production is reportedly more likely to lead to mitochondria-mediated apoptosis and anti-tumour immune responses (<a href="#B318" rid="B318" class=" bibr popnode">318</a>, <a href="#B321" rid="B321" class=" bibr popnode">321</a>).</p><p class="p p-last">The most appropriate scheduling of DDR agents with respect to radiotherapy also needs to be investigated further. For example, a study investigating a novel TLR7/8 agonist in combination with radiotherapy showed that the optimal combination efficacy required the drug to be administered concurrently at the start rather than end of radiotherapy (<a href="#B98" rid="B98" class=" bibr popnode">98</a>). However, another investigation of a TLR9 agonist showed maximum synergy was observed when mice received the agent three days after radiotherapy in the adjuvant setting (<a href="#B102" rid="B102" class=" bibr popnode">102</a>). Clinical trials investigating TLR3 agonists used in the concurrent or adjuvant setting with respect to radiotherapy both showed activity (<a href="#B258" rid="B258" class=" bibr popnode">258</a>, <a href="#B260" rid="B260" class=" bibr popnode">260</a>, <a href="#B261" rid="B261" class=" bibr popnode">261</a>, <a href="#B322" rid="B322" class=" bibr popnode">322</a>). More preclinical studies investigating the biological basis of optimal scheduling are required, although it may be that optimal scheduling may ultimately be both treatment- and tumour-specific.</p></div></div><div id="s5" class="tsec sec"><h2 class="head no_bottom_margin" id="s5title">5 Conclusion</h2><p class="p p-first-last">Our increasing knowledge of the mechanisms of how radiotherapy-induced DDR interacts intimately with the host immune response is critical to the discovery of novel therapeutic targets and effective strategies against cancer. DDR-targeted agents are an exciting avenue for overcoming radioresistance and improving patient outcomes through enhancement of anti-tumour immunity. Understanding the molecular mechanisms and immunological effects of these DDR agents, through rigorous preclinical testing and translational analyses, is key to guiding rational clinical trial design in terms of drug route of delivery, schedules and choice of additional combination treatments, such as chemotherapy or immunotherapy.</p></div><div id="s6" class="tsec sec"><h2 class="head no_bottom_margin" id="s6title">Author contributions</h2><p class="p p-first-last">CC conceptualised this review and drafted the manuscript. AR, EP, MP, AM and KH contributed to the writing and critical revision of this article. All authors contributed to the article and approved the submitted version.</p></div><div id="s7" class="tsec sec"><h2 class="head no_bottom_margin" id="s7title">Funding</h2><p class="p p-first-last">This work was supported by the Wellcome Trust,&#x000a0;ICR/RM NIHR Biomedical Research Centre, The Institute of Cancer Research/Royal Marsden Hospital Centre for Translational Immunotherapy,&#x000a0;CRUK Head and Neck Programme Grant (C7224/A23275)&#x000a0;and ICR/RM CRUK&#x000a0;RadNet Centre of Excellence (C7224/A28724).</p></div><div id="s8" class="tsec sec"><h2 class="head no_bottom_margin" id="s8title">Conflict of interest</h2><p class="p p-first-last">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></div><div id="s9" class="tsec sec"><h2 class="head no_bottom_margin" id="s9title">Publisher&#x02019;s note</h2><p class="p p-first-last">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></div><div id="ref-list-a.j.a" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.j.atitle">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="B1">1. <span class="mixed-citation">
Delaney G, Jacob S, Featherstone C, Barton M. <span class="ref-title">The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines</span>. <span class="ref-journal">Cancer</span> (2005) <span class="ref-vol">104</span>(<span class="ref-iss">6</span>):1129&#x02013;37. doi: 10.1002/cncr.21324
 [<a href="https://pubmed.ncbi.nlm.nih.gov/16080176" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fcncr.21324" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=The+role+of+radiotherapy+in+cancer+treatment:+estimating+optimal+utilization+from+a+review+of+evidence-based+clinical+guidelines&amp;author=G+Delaney&amp;author=S+Jacob&amp;author=C+Featherstone&amp;author=M+Barton&amp;volume=104&amp;issue=6&amp;publication_year=2005&amp;doi=10.1002/cncr.21324&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B2">2. <span class="mixed-citation">
Verheij M. <span class="ref-title">Clinical biomarkers and imaging for radiotherapy-induced cell death</span>. <span class="ref-journal">Cancer Metastasis Rev</span> (2008) <span class="ref-vol">27</span>(<span class="ref-iss">3</span>):471&#x02013;80. doi: 10.1007/s10555-008-9131-1
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18470482" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs10555-008-9131-1" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Metastasis+Rev&amp;title=Clinical+biomarkers+and+imaging+for+radiotherapy-induced+cell+death&amp;author=M+Verheij&amp;volume=27&amp;issue=3&amp;publication_year=2008&amp;doi=10.1007/s10555-008-9131-1&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B3">3. <span class="mixed-citation">
Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A. <span class="ref-title">Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy</span>. <span class="ref-journal">Cancer Res</span> (2008) <span class="ref-vol">68</span>(<span class="ref-iss">5</span>):1485&#x02013;94. doi: 10.1158/0008-5472.CAN-07-0562
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18316613" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-07-0562" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Blocked+autophagy+sensitizes+resistant+carcinoma+cells+to+radiation+therapy&amp;author=A+Apel&amp;author=I+Herr&amp;author=H+Schwarz&amp;author=HP+Rodemann&amp;author=A+Mayer&amp;volume=68&amp;issue=5&amp;publication_year=2008&amp;doi=10.1158/0008-5472.CAN-07-0562&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B4">4. <span class="mixed-citation">
Maier P, Hartmann L, Wenz F, Herskind C. <span class="ref-title">Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization</span>. <span class="ref-journal">Int J Mol Sci</span> (2016) <span class="ref-vol">17</span>(<span class="ref-iss">1</span>). doi: 10.3390/ijms17010102
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4730344/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26784176" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fijms17010102" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Mol+Sci&amp;title=Cellular+pathways+in+response+to+ionizing+radiation+and+their+targetability+for+tumor+radiosensitization&amp;author=P+Maier&amp;author=L+Hartmann&amp;author=F+Wenz&amp;author=C+Herskind&amp;volume=17&amp;issue=1&amp;publication_year=2016&amp;doi=10.3390/ijms17010102&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B5">5. <span class="mixed-citation">
Withers HR. <span class="ref-title">The four r&#x02019;s of radiotherapy</span>. In: Lett JTAH, editor. <span class="ref-journal">Advances in radiation biology</span>. New York: Academic Press;  (1975). <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Advances+in+radiation+biology&amp;author=HR+Withers&amp;publication_year=1975&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B6">6. <span class="mixed-citation">
Steel GG, McMillan TJ, Peacock JH. <span class="ref-title">The 5Rs of radiobiology</span>. <span class="ref-journal">Int J Radiat Biol</span> (1989) <span class="ref-vol">56</span>(<span class="ref-iss">6</span>):1045&#x02013;8. doi: 10.1080/09553008914552491
 [<a href="https://pubmed.ncbi.nlm.nih.gov/2574214" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F09553008914552491" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Radiat+Biol&amp;title=The+5Rs+of+radiobiology&amp;author=GG+Steel&amp;author=TJ+McMillan&amp;author=JH+Peacock&amp;volume=56&amp;issue=6&amp;publication_year=1989&amp;doi=10.1080/09553008914552491&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B7">7. <span class="mixed-citation">
Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. <span class="ref-title">Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death</span>. <span class="ref-journal">Oncoimmunology</span> (2014) <span class="ref-vol">3</span>:e28518. doi: 10.4161/onci.28518
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4106151/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25071979" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4161%2Fonci.28518" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=Radiation+fosters+dose-dependent+and+chemotherapy-induced+immunogenic+cell+death&amp;author=EB+Golden&amp;author=D+Frances&amp;author=I+Pellicciotta&amp;author=S+Demaria&amp;author=M+Helen+Barcellos-Hoff&amp;volume=3&amp;publication_year=2014&amp;pages=e28518&amp;pmid=25071979&amp;doi=10.4161/onci.28518&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B8">8. <span class="mixed-citation">
McLaughlin M, Patin EC, Pedersen M, Wilkins A, Dillon MT, Melcher AA, et al.. <span class="ref-title">Inflammatory microenvironment remodelling by tumour cells after radiotherapy</span>. <span class="ref-journal">Nat Rev Cancer</span> (2020) <span class="ref-vol">20</span>(<span class="ref-iss">4</span>):203&#x02013;17. doi: 10.1038/s41568-020-0246-1
 [<a href="https://pubmed.ncbi.nlm.nih.gov/32161398" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41568-020-0246-1" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&amp;title=Inflammatory+microenvironment+remodelling+by+tumour+cells+after+radiotherapy&amp;author=M+McLaughlin&amp;author=EC+Patin&amp;author=M+Pedersen&amp;author=A+Wilkins&amp;author=MT+Dillon&amp;volume=20&amp;issue=4&amp;publication_year=2020&amp;doi=10.1038/s41568-020-0246-1&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B9">9. <span class="mixed-citation">
Hanahan D, Weinberg RA. <span class="ref-title">Hallmarks of cancer: the next generation</span>. <span class="ref-journal">Cell</span> (2011) <span class="ref-vol">144</span>(<span class="ref-iss">5</span>):646&#x02013;74. doi: 10.1016/j.cell.2011.02.013
 [<a href="https://pubmed.ncbi.nlm.nih.gov/21376230" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cell.2011.02.013" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Hallmarks+of+cancer:+the+next+generation&amp;author=D+Hanahan&amp;author=RA+Weinberg&amp;volume=144&amp;issue=5&amp;publication_year=2011&amp;doi=10.1016/j.cell.2011.02.013&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B10">10. <span class="mixed-citation">
Hanahan D, Weinberg RA. <span class="ref-title">The hallmarks of cancer</span>. <span class="ref-journal">Cell</span> (2000) <span class="ref-vol">100</span>(<span class="ref-iss">1</span>):57&#x02013;70. doi: 10.1016/S0092-8674(00)81683-9
 [<a href="https://pubmed.ncbi.nlm.nih.gov/10647931" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS0092-8674(00)81683-9" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=The+hallmarks+of+cancer&amp;author=D+Hanahan&amp;author=RA+Weinberg&amp;volume=100&amp;issue=1&amp;publication_year=2000&amp;pages=57-70&amp;pmid=10647931&amp;doi=10.1016/S0092-8674(00)81683-9&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B11">11. <span class="mixed-citation">
Jackson SP, Bartek J. <span class="ref-title">The DNA-damage response in human biology and disease</span>. <span class="ref-journal">Nature</span> (2009) <span class="ref-vol">461</span>(<span class="ref-iss">7267</span>):1071&#x02013;8. doi: 10.1038/nature08467
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2906700/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19847258" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnature08467" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=The+DNA-damage+response+in+human+biology+and+disease&amp;author=SP+Jackson&amp;author=J+Bartek&amp;volume=461&amp;issue=7267&amp;publication_year=2009&amp;doi=10.1038/nature08467&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B12">12. <span class="mixed-citation">
Matzinger P. <span class="ref-title">Tolerance, danger, and the extended family</span>. <span class="ref-journal">Annu Rev Immunol</span> (1994) <span class="ref-vol">12</span>:991&#x02013;1045. doi: 10.1146/annurev.iy.12.040194.005015
 [<a href="https://pubmed.ncbi.nlm.nih.gov/8011301" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1146%2Fannurev.iy.12.040194.005015" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annu+Rev+Immunol&amp;title=Tolerance,+danger,+and+the+extended+family&amp;author=P+Matzinger&amp;volume=12&amp;publication_year=1994&amp;pages=991-1045&amp;pmid=8011301&amp;doi=10.1146/annurev.iy.12.040194.005015&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B13">13. <span class="mixed-citation">
Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. <span class="ref-title">Immunogenic cell death and DAMPs in cancer therapy</span>. <span class="ref-journal">Nat Rev Cancer</span> (2012) <span class="ref-vol">12</span>(<span class="ref-iss">12</span>):860&#x02013;75. doi: 10.1038/nrc3380
 [<a href="https://pubmed.ncbi.nlm.nih.gov/23151605" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnrc3380" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&amp;title=Immunogenic+cell+death+and+DAMPs+in+cancer+therapy&amp;author=DV+Krysko&amp;author=AD+Garg&amp;author=A+Kaczmarek&amp;author=O+Krysko&amp;author=P+Agostinis&amp;volume=12&amp;issue=12&amp;publication_year=2012&amp;doi=10.1038/nrc3380&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B14">14. <span class="mixed-citation">
Schaue D, McBride WH. <span class="ref-title">Links between innate immunity and normal tissue radiobiology</span>. <span class="ref-journal">Radiat Res</span> (2010) <span class="ref-vol">173</span>(<span class="ref-iss">4</span>):406&#x02013;17. doi: 10.1667/RR1931.1
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2865470/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20334512" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1667%2FRR1931.1" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Radiat+Res&amp;title=Links+between+innate+immunity+and+normal+tissue+radiobiology&amp;author=D+Schaue&amp;author=WH+McBride&amp;volume=173&amp;issue=4&amp;publication_year=2010&amp;doi=10.1667/RR1931.1&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B15">15. <span class="mixed-citation">
Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. <span class="ref-title">Immunogenic cell death in cancer therapy: Present and emerging inducers</span>. <span class="ref-journal">J Cell Mol Med</span> (2019) <span class="ref-vol">23</span>(<span class="ref-iss">8</span>):4854&#x02013;65. doi: 10.1111/jcmm.14356
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6653385/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31210425" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fjcmm.14356" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Cell+Mol+Med&amp;title=Immunogenic+cell+death+in+cancer+therapy:+Present+and+emerging+inducers&amp;author=J+Zhou&amp;author=G+Wang&amp;author=Y+Chen&amp;author=H+Wang&amp;author=Y+Hua&amp;volume=23&amp;issue=8&amp;publication_year=2019&amp;doi=10.1111/jcmm.14356&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B16">16. <span class="mixed-citation">
Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al.. <span class="ref-title">Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells</span>. <span class="ref-journal">Immunity</span> (2013) <span class="ref-vol">38</span>(<span class="ref-iss">4</span>):729&#x02013;41. doi: 10.1016/j.immuni.2013.03.003
 [<a href="https://pubmed.ncbi.nlm.nih.gov/23562161" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.immuni.2013.03.003" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=Anticancer+chemotherapy-induced+intratumoral+recruitment+and+differentiation+of+antigen-presenting+cells&amp;author=Y+Ma&amp;author=S+Adjemian&amp;author=SR+Mattarollo&amp;author=T+Yamazaki&amp;author=L+Aymeric&amp;volume=38&amp;issue=4&amp;publication_year=2013&amp;doi=10.1016/j.immuni.2013.03.003&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B17">17. <span class="mixed-citation">
Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, et al.. <span class="ref-title">ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy</span>. <span class="ref-journal">Oncoimmunology</span> (2013) <span class="ref-vol">2</span>(<span class="ref-iss">6</span>):e24568. doi: 10.4161/onci.24568
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3716753/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23894718" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4161%2Fonci.24568" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=ATP-dependent+recruitment,+survival+and+differentiation+of+dendritic+cell+precursors+in+the+tumor+bed+after+anticancer+chemotherapy&amp;author=Y+Ma&amp;author=S+Adjemian&amp;author=H+Yang&amp;author=JP+Catani&amp;author=D+Hannani&amp;volume=2&amp;issue=6&amp;publication_year=2013&amp;pages=e24568&amp;pmid=23894718&amp;doi=10.4161/onci.24568&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B18">18. <span class="mixed-citation">
Kono K, Mimura K. <span class="ref-title">Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting</span>. <span class="ref-journal">Oncoimmunology</span> (2013) <span class="ref-vol">2</span>(<span class="ref-iss">1</span>):e22197. doi: 10.4161/onci.22197
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3583908/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23482346" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4161%2Fonci.22197" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=Immunogenic+tumor+cell+death+induced+by+chemoradiotherapy+in+a+clinical+setting&amp;author=K+Kono&amp;author=K+Mimura&amp;volume=2&amp;issue=1&amp;publication_year=2013&amp;pages=e22197&amp;pmid=23482346&amp;doi=10.4161/onci.22197&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B19">19. <span class="mixed-citation">
Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. <span class="ref-title">Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing</span>. <span class="ref-journal">Oncotarget</span> (2014) <span class="ref-vol">5</span>(<span class="ref-iss">2</span>):403&#x02013;16. doi: 10.18632/oncotarget.1719
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3964216/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24480782" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.18632%2Foncotarget.1719" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Radiation-induced+immunogenic+modulation+of+tumor+enhances+antigen+processing+and+calreticulin+exposure,+resulting+in+enhanced+T-cell+killing&amp;author=SR+Gameiro&amp;author=ML+Jammeh&amp;author=MM+Wattenberg&amp;author=KY+Tsang&amp;author=S+Ferrone&amp;volume=5&amp;issue=2&amp;publication_year=2014&amp;doi=10.18632/oncotarget.1719&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B20">20. <span class="mixed-citation">
Lhuillier C, Rudqvist NP, Elemento O, Formenti SC, Demaria S. <span class="ref-title">Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system</span>. <span class="ref-journal">Genome Med</span> (2019) <span class="ref-vol">11</span>(<span class="ref-iss">1</span>):40. doi: 10.1186/s13073-019-0653-7
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6587285/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31221199" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs13073-019-0653-7" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Genome+Med&amp;title=Radiation+therapy+and+anti-tumor+immunity:+exposing+immunogenic+mutations+to+the+immune+system&amp;author=C+Lhuillier&amp;author=NP+Rudqvist&amp;author=O+Elemento&amp;author=SC+Formenti&amp;author=S+Demaria&amp;volume=11&amp;issue=1&amp;publication_year=2019&amp;pages=40&amp;pmid=31221199&amp;doi=10.1186/s13073-019-0653-7&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B21">21. <span class="mixed-citation">
Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, et al.. <span class="ref-title">Molecular and translational classifications of DAMPs in immunogenic cell death</span>. <span class="ref-journal">Front Immunol</span> (2015) <span class="ref-vol">6</span>:588. doi: 10.3389/fimmu.2015.00588
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4653610/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26635802" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffimmu.2015.00588" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Immunol&amp;title=Molecular+and+translational+classifications+of+DAMPs+in+immunogenic+cell+death&amp;author=AD+Garg&amp;author=L+Galluzzi&amp;author=L+Apetoh&amp;author=T+Baert&amp;author=RB+Birge&amp;volume=6&amp;publication_year=2015&amp;pages=588&amp;pmid=26635802&amp;doi=10.3389/fimmu.2015.00588&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B22">22. <span class="mixed-citation">
Sprung CN, Forrester HB, Siva S, Martin OA. <span class="ref-title">Immunological markers that predict radiation toxicity</span>. <span class="ref-journal">Cancer Lett</span> (2015) <span class="ref-vol">368</span>(<span class="ref-iss">2</span>):191&#x02013;7. doi: 10.1016/j.canlet.2015.01.045
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25681035" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.canlet.2015.01.045" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Lett&amp;title=Immunological+markers+that+predict+radiation+toxicity&amp;author=CN+Sprung&amp;author=HB+Forrester&amp;author=S+Siva&amp;author=OA+Martin&amp;volume=368&amp;issue=2&amp;publication_year=2015&amp;doi=10.1016/j.canlet.2015.01.045&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B23">23. <span class="mixed-citation">
Ozsoy HZ, Sivasubramanian N, Wieder ED, Pedersen S, Mann DL. <span class="ref-title">Oxidative stress promotes ligand-independent and enhanced ligand-dependent tumor necrosis factor receptor signaling</span>. <span class="ref-journal">J Biol Chem</span> (2008) <span class="ref-vol">283</span>(<span class="ref-iss">34</span>):23419&#x02013;28. doi: 10.1074/jbc.M802967200
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2516989/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18544535" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1074%2Fjbc.M802967200" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Oxidative+stress+promotes+ligand-independent+and+enhanced+ligand-dependent+tumor+necrosis+factor+receptor+signaling&amp;author=HZ+Ozsoy&amp;author=N+Sivasubramanian&amp;author=ED+Wieder&amp;author=S+Pedersen&amp;author=DL+Mann&amp;volume=283&amp;issue=34&amp;publication_year=2008&amp;doi=10.1074/jbc.M802967200&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B24">24. <span class="mixed-citation">
Schaue D, Xie MW, Ratikan JA, McBride WH. <span class="ref-title">Regulatory T cells in radiotherapeutic responses</span>. <span class="ref-journal">Front Oncol</span> (2012) <span class="ref-vol">2</span>:90. doi: 10.3389/fonc.2012.00090
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3421147/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22912933" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffonc.2012.00090" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Oncol&amp;title=Regulatory+T+cells+in+radiotherapeutic+responses&amp;author=D+Schaue&amp;author=MW+Xie&amp;author=JA+Ratikan&amp;author=WH+McBride&amp;volume=2&amp;publication_year=2012&amp;pages=90&amp;pmid=22912933&amp;doi=10.3389/fonc.2012.00090&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B25">25. <span class="mixed-citation">
Jia S, Ge S, Fan X, Leong KW, Ruan J. <span class="ref-title">Promoting reactive oxygen species generation: a key strategy in nanosensitizer-mediated radiotherapy</span>. <span class="ref-journal">Nanomed (Lond)</span> (2021) <span class="ref-vol">16</span>(<span class="ref-iss">9</span>):759&#x02013;78. doi: 10.2217/nnm-2020-0448
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33856241" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2217%2Fnnm-2020-0448" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nanomed+(Lond)&amp;title=Promoting+reactive+oxygen+species+generation:+a+key+strategy+in+nanosensitizer-mediated+radiotherapy&amp;author=S+Jia&amp;author=S+Ge&amp;author=X+Fan&amp;author=KW+Leong&amp;author=J+Ruan&amp;volume=16&amp;issue=9&amp;publication_year=2021&amp;doi=10.2217/nnm-2020-0448&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B26">26. <span class="mixed-citation">
Barker HE, Paget JT, Khan AA, Harrington KJ. <span class="ref-title">The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence</span>. <span class="ref-journal">Nat Rev Cancer</span> (2015) <span class="ref-vol">15</span>(<span class="ref-iss">7</span>):409&#x02013;25. doi: 10.1038/nrc3958
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4896389/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26105538" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnrc3958" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&amp;title=The+tumour+microenvironment+after+radiotherapy:+mechanisms+of+resistance+and+recurrence&amp;author=HE+Barker&amp;author=JT+Paget&amp;author=AA+Khan&amp;author=KJ+Harrington&amp;volume=15&amp;issue=7&amp;publication_year=2015&amp;doi=10.1038/nrc3958&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B27">27. <span class="mixed-citation">
Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, et al.. <span class="ref-title">Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells</span>. <span class="ref-journal">J Immunol</span> (2008) <span class="ref-vol">181</span>(<span class="ref-iss">5</span>):3099&#x02013;107. doi: 10.4049/jimmunol.181.5.3099
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2587101/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18713980" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.181.5.3099" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Radiation-induced+CXCL16+release+by+breast+cancer+cells+attracts+effector+T+cells&amp;author=S+Matsumura&amp;author=B+Wang&amp;author=N+Kawashima&amp;author=S+Braunstein&amp;author=M+Badura&amp;volume=181&amp;issue=5&amp;publication_year=2008&amp;doi=10.4049/jimmunol.181.5.3099&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B28">28. <span class="mixed-citation">
Banchereau J, Steinman RM. <span class="ref-title">Dendritic cells and the control of immunity</span>. <span class="ref-journal">Nature</span> (1998) <span class="ref-vol">392</span>(<span class="ref-iss">6673</span>):245&#x02013;52. doi: 10.1038/32588
 [<a href="https://pubmed.ncbi.nlm.nih.gov/9521319" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2F32588" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Dendritic+cells+and+the+control+of+immunity&amp;author=J+Banchereau&amp;author=RM+Steinman&amp;volume=392&amp;issue=6673&amp;publication_year=1998&amp;doi=10.1038/32588&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B29">29. <span class="mixed-citation">
Wilkins AC, Patin EC, Harrington KJ, Melcher AA. <span class="ref-title">The immunological consequences of radiation-induced DNA damage</span>. <span class="ref-journal">J Pathol</span> (2019) <span class="ref-vol">247</span>(<span class="ref-iss">5</span>):606&#x02013;14. doi: 10.1002/path.5232
 [<a href="https://pubmed.ncbi.nlm.nih.gov/30632153" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fpath.5232" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Pathol&amp;title=The+immunological+consequences+of+radiation-induced+DNA+damage&amp;author=AC+Wilkins&amp;author=EC+Patin&amp;author=KJ+Harrington&amp;author=AA+Melcher&amp;volume=247&amp;issue=5&amp;publication_year=2019&amp;doi=10.1002/path.5232&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B30">30. <span class="mixed-citation">
Rudqvist NP, Pilones KA, Lhuillier C, Wennerberg E, Sidhom JW, Emerson RO, et al.. <span class="ref-title">Radiotherapy and CTLA-4 blockade shape the TCR repertoire of tumor-infiltrating T cells</span>. <span class="ref-journal">Cancer Immunol Res</span> (2018) <span class="ref-vol">6</span>(<span class="ref-iss">2</span>):139&#x02013;50. doi: 10.1158/2326-6066.CIR-17-0134
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6020019/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29180535" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F2326-6066.CIR-17-0134" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Immunol+Res&amp;title=Radiotherapy+and+CTLA-4+blockade+shape+the+TCR+repertoire+of+tumor-infiltrating+T+cells&amp;author=NP+Rudqvist&amp;author=KA+Pilones&amp;author=C+Lhuillier&amp;author=E+Wennerberg&amp;author=JW+Sidhom&amp;volume=6&amp;issue=2&amp;publication_year=2018&amp;doi=10.1158/2326-6066.CIR-17-0134&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B31">31. <span class="mixed-citation">
Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, et al.. <span class="ref-title">Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade</span>. <span class="ref-journal">Clin Cancer Res</span> (2017) <span class="ref-vol">23</span>(<span class="ref-iss">18</span>):5514&#x02013;26. doi: 10.1158/1078-0432.CCR-16-1673
 [<a href="https://pubmed.ncbi.nlm.nih.gov/28533222" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-16-1673" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Fractionated+radiation+therapy+stimulates+antitumor+immunity+mediated+by+both+resident+and+infiltrating+polyclonal+T-cell+populations+when+combined+with+PD-1+blockade&amp;author=SJ+Dovedi&amp;author=EJ+Cheadle&amp;author=AL+Popple&amp;author=E+Poon&amp;author=M+Morrow&amp;volume=23&amp;issue=18&amp;publication_year=2017&amp;doi=10.1158/1078-0432.CCR-16-1673&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B32">32. <span class="mixed-citation">
Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al.. <span class="ref-title">Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer</span>. <span class="ref-journal">Nature</span> (2015) <span class="ref-vol">520</span>(<span class="ref-iss">7547</span>):373&#x02013;7. doi: 10.1038/nature14292
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4401634/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25754329" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnature14292" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Radiation+and+dual+checkpoint+blockade+activate+non-redundant+immune+mechanisms+in+cancer&amp;author=C+Twyman-Saint+Victor&amp;author=AJ+Rech&amp;author=A+Maity&amp;author=R+Rengan&amp;author=KE+Pauken&amp;volume=520&amp;issue=7547&amp;publication_year=2015&amp;doi=10.1038/nature14292&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B33">33. <span class="mixed-citation">
Philip M, Rowley DA, Schreiber H. <span class="ref-title">Inflammation as a tumor promoter in cancer induction</span>. <span class="ref-journal">Semin Cancer Biol</span> (2004) <span class="ref-vol">14</span>(<span class="ref-iss">6</span>):433&#x02013;9. doi: 10.1016/j.semcancer.2004.06.006
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15489136" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.semcancer.2004.06.006" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Semin+Cancer+Biol&amp;title=Inflammation+as+a+tumor+promoter+in+cancer+induction&amp;author=M+Philip&amp;author=DA+Rowley&amp;author=H+Schreiber&amp;volume=14&amp;issue=6&amp;publication_year=2004&amp;doi=10.1016/j.semcancer.2004.06.006&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B34">34. <span class="mixed-citation">
Lin WW, Karin M. <span class="ref-title">A cytokine-mediated link between innate immunity, inflammation, and cancer</span>. <span class="ref-journal">J Clin Invest</span> (2007) <span class="ref-vol">117</span>(<span class="ref-iss">5</span>):1175&#x02013;83. doi: 10.1172/JCI31537
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1857251/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17476347" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1172%2FJCI31537" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Invest&amp;title=A+cytokine-mediated+link+between+innate+immunity,+inflammation,+and+cancer&amp;author=WW+Lin&amp;author=M+Karin&amp;volume=117&amp;issue=5&amp;publication_year=2007&amp;doi=10.1172/JCI31537&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B35">35. <span class="mixed-citation">
Li Q, Withoff S, Verma IM. <span class="ref-title">Inflammation-associated cancer: NF-kappaB is the lynchpin</span>. <span class="ref-journal">Trends Immunol</span> (2005) <span class="ref-vol">26</span>(<span class="ref-iss">6</span>):318&#x02013;25. doi: 10.1016/j.it.2005.04.003
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15922948" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.it.2005.04.003" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Trends+Immunol&amp;title=Inflammation-associated+cancer:+NF-kappaB+is+the+lynchpin&amp;author=Q+Li&amp;author=S+Withoff&amp;author=IM+Verma&amp;volume=26&amp;issue=6&amp;publication_year=2005&amp;doi=10.1016/j.it.2005.04.003&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B36">36. <span class="mixed-citation">
Dunn GP, Old LJ, Schreiber RD. <span class="ref-title">The three Es of cancer immunoediting</span>. <span class="ref-journal">Annu Rev Immunol</span> (2004) <span class="ref-vol">22</span>:329&#x02013;60. doi: 10.1146/annurev.immunol.22.012703.104803
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15032581" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1146%2Fannurev.immunol.22.012703.104803" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annu+Rev+Immunol&amp;title=The+three+Es+of+cancer+immunoediting&amp;author=GP+Dunn&amp;author=LJ+Old&amp;author=RD+Schreiber&amp;volume=22&amp;publication_year=2004&amp;doi=10.1146/annurev.immunol.22.012703.104803&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B37">37. <span class="mixed-citation">
Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, et al.. <span class="ref-title">A systemic complete response of metastatic melanoma to local radiation and immunotherapy</span>. <span class="ref-journal">Transl Oncol</span> (2012) <span class="ref-vol">5</span>(<span class="ref-iss">6</span>):404&#x02013;7. doi:&#x000a0; 10.1593/tlo.12280
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3542835/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23323154" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1593%2Ftlo.12280" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Transl+Oncol&amp;title=A+systemic+complete+response+of+metastatic+melanoma+to+local+radiation+and+immunotherapy&amp;author=SM+Hiniker&amp;author=DS+Chen&amp;author=S+Reddy&amp;author=DT+Chang&amp;author=JC+Jones&amp;volume=5&amp;issue=6&amp;publication_year=2012&amp;doi=10.1593/tlo.12280&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B38">38. <span class="mixed-citation">
Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen HR, et al.. <span class="ref-title">Radiotherapy augments the immune response to prostate cancer in a time-dependent manner</span>. <span class="ref-journal">Prostate</span> (2008) <span class="ref-vol">68</span>(<span class="ref-iss">12</span>):1319&#x02013;29. doi:&#x000a0; 10.1002/pros.20794
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2710770/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18561247" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fpros.20794" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Prostate&amp;title=Radiotherapy+augments+the+immune+response+to+prostate+cancer+in+a+time-dependent+manner&amp;author=TJ+Harris&amp;author=EL+Hipkiss&amp;author=S+Borzillary&amp;author=S+Wada&amp;author=JF+Grosso&amp;volume=68&amp;issue=12&amp;publication_year=2008&amp;doi=10.1002/pros.20794&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B39">39. <span class="mixed-citation">
Laoui D, Van Overmeire E, De Baetselier P, Van Ginderachter JA, Raes G. <span class="ref-title">Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression</span>. <span class="ref-journal">Front Immunol</span> (2014) <span class="ref-vol">5</span>:489. doi:&#x000a0; 10.3389/fimmu.2014.00489
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4188035/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25339957" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffimmu.2014.00489" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Immunol&amp;title=Functional+relationship+between+tumor-associated+macrophages+and+macrophage+colony-stimulating+factor+as+contributors+to+cancer+progression&amp;author=D+Laoui&amp;author=E+Van+Overmeire&amp;author=P+De+Baetselier&amp;author=JA+Van+Ginderachter&amp;author=G+Raes&amp;volume=5&amp;publication_year=2014&amp;pages=489&amp;pmid=25339957&amp;doi=10.3389/fimmu.2014.00489&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B40">40. <span class="mixed-citation">
Kachikwu EL, Iwamoto KS, Liao YP, DeMarco JJ, Agazaryan N, Economou JS, et al.. <span class="ref-title">Radiation enhances regulatory T cell representation</span>. <span class="ref-journal">Int J Radiat Oncol Biol Phys</span> (2011) <span class="ref-vol">81</span>(<span class="ref-iss">4</span>):1128&#x02013;35. doi:&#x000a0; 10.1016/j.ijrobp.2010.09.034
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3117954/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21093169" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ijrobp.2010.09.034" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Radiat+Oncol+Biol+Phys&amp;title=Radiation+enhances+regulatory+T+cell+representation&amp;author=EL+Kachikwu&amp;author=KS+Iwamoto&amp;author=YP+Liao&amp;author=JJ+DeMarco&amp;author=N+Agazaryan&amp;volume=81&amp;issue=4&amp;publication_year=2011&amp;doi=10.1016/j.ijrobp.2010.09.034&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B41">41. <span class="mixed-citation">
Qu Y, Jin S, Zhang A, Zhang B, Shi X, Wang J, et al.. <span class="ref-title">Gamma-ray resistance of regulatory CD4+CD25+Foxp3+ T cells in mice</span>. <span class="ref-journal">Radiat Res</span> (2010) <span class="ref-vol">173</span>(<span class="ref-iss">2</span>):148&#x02013;57. doi:&#x000a0; 10.1667/RR0978.1
 [<a href="https://pubmed.ncbi.nlm.nih.gov/20095846" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1667%2FRR0978.1" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Radiat+Res&amp;title=Gamma-ray+resistance+of+regulatory+CD4+CD25+Foxp3++T+cells+in+mice&amp;author=Y+Qu&amp;author=S+Jin&amp;author=A+Zhang&amp;author=B+Zhang&amp;author=X+Shi&amp;volume=173&amp;issue=2&amp;publication_year=2010&amp;doi=10.1667/RR0978.1&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B42">42. <span class="mixed-citation">
Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al.. <span class="ref-title">Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade</span>. <span class="ref-journal">Cancer Res</span> (2014) <span class="ref-vol">74</span>(<span class="ref-iss">19</span>):5458&#x02013;68. doi: 10.1158/0008-5472.CAN-14-1258
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25274032" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-14-1258" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Acquired+resistance+to+fractionated+radiotherapy+can+be+overcome+by+concurrent+PD-L1+blockade&amp;author=SJ+Dovedi&amp;author=AL+Adlard&amp;author=G+Lipowska-Bhalla&amp;author=C+McKenna&amp;author=S+Jones&amp;volume=74&amp;issue=19&amp;publication_year=2014&amp;doi=10.1158/0008-5472.CAN-14-1258&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B43">43. <span class="mixed-citation">
Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, et al.. <span class="ref-title">Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming</span>. <span class="ref-journal">Cancer Res</span> (2016) <span class="ref-vol">76</span>(<span class="ref-iss">20</span>):5994&#x02013;6005. doi: 10.1158/0008-5472.CAN-16-0549
 [<a href="https://pubmed.ncbi.nlm.nih.gov/27550452" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-16-0549" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Abscopal+effects+of+radiotherapy+are+enhanced+by+combined+immunostimulatory+mAbs+and+are+dependent+on+CD8+T+cells+and+crosspriming&amp;author=ME+Rodriguez-Ruiz&amp;author=I+Rodriguez&amp;author=S+Garasa&amp;author=B+Barbes&amp;author=JL+Solorzano&amp;volume=76&amp;issue=20&amp;publication_year=2016&amp;pages=5994-6005&amp;pmid=27550452&amp;doi=10.1158/0008-5472.CAN-16-0549&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B44">44. <span class="mixed-citation">
Hsieh RC, Krishnan S, Wu RC, Boda AR, Liu A, Winkler M, et al.. <span class="ref-title">ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer</span>. <span class="ref-journal">Sci Immunol</span> (2022) <span class="ref-vol">7</span>(<span class="ref-iss">72</span>):eabl9330. doi: 10.1126/sciimmunol.abl9330
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9373855/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35687697" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fsciimmunol.abl9330" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Immunol&amp;title=ATR-mediated+CD47+and+PD-L1+up-regulation+restricts+radiotherapy-induced+immune+priming+and+abscopal+responses+in+colorectal+cancer&amp;author=RC+Hsieh&amp;author=S+Krishnan&amp;author=RC+Wu&amp;author=AR+Boda&amp;author=A+Liu&amp;volume=7&amp;issue=72&amp;publication_year=2022&amp;pages=eabl9330&amp;pmid=35687697&amp;doi=10.1126/sciimmunol.abl9330&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B45">45. <span class="mixed-citation">
Mantovani A, Romero P, Palucka AK, Marincola FM. <span class="ref-title">Tumour immunity: effector response to tumour and role of the microenvironment</span>. <span class="ref-journal">Lancet</span> (2008) <span class="ref-vol">371</span>(<span class="ref-iss">9614</span>):771&#x02013;83. doi: 10.1016/S0140-6736(08)60241-X
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18275997" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS0140-6736(08)60241-X" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Tumour+immunity:+effector+response+to+tumour+and+role+of+the+microenvironment&amp;author=A+Mantovani&amp;author=P+Romero&amp;author=AK+Palucka&amp;author=FM+Marincola&amp;volume=371&amp;issue=9614&amp;publication_year=2008&amp;doi=10.1016/S0140-6736(08)60241-X&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B46">46. <span class="mixed-citation">
Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J, et al.. <span class="ref-title">Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients</span>. <span class="ref-journal">Int J Radiat Oncol Biol Phys</span> (2012) <span class="ref-vol">82</span>(<span class="ref-iss">2</span>):924&#x02013;32. doi: 10.1016/j.ijrobp.2010.12.068
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4241354/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21398051" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ijrobp.2010.12.068" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Radiat+Oncol+Biol+Phys&amp;title=Combination+of+external+beam+radiotherapy+(EBRT)+with+intratumoral+injection+of+dendritic+cells+as+neo-adjuvant+treatment+of+high-risk+soft+tissue+sarcoma+patients&amp;author=SE+Finkelstein&amp;author=C+Iclozan&amp;author=MM+Bui&amp;author=MJ+Cotter&amp;author=R+Ramakrishnan&amp;volume=82&amp;issue=2&amp;publication_year=2012&amp;doi=10.1016/j.ijrobp.2010.12.068&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B47">47. <span class="mixed-citation">
Muroyama Y, Nirschl TR, Kochel CM, Lopez-Bujanda Z, Theodros D, Mao W, et al.. <span class="ref-title">Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment</span>. <span class="ref-journal">Cancer Immunol Res</span> (2017) <span class="ref-vol">5</span>(<span class="ref-iss">11</span>):992&#x02013;1004. doi: 10.1158/2326-6066.CIR-17-0040
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5793220/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28970196" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F2326-6066.CIR-17-0040" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Immunol+Res&amp;title=Stereotactic+radiotherapy+increases+functionally+suppressive+regulatory+T+cells+in+the+tumor+microenvironment&amp;author=Y+Muroyama&amp;author=TR+Nirschl&amp;author=CM+Kochel&amp;author=Z+Lopez-Bujanda&amp;author=D+Theodros&amp;volume=5&amp;issue=11&amp;publication_year=2017&amp;pages=992-1004&amp;pmid=28970196&amp;doi=10.1158/2326-6066.CIR-17-0040&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B48">48. <span class="mixed-citation">
Hellevik T, Pettersen I, Berg V, Winberg JO, Moe BT, Bartnes K, et al.. <span class="ref-title">Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced</span>. <span class="ref-journal">Radiat Oncol</span> (2012) <span class="ref-vol">7</span>:59. doi: 10.1186/1748-717X-7-59
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3359264/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22500976" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2F1748-717X-7-59" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Radiat+Oncol&amp;title=Cancer-associated+fibroblasts+from+human+NSCLC+survive+ablative+doses+of+radiation+but+their+invasive+capacity+is+reduced&amp;author=T+Hellevik&amp;author=I+Pettersen&amp;author=V+Berg&amp;author=JO+Winberg&amp;author=BT+Moe&amp;volume=7&amp;publication_year=2012&amp;pages=59&amp;pmid=22500976&amp;doi=10.1186/1748-717X-7-59&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B49">49. <span class="mixed-citation">
Mantoni TS, Lunardi S, Al-Assar O, Masamune A, Brunner TB. <span class="ref-title">Pancreatic stellate cells radioprotect pancreatic cancer cells through &#x003b2;1-integrin signaling</span>. <span class="ref-journal">Cancer Res</span> (2011) <span class="ref-vol">71</span>(<span class="ref-iss">10</span>):3453&#x02013;8. doi: 10.1158/0008-5472.CAN-10-1633
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3097171/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21558392" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-10-1633" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Pancreatic+stellate+cells+radioprotect+pancreatic+cancer+cells+through+&#x003b2;1-integrin+signaling&amp;author=TS+Mantoni&amp;author=S+Lunardi&amp;author=O+Al-Assar&amp;author=A+Masamune&amp;author=TB+Brunner&amp;volume=71&amp;issue=10&amp;publication_year=2011&amp;doi=10.1158/0008-5472.CAN-10-1633&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B50">50. <span class="mixed-citation">
Erez N, Truitt M, Olson P, Arron ST, Hanahan D. <span class="ref-title">Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-Dependent manner</span>. <span class="ref-journal">Cancer Cell</span> (2010) <span class="ref-vol">17</span>(<span class="ref-iss">2</span>):135&#x02013;47. doi: 10.1016/j.ccr.2009.12.041
 [<a href="https://pubmed.ncbi.nlm.nih.gov/20138012" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ccr.2009.12.041" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Cell&amp;title=Cancer-associated+fibroblasts+are+activated+in+incipient+neoplasia+to+orchestrate+tumor-promoting+inflammation+in+an+NF-kappaB-Dependent+manner&amp;author=N+Erez&amp;author=M+Truitt&amp;author=P+Olson&amp;author=ST+Arron&amp;author=D+Hanahan&amp;volume=17&amp;issue=2&amp;publication_year=2010&amp;doi=10.1016/j.ccr.2009.12.041&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B51">51. <span class="mixed-citation">
Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al.. <span class="ref-title">Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha</span>. <span class="ref-journal">Science</span> (2010) <span class="ref-vol">330</span>(<span class="ref-iss">6005</span>):827&#x02013;30. doi: 10.1126/science.1195300
 [<a href="https://pubmed.ncbi.nlm.nih.gov/21051638" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fscience.1195300" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Suppression+of+antitumor+immunity+by+stromal+cells+expressing+fibroblast+activation+protein-alpha&amp;author=M+Kraman&amp;author=PJ+Bambrough&amp;author=JN+Arnold&amp;author=EW+Roberts&amp;author=L+Magiera&amp;volume=330&amp;issue=6005&amp;publication_year=2010&amp;doi=10.1126/science.1195300&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B52">52. <span class="mixed-citation">
Kugeratski FG, Atkinson SJ, Neilson LJ, Lilla S, Knight JRP, Serneels J, et al.. <span class="ref-title">Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling</span>. <span class="ref-journal">Sci Signal</span> (2019) <span class="ref-vol">12</span>(<span class="ref-iss">567</span>):1&#x02013;33. doi: 10.1126/scisignal.aan8247
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6794160/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30723174" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fscisignal.aan8247" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Signal&amp;title=Hypoxic+cancer-associated+fibroblasts+increase+NCBP2-AS2/HIAR+to+promote+endothelial+sprouting+through+enhanced+VEGF+signaling&amp;author=FG+Kugeratski&amp;author=SJ+Atkinson&amp;author=LJ+Neilson&amp;author=S+Lilla&amp;author=JRP+Knight&amp;volume=12&amp;issue=567&amp;publication_year=2019&amp;pages=1-33&amp;doi=10.1126/scisignal.aan8247&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B53">53. <span class="mixed-citation">
Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. <span class="ref-title">Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model</span>. <span class="ref-journal">PloS One</span> (2009) <span class="ref-vol">4</span>(<span class="ref-iss">11</span>):e7965. doi: 10.1371/journal.pone.0007965
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2775953/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19956757" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1371%2Fjournal.pone.0007965" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PloS+One&amp;title=Cancer+associated+fibroblasts+promote+tumor+growth+and+metastasis+by+modulating+the+tumor+immune+microenvironment+in+a+4T1+murine+breast+cancer+model&amp;author=D+Liao&amp;author=Y+Luo&amp;author=D+Markowitz&amp;author=R+Xiang&amp;author=RA+Reisfeld&amp;volume=4&amp;issue=11&amp;publication_year=2009&amp;pages=e7965&amp;pmid=19956757&amp;doi=10.1371/journal.pone.0007965&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B54">54. <span class="mixed-citation">
Vigano S, Alatzoglou D, Irving M, M&#x000e9;n&#x000e9;trier-Caux C, Caux C, Romero P, et al.. <span class="ref-title">Targeting adenosine in cancer immunotherapy to enhance T-cell function</span>. <span class="ref-journal">Front Immunol</span> (2019) <span class="ref-vol">10</span>:925. doi: 10.3389/fimmu.2019.00925
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6562565/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31244820" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffimmu.2019.00925" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Immunol&amp;title=Targeting+adenosine+in+cancer+immunotherapy+to+enhance+T-cell+function&amp;author=S+Vigano&amp;author=D+Alatzoglou&amp;author=M+Irving&amp;author=C+M&#x000e9;n&#x000e9;trier-Caux&amp;author=C+Caux&amp;volume=10&amp;publication_year=2019&amp;pages=925&amp;pmid=31244820&amp;doi=10.3389/fimmu.2019.00925&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B55">55. <span class="mixed-citation">
Stagg J, Smyth MJ. <span class="ref-title">Extracellular adenosine triphosphate and adenosine in cancer</span>. <span class="ref-journal">Oncogene</span> (2010) <span class="ref-vol">29</span>(<span class="ref-iss">39</span>):5346&#x02013;58. doi: 10.1038/onc.2010.292
 [<a href="https://pubmed.ncbi.nlm.nih.gov/20661219" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fonc.2010.292" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Extracellular+adenosine+triphosphate+and+adenosine+in+cancer&amp;author=J+Stagg&amp;author=MJ+Smyth&amp;volume=29&amp;issue=39&amp;publication_year=2010&amp;doi=10.1038/onc.2010.292&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B56">56. <span class="mixed-citation">
Montalb&#x000e1;n Del Barrio I, Penski C, Schlahsa L, Stein RG, Diessner J, W&#x000f6;ckel A, et al.. <span class="ref-title">Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape</span>. <span class="ref-journal">J Immunother Cancer</span> (2016) <span class="ref-vol">4</span>:49. doi: 10.1186/s40425-016-0154-9
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4986205/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27532024" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs40425-016-0154-9" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunother+Cancer&amp;title=Adenosine-generating+ovarian+cancer+cells+attract+myeloid+cells+which+differentiate+into+adenosine-generating+tumor+associated+macrophages+-+a+self-amplifying,+CD39-+and+CD73-dependent+mechanism+for+tumor+immune+escape&amp;author=I+Montalb&#x000e1;n+Del+Barrio&amp;author=C+Penski&amp;author=L+Schlahsa&amp;author=RG+Stein&amp;author=J+Diessner&amp;volume=4&amp;publication_year=2016&amp;pages=49&amp;pmid=27532024&amp;doi=10.1186/s40425-016-0154-9&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B57">57. <span class="mixed-citation">
Li J, Wang L, Chen X, Li L, Li Y, Ping Y, et al.. <span class="ref-title">CD39/CD73 upregulation on myeloid-derived suppressor cells <em>via</em> TGF-&#x003b2;-mTOR-HIF-1 signaling in patients with non-small cell lung cancer</span>. <span class="ref-journal">Oncoimmunology</span> (2017) <span class="ref-vol">6</span>(<span class="ref-iss">6</span>):e1320011. doi: 10.1080/2162402X.2017.1320011
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5486179/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28680754" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F2162402X.2017.1320011" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=CD39/CD73+upregulation+on+myeloid-derived+suppressor+cells+via+TGF-&#x003b2;-mTOR-HIF-1+signaling+in+patients+with+non-small+cell+lung+cancer&amp;author=J+Li&amp;author=L+Wang&amp;author=X+Chen&amp;author=L+Li&amp;author=Y+Li&amp;volume=6&amp;issue=6&amp;publication_year=2017&amp;pages=e1320011&amp;pmid=28680754&amp;doi=10.1080/2162402X.2017.1320011&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B58">58. <span class="mixed-citation">
d'Almeida SM, Kauffenstein G, Roy C, Basset L, Papargyris L, Henrion D, et al.. <span class="ref-title">The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by m-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27</span>. <span class="ref-journal">Oncoimmunology</span> (2016) <span class="ref-vol">5</span>(<span class="ref-iss">7</span>):e1178025. doi: 10.1080/2162402X.2016.1178025
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5006905/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27622030" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F2162402X.2016.1178025" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=The+ecto-ATPDase+CD39+is+involved+in+the+acquisition+of+the+immunoregulatory+phenotype+by+m-CSF-macrophages+and+ovarian+cancer+tumor-associated+macrophages:+Regulatory+role+of+IL-27&amp;author=SM+d'Almeida&amp;author=G+Kauffenstein&amp;author=C+Roy&amp;author=L+Basset&amp;author=L+Papargyris&amp;volume=5&amp;issue=7&amp;publication_year=2016&amp;pages=e1178025&amp;pmid=27622030&amp;doi=10.1080/2162402X.2016.1178025&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B59">59. <span class="mixed-citation">
Hilchey SP, Kobie JJ, Cochran MR, Secor-Socha S, Wang JC, Hyrien O, et al.. <span class="ref-title">Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness</span>. <span class="ref-journal">J Immunol</span> (2009) <span class="ref-vol">183</span>(<span class="ref-iss">10</span>):6157&#x02013;66. doi: 10.4049/jimmunol.0900475
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2917799/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19864600" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.0900475" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Human+follicular+lymphoma+CD39+-infiltrating+T+cells+contribute+to+adenosine-mediated+T+cell+hyporesponsiveness&amp;author=SP+Hilchey&amp;author=JJ+Kobie&amp;author=MR+Cochran&amp;author=S+Secor-Socha&amp;author=JC+Wang&amp;volume=183&amp;issue=10&amp;publication_year=2009&amp;doi=10.4049/jimmunol.0900475&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B60">60. <span class="mixed-citation">
Gourdin N, Bossennec M, Rodriguez C, Vigano S, Machon C, Jandus C, et al.. <span class="ref-title">Autocrine adenosine regulates tumor polyfunctional CD73(+)CD4(+) effector T cells devoid of immune checkpoints</span>. <span class="ref-journal">Cancer Res</span> (2018) <span class="ref-vol">78</span>(<span class="ref-iss">13</span>):3604&#x02013;18. doi: 10.1158/0008-5472.CAN-17-2405
 [<a href="https://pubmed.ncbi.nlm.nih.gov/29559470" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-17-2405" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Autocrine+adenosine+regulates+tumor+polyfunctional+CD73(+)CD4(+)+effector+T+cells+devoid+of+immune+checkpoints&amp;author=N+Gourdin&amp;author=M+Bossennec&amp;author=C+Rodriguez&amp;author=S+Vigano&amp;author=C+Machon&amp;volume=78&amp;issue=13&amp;publication_year=2018&amp;doi=10.1158/0008-5472.CAN-17-2405&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B61">61. <span class="mixed-citation">
Canale FP, Ramello MC, N&#x000fa;&#x000f1;ez N, Araujo Furlan CL, Bossio SN, Gorosito Serr&#x000e1;n M, et al.. <span class="ref-title">CD39 expression defines cell exhaustion in tumor-infiltrating CD8(+) T cells</span>. <span class="ref-journal">Cancer Res</span> (2018) <span class="ref-vol">78</span>(<span class="ref-iss">1</span>):115&#x02013;28. doi: 10.1158/0008-5472.CAN-16-2684
 [<a href="https://pubmed.ncbi.nlm.nih.gov/29066514" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-16-2684" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=CD39+expression+defines+cell+exhaustion+in+tumor-infiltrating+CD8(+)+T+cells&amp;author=FP+Canale&amp;author=MC+Ramello&amp;author=N+N&#x000fa;&#x000f1;ez&amp;author=CL+Araujo+Furlan&amp;author=SN+Bossio&amp;volume=78&amp;issue=1&amp;publication_year=2018&amp;doi=10.1158/0008-5472.CAN-16-2684&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B62">62. <span class="mixed-citation">
Kim JJ, Tannock IF. <span class="ref-title">Repopulation of cancer cells during therapy: an important cause of treatment failure</span>. <span class="ref-journal">Nat Rev Cancer</span> (2005) <span class="ref-vol">5</span>(<span class="ref-iss">7</span>):516&#x02013;25. doi: 10.1038/nrc1650
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15965493" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnrc1650" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&amp;title=Repopulation+of+cancer+cells+during+therapy:+an+important+cause+of+treatment+failure&amp;author=JJ+Kim&amp;author=IF+Tannock&amp;volume=5&amp;issue=7&amp;publication_year=2005&amp;doi=10.1038/nrc1650&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B63">63. <span class="mixed-citation">
Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, et al.. <span class="ref-title">Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy</span>. <span class="ref-journal">Nat Med</span> (2011) <span class="ref-vol">17</span>(<span class="ref-iss">7</span>):860&#x02013;6. doi: 10.1038/nm.2385
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3132290/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21725296" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnm.2385" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Med&amp;title=Caspase+3-mediated+stimulation+of+tumor+cell+repopulation+during+cancer+radiotherapy&amp;author=Q+Huang&amp;author=F+Li&amp;author=X+Liu&amp;author=W+Li&amp;author=W+Shi&amp;volume=17&amp;issue=7&amp;publication_year=2011&amp;doi=10.1038/nm.2385&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B64">64. <span class="mixed-citation">
Vlashi E, Pajonk F. <span class="ref-title">Cancer stem cells, cancer cell plasticity and radiation therapy</span>. <span class="ref-journal">Semin Cancer Biol</span> (2015) <span class="ref-vol">31</span>:28&#x02013;35. doi: 10.1016/j.semcancer.2014.07.001
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4291301/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25025713" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.semcancer.2014.07.001" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Semin+Cancer+Biol&amp;title=Cancer+stem+cells,+cancer+cell+plasticity+and+radiation+therapy&amp;author=E+Vlashi&amp;author=F+Pajonk&amp;volume=31&amp;publication_year=2015&amp;pages=28-35&amp;pmid=25025713&amp;doi=10.1016/j.semcancer.2014.07.001&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B65">65. <span class="mixed-citation">
Lagadec C, Vlashi E, Della Donna L, Meng Y, Dekmezian C, Kim K, et al.. <span class="ref-title">Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment</span>. <span class="ref-journal">Breast Cancer Res</span> (2010) <span class="ref-vol">12</span>(<span class="ref-iss">1</span>):R13. doi: 10.1186/bcr2479
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2880434/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20158881" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fbcr2479" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res&amp;title=Survival+and+self-renewing+capacity+of+breast+cancer+initiating+cells+during+fractionated+radiation+treatment&amp;author=C+Lagadec&amp;author=E+Vlashi&amp;author=L+Della+Donna&amp;author=Y+Meng&amp;author=C+Dekmezian&amp;volume=12&amp;issue=1&amp;publication_year=2010&amp;pages=R13&amp;pmid=20158881&amp;doi=10.1186/bcr2479&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B66">66. <span class="mixed-citation">
Huang RX, Zhou PK. <span class="ref-title">DNA Damage response signaling pathways and targets for radiotherapy sensitization in cancer</span>. <span class="ref-journal">Signal Transduct Target Ther</span> (2020) <span class="ref-vol">5</span>(<span class="ref-iss">1</span>):60. doi: 10.1038/s41392-020-0150-x
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7192953/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32355263" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41392-020-0150-x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Signal+Transduct+Target+Ther&amp;title=DNA+Damage+response+signaling+pathways+and+targets+for+radiotherapy+sensitization+in+cancer&amp;author=RX+Huang&amp;author=PK+Zhou&amp;volume=5&amp;issue=1&amp;publication_year=2020&amp;pages=60&amp;pmid=32355263&amp;doi=10.1038/s41392-020-0150-x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B67">67. <span class="mixed-citation">
Mladenov E, Magin S, Soni A, Iliakis G. <span class="ref-title">DNA Double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy</span>. <span class="ref-journal">Front Oncol</span> (2013) <span class="ref-vol">3</span>:113. doi: 10.3389/fonc.2013.00113
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3650303/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23675572" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffonc.2013.00113" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Oncol&amp;title=DNA+Double-strand+break+repair+as+determinant+of+cellular+radiosensitivity+to+killing+and+target+in+radiation+therapy&amp;author=E+Mladenov&amp;author=S+Magin&amp;author=A+Soni&amp;author=G+Iliakis&amp;volume=3&amp;publication_year=2013&amp;pages=113&amp;pmid=23675572&amp;doi=10.3389/fonc.2013.00113&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B68">68. <span class="mixed-citation">
Iliakis G, Mladenov E, Mladenova V. <span class="ref-title">Necessities in the processing of DNA double strand breaks and their effects on genomic instability and cancer</span>. <span class="ref-journal">Cancers (Basel)</span> (2019) <span class="ref-vol">11</span>(<span class="ref-iss">11</span>). doi: 10.3390/cancers11111671
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6896103/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31661831" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fcancers11111671" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancers+(Basel)&amp;title=Necessities+in+the+processing+of+DNA+double+strand+breaks+and+their+effects+on+genomic+instability+and+cancer&amp;author=G+Iliakis&amp;author=E+Mladenov&amp;author=V+Mladenova&amp;volume=11&amp;issue=11&amp;publication_year=2019&amp;doi=10.3390/cancers11111671&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B69">69. <span class="mixed-citation">
Weber AM, Ryan AJ. <span class="ref-title">ATM And ATR as therapeutic targets in cancer</span>. <span class="ref-journal">Pharmacol Ther</span> (2015) <span class="ref-vol">149</span>:124&#x02013;38. doi: 10.1016/j.pharmthera.2014.12.001
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25512053" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.pharmthera.2014.12.001" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacol+Ther&amp;title=ATM+And+ATR+as+therapeutic+targets+in+cancer&amp;author=AM+Weber&amp;author=AJ+Ryan&amp;volume=149&amp;publication_year=2015&amp;doi=10.1016/j.pharmthera.2014.12.001&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B70">70. <span class="mixed-citation">
Gasser S, Orsulic S, Brown EJ, Raulet DH. <span class="ref-title">The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor</span>. <span class="ref-journal">Nature</span> (2005) <span class="ref-vol">436</span>(<span class="ref-iss">7054</span>):1186&#x02013;90. doi: 10.1038/nature03884
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1352168/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15995699" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnature03884" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=The+DNA+damage+pathway+regulates+innate+immune+system+ligands+of+the+NKG2D+receptor&amp;author=S+Gasser&amp;author=S+Orsulic&amp;author=EJ+Brown&amp;author=DH+Raulet&amp;volume=436&amp;issue=7054&amp;publication_year=2005&amp;doi=10.1038/nature03884&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B71">71. <span class="mixed-citation">
Zou L, Elledge SJ. <span class="ref-title">Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes</span>. <span class="ref-journal">Science</span> (2003) <span class="ref-vol">300</span>(<span class="ref-iss">5625</span>):1542&#x02013;8. doi: 10.1126/science.1083430
 [<a href="https://pubmed.ncbi.nlm.nih.gov/12791985" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fscience.1083430" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Sensing+DNA+damage+through+ATRIP+recognition+of+RPA-ssDNA+complexes&amp;author=L+Zou&amp;author=SJ+Elledge&amp;volume=300&amp;issue=5625&amp;publication_year=2003&amp;doi=10.1126/science.1083430&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B72">72. <span class="mixed-citation">
Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, 3rd, Hurov KE, Luo J, et al.. <span class="ref-title">ATM And ATR substrate analysis reveals extensive protein networks responsive to DNA damage</span>. <span class="ref-journal">Science</span> (2007) <span class="ref-vol">316</span>(<span class="ref-iss">5828</span>):1160&#x02013;6. doi: 10.1126/science.1140321
 [<a href="https://pubmed.ncbi.nlm.nih.gov/17525332" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fscience.1140321" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=ATM+And+ATR+substrate+analysis+reveals+extensive+protein+networks+responsive+to+DNA+damage&amp;author=S+Matsuoka&amp;author=BA+Ballif&amp;author=A+Smogorzewska&amp;author=ER+McDonald&amp;author=KE+Hurov&amp;volume=316&amp;issue=5828&amp;publication_year=2007&amp;doi=10.1126/science.1140321&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B73">73. <span class="mixed-citation">
Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, et al.. <span class="ref-title">Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors</span>. <span class="ref-journal">J Clin Invest</span> (2020) <span class="ref-vol">130</span>(<span class="ref-iss">11</span>):5951&#x02013;66. doi: 10.1172/JCI130445
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7598069/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33016929" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1172%2FJCI130445" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Invest&amp;title=Inhibition+of+the+ATM/Chk2+axis+promotes+cGAS/STING+signaling+in+ARID1A-deficient+tumors&amp;author=L+Wang&amp;author=L+Yang&amp;author=C+Wang&amp;author=W+Zhao&amp;author=Z+Ju&amp;volume=130&amp;issue=11&amp;publication_year=2020&amp;doi=10.1172/JCI130445&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B74">74. <span class="mixed-citation">
Savitsky K, Platzer M, Uziel T, Gilad S, Sartiel A, Rosenthal A, et al.. <span class="ref-title">Ataxia-telangiectasia: structural diversity of untranslated sequences suggests complex post-transcriptional regulation of ATM gene expression</span>. <span class="ref-journal">Nucleic Acids Res</span> (1997) <span class="ref-vol">25</span>(<span class="ref-iss">9</span>):1678&#x02013;84. doi: 10.1093/nar/25.9.1678
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC146671/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9108147" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fnar%2F25.9.1678" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic+Acids+Res&amp;title=Ataxia-telangiectasia:+structural+diversity+of+untranslated+sequences+suggests+complex+post-transcriptional+regulation+of+ATM+gene+expression&amp;author=K+Savitsky&amp;author=M+Platzer&amp;author=T+Uziel&amp;author=S+Gilad&amp;author=A+Sartiel&amp;volume=25&amp;issue=9&amp;publication_year=1997&amp;doi=10.1093/nar/25.9.1678&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B75">75. <span class="mixed-citation">
Taylor AM, Harnden DG, Arlett CF, Harcourt SA, Lehmann AR, Stevens S, et al.. <span class="ref-title">Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity</span>. <span class="ref-journal">Nature</span> (1975) <span class="ref-vol">258</span>(<span class="ref-iss">5534</span>):427&#x02013;9. doi: 10.1038/258427a0
 [<a href="https://pubmed.ncbi.nlm.nih.gov/1196376" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2F258427a0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Ataxia+telangiectasia:+a+human+mutation+with+abnormal+radiation+sensitivity&amp;author=AM+Taylor&amp;author=DG+Harnden&amp;author=CF+Arlett&amp;author=SA+Harcourt&amp;author=AR+Lehmann&amp;volume=258&amp;issue=5534&amp;publication_year=1975&amp;doi=10.1038/258427a0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B76">76. <span class="mixed-citation">
Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, et al.. <span class="ref-title">Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner</span>. <span class="ref-journal">Mol Cell Biol</span> (2002) <span class="ref-vol">22</span>(<span class="ref-iss">18</span>):6521&#x02013;32. doi: 10.1128/MCB.22.18.6521-6532.2002
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC135625/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12192050" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1128%2FMCB.22.18.6521-6532.2002" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell+Biol&amp;title=Chk2+is+a+tumor+suppressor+that+regulates+apoptosis+in+both+an+ataxia+telangiectasia+mutated+(ATM)-dependent+and+an+ATM-independent+manner&amp;author=A+Hirao&amp;author=A+Cheung&amp;author=G+Duncan&amp;author=PM+Girard&amp;author=AJ+Elia&amp;volume=22&amp;issue=18&amp;publication_year=2002&amp;doi=10.1128/MCB.22.18.6521-6532.2002&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B77">77. <span class="mixed-citation">
Powell SN, DeFrank JS, Connell P, Eogan M, Preffer F, Dombkowski D, et al.. <span class="ref-title">Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay</span>. <span class="ref-journal">Cancer Res</span> (1995) <span class="ref-vol">55</span>(<span class="ref-iss">8</span>):1643&#x02013;8. doi: 10.1016/0360-3016(95)97825-L
 [<a href="https://pubmed.ncbi.nlm.nih.gov/7712468" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2F0360-3016(95)97825-L" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Differential+sensitivity+of+p53(-)+and+p53(+)+cells+to+caffeine-induced+radiosensitization+and+override+of+G2+delay&amp;author=SN+Powell&amp;author=JS+DeFrank&amp;author=P+Connell&amp;author=M+Eogan&amp;author=F+Preffer&amp;volume=55&amp;issue=8&amp;publication_year=1995&amp;doi=10.1016/0360-3016(95)97825-L&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B78">78. <span class="mixed-citation">
Price BD, Youmell MB. <span class="ref-title">The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage</span>. <span class="ref-journal">Cancer Res</span> (1996) <span class="ref-vol">56</span>(<span class="ref-iss">2</span>):246&#x02013;50. [<a href="https://pubmed.ncbi.nlm.nih.gov/8542574" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=The+phosphatidylinositol+3-kinase+inhibitor+wortmannin+sensitizes+murine+fibroblasts+and+human+tumor+cells+to+radiation+and+blocks+induction+of+p53+following+DNA+damage&amp;author=BD+Price&amp;author=MB+Youmell&amp;volume=56&amp;issue=2&amp;publication_year=1996&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B79">79. <span class="mixed-citation">
Rainey MD, Charlton ME, Stanton RV, Kastan MB. <span class="ref-title">Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation</span>. <span class="ref-journal">Cancer Res</span> (2008) <span class="ref-vol">68</span>(<span class="ref-iss">18</span>):7466&#x02013;74. doi: 10.1158/0008-5472.CAN-08-0763
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2559948/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18794134" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-08-0763" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Transient+inhibition+of+ATM+kinase+is+sufficient+to+enhance+cellular+sensitivity+to+ionizing+radiation&amp;author=MD+Rainey&amp;author=ME+Charlton&amp;author=RV+Stanton&amp;author=MB+Kastan&amp;volume=68&amp;issue=18&amp;publication_year=2008&amp;doi=10.1158/0008-5472.CAN-08-0763&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B80">80. <span class="mixed-citation">
Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, et al.. <span class="ref-title">Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM</span>. <span class="ref-journal">Cancer Res</span> (2004) <span class="ref-vol">64</span>(<span class="ref-iss">24</span>):9152&#x02013;9. doi: 10.1158/0008-5472.CAN-04-2727
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15604286" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-04-2727" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Identification+and+characterization+of+a+novel+and+specific+inhibitor+of+the+ataxia-telangiectasia+mutated+kinase+ATM&amp;author=I+Hickson&amp;author=Y+Zhao&amp;author=CJ+Richardson&amp;author=SJ+Green&amp;author=NM+Martin&amp;volume=64&amp;issue=24&amp;publication_year=2004&amp;doi=10.1158/0008-5472.CAN-04-2727&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B81">81. <span class="mixed-citation">
Golding SE, Rosenberg E, Adams BR, Wignarajah S, Beckta JM, O'Connor MJ., et al.. <span class="ref-title">Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control</span>. <span class="ref-journal">Cell Cycle</span> (2012) <span class="ref-vol">11</span>(<span class="ref-iss">6</span>):1167&#x02013;73. doi: 10.4161/cc.11.6.19576
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3335919/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22370485" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4161%2Fcc.11.6.19576" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Cycle&amp;title=Dynamic+inhibition+of+ATM+kinase+provides+a+strategy+for+glioblastoma+multiforme+radiosensitization+and+growth+control&amp;author=SE+Golding&amp;author=E+Rosenberg&amp;author=BR+Adams&amp;author=S+Wignarajah&amp;author=JM+Beckta&amp;volume=11&amp;issue=6&amp;publication_year=2012&amp;doi=10.4161/cc.11.6.19576&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B82">82. <span class="mixed-citation">
Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NM, et al.. <span class="ref-title">Preclinical evaluation of a novel ATM inhibitor, KU59403, <em>in vitro</em> and <em>in vivo</em> in p53 functional and dysfunctional models of human cancer</span>. <span class="ref-journal">Mol Cancer Ther</span> (2013) <span class="ref-vol">12</span>(<span class="ref-iss">6</span>):959&#x02013;67. doi: 10.1158/1535-7163.MCT-12-0707
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3736091/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23512991" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.MCT-12-0707" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Preclinical+evaluation+of+a+novel+ATM+inhibitor,+KU59403,+in+vitro+and+in+vivo+in+p53+functional+and+dysfunctional+models+of+human+cancer&amp;author=MA+Batey&amp;author=Y+Zhao&amp;author=S+Kyle&amp;author=C+Richardson&amp;author=A+Slade&amp;volume=12&amp;issue=6&amp;publication_year=2013&amp;doi=10.1158/1535-7163.MCT-12-0707&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B83">83. <span class="mixed-citation">
Vecchio D, Daga A, Carra E, Marubbi D, Raso A, Mascelli S, et al.. <span class="ref-title">Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019</span>. <span class="ref-journal">Int J Cancer</span> (2015) <span class="ref-vol">136</span>(<span class="ref-iss">6</span>):1445&#x02013;57. doi: 10.1002/ijc.29121
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25091220" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fijc.29121" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Cancer&amp;title=Pharmacokinetics,+pharmacodynamics+and+efficacy+on+pediatric+tumors+of+the+glioma+radiosensitizer+KU60019&amp;author=D+Vecchio&amp;author=A+Daga&amp;author=E+Carra&amp;author=D+Marubbi&amp;author=A+Raso&amp;volume=136&amp;issue=6&amp;publication_year=2015&amp;doi=10.1002/ijc.29121&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B84">84. <span class="mixed-citation">
Zhang T, Shen Y, Chen Y, Hsieh JT, Kong Z. <span class="ref-title">The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect</span>. <span class="ref-journal">Int J Radiat Biol</span> (2015) <span class="ref-vol">91</span>(<span class="ref-iss">4</span>):368&#x02013;78. doi: 10.3109/09553002.2015.1001531
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25585815" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3109%2F09553002.2015.1001531" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Radiat+Biol&amp;title=The+ATM+inhibitor+KU55933+sensitizes+radioresistant+bladder+cancer+cells+with+DAB2IP+gene+defect&amp;author=T+Zhang&amp;author=Y+Shen&amp;author=Y+Chen&amp;author=JT+Hsieh&amp;author=Z+Kong&amp;volume=91&amp;issue=4&amp;publication_year=2015&amp;doi=10.3109/09553002.2015.1001531&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B85">85. <span class="mixed-citation">
Vecchio D, Daga A, Carra E, Marubbi D, Baio G, Neumaier CE, et al.. <span class="ref-title">Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019</span>. <span class="ref-journal">Int J Cancer</span> (2014) <span class="ref-vol">135</span>(<span class="ref-iss">2</span>):479&#x02013;91. doi: 10.1002/ijc.28680
 [<a href="https://pubmed.ncbi.nlm.nih.gov/24443327" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fijc.28680" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Cancer&amp;title=Predictability,+efficacy+and+safety+of+radiosensitization+of+glioblastoma-initiating+cells+by+the+ATM+inhibitor+KU-60019&amp;author=D+Vecchio&amp;author=A+Daga&amp;author=E+Carra&amp;author=D+Marubbi&amp;author=G+Baio&amp;volume=135&amp;issue=2&amp;publication_year=2014&amp;doi=10.1002/ijc.28680&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B86">86. <span class="mixed-citation">
Zhang Q, Green MD, Lang X, Lazarus J, Parsels JD, Wei S, et al.. <span class="ref-title">Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy</span>. <span class="ref-journal">Cancer Res</span> (2019) <span class="ref-vol">79</span>(<span class="ref-iss">15</span>):3940&#x02013;51. doi: 10.1158/0008-5472.CAN-19-0761
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6684166/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31101760" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-19-0761" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Inhibition+of+ATM+increases+interferon+signaling+and+sensitizes+pancreatic+cancer+to+immune+checkpoint+blockade+therapy&amp;author=Q+Zhang&amp;author=MD+Green&amp;author=X+Lang&amp;author=J+Lazarus&amp;author=JD+Parsels&amp;volume=79&amp;issue=15&amp;publication_year=2019&amp;doi=10.1158/0008-5472.CAN-19-0761&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B87">87. <span class="mixed-citation">
Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, et al.. <span class="ref-title">ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation</span>. <span class="ref-journal">J Clin Invest</span> (2018) <span class="ref-vol">128</span>(<span class="ref-iss">9</span>):3926&#x02013;40. doi: 10.1172/JCI96519
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6118586/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29952768" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1172%2FJCI96519" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Invest&amp;title=ATR+kinase+inhibitor+AZD6738+potentiates+CD8++T+cell-dependent+antitumor+activity+following+radiation&amp;author=FP+Vendetti&amp;author=P+Karukonda&amp;author=DA+Clump&amp;author=T+Teo&amp;author=R+Lalonde&amp;volume=128&amp;issue=9&amp;publication_year=2018&amp;doi=10.1172/JCI96519&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B88">88. <span class="mixed-citation">
Dillon MT, Bergerhoff KF, Pedersen M, Whittock H, Crespo-Rodriguez E, Patin EC, et al.. <span class="ref-title">ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment</span>. <span class="ref-journal">Clin Cancer Res</span> (2019) <span class="ref-vol">25</span>(<span class="ref-iss">11</span>):3392&#x02013;403. doi: 10.1158/1078-0432.CCR-18-1821
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6551222/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30770349" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-18-1821" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=ATR+inhibition+potentiates+the+radiation-induced+inflammatory+tumor+microenvironment&amp;author=MT+Dillon&amp;author=KF+Bergerhoff&amp;author=M+Pedersen&amp;author=H+Whittock&amp;author=E+Crespo-Rodriguez&amp;volume=25&amp;issue=11&amp;publication_year=2019&amp;doi=10.1158/1078-0432.CCR-18-1821&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B89">89. <span class="mixed-citation">
Sheng H, Huang Y, Xiao Y, Zhu Z, Shen M, Zhou P, et al.. <span class="ref-title">ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma</span>. <span class="ref-journal">J Immunother Cancer</span> (2020) <span class="ref-vol">8</span>(<span class="ref-iss">1</span>). doi: 10.1136/jitc-2019-000340
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7254123/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32461345" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1136%2Fjitc-2019-000340" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunother+Cancer&amp;title=ATR+inhibitor+AZD6738+enhances+the+antitumor+activity+of+radiotherapy+and+immune+checkpoint+inhibitors+by+potentiating+the+tumor+immune+microenvironment+in+hepatocellular+carcinoma&amp;author=H+Sheng&amp;author=Y+Huang&amp;author=Y+Xiao&amp;author=Z+Zhu&amp;author=M+Shen&amp;volume=8&amp;issue=1&amp;publication_year=2020&amp;doi=10.1136/jitc-2019-000340&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B90">90. <span class="mixed-citation">
Patin EC, Dillon MT, Nenclares P, Grove L, Soliman H, Leslie I, et al.. <span class="ref-title">Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade</span>. <span class="ref-journal">J Immunother Cancer</span> (2022) <span class="ref-vol">10</span>(<span class="ref-iss">3</span>). doi: 10.1136/jitc-2021-004306
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8938703/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35314434" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1136%2Fjitc-2021-004306" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunother+Cancer&amp;title=Harnessing+radiotherapy-induced+NK-cell+activity+by+combining+DNA+damage-response+inhibition+and+immune+checkpoint+blockade&amp;author=EC+Patin&amp;author=MT+Dillon&amp;author=P+Nenclares&amp;author=L+Grove&amp;author=H+Soliman&amp;volume=10&amp;issue=3&amp;publication_year=2022&amp;doi=10.1136/jitc-2021-004306&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B91">91. <span class="mixed-citation">
Wang W, McMillan MT, Zhao X, Wang Z, Jiang L, Karnak D, et al.. <span class="ref-title">DNA-PK inhibition and radiation promote anti-tumoral immunity through RNA polymerase III in pancreatic cancer</span>. <span class="ref-journal">Mol Cancer Res</span> (2022) <span class="ref-vol">20</span>(<span class="ref-iss">7</span>):1137&#x02013;1150. doi:&#x000a0; 10.1158/1541-7786.MCR-21-0725
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9262824/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35348737" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1541-7786.MCR-21-0725" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Res&amp;title=DNA-PK+inhibition+and+radiation+promote+anti-tumoral+immunity+through+RNA+polymerase+III+in+pancreatic+cancer&amp;author=W+Wang&amp;author=MT+McMillan&amp;author=X+Zhao&amp;author=Z+Wang&amp;author=L+Jiang&amp;volume=20&amp;issue=7&amp;publication_year=2022&amp;pages=1137-1150&amp;pmid=35348737&amp;doi=10.1158/1541-7786.MCR-21-0725&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B92">92. <span class="mixed-citation">
Patel P, Sun L, Robbins Y, Clavijo PE, Friedman J, Silvin C, et al.. <span class="ref-title">Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition</span>. <span class="ref-journal">Oncoimmunology</span> (2019) <span class="ref-vol">8</span>(<span class="ref-iss">11</span>):e1638207. doi: 10.1080/2162402X.2019.1638207
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6791428/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31646086" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F2162402X.2019.1638207" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=Enhancing+direct+cytotoxicity+and+response+to+immune+checkpoint+blockade+following+ionizing+radiation+with+Wee1+kinase+inhibition&amp;author=P+Patel&amp;author=L+Sun&amp;author=Y+Robbins&amp;author=PE+Clavijo&amp;author=J+Friedman&amp;volume=8&amp;issue=11&amp;publication_year=2019&amp;pages=e1638207&amp;pmid=31646086&amp;doi=10.1080/2162402X.2019.1638207&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B93">93. <span class="mixed-citation">
Baird JR, Friedman D, Cottam B, Dubensky TW, Jr, Kanne DB, Bambina S, et al.. <span class="ref-title">Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors</span>. <span class="ref-journal">Cancer Res</span> (2016) <span class="ref-vol">76</span>(<span class="ref-iss">1</span>):50&#x02013;61. doi: 10.1158/0008-5472.CAN-14-3619
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4703500/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26567136" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-14-3619" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Radiotherapy+combined+with+novel+STING-targeting+oligonucleotides+results+in+regression+of+established+tumors&amp;author=JR+Baird&amp;author=D+Friedman&amp;author=B+Cottam&amp;author=TW+Dubensky&amp;author=DB+Kanne&amp;volume=76&amp;issue=1&amp;publication_year=2016&amp;pages=50-61&amp;pmid=26567136&amp;doi=10.1158/0008-5472.CAN-14-3619&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B94">94. <span class="mixed-citation">
Dewan MZ, Vanpouille-Box C, Kawashima N, DiNapoli S, Babb JS, Formenti SC, et al.. <span class="ref-title">Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer</span>. <span class="ref-journal">Clin Cancer Res</span> (2012) <span class="ref-vol">18</span>(<span class="ref-iss">24</span>):6668&#x02013;78. doi: 10.1158/1078-0432.CCR-12-0984
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3525760/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23048078" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-12-0984" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Synergy+of+topical+toll-like+receptor+7+agonist+with+radiation+and+low-dose+cyclophosphamide+in+a+mouse+model+of+cutaneous+breast+cancer&amp;author=MZ+Dewan&amp;author=C+Vanpouille-Box&amp;author=N+Kawashima&amp;author=S+DiNapoli&amp;author=JS+Babb&amp;volume=18&amp;issue=24&amp;publication_year=2012&amp;doi=10.1158/1078-0432.CCR-12-0984&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B95">95. <span class="mixed-citation">
Cho JH, Lee HJ, Ko HJ, Yoon BI, Choe J, Kim KC, et al.. <span class="ref-title">The TLR7 agonist imiquimod induces anti-cancer effects <em>via</em> autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma</span>. <span class="ref-journal">Oncotarget</span> (2017) <span class="ref-vol">8</span>(<span class="ref-iss">15</span>):24932&#x02013;48. doi: 10.18632/oncotarget.15326
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5421900/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28212561" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.18632%2Foncotarget.15326" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=The+TLR7+agonist+imiquimod+induces+anti-cancer+effects+via+autophagic+cell+death+and+enhances+anti-tumoral+and+systemic+immunity+during+radiotherapy+for+melanoma&amp;author=JH+Cho&amp;author=HJ+Lee&amp;author=HJ+Ko&amp;author=BI+Yoon&amp;author=J+Choe&amp;volume=8&amp;issue=15&amp;publication_year=2017&amp;doi=10.18632/oncotarget.15326&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B96">96. <span class="mixed-citation">
Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, et al.. <span class="ref-title">Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma</span>. <span class="ref-journal">Blood</span> (2013) <span class="ref-vol">121</span>(<span class="ref-iss">2</span>):251&#x02013;9. doi: 10.1182/blood-2012-05-432393
 [<a href="https://pubmed.ncbi.nlm.nih.gov/23086756" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1182%2Fblood-2012-05-432393" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Systemic+delivery+of+a+TLR7+agonist+in+combination+with+radiation+primes+durable+antitumor+immune+responses+in+mouse+models+of+lymphoma&amp;author=SJ+Dovedi&amp;author=MH+Melis&amp;author=RW+Wilkinson&amp;author=AL+Adlard&amp;author=IJ+Stratford&amp;volume=121&amp;issue=2&amp;publication_year=2013&amp;doi=10.1182/blood-2012-05-432393&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B97">97. <span class="mixed-citation">
Adlard AL, Dovedi SJ, Telfer BA, Koga-Yamakawa E, Pollard C, Honeychurch J, et al.. <span class="ref-title">A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models</span>. <span class="ref-journal">Int J Cancer</span> (2014) <span class="ref-vol">135</span>(<span class="ref-iss">4</span>):820&#x02013;9. doi: 10.1002/ijc.28711
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4286010/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24390981" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fijc.28711" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Cancer&amp;title=A+novel+systemically+administered+toll-like+receptor+7+agonist+potentiates+the+effect+of+ionizing+radiation+in+murine+solid+tumor+models&amp;author=AL+Adlard&amp;author=SJ+Dovedi&amp;author=BA+Telfer&amp;author=E+Koga-Yamakawa&amp;author=C+Pollard&amp;volume=135&amp;issue=4&amp;publication_year=2014&amp;doi=10.1002/ijc.28711&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B98">98. <span class="mixed-citation">
Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, et al.. <span class="ref-title">Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy</span>. <span class="ref-journal">Oncotarget</span> (2016) <span class="ref-vol">7</span>(<span class="ref-iss">13</span>):17035&#x02013;46. doi: 10.18632/oncotarget.7928
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4941369/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26959743" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.18632%2Foncotarget.7928" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Intravenous+administration+of+the+selective+toll-like+receptor+7+agonist+DSR-29133+leads+to+anti-tumor+efficacy+in+murine+solid+tumor+models+which+can+be+potentiated+by+combination+with+fractionated+radiotherapy&amp;author=SJ+Dovedi&amp;author=AL+Adlard&amp;author=Y+Ota&amp;author=M+Murata&amp;author=E+Sugaru&amp;volume=7&amp;issue=13&amp;publication_year=2016&amp;doi=10.18632/oncotarget.7928&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B99">99. <span class="mixed-citation">
Sch&#x000f6;lch S, Rauber C, Tietz A, Rahbari NN, Bork U, Schmidt T, et al.. <span class="ref-title">Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors</span>. <span class="ref-journal">Oncotarget</span> (2015) <span class="ref-vol">6</span>(<span class="ref-iss">7</span>):4663&#x02013;76. doi: 10.18632/oncotarget.3081
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4467106/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25609199" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.18632%2Foncotarget.3081" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Radiotherapy+combined+with+TLR7/8+activation+induces+strong+immune+responses+against+gastrointestinal+tumors&amp;author=S+Sch&#x000f6;lch&amp;author=C+Rauber&amp;author=A+Tietz&amp;author=NN+Rahbari&amp;author=U+Bork&amp;volume=6&amp;issue=7&amp;publication_year=2015&amp;doi=10.18632/oncotarget.3081&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B100">100. <span class="mixed-citation">
Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, et al.. <span class="ref-title">Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy</span>. <span class="ref-journal">Clin Cancer Res</span> (2005) <span class="ref-vol">11</span>(<span class="ref-iss">1</span>):361&#x02013;9. doi: 10.1158/1078-0432.361.11.1
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15671567" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.361.11.1" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Targeting+toll-like+receptor+9+with+CpG+oligodeoxynucleotides+enhances+tumor+response+to+fractionated+radiotherapy&amp;author=KA+Mason&amp;author=H+Ariga&amp;author=R+Neal&amp;author=D+Valdecanas&amp;author=N+Hunter&amp;volume=11&amp;issue=1&amp;publication_year=2005&amp;doi=10.1158/1078-0432.361.11.1&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B101">101. <span class="mixed-citation">
Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, et al.. <span class="ref-title">CpG oligodeoxynucleotide enhances tumor response to radiation</span>. <span class="ref-journal">Cancer Res</span> (2004) <span class="ref-vol">64</span>(<span class="ref-iss">15</span>):5074&#x02013;7. doi: 10.1158/0008-5472.CAN-04-0926
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15289307" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-04-0926" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=CpG+oligodeoxynucleotide+enhances+tumor+response+to+radiation&amp;author=L+Milas&amp;author=KA+Mason&amp;author=H+Ariga&amp;author=N+Hunter&amp;author=R+Neal&amp;volume=64&amp;issue=15&amp;publication_year=2004&amp;doi=10.1158/0008-5472.CAN-04-0926&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B102">102. <span class="mixed-citation">
Meng Y, Carpentier AF, Chen L, Boisserie G, Simon JM, Mazeron JJ, et al.. <span class="ref-title">Successful combination of local CpG-ODN and radiotherapy in malignant glioma</span>. <span class="ref-journal">Int J Cancer</span> (2005) <span class="ref-vol">116</span>(<span class="ref-iss">6</span>):992&#x02013;7. doi: 10.1002/ijc.21131
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15856470" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fijc.21131" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Cancer&amp;title=Successful+combination+of+local+CpG-ODN+and+radiotherapy+in+malignant+glioma&amp;author=Y+Meng&amp;author=AF+Carpentier&amp;author=L+Chen&amp;author=G+Boisserie&amp;author=JM+Simon&amp;volume=116&amp;issue=6&amp;publication_year=2005&amp;doi=10.1002/ijc.21131&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B103">103. <span class="mixed-citation">
Zhang H, Liu L, Yu D, Kandimalla ER, Sun HB, Agrawal S, et al.. <span class="ref-title">An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy</span>. <span class="ref-journal">PloS One</span> (2012) <span class="ref-vol">7</span>(<span class="ref-iss">5</span>):e38111. doi: 10.1371/journal.pone.0038111
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3364192/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22666458" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1371%2Fjournal.pone.0038111" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PloS+One&amp;title=An+in+situ+autologous+tumor+vaccination+with+combined+radiation+therapy+and+TLR9+agonist+therapy&amp;author=H+Zhang&amp;author=L+Liu&amp;author=D+Yu&amp;author=ER+Kandimalla&amp;author=HB+Sun&amp;volume=7&amp;issue=5&amp;publication_year=2012&amp;pages=e38111&amp;pmid=22666458&amp;doi=10.1371/journal.pone.0038111&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B104">104. <span class="mixed-citation">
Domankevich V, Efrati M, Schmidt M, Glikson E, Mansour F, Shai A, et al.. <span class="ref-title">RIG-1-Like receptor activation synergizes with intratumoral alpha radiation to induce pancreatic tumor rejection, triple-negative breast metastases clearance, and antitumor immune memory in mice</span>. <span class="ref-journal">Front Oncol</span> (2020) <span class="ref-vol">10</span>:990. doi: 10.3389/fonc.2020.00990
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7379859/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32766128" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffonc.2020.00990" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Oncol&amp;title=RIG-1-Like+receptor+activation+synergizes+with+intratumoral+alpha+radiation+to+induce+pancreatic+tumor+rejection,+triple-negative+breast+metastases+clearance,+and+antitumor+immune+memory+in+mice&amp;author=V+Domankevich&amp;author=M+Efrati&amp;author=M+Schmidt&amp;author=E+Glikson&amp;author=F+Mansour&amp;volume=10&amp;publication_year=2020&amp;pages=990&amp;pmid=32766128&amp;doi=10.3389/fonc.2020.00990&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B105">105. <span class="mixed-citation">
Wold MS. <span class="ref-title">Replication protein a: a heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism</span>. <span class="ref-journal">Annu Rev Biochem</span> (1997) <span class="ref-vol">66</span>:61&#x02013;92. doi: 10.1146/annurev.biochem.66.1.61
 [<a href="https://pubmed.ncbi.nlm.nih.gov/9242902" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1146%2Fannurev.biochem.66.1.61" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annu+Rev+Biochem&amp;title=Replication+protein+a:+a+heterotrimeric,+single-stranded+DNA-binding+protein+required+for+eukaryotic+DNA+metabolism&amp;author=MS+Wold&amp;volume=66&amp;publication_year=1997&amp;pages=61-92&amp;pmid=9242902&amp;doi=10.1146/annurev.biochem.66.1.61&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B106">106. <span class="mixed-citation">
Kumagai A, Lee J, Yoo HY, Dunphy WG. <span class="ref-title">TopBP1 activates the ATR-ATRIP complex</span>. <span class="ref-journal">Cell</span> (2006) <span class="ref-vol">124</span>(<span class="ref-iss">5</span>):943&#x02013;55. doi: 10.1016/j.cell.2005.12.041
 [<a href="https://pubmed.ncbi.nlm.nih.gov/16530042" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cell.2005.12.041" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=TopBP1+activates+the+ATR-ATRIP+complex&amp;author=A+Kumagai&amp;author=J+Lee&amp;author=HY+Yoo&amp;author=WG+Dunphy&amp;volume=124&amp;issue=5&amp;publication_year=2006&amp;doi=10.1016/j.cell.2005.12.041&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B107">107. <span class="mixed-citation">
Chen J. <span class="ref-title">Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage</span>. <span class="ref-journal">Cancer Res</span> (2000) <span class="ref-vol">60</span>(<span class="ref-iss">18</span>):5037&#x02013;9. [<a href="https://pubmed.ncbi.nlm.nih.gov/11016625" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Ataxia+telangiectasia-related+protein+is+involved+in+the+phosphorylation+of+BRCA1+following+deoxyribonucleic+acid+damage&amp;author=J+Chen&amp;volume=60&amp;issue=18&amp;publication_year=2000&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B108">108. <span class="mixed-citation">
Tibbetts RS, Cortez D, Brumbaugh KM, Scully R, Livingston D, Elledge SJ, et al.. <span class="ref-title">Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress</span>. <span class="ref-journal">Genes Dev</span> (2000) <span class="ref-vol">14</span>(<span class="ref-iss">23</span>):2989&#x02013;3002. doi: 10.1101/gad.851000
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC317107/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11114888" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1101%2Fgad.851000" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Genes+Dev&amp;title=Functional+interactions+between+BRCA1+and+the+checkpoint+kinase+ATR+during+genotoxic+stress&amp;author=RS+Tibbetts&amp;author=D+Cortez&amp;author=KM+Brumbaugh&amp;author=R+Scully&amp;author=D+Livingston&amp;volume=14&amp;issue=23&amp;publication_year=2000&amp;pages=2989-3002&amp;pmid=11114888&amp;doi=10.1101/gad.851000&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B109">109. <span class="mixed-citation">
Errico A, Costanzo V. <span class="ref-title">Mechanisms of replication fork protection: a safeguard for genome stability</span>. <span class="ref-journal">Crit Rev Biochem Mol Biol</span> (2012) <span class="ref-vol">47</span>(<span class="ref-iss">3</span>):222&#x02013;35. doi: 10.3109/10409238.2012.655374
 [<a href="https://pubmed.ncbi.nlm.nih.gov/22324461" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3109%2F10409238.2012.655374" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Crit+Rev+Biochem+Mol+Biol&amp;title=Mechanisms+of+replication+fork+protection:+a+safeguard+for+genome+stability&amp;author=A+Errico&amp;author=V+Costanzo&amp;volume=47&amp;issue=3&amp;publication_year=2012&amp;doi=10.3109/10409238.2012.655374&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B110">110. <span class="mixed-citation">
S&#x000f8;rensen CS, Sylju&#x000e5;sen RG, Falck J, Schroeder T, R&#x000f6;nnstrand L, Khanna KK, et al.. <span class="ref-title">Chk1 regulates the s phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A</span>. <span class="ref-journal">Cancer Cell</span> (2003) <span class="ref-vol">3</span>(<span class="ref-iss">3</span>):247&#x02013;58. doi: 10.1016/S1535-6108(03)00048-5
 [<a href="https://pubmed.ncbi.nlm.nih.gov/12676583" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS1535-6108(03)00048-5" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Cell&amp;title=Chk1+regulates+the+s+phase+checkpoint+by+coupling+the+physiological+turnover+and+ionizing+radiation-induced+accelerated+proteolysis+of+Cdc25A&amp;author=CS+S&#x000f8;rensen&amp;author=RG+Sylju&#x000e5;sen&amp;author=J+Falck&amp;author=T+Schroeder&amp;author=L+R&#x000f6;nnstrand&amp;volume=3&amp;issue=3&amp;publication_year=2003&amp;doi=10.1016/S1535-6108(03)00048-5&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B111">111. <span class="mixed-citation">
Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S, et al.. <span class="ref-title">Chk1 mediates s and G2 arrests through Cdc25A degradation in response to DNA-damaging agents</span>. <span class="ref-journal">J Biol Chem</span> (2003) <span class="ref-vol">278</span>(<span class="ref-iss">24</span>):21767&#x02013;73. doi: 10.1074/jbc.M300229200
 [<a href="https://pubmed.ncbi.nlm.nih.gov/12676925" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1074%2Fjbc.M300229200" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Chk1+mediates+s+and+G2+arrests+through+Cdc25A+degradation+in+response+to+DNA-damaging+agents&amp;author=Z+Xiao&amp;author=Z+Chen&amp;author=AH+Gunasekera&amp;author=TJ+Sowin&amp;author=SH+Rosenberg&amp;volume=278&amp;issue=24&amp;publication_year=2003&amp;doi=10.1074/jbc.M300229200&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B112">112. <span class="mixed-citation">
Graves PR, Lovly CM, Uy GL, Piwnica-Worms H. <span class="ref-title">Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding</span>. <span class="ref-journal">Oncogene</span> (2001) <span class="ref-vol">20</span>(<span class="ref-iss">15</span>):1839&#x02013;51. doi: 10.1038/sj.onc.1204259
 [<a href="https://pubmed.ncbi.nlm.nih.gov/11313932" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fsj.onc.1204259" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Localization+of+human+Cdc25C+is+regulated+both+by+nuclear+export+and+14-3-3+protein+binding&amp;author=PR+Graves&amp;author=CM+Lovly&amp;author=GL+Uy&amp;author=H+Piwnica-Worms&amp;volume=20&amp;issue=15&amp;publication_year=2001&amp;doi=10.1038/sj.onc.1204259&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B113">113. <span class="mixed-citation">
Nishida H, Tatewaki N, Nakajima Y, Magara T, Ko KM, Hamamori Y, et al.. <span class="ref-title">Inhibition of ATR protein kinase activity by schisandrin b in DNA damage response</span>. <span class="ref-journal">Nucleic Acids Res</span> (2009) <span class="ref-vol">37</span>(<span class="ref-iss">17</span>):5678&#x02013;89. doi: 10.1093/nar/gkp593
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2761266/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19625493" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fnar%2Fgkp593" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic+Acids+Res&amp;title=Inhibition+of+ATR+protein+kinase+activity+by+schisandrin+b+in+DNA+damage+response&amp;author=H+Nishida&amp;author=N+Tatewaki&amp;author=Y+Nakajima&amp;author=T+Magara&amp;author=KM+Ko&amp;volume=37&amp;issue=17&amp;publication_year=2009&amp;doi=10.1093/nar/gkp593&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B114">114. <span class="mixed-citation">
Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A, et al.. <span class="ref-title">Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines</span>. <span class="ref-journal">Br J Cancer</span> (2011) <span class="ref-vol">105</span>(<span class="ref-iss">3</span>):372&#x02013;81. doi: 10.1038/bjc.2011.243
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3172902/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21730979" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fbjc.2011.243" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Cancer&amp;title=Identification+and+evaluation+of+a+potent+novel+ATR+inhibitor,+NU6027,+in+breast+and+ovarian+cancer+cell+lines&amp;author=A+Peasland&amp;author=LZ+Wang&amp;author=E+Rowling&amp;author=S+Kyle&amp;author=T+Chen&amp;volume=105&amp;issue=3&amp;publication_year=2011&amp;doi=10.1038/bjc.2011.243&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B115">115. <span class="mixed-citation">
Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al.. <span class="ref-title">Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <em>in vivo</em> antitumor activity</span>. <span class="ref-journal">Mol Cancer Ther</span> (2008) <span class="ref-vol">7</span>(<span class="ref-iss">7</span>):1851&#x02013;63. doi: 10.1158/1535-7163.MCT-08-0017
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18606717" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.MCT-08-0017" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Identification+and+characterization+of+NVP-BEZ235,+a+new+orally+available+dual+phosphatidylinositol+3-kinase/mammalian+target+of+rapamycin+inhibitor+with+potent+in+vivo+antitumor+activity&amp;author=SM+Maira&amp;author=F+Stauffer&amp;author=J+Brueggen&amp;author=P+Furet&amp;author=C+Schnell&amp;volume=7&amp;issue=7&amp;publication_year=2008&amp;doi=10.1158/1535-7163.MCT-08-0017&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B116">116. <span class="mixed-citation">
Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S, et al.. <span class="ref-title">Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents</span>. <span class="ref-journal">J Med Chem</span> (2011) <span class="ref-vol">54</span>(<span class="ref-iss">7</span>):2320&#x02013;30. doi: 10.1021/jm101488z
 [<a href="https://pubmed.ncbi.nlm.nih.gov/21413798" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1021%2Fjm101488z" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Chem&amp;title=Discovery+of+potent+and+selective+inhibitors+of+ataxia+telangiectasia+mutated+and+Rad3+related+(ATR)+protein+kinase+as+potential+anticancer+agents&amp;author=JD+Charrier&amp;author=SJ+Durrant&amp;author=JM+Golec&amp;author=DP+Kay&amp;author=RM+Knegtel&amp;volume=54&amp;issue=7&amp;publication_year=2011&amp;doi=10.1021/jm101488z&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B117">117. <span class="mixed-citation">
Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, et al.. <span class="ref-title">Targeting ATR <em>in vivo</em> using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation</span>. <span class="ref-journal">Cell Death Dis</span> (2012) <span class="ref-vol">3</span>(<span class="ref-iss">12</span>):e441. doi: 10.1038/cddis.2012.181
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3542617/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23222511" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fcddis.2012.181" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Death+Dis&amp;title=Targeting+ATR+in+vivo+using+the+novel+inhibitor+VE-822+results+in+selective+sensitization+of+pancreatic+tumors+to+radiation&amp;author=E+Fokas&amp;author=R+Prevo&amp;author=JR+Pollard&amp;author=PM+Reaper&amp;author=PA+Charlton&amp;volume=3&amp;issue=12&amp;publication_year=2012&amp;pages=e441&amp;pmid=23222511&amp;doi=10.1038/cddis.2012.181&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B118">118. <span class="mixed-citation">
Foote KM, Blades K, Cronin A, Fillery S, Guichard SS, Hassall L, et al.. <span class="ref-title">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy <em>in vivo</em> antitumor activity</span>. <span class="ref-journal">J Med Chem</span> (2013) <span class="ref-vol">56</span>(<span class="ref-iss">5</span>):2125&#x02013;38. doi: 10.1021/jm301859s
 [<a href="https://pubmed.ncbi.nlm.nih.gov/23394205" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1021%2Fjm301859s" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Chem&amp;title=Discovery+of+4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole+(AZ20):+a+potent+and+selective+inhibitor+of+ATR+protein+kinase+with+monotherapy+in+vivo+antitumor+activity&amp;author=KM+Foote&amp;author=K+Blades&amp;author=A+Cronin&amp;author=S+Fillery&amp;author=SS+Guichard&amp;volume=56&amp;issue=5&amp;publication_year=2013&amp;doi=10.1021/jm301859s&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B119">119. <span class="mixed-citation">
Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, et al.. <span class="ref-title">Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent</span>. <span class="ref-journal">J Med Chem</span> (2018) <span class="ref-vol">61</span>(<span class="ref-iss">22</span>):9889&#x02013;907. doi: 10.1021/acs.jmedchem.8b01187
 [<a href="https://pubmed.ncbi.nlm.nih.gov/30346772" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1021%2Facs.jmedchem.8b01187" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Chem&amp;title=Discovery+and+characterization+of+AZD6738,+a+potent+inhibitor+of+ataxia+telangiectasia+mutated+and+Rad3+related+(ATR)+kinase+with+application+as+an+anticancer+agent&amp;author=KM+Foote&amp;author=JWM+Nissink&amp;author=T+McGuire&amp;author=P+Turner&amp;author=S+Guichard&amp;volume=61&amp;issue=22&amp;publication_year=2018&amp;doi=10.1021/acs.jmedchem.8b01187&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B120">120. <span class="mixed-citation">
Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, Newbold KL, et al.. <span class="ref-title">Radiosensitization by the ATR inhibitor AZD6738 through generation of acentric micronuclei</span>. <span class="ref-journal">Mol Cancer Ther</span> (2017) <span class="ref-vol">16</span>(<span class="ref-iss">1</span>):25&#x02013;34. doi: 10.1158/1535-7163.MCT-16-0239
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5302142/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28062704" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.MCT-16-0239" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Radiosensitization+by+the+ATR+inhibitor+AZD6738+through+generation+of+acentric+micronuclei&amp;author=MT+Dillon&amp;author=HE+Barker&amp;author=M+Pedersen&amp;author=H+Hafsi&amp;author=SA+Bhide&amp;volume=16&amp;issue=1&amp;publication_year=2017&amp;pages=25-34&amp;pmid=28062704&amp;doi=10.1158/1535-7163.MCT-16-0239&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B121">121. <span class="mixed-citation">
Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, Gazdar AF, et al.. <span class="ref-title">Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations</span>. <span class="ref-journal">Cancer Res</span> (2009) <span class="ref-vol">69</span>(<span class="ref-iss">19</span>):7644&#x02013;52. doi: 10.1158/0008-5472.CAN-09-0823
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2760010/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19789349" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-09-0823" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Dual+phosphoinositide+3-kinase/mammalian+target+of+rapamycin+blockade+is+an+effective+radiosensitizing+strategy+for+the+treatment+of+non-small+cell+lung+cancer+harboring+K-RAS+mutations&amp;author=G+Konstantinidou&amp;author=EA+Bey&amp;author=A+Rabellino&amp;author=K+Schuster&amp;author=MS+Maira&amp;volume=69&amp;issue=19&amp;publication_year=2009&amp;doi=10.1158/0008-5472.CAN-09-0823&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B122">122. <span class="mixed-citation">
Sun LL, Yang RY, Li CW, Chen MK, Shao B, Hsu JM, et al.. <span class="ref-title">Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing</span>. <span class="ref-journal">Am J Cancer Res</span> (2018) <span class="ref-vol">8</span>(<span class="ref-iss">7</span>):1307&#x02013;16. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6079156/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30094103" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Cancer+Res&amp;title=Inhibition+of+ATR+downregulates+PD-L1+and+sensitizes+tumor+cells+to+T+cell-mediated+killing&amp;author=LL+Sun&amp;author=RY+Yang&amp;author=CW+Li&amp;author=MK+Chen&amp;author=B+Shao&amp;volume=8&amp;issue=7&amp;publication_year=2018&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B123">123. <span class="mixed-citation">
Gonz&#x000e1;lez Besteiro MA, Gottifredi V. <span class="ref-title">The fork and the kinase: a DNA replication tale from a CHK1 perspective</span>. <span class="ref-journal">Mutat Res Rev Mutat Res</span> (2015) <span class="ref-vol">763</span>:168&#x02013;80. doi: 10.1016/j.mrrev.2014.10.003
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4369321/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25795119" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.mrrev.2014.10.003" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mutat+Res+Rev+Mutat+Res&amp;title=The+fork+and+the+kinase:+a+DNA+replication+tale+from+a+CHK1+perspective&amp;author=MA+Gonz&#x000e1;lez+Besteiro&amp;author=V+Gottifredi&amp;volume=763&amp;publication_year=2015&amp;doi=10.1016/j.mrrev.2014.10.003&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B124">124. <span class="mixed-citation">
Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, Kovar P, et al.. <span class="ref-title">Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics</span>. <span class="ref-journal">Int J Cancer</span> (2006) <span class="ref-vol">119</span>(<span class="ref-iss">12</span>):2784&#x02013;94. doi: 10.1002/ijc.22198
 [<a href="https://pubmed.ncbi.nlm.nih.gov/17019715" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fijc.22198" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Cancer&amp;title=Selective+Chk1+inhibitors+differentially+sensitize+p53-deficient+cancer+cells+to+cancer+therapeutics&amp;author=Z+Chen&amp;author=Z+Xiao&amp;author=WZ+Gu&amp;author=J+Xue&amp;author=MH+Bui&amp;volume=119&amp;issue=12&amp;publication_year=2006&amp;doi=10.1002/ijc.22198&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B125">125. <span class="mixed-citation">
Bunch RT, Eastman A. <span class="ref-title">Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor</span>. <span class="ref-journal">Clin Cancer Res</span> (1996) <span class="ref-vol">2</span>(<span class="ref-iss">5</span>):791&#x02013;7. [<a href="https://pubmed.ncbi.nlm.nih.gov/9816232" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Enhancement+of+cisplatin-induced+cytotoxicity+by+7-hydroxystaurosporine+(UCN-01),+a+new+G2-checkpoint+inhibitor&amp;author=RT+Bunch&amp;author=A+Eastman&amp;volume=2&amp;issue=5&amp;publication_year=1996&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B126">126. <span class="mixed-citation">
King C, Diaz HB, McNeely S, Barnard D, Dempsey J, Blosser W, et al.. <span class="ref-title">LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms</span>. <span class="ref-journal">Mol Cancer Ther</span> (2015) <span class="ref-vol">14</span>(<span class="ref-iss">9</span>):2004&#x02013;13. doi: 10.1158/1535-7163.MCT-14-1037
 [<a href="https://pubmed.ncbi.nlm.nih.gov/26141948" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.MCT-14-1037" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=LY2606368+causes+replication+catastrophe+and+antitumor+effects+through+CHK1-dependent+mechanisms&amp;author=C+King&amp;author=HB+Diaz&amp;author=S+McNeely&amp;author=D+Barnard&amp;author=J+Dempsey&amp;volume=14&amp;issue=9&amp;publication_year=2015&amp;doi=10.1158/1535-7163.MCT-14-1037&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B127">127. <span class="mixed-citation">
G&#x000fc;ster JD, Weissleder SV, Busch CJ, Kriegs M, Petersen C, Knecht R, et al.. <span class="ref-title">The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines</span>. <span class="ref-journal">Radiother Oncol</span> (2014) <span class="ref-vol">113</span>(<span class="ref-iss">3</span>):345&#x02013;51. doi: 10.1016/j.radonc.2014.10.011
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25467050" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.radonc.2014.10.011" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Radiother+Oncol&amp;title=The+inhibition+of+PARP+but+not+EGFR+results+in+the+radiosensitization+of+HPV/p16-positive+HNSCC+cell+lines&amp;author=JD+G&#x000fc;ster&amp;author=SV+Weissleder&amp;author=CJ+Busch&amp;author=M+Kriegs&amp;author=C+Petersen&amp;volume=113&amp;issue=3&amp;publication_year=2014&amp;doi=10.1016/j.radonc.2014.10.011&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B128">128. <span class="mixed-citation">
Suzuki M, Yamamori T, Bo T, Sakai Y, Inanami O. <span class="ref-title">MK-8776, a novel Chk1 inhibitor, exhibits an improved radiosensitizing effect compared to UCN-01 by exacerbating radiation-induced aberrant mitosis</span>. <span class="ref-journal">Transl Oncol</span> (2017) <span class="ref-vol">10</span>(<span class="ref-iss">4</span>):491&#x02013;500. doi: 10.1016/j.tranon.2017.04.002
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5447387/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28550769" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.tranon.2017.04.002" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Transl+Oncol&amp;title=MK-8776,+a+novel+Chk1+inhibitor,+exhibits+an+improved+radiosensitizing+effect+compared+to+UCN-01+by+exacerbating+radiation-induced+aberrant+mitosis&amp;author=M+Suzuki&amp;author=T+Yamamori&amp;author=T+Bo&amp;author=Y+Sakai&amp;author=O+Inanami&amp;volume=10&amp;issue=4&amp;publication_year=2017&amp;pages=491-500&amp;pmid=28550769&amp;doi=10.1016/j.tranon.2017.04.002&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B129">129. <span class="mixed-citation">
Barker HE, Patel R, McLaughlin M, Schick U, Zaidi S, Nutting CM, et al.. <span class="ref-title">CHK1 inhibition radiosensitizes head and neck cancers to paclitaxel-based chemoradiotherapy</span>. <span class="ref-journal">Mol Cancer Ther</span> (2016) <span class="ref-vol">15</span>(<span class="ref-iss">9</span>):2042&#x02013;54. doi: 10.1158/1535-7163.MCT-15-0998
 [<a href="https://pubmed.ncbi.nlm.nih.gov/27422809" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.MCT-15-0998" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=CHK1+inhibition+radiosensitizes+head+and+neck+cancers+to+paclitaxel-based+chemoradiotherapy&amp;author=HE+Barker&amp;author=R+Patel&amp;author=M+McLaughlin&amp;author=U+Schick&amp;author=S+Zaidi&amp;volume=15&amp;issue=9&amp;publication_year=2016&amp;doi=10.1158/1535-7163.MCT-15-0998&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B130">130. <span class="mixed-citation">
Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, et al.. <span class="ref-title">AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies</span>. <span class="ref-journal">Mol Cancer Ther</span> (2008) <span class="ref-vol">7</span>(<span class="ref-iss">9</span>):2955&#x02013;66. doi: 10.1158/1535-7163.MCT-08-0492
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18790776" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.MCT-08-0492" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=AZD7762,+a+novel+checkpoint+kinase+inhibitor,+drives+checkpoint+abrogation+and+potentiates+DNA-targeted+therapies&amp;author=SD+Zabludoff&amp;author=C+Deng&amp;author=MR+Grondine&amp;author=AM+Sheehy&amp;author=S+Ashwell&amp;volume=7&amp;issue=9&amp;publication_year=2008&amp;doi=10.1158/1535-7163.MCT-08-0492&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B131">131. <span class="mixed-citation">
Weiss GJ, Donehower RC, Iyengar T, Ramanathan RK, Lewandowski K, Westin E, et al.. <span class="ref-title">Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer</span>. <span class="ref-journal">Invest N Drugs</span> (2013) <span class="ref-vol">31</span>(<span class="ref-iss">1</span>):136&#x02013;44. doi: 10.1007/s10637-012-9815-9
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3715080/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22492020" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs10637-012-9815-9" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Invest+N+Drugs&amp;title=Phase+I+dose-escalation+study+to+examine+the+safety+and+tolerability+of+LY2603618,+a+checkpoint+1+kinase+inhibitor,+administered+1+day+after+pemetrexed+500+mg/m(2)+every+21+days+in+patients+with+cancer&amp;author=GJ+Weiss&amp;author=RC+Donehower&amp;author=T+Iyengar&amp;author=RK+Ramanathan&amp;author=K+Lewandowski&amp;volume=31&amp;issue=1&amp;publication_year=2013&amp;doi=10.1007/s10637-012-9815-9&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B132">132. <span class="mixed-citation">
Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, et al.. <span class="ref-title">Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor sch 900776 in refractory acute leukemias</span>. <span class="ref-journal">Clin Cancer Res</span> (2012) <span class="ref-vol">18</span>(<span class="ref-iss">24</span>):6723&#x02013;31. doi: 10.1158/1078-0432.CCR-12-2442
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3596113/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23092873" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-12-2442" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Phase+I+and+pharmacologic+trial+of+cytosine+arabinoside+with+the+selective+checkpoint+1+inhibitor+sch+900776+in+refractory+acute+leukemias&amp;author=JE+Karp&amp;author=BM+Thomas&amp;author=JM+Greer&amp;author=C+Sorge&amp;author=SD+Gore&amp;volume=18&amp;issue=24&amp;publication_year=2012&amp;doi=10.1158/1078-0432.CCR-12-2442&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B133">133. <span class="mixed-citation">
Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, et al.. <span class="ref-title">Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors</span>. <span class="ref-journal">J Clin Oncol</span> (2015) <span class="ref-vol">33</span>(<span class="ref-iss">9</span>):1060&#x02013;6. doi: 10.1200/JCO.2014.57.5027
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25605849" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1200%2FJCO.2014.57.5027" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Phase+I+dose-escalation+trial+of+checkpoint+kinase+1+inhibitor+MK-8776+as+monotherapy+and+in+combination+with+gemcitabine+in+patients+with+advanced+solid+tumors&amp;author=AI+Daud&amp;author=MT+Ashworth&amp;author=J+Strosberg&amp;author=JW+Goldman&amp;author=D+Mendelson&amp;volume=33&amp;issue=9&amp;publication_year=2015&amp;doi=10.1200/JCO.2014.57.5027&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B134">134. <span class="mixed-citation">
Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, et al.. <span class="ref-title">Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer</span>. <span class="ref-journal">J Clin Oncol</span> (2016) <span class="ref-vol">34</span>(<span class="ref-iss">15</span>):1764&#x02013;71. doi: 10.1200/JCO.2015.64.5788
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5321045/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27044938" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1200%2FJCO.2015.64.5788" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Phase+I+study+of+LY2606368,+a+checkpoint+kinase+1+inhibitor,+in+patients+with+advanced+cancer&amp;author=D+Hong&amp;author=J+Infante&amp;author=F+Janku&amp;author=S+Jones&amp;author=LM+Nguyen&amp;volume=34&amp;issue=15&amp;publication_year=2016&amp;doi=10.1200/JCO.2015.64.5788&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B135">135. <span class="mixed-citation">
Seto T, Esaki T, Hirai F, Arita S, Nosaki K, Makiyama A, et al.. <span class="ref-title">Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours</span>. <span class="ref-journal">Cancer Chemother Pharmacol</span> (2013) <span class="ref-vol">72</span>(<span class="ref-iss">3</span>):619&#x02013;27. doi: 10.1007/s00280-013-2234-6
 [<a href="https://pubmed.ncbi.nlm.nih.gov/23892959" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs00280-013-2234-6" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Chemother+Pharmacol&amp;title=Phase+I,+dose-escalation+study+of+AZD7762+alone+and+in+combination+with+gemcitabine+in+Japanese+patients+with+advanced+solid+tumours&amp;author=T+Seto&amp;author=T+Esaki&amp;author=F+Hirai&amp;author=S+Arita&amp;author=K+Nosaki&amp;volume=72&amp;issue=3&amp;publication_year=2013&amp;doi=10.1007/s00280-013-2234-6&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B136">136. <span class="mixed-citation">
Lu H, Saha J, Beckmann PJ, Hendrickson EA, Davis AJ. <span class="ref-title">DNA-PKcs promotes chromatin decondensation to facilitate initiation of the DNA damage response</span>. <span class="ref-journal">Nucleic Acids Res</span> (2019) <span class="ref-vol">47</span>(<span class="ref-iss">18</span>):9467&#x02013;79. doi: 10.1093/nar/gkz694
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6765147/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31396623" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fnar%2Fgkz694" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic+Acids+Res&amp;title=DNA-PKcs+promotes+chromatin+decondensation+to+facilitate+initiation+of+the+DNA+damage+response&amp;author=H+Lu&amp;author=J+Saha&amp;author=PJ+Beckmann&amp;author=EA+Hendrickson&amp;author=AJ+Davis&amp;volume=47&amp;issue=18&amp;publication_year=2019&amp;doi=10.1093/nar/gkz694&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B137">137. <span class="mixed-citation">
Douglas P, Gupta S, Morrice N, Meek K, Lees-Miller SP. <span class="ref-title">DNA-PK-dependent phosphorylation of Ku70/80 is not required for non-homologous end joining</span>. <span class="ref-journal">DNA Repair (Amst)</span> (2005) <span class="ref-vol">4</span>(<span class="ref-iss">9</span>):1006&#x02013;18. doi: 10.1016/j.dnarep.2005.05.003
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15941674" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.dnarep.2005.05.003" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=DNA+Repair+(Amst)&amp;title=DNA-PK-dependent+phosphorylation+of+Ku70/80+is+not+required+for+non-homologous+end+joining&amp;author=P+Douglas&amp;author=S+Gupta&amp;author=N+Morrice&amp;author=K+Meek&amp;author=SP+Lees-Miller&amp;volume=4&amp;issue=9&amp;publication_year=2005&amp;doi=10.1016/j.dnarep.2005.05.003&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B138">138. <span class="mixed-citation">
Liu Y, Zhang L, Liu Y, Sun C, Zhang H, Miao G, et al.. <span class="ref-title">DNA-PKcs deficiency inhibits glioblastoma cell-derived angiogenesis after ionizing radiation</span>. <span class="ref-journal">J Cell Physiol</span> (2015) <span class="ref-vol">230</span>(<span class="ref-iss">5</span>):1094&#x02013;103. doi: 10.1002/jcp.24841
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25294801" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fjcp.24841" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Cell+Physiol&amp;title=DNA-PKcs+deficiency+inhibits+glioblastoma+cell-derived+angiogenesis+after+ionizing+radiation&amp;author=Y+Liu&amp;author=L+Zhang&amp;author=Y+Liu&amp;author=C+Sun&amp;author=H+Zhang&amp;volume=230&amp;issue=5&amp;publication_year=2015&amp;doi=10.1002/jcp.24841&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B139">139. <span class="mixed-citation">
Mamo T, Mladek AC, Shogren KL, Gustafson C, Gupta SK, Riester SM, et al.. <span class="ref-title">Inhibiting DNA-PK(CS) radiosensitizes human osteosarcoma cells</span>. <span class="ref-journal">Biochem Biophys Res Commun</span> (2017) <span class="ref-vol">486</span>(<span class="ref-iss">2</span>):307&#x02013;13. doi: 10.1016/j.bbrc.2017.03.033
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5489116/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28300555" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.bbrc.2017.03.033" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Commun&amp;title=Inhibiting+DNA-PK(CS)+radiosensitizes+human+osteosarcoma+cells&amp;author=T+Mamo&amp;author=AC+Mladek&amp;author=KL+Shogren&amp;author=C+Gustafson&amp;author=SK+Gupta&amp;volume=486&amp;issue=2&amp;publication_year=2017&amp;doi=10.1016/j.bbrc.2017.03.033&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B140">140. <span class="mixed-citation">
Mohiuddin IS, Kang MH. <span class="ref-title">DNA-PK as an emerging therapeutic target in cancer</span>. <span class="ref-journal">Front Oncol</span> (2019) <span class="ref-vol">9</span>:635. doi: 10.3389/fonc.2019.00635
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6650781/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31380275" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffonc.2019.00635" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Oncol&amp;title=DNA-PK+as+an+emerging+therapeutic+target+in+cancer&amp;author=IS+Mohiuddin&amp;author=MH+Kang&amp;volume=9&amp;publication_year=2019&amp;pages=635&amp;pmid=31380275&amp;doi=10.3389/fonc.2019.00635&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B141">141. <span class="mixed-citation">
Willoughby CE, Jiang Y, Thomas HD, Willmore E, Kyle S, Wittner A, et al.. <span class="ref-title">Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy</span>. <span class="ref-journal">J Clin Invest</span> (2020) <span class="ref-vol">130</span>(<span class="ref-iss">1</span>):258&#x02013;71. doi:&#x000a0; 10.1172/JCI127483
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6934184/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31581151" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1172%2FJCI127483" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Invest&amp;title=Selective+DNA-PKcs+inhibition+extends+the+therapeutic+index+of+localized+radiotherapy+and+chemotherapy&amp;author=CE+Willoughby&amp;author=Y+Jiang&amp;author=HD+Thomas&amp;author=E+Willmore&amp;author=S+Kyle&amp;volume=130&amp;issue=1&amp;publication_year=2020&amp;doi=10.1172/JCI127483&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B142">142. <span class="mixed-citation">
Critchlow SE, Bowater RP, Jackson SP. <span class="ref-title">Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV</span>. <span class="ref-journal">Curr Biol</span> (1997) <span class="ref-vol">7</span>(<span class="ref-iss">8</span>):588&#x02013;98. doi: 10.1016/S0960-9822(06)00258-2
 [<a href="https://pubmed.ncbi.nlm.nih.gov/9259561" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS0960-9822(06)00258-2" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+Biol&amp;title=Mammalian+DNA+double-strand+break+repair+protein+XRCC4+interacts+with+DNA+ligase+IV&amp;author=SE+Critchlow&amp;author=RP+Bowater&amp;author=SP+Jackson&amp;volume=7&amp;issue=8&amp;publication_year=1997&amp;doi=10.1016/S0960-9822(06)00258-2&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B143">143. <span class="mixed-citation">
Davidson D, Amrein L, Panasci L, Aloyz R. <span class="ref-title">Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond</span>. <span class="ref-journal">Front Pharmacol</span> (2013) <span class="ref-vol">4</span>:5. doi: 10.3389/fphar.2013.00005
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3560216/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23386830" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffphar.2013.00005" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Pharmacol&amp;title=Small+molecules,+inhibitors+of+DNA-PK,+targeting+DNA+repair,+and+beyond&amp;author=D+Davidson&amp;author=L+Amrein&amp;author=L+Panasci&amp;author=R+Aloyz&amp;volume=4&amp;publication_year=2013&amp;pages=5&amp;pmid=23386830&amp;doi=10.3389/fphar.2013.00005&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B144">144. <span class="mixed-citation">
Collis SJ, DeWeese TL, Jeggo PA, Parker AR. <span class="ref-title">The life and death of DNA-PK</span>. <span class="ref-journal">Oncogene</span> (2005) <span class="ref-vol">24</span>(<span class="ref-iss">6</span>):949&#x02013;61. doi: 10.1038/sj.onc.1208332
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15592499" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fsj.onc.1208332" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=The+life+and+death+of+DNA-PK&amp;author=SJ+Collis&amp;author=TL+DeWeese&amp;author=PA+Jeggo&amp;author=AR+Parker&amp;volume=24&amp;issue=6&amp;publication_year=2005&amp;doi=10.1038/sj.onc.1208332&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B145">145. <span class="mixed-citation">
Gurung RL, Lim HK, Venkatesan S, Lee PS, Hande MP. <span class="ref-title">Targeting DNA-PKcs and telomerase in brain tumour cells</span>. <span class="ref-journal">Mol Cancer</span> (2014) <span class="ref-vol">13</span>:232. doi: 10.1186/1476-4598-13-232
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4213508/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25307264" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2F1476-4598-13-232" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer&amp;title=Targeting+DNA-PKcs+and+telomerase+in+brain+tumour+cells&amp;author=RL+Gurung&amp;author=HK+Lim&amp;author=S+Venkatesan&amp;author=PS+Lee&amp;author=MP+Hande&amp;volume=13&amp;publication_year=2014&amp;pages=232&amp;pmid=25307264&amp;doi=10.1186/1476-4598-13-232&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B146">146. <span class="mixed-citation">
Yang C, Wang Q, Liu X, Cheng X, Jiang X, Zhang Y, et al.. <span class="ref-title">NU7441 enhances the radiosensitivity of liver cancer cells</span>. <span class="ref-journal">Cell Physiol Biochem</span> (2016) <span class="ref-vol">38</span>(<span class="ref-iss">5</span>):1897&#x02013;905. doi: 10.1159/000445551
 [<a href="https://pubmed.ncbi.nlm.nih.gov/27160694" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1159%2F000445551" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Physiol+Biochem&amp;title=NU7441+enhances+the+radiosensitivity+of+liver+cancer+cells&amp;author=C+Yang&amp;author=Q+Wang&amp;author=X+Liu&amp;author=X+Cheng&amp;author=X+Jiang&amp;volume=38&amp;issue=5&amp;publication_year=2016&amp;doi=10.1159/000445551&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B147">147. <span class="mixed-citation">
Shinohara ET, Geng L, Tan J, Chen H, Shir Y, Edwards E, et al.. <span class="ref-title">DNA-Dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs</span>. <span class="ref-journal">Cancer Res</span> (2005) <span class="ref-vol">65</span>(<span class="ref-iss">12</span>):4987&#x02013;92. doi: 10.1158/0008-5472.CAN-04-4250
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15958537" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-04-4250" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=DNA-Dependent+protein+kinase+is+a+molecular+target+for+the+development+of+noncytotoxic+radiation-sensitizing+drugs&amp;author=ET+Shinohara&amp;author=L+Geng&amp;author=J+Tan&amp;author=H+Chen&amp;author=Y+Shir&amp;volume=65&amp;issue=12&amp;publication_year=2005&amp;doi=10.1158/0008-5472.CAN-04-4250&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B148">148. <span class="mixed-citation">
Durant S, Karran P. <span class="ref-title">Vanillins&#x02013;a novel family of DNA-PK inhibitors</span>. <span class="ref-journal">Nucleic Acids Res</span> (2003) <span class="ref-vol">31</span>(<span class="ref-iss">19</span>):5501&#x02013;12. doi: 10.1093/nar/gkg753
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC206453/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14500812" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fnar%2Fgkg753" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic+Acids+Res&amp;title=Vanillins&#x02013;a+novel+family+of+DNA-PK+inhibitors&amp;author=S+Durant&amp;author=P+Karran&amp;volume=31&amp;issue=19&amp;publication_year=2003&amp;doi=10.1093/nar/gkg753&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B149">149. <span class="mixed-citation">
Take Y, Kumano M, Hamano Y, Fukatsu H, Teraoka H, Nishimura S, et al.. <span class="ref-title">OK-1035, a selective inhibitor of DNA-dependent protein kinase</span>. <span class="ref-journal">Biochem Biophys Res Commun</span> (1995) <span class="ref-vol">215</span>(<span class="ref-iss">1</span>):41&#x02013;7. doi: 10.1006/bbrc.1995.2431
 [<a href="https://pubmed.ncbi.nlm.nih.gov/7575620" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1006%2Fbbrc.1995.2431" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Commun&amp;title=OK-1035,+a+selective+inhibitor+of+DNA-dependent+protein+kinase&amp;author=Y+Take&amp;author=M+Kumano&amp;author=Y+Hamano&amp;author=H+Fukatsu&amp;author=H+Teraoka&amp;volume=215&amp;issue=1&amp;publication_year=1995&amp;doi=10.1006/bbrc.1995.2431&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B150">150. <span class="mixed-citation">
Ismail IH, M&#x000e5;rtensson S, Moshinsky D, Rice A, Tang C, Howlett A, et al.. <span class="ref-title">SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization</span>. <span class="ref-journal">Oncogene</span> (2004) <span class="ref-vol">23</span>(<span class="ref-iss">4</span>):873&#x02013;82. doi: 10.1038/sj.onc.1207303
 [<a href="https://pubmed.ncbi.nlm.nih.gov/14661061" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fsj.onc.1207303" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=SU11752+inhibits+the+DNA-dependent+protein+kinase+and+DNA+double-strand+break+repair+resulting+in+ionizing+radiation+sensitization&amp;author=IH+Ismail&amp;author=S+M&#x000e5;rtensson&amp;author=D+Moshinsky&amp;author=A+Rice&amp;author=C+Tang&amp;volume=23&amp;issue=4&amp;publication_year=2004&amp;doi=10.1038/sj.onc.1207303&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B151">151. <span class="mixed-citation">
Zhang B, Huang B, Guan H, Zhang SM, Xu QZ, He XP, et al.. <span class="ref-title">Proteomic profiling revealed the functional networks associated with mitotic catastrophe of HepG2 hepatoma cells induced by 6-bromine-5-hydroxy-4-methoxybenzaldehyde</span>. <span class="ref-journal">Toxicol Appl Pharmacol</span> (2011) <span class="ref-vol">252</span>(<span class="ref-iss">3</span>):307&#x02013;17. doi: 10.1016/j.taap.2011.03.003
 [<a href="https://pubmed.ncbi.nlm.nih.gov/21419150" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.taap.2011.03.003" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Toxicol+Appl+Pharmacol&amp;title=Proteomic+profiling+revealed+the+functional+networks+associated+with+mitotic+catastrophe+of+HepG2+hepatoma+cells+induced+by+6-bromine-5-hydroxy-4-methoxybenzaldehyde&amp;author=B+Zhang&amp;author=B+Huang&amp;author=H+Guan&amp;author=SM+Zhang&amp;author=QZ+Xu&amp;volume=252&amp;issue=3&amp;publication_year=2011&amp;doi=10.1016/j.taap.2011.03.003&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B152">152. <span class="mixed-citation">
Davidson D, Grenier J, Martinez-Marignac V, Amrein L, Shawi M, Tokars M, et al.. <span class="ref-title">Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells</span>. <span class="ref-journal">Invest N Drugs</span> (2012) <span class="ref-vol">30</span>(<span class="ref-iss">4</span>):1736&#x02013;42. doi: 10.1007/s10637-011-9678-5
 [<a href="https://pubmed.ncbi.nlm.nih.gov/21567185" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs10637-011-9678-5" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Invest+N+Drugs&amp;title=Effects+of+the+novel+DNA+dependent+protein+kinase+inhibitor,+IC486241,+on+the+DNA+damage+response+to+doxorubicin+and+cisplatin+in+breast+cancer+cells&amp;author=D+Davidson&amp;author=J+Grenier&amp;author=V+Martinez-Marignac&amp;author=L+Amrein&amp;author=M+Shawi&amp;volume=30&amp;issue=4&amp;publication_year=2012&amp;doi=10.1007/s10637-011-9678-5&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B153">153. <span class="mixed-citation">
Guo L, Liu X, Nishikawa K, Plunkett W. <span class="ref-title">Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials</span>. <span class="ref-journal">Mol Cancer Ther</span> (2007) <span class="ref-vol">6</span>(<span class="ref-iss">5</span>):1501&#x02013;8. doi: 10.1158/1535-7163.MCT-06-0780
 [<a href="https://pubmed.ncbi.nlm.nih.gov/17513599" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.MCT-06-0780" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Inhibition+of+topoisomerase+IIalpha+and+G2+cell+cycle+arrest+by+NK314,+a+novel+benzo[c]phenanthridine+currently+in+clinical+trials&amp;author=L+Guo&amp;author=X+Liu&amp;author=K+Nishikawa&amp;author=W+Plunkett&amp;volume=6&amp;issue=5&amp;publication_year=2007&amp;doi=10.1158/1535-7163.MCT-06-0780&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B154">154. <span class="mixed-citation">
Wise HC, Iyer GV, Moore K, Temkin SM, Gordon S, Aghajanian C, et al.. <span class="ref-title">Activity of M3814, an oral DNA-PK inhibitor, in combination with topoisomerase II inhibitors in ovarian cancer models</span>. <span class="ref-journal">Sci Rep</span> (2019) <span class="ref-vol">9</span>(<span class="ref-iss">1</span>):18882. doi: 10.1038/s41598-019-54796-6
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6906487/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31827119" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41598-019-54796-6" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Rep&amp;title=Activity+of+M3814,+an+oral+DNA-PK+inhibitor,+in+combination+with+topoisomerase+II+inhibitors+in+ovarian+cancer+models&amp;author=HC+Wise&amp;author=GV+Iyer&amp;author=K+Moore&amp;author=SM+Temkin&amp;author=S+Gordon&amp;volume=9&amp;issue=1&amp;publication_year=2019&amp;pages=18882&amp;pmid=31827119&amp;doi=10.1038/s41598-019-54796-6&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B155">155. <span class="mixed-citation">
Fok JHL, Ramos-Montoya A, Vazquez-Chantada M, Wijnhoven PWG, Follia V, James N, et al.. <span class="ref-title">AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity</span>. <span class="ref-journal">Nat Commun</span> (2019) <span class="ref-vol">10</span>(<span class="ref-iss">1</span>):5065. doi: 10.1038/s41467-019-12836-9
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6838110/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31699977" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41467-019-12836-9" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Commun&amp;title=AZD7648+is+a+potent+and+selective+DNA-PK+inhibitor+that+enhances+radiation,+chemotherapy+and+olaparib+activity&amp;author=JHL+Fok&amp;author=A+Ramos-Montoya&amp;author=M+Vazquez-Chantada&amp;author=PWG+Wijnhoven&amp;author=V+Follia&amp;volume=10&amp;issue=1&amp;publication_year=2019&amp;pages=5065&amp;pmid=31699977&amp;doi=10.1038/s41467-019-12836-9&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B156">156. <span class="mixed-citation">
Khan AJ, Misenko SM, Thandoni A, Schiff D, Jhawar SR, Bunting SF, et al.. <span class="ref-title">VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells</span>. <span class="ref-journal">Oncotarget</span> (2018) <span class="ref-vol">9</span>(<span class="ref-iss">40</span>):25833&#x02013;41. doi: 10.18632/oncotarget.25383
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5995231/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29899825" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.18632%2Foncotarget.25383" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=VX-984+is+a+selective+inhibitor+of+non-homologous+end+joining,+with+possible+preferential+activity+in+transformed+cells&amp;author=AJ+Khan&amp;author=SM+Misenko&amp;author=A+Thandoni&amp;author=D+Schiff&amp;author=SR+Jhawar&amp;volume=9&amp;issue=40&amp;publication_year=2018&amp;doi=10.18632/oncotarget.25383&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B157">157. <span class="mixed-citation">
Lamb R, Fiorillo M, Chadwick A, Ozsvari B, Reeves KJ, Smith DL, et al.. <span class="ref-title">Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy</span>. <span class="ref-journal">Oncotarget</span> (2015) <span class="ref-vol">6</span>(<span class="ref-iss">16</span>):14005&#x02013;25. doi: 10.18632/oncotarget.4159
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4546447/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26087309" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.18632%2Foncotarget.4159" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Doxycycline+down-regulates+DNA-PK+and+radiosensitizes+tumor+initiating+cells:+Implications+for+more+effective+radiation+therapy&amp;author=R+Lamb&amp;author=M+Fiorillo&amp;author=A+Chadwick&amp;author=B+Ozsvari&amp;author=KJ+Reeves&amp;volume=6&amp;issue=16&amp;publication_year=2015&amp;doi=10.18632/oncotarget.4159&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B158">158. <span class="mixed-citation">
Dong J, Zhang T, Ren Y, Wang Z, Ling CC, He F, et al.. <span class="ref-title">Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks</span>. <span class="ref-journal">Oncotarget</span> (2017) <span class="ref-vol">8</span>(<span class="ref-iss">14</span>):22662&#x02013;73. doi: 10.18632/oncotarget.15153
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5410253/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28186989" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.18632%2Foncotarget.15153" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Inhibiting+DNA-PKcs+in+a+non-homologous+end-joining+pathway+in+response+to+DNA+double-strand+breaks&amp;author=J+Dong&amp;author=T+Zhang&amp;author=Y+Ren&amp;author=Z+Wang&amp;author=CC+Ling&amp;volume=8&amp;issue=14&amp;publication_year=2017&amp;doi=10.18632/oncotarget.15153&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B159">159. <span class="mixed-citation">
Sun Q, Guo Y, Liu X, Czauderna F, Carr MI, Zenke FT, et al.. <span class="ref-title">Therapeutic implications of p53 status on cancer cell fate following exposure to ionizing radiation and the DNA-PK inhibitor M3814</span>. <span class="ref-journal">Mol Cancer Res</span> (2019) <span class="ref-vol">17</span>(<span class="ref-iss">12</span>):2457&#x02013;68. doi: 10.1158/1541-7786.MCR-19-0362
 [<a href="https://pubmed.ncbi.nlm.nih.gov/31551253" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1541-7786.MCR-19-0362" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Res&amp;title=Therapeutic+implications+of+p53+status+on+cancer+cell+fate+following+exposure+to+ionizing+radiation+and+the+DNA-PK+inhibitor+M3814&amp;author=Q+Sun&amp;author=Y+Guo&amp;author=X+Liu&amp;author=F+Czauderna&amp;author=MI+Carr&amp;volume=17&amp;issue=12&amp;publication_year=2019&amp;doi=10.1158/1541-7786.MCR-19-0362&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B160">160. <span class="mixed-citation">
Ferguson BJ, Mansur DS, Peters NE, Ren H, Smith GL. <span class="ref-title">DNA-PK is a DNA sensor for IRF-3-dependent innate immunity</span>. <span class="ref-journal">Elife</span> (2012) <span class="ref-vol">1</span>:e00047. doi: 10.7554/eLife.00047
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3524801/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23251783" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.7554%2FeLife.00047" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Elife&amp;title=DNA-PK+is+a+DNA+sensor+for+IRF-3-dependent+innate+immunity&amp;author=BJ+Ferguson&amp;author=DS+Mansur&amp;author=NE+Peters&amp;author=H+Ren&amp;author=GL+Smith&amp;volume=1&amp;publication_year=2012&amp;pages=e00047&amp;pmid=23251783&amp;doi=10.7554/eLife.00047&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B161">161. <span class="mixed-citation">
Burleigh K, Maltbaek JH, Cambier S, Green R, Gale M, Jr, James RC, et al.. <span class="ref-title">Human DNA-PK activates a STING-independent DNA sensing pathway</span>. <span class="ref-journal">Sci Immunol</span> (2020) <span class="ref-vol">5</span>(<span class="ref-iss">43</span>). doi: 10.1126/sciimmunol.aba4219
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7081723/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31980485" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fsciimmunol.aba4219" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Immunol&amp;title=Human+DNA-PK+activates+a+STING-independent+DNA+sensing+pathway&amp;author=K+Burleigh&amp;author=JH+Maltbaek&amp;author=S+Cambier&amp;author=R+Green&amp;author=M+Gale&amp;volume=5&amp;issue=43&amp;publication_year=2020&amp;doi=10.1126/sciimmunol.aba4219&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B162">162. <span class="mixed-citation">
Kim DS, Camacho CV, Nagari A, Malladi VS, Challa S, Kraus WL. <span class="ref-title">Activation of PARP-1 by snoRNAs controls ribosome biogenesis and cell growth <em>via</em> the RNA helicase DDX21</span>. <span class="ref-journal">Mol Cell</span> (2019) <span class="ref-vol">75</span>(<span class="ref-iss">6</span>):1270&#x02013;1285.e14. doi: 10.1016/j.molcel.2019.06.020
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6754283/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31351877" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.molcel.2019.06.020" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell&amp;title=Activation+of+PARP-1+by+snoRNAs+controls+ribosome+biogenesis+and+cell+growth+via+the+RNA+helicase+DDX21&amp;author=DS+Kim&amp;author=CV+Camacho&amp;author=A+Nagari&amp;author=VS+Malladi&amp;author=S+Challa&amp;volume=75&amp;issue=6&amp;publication_year=2019&amp;pages=1270-1285.e14&amp;pmid=31351877&amp;doi=10.1016/j.molcel.2019.06.020&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B163">163. <span class="mixed-citation">
Maltseva EA, Rechkunova NI, Sukhanova MV, Lavrik OI. <span class="ref-title">Poly(ADP-ribose) polymerase 1 modulates interaction of the nucleotide excision repair factor XPC-RAD23B with DNA <em>via</em> Poly(ADP-ribosyl)ation</span>. <span class="ref-journal">J Biol Chem</span> (2015) <span class="ref-vol">290</span>(<span class="ref-iss">36</span>):21811&#x02013;20. doi: 10.1074/jbc.M115.646638
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4571937/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26170451" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1074%2Fjbc.M115.646638" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Poly(ADP-ribose)+polymerase+1+modulates+interaction+of+the+nucleotide+excision+repair+factor+XPC-RAD23B+with+DNA+via+Poly(ADP-ribosyl)ation&amp;author=EA+Maltseva&amp;author=NI+Rechkunova&amp;author=MV+Sukhanova&amp;author=OI+Lavrik&amp;volume=290&amp;issue=36&amp;publication_year=2015&amp;doi=10.1074/jbc.M115.646638&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B164">164. <span class="mixed-citation">
Sodhi RK, Singh N, Jaggi AS. <span class="ref-title">Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications</span>. <span class="ref-journal">Vascul Pharmacol</span> (2010) <span class="ref-vol">53</span>(<span class="ref-iss">3-4</span>):77&#x02013;87. doi: 10.1016/j.vph.2010.06.003
 [<a href="https://pubmed.ncbi.nlm.nih.gov/20633699" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.vph.2010.06.003" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vascul+Pharmacol&amp;title=Poly(ADP-ribose)+polymerase-1+(PARP-1)+and+its+therapeutic+implications&amp;author=RK+Sodhi&amp;author=N+Singh&amp;author=AS+Jaggi&amp;volume=53&amp;issue=3-4&amp;publication_year=2010&amp;pages=77-87&amp;pmid=20633699&amp;doi=10.1016/j.vph.2010.06.003&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B165">165. <span class="mixed-citation">
Han Y, Jin F, Xie Y, Liu Y, Hu S, Liu XD, et al.. <span class="ref-title">DNA&#x02212;PKcs PARylation regulates DNA&#x02212;PK kinase activity in the DNA damage response</span>. <span class="ref-journal">Mol Med Rep</span> (2019) <span class="ref-vol">20</span>(<span class="ref-iss">4</span>):3609&#x02013;16. doi:&#x000a0; 10.3892/mmr.2019.10640
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6755157/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31485633" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3892%2Fmmr.2019.10640" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Med+Rep&amp;title=DNA&#x02212;PKcs+PARylation+regulates+DNA&#x02212;PK+kinase+activity+in+the+DNA+damage+response&amp;author=Y+Han&amp;author=F+Jin&amp;author=Y+Xie&amp;author=Y+Liu&amp;author=S+Hu&amp;volume=20&amp;issue=4&amp;publication_year=2019&amp;doi=10.3892/mmr.2019.10640&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B166">166. <span class="mixed-citation">
Vormoor B, Schlosser YT, Blair H, Sharma A, Wilkinson S, Newell DR, et al.. <span class="ref-title">Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2</span>. <span class="ref-journal">Oncotarget</span> (2017) <span class="ref-vol">8</span>(<span class="ref-iss">69</span>):113418&#x02013;30. doi: 10.18632/oncotarget.21300
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5768336/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29371919" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.18632%2Foncotarget.21300" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Sensitizing+Ewing+sarcoma+to+chemo-+and+radiotherapy+by+inhibition+of+the+DNA-repair+enzymes+DNA+protein+kinase+(DNA-PK)+and+poly-ADP-ribose+polymerase+(PARP)+1/2&amp;author=B+Vormoor&amp;author=YT+Schlosser&amp;author=H+Blair&amp;author=A+Sharma&amp;author=S+Wilkinson&amp;volume=8&amp;issue=69&amp;publication_year=2017&amp;doi=10.18632/oncotarget.21300&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B167">167. <span class="mixed-citation">
Hirai T, Saito S, Fujimori H, Matsushita K, Nishio T, Okayasu R, et al.. <span class="ref-title">Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells</span>. <span class="ref-journal">Biochem Biophys Res Commun</span> (2016) <span class="ref-vol">478</span>(<span class="ref-iss">1</span>):234&#x02013;40. doi: 10.1016/j.bbrc.2016.07.062
 [<a href="https://pubmed.ncbi.nlm.nih.gov/27425251" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.bbrc.2016.07.062" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Commun&amp;title=Radiosensitization+by+PARP+inhibition+to+proton+beam+irradiation+in+cancer+cells&amp;author=T+Hirai&amp;author=S+Saito&amp;author=H+Fujimori&amp;author=K+Matsushita&amp;author=T+Nishio&amp;volume=478&amp;issue=1&amp;publication_year=2016&amp;doi=10.1016/j.bbrc.2016.07.062&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B168">168. <span class="mixed-citation">
Begg AC, Stewart FA, Vens C. <span class="ref-title">Strategies to improve radiotherapy with targeted drugs</span>. <span class="ref-journal">Nat Rev Cancer</span> (2011) <span class="ref-vol">11</span>(<span class="ref-iss">4</span>):239&#x02013;53. doi: 10.1038/nrc3007
 [<a href="https://pubmed.ncbi.nlm.nih.gov/21430696" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnrc3007" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&amp;title=Strategies+to+improve+radiotherapy+with+targeted+drugs&amp;author=AC+Begg&amp;author=FA+Stewart&amp;author=C+Vens&amp;volume=11&amp;issue=4&amp;publication_year=2011&amp;doi=10.1038/nrc3007&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B169">169. <span class="mixed-citation">
Jannetti SA, Carlucci G, Carney B, Kossatz S, Shenker L, Carter LM, et al.. <span class="ref-title">PARP-1-Targeted radiotherapy in mouse models of glioblastoma</span>. <span class="ref-journal">J Nucl Med</span> (2018) <span class="ref-vol">59</span>(<span class="ref-iss">8</span>):1225&#x02013;33. doi: 10.2967/jnumed.117.205054
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6071508/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29572254" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2967%2Fjnumed.117.205054" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Nucl+Med&amp;title=PARP-1-Targeted+radiotherapy+in+mouse+models+of+glioblastoma&amp;author=SA+Jannetti&amp;author=G+Carlucci&amp;author=B+Carney&amp;author=S+Kossatz&amp;author=L+Shenker&amp;volume=59&amp;issue=8&amp;publication_year=2018&amp;doi=10.2967/jnumed.117.205054&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B170">170. <span class="mixed-citation">
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al.. <span class="ref-title">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span>. <span class="ref-journal">Nature</span> (2005) <span class="ref-vol">434</span>(<span class="ref-iss">7035</span>):917&#x02013;21. doi: 10.1038/nature03445
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15829967" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnature03445" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Targeting+the+DNA+repair+defect+in+BRCA+mutant+cells+as+a+therapeutic+strategy&amp;author=H+Farmer&amp;author=N+McCabe&amp;author=CJ+Lord&amp;author=AN+Tutt&amp;author=DA+Johnson&amp;volume=434&amp;issue=7035&amp;publication_year=2005&amp;doi=10.1038/nature03445&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B171">171. <span class="mixed-citation">
Laudisi F, Sambucci M, Pioli C. <span class="ref-title">Poly (ADP-ribose) polymerase-1 (PARP-1) as immune regulator</span>. <span class="ref-journal">Endocr Metab Immune Disord Drug Targets</span> (2011) <span class="ref-vol">11</span>(<span class="ref-iss">4</span>):326&#x02013;33. doi: 10.2174/187153011797881184
 [<a href="https://pubmed.ncbi.nlm.nih.gov/21476963" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2174%2F187153011797881184" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Endocr+Metab+Immune+Disord+Drug+Targets&amp;title=Poly+(ADP-ribose)+polymerase-1+(PARP-1)+as+immune+regulator&amp;author=F+Laudisi&amp;author=M+Sambucci&amp;author=C+Pioli&amp;volume=11&amp;issue=4&amp;publication_year=2011&amp;doi=10.2174/187153011797881184&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B172">172. <span class="mixed-citation">
Rosado MM, Bennici E, Novelli F, Pioli C. <span class="ref-title">Beyond DNA repair, the immunological role of PARP-1 and its siblings</span>. <span class="ref-journal">Immunology</span> (2013) <span class="ref-vol">139</span>(<span class="ref-iss">4</span>):428&#x02013;37. doi: 10.1111/imm.12099
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3719060/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23489378" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fimm.12099" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunology&amp;title=Beyond+DNA+repair,+the+immunological+role+of+PARP-1+and+its+siblings&amp;author=MM+Rosado&amp;author=E+Bennici&amp;author=F+Novelli&amp;author=C+Pioli&amp;volume=139&amp;issue=4&amp;publication_year=2013&amp;doi=10.1111/imm.12099&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B173">173. <span class="mixed-citation">
Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, et al.. <span class="ref-title">PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer</span>. <span class="ref-journal">J Clin Invest</span> (2019) <span class="ref-vol">129</span>(<span class="ref-iss">3</span>):1211&#x02013;28. doi: 10.1172/JCI123319
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6391116/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30589644" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1172%2FJCI123319" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Invest&amp;title=PARP+inhibition+enhances+tumor+cell-intrinsic+immunity+in+ERCC1-deficient+non-small+cell+lung+cancer&amp;author=RM+Chabanon&amp;author=G+Muirhead&amp;author=DB+Krastev&amp;author=J+Adam&amp;author=D+Morel&amp;volume=129&amp;issue=3&amp;publication_year=2019&amp;doi=10.1172/JCI123319&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B174">174. <span class="mixed-citation">
Kim C, Wang XD, Yu Y. <span class="ref-title">PARP1 inhibitors trigger innate immunity <em>via</em> PARP1 trapping-induced DNA damage response</span>. <span class="ref-journal">Elife</span> (2020) <span class="ref-vol">9</span>. doi: 10.7554/eLife.60637
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7486119/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32844745" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.7554%2FeLife.60637" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Elife&amp;title=PARP1+inhibitors+trigger+innate+immunity+via+PARP1+trapping-induced+DNA+damage+response&amp;author=C+Kim&amp;author=XD+Wang&amp;author=Y+Yu&amp;volume=9&amp;publication_year=2020&amp;doi=10.7554/eLife.60637&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B175">175. <span class="mixed-citation">
McLaughlin LJ, Stojanovic L, Kogan AA, Rutherford JL, Choi EY, Yen RC, et al.. <span class="ref-title">Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency</span>. <span class="ref-journal">Proc Natl Acad Sci U.S.A.</span> (2020) <span class="ref-vol">117</span>(<span class="ref-iss">30</span>):17785&#x02013;95. doi: 10.1073/pnas.2003499117
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7395437/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32651270" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.2003499117" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U.S.A.&amp;title=Pharmacologic+induction+of+innate+immune+signaling+directly+drives+homologous+recombination+deficiency&amp;author=LJ+McLaughlin&amp;author=L+Stojanovic&amp;author=AA+Kogan&amp;author=JL+Rutherford&amp;author=EY+Choi&amp;volume=117&amp;issue=30&amp;publication_year=2020&amp;doi=10.1073/pnas.2003499117&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B176">176. <span class="mixed-citation">
Wang F, Zhao M, Chang B, Zhou Y, Wu X, Ma M, et al.. <span class="ref-title">Cytoplasmic PARP1 links the genome instability to the inhibition of antiviral immunity through PARylating cGAS</span>. <span class="ref-journal">Mol Cell</span> (2022) <span class="ref-vol">82</span>(<span class="ref-iss">11</span>):2032&#x02013;2049.e7. doi: 10.1016/j.molcel.2022.03.034
 [<a href="https://pubmed.ncbi.nlm.nih.gov/35460603" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.molcel.2022.03.034" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell&amp;title=Cytoplasmic+PARP1+links+the+genome+instability+to+the+inhibition+of+antiviral+immunity+through+PARylating+cGAS&amp;author=F+Wang&amp;author=M+Zhao&amp;author=B+Chang&amp;author=Y+Zhou&amp;author=X+Wu&amp;volume=82&amp;issue=11&amp;publication_year=2022&amp;pages=2032-2049.e7&amp;pmid=35460603&amp;doi=10.1016/j.molcel.2022.03.034&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B177">177. <span class="mixed-citation">
Ieraci A, Herrera DG. <span class="ref-title">Nicotinamide inhibits ethanol-induced caspase-3 and PARP-1 over-activation and subsequent neurodegeneration in the developing mouse cerebellum</span>. <span class="ref-journal">Cerebellum</span> (2018) <span class="ref-vol">17</span>(<span class="ref-iss">3</span>):326&#x02013;35. doi: 10.1007/s12311-017-0916-z
 [<a href="https://pubmed.ncbi.nlm.nih.gov/29327278" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs12311-017-0916-z" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cerebellum&amp;title=Nicotinamide+inhibits+ethanol-induced+caspase-3+and+PARP-1+over-activation+and+subsequent+neurodegeneration+in+the+developing+mouse+cerebellum&amp;author=A+Ieraci&amp;author=DG+Herrera&amp;volume=17&amp;issue=3&amp;publication_year=2018&amp;doi=10.1007/s12311-017-0916-z&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B178">178. <span class="mixed-citation">
Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, et al.. <span class="ref-title">Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361</span>. <span class="ref-journal">J Natl Cancer Inst</span> (2004) <span class="ref-vol">96</span>(<span class="ref-iss">1</span>):56&#x02013;67. doi: 10.1093/jnci/djh005
 [<a href="https://pubmed.ncbi.nlm.nih.gov/14709739" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fjnci%2Fdjh005" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Natl+Cancer+Inst&amp;title=Anticancer+chemosensitization+and+radiosensitization+by+the+novel+poly(ADP-ribose)+polymerase-1+inhibitor+AG14361&amp;author=CR+Calabrese&amp;author=R+Almassy&amp;author=S+Barton&amp;author=MA+Batey&amp;author=AH+Calvert&amp;volume=96&amp;issue=1&amp;publication_year=2004&amp;pages=56-67&amp;pmid=14709739&amp;doi=10.1093/jnci/djh005&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B179">179. <span class="mixed-citation">
No&#x000eb;l G, Godon C, Fernet M, Giocanti N, M&#x000e9;gnin-Chanet F, Favaudon V. <span class="ref-title">Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the s phase of the cell cycle and involves arrest of DNA synthesis</span>. <span class="ref-journal">Mol Cancer Ther</span> (2006) <span class="ref-vol">5</span>(<span class="ref-iss">3</span>):564&#x02013;74. doi: 10.1158/1535-7163.MCT-05-0418
 [<a href="https://pubmed.ncbi.nlm.nih.gov/16546970" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.MCT-05-0418" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Radiosensitization+by+the+poly(ADP-ribose)+polymerase+inhibitor+4-amino-1,8-naphthalimide+is+specific+of+the+s+phase+of+the+cell+cycle+and+involves+arrest+of+DNA+synthesis&amp;author=G+No&#x000eb;l&amp;author=C+Godon&amp;author=M+Fernet&amp;author=N+Giocanti&amp;author=F+M&#x000e9;gnin-Chanet&amp;volume=5&amp;issue=3&amp;publication_year=2006&amp;doi=10.1158/1535-7163.MCT-05-0418&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B180">180. <span class="mixed-citation">
Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, et al.. <span class="ref-title">FDA Approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy</span>. <span class="ref-journal">Clin Cancer Res</span> (2015) <span class="ref-vol">21</span>(<span class="ref-iss">19</span>):4257&#x02013;61. doi: 10.1158/1078-0432.CCR-15-0887
 [<a href="https://pubmed.ncbi.nlm.nih.gov/26187614" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-15-0887" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=FDA+Approval+summary:+Olaparib+monotherapy+in+patients+with+deleterious+germline+BRCA-mutated+advanced+ovarian+cancer+treated+with+three+or+more+lines+of+chemotherapy&amp;author=G+Kim&amp;author=G+Ison&amp;author=AE+McKee&amp;author=H+Zhang&amp;author=S+Tang&amp;volume=21&amp;issue=19&amp;publication_year=2015&amp;doi=10.1158/1078-0432.CCR-15-0887&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B181">181. <span class="mixed-citation">
Mullard A. <span class="ref-title">European Regulators approve first PARP inhibitor</span>. <span class="ref-journal">Nat Rev Drug Discov</span> (2014) <span class="ref-vol">13</span>(<span class="ref-iss">12</span>):877&#x02013;7. doi: 10.1038/nrd4508
 [<a href="//doi.org/10.1038%2Fnrd4508" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Drug+Discov&amp;title=European+Regulators+approve+first+PARP+inhibitor&amp;author=A+Mullard&amp;volume=13&amp;issue=12&amp;publication_year=2014&amp;doi=10.1038/nrd4508&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B182">182. <span class="mixed-citation">
<span class="ref-journal">L, a. FDA grants breakthrough designation to niraparib for metastatic CRPC</span> (2019). Available at: <a href="https://www.targetedonc.com/view/fda-grants-breakthrough-designation-to-niraparib-for-metastatic-crpc">https://www.targetedonc.com/view/fda-grants-breakthrough-designation-to-niraparib-for-metastatic-crpc</a>.</span></div><div class="ref-cit-blk half_rhythm" id="B183">183. <span class="mixed-citation">
<span class="ref-title">FDA Approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer</span>. In: <span class="ref-journal">Drug approvals and databases 2020</span>. Available at: <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer#:~:text=On%20May%2019%2C%202020%2C%20the,(mCRPC)%2C%20who%20have%20progressed">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer#:~:text=On%20May%2019%2C%202020%2C%20the,(mCRPC)%2C%20who%20have%20progressed</a>. (Silver Spring, MD: U.S. Food and Drug Administration; ) <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Drug+approvals+and+databases+2020&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B184">184. <span class="mixed-citation">
<span class="ref-title">FDA Approves olaparib tablets for maintenance treatment in ovarian cancer</span>. In: <span class="ref-journal">Drug approvals and databases 2017</span>. Available at: <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer</a>. (Silver Spring, MD: U.S. Food and Drug Administration; ) <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Drug+approvals+and+databases+2017&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B185">185. <span class="mixed-citation">
Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, et al.. <span class="ref-title">FDA Approval summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy</span>. <span class="ref-journal">Clin Cancer Res</span> (2018) <span class="ref-vol">24</span>(<span class="ref-iss">17</span>):4066&#x02013;71. doi: 10.1158/1078-0432.CCR-18-0042
 [<a href="https://pubmed.ncbi.nlm.nih.gov/29650751" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-18-0042" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=FDA+Approval+summary:+Niraparib+for+the+maintenance+treatment+of+patients+with+recurrent+ovarian+cancer+in+response+to+platinum-based+chemotherapy&amp;author=G+Ison&amp;author=LJ+Howie&amp;author=L+Amiri-Kordestani&amp;author=L+Zhang&amp;author=S+Tang&amp;volume=24&amp;issue=17&amp;publication_year=2018&amp;doi=10.1158/1078-0432.CCR-18-0042&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B186">186. <span class="mixed-citation">
Bourton EC, Ahorner PA, Plowman PN, Zahir SA, Al-Ali H, Parris CN. <span class="ref-title">The PARP-1 inhibitor olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+/-) lymphoblastoid cells</span>. <span class="ref-journal">J Cancer</span> (2017) <span class="ref-vol">8</span>(<span class="ref-iss">19</span>):4048&#x02013;56. doi: 10.7150/jca.21338
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5706007/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29187880" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.7150%2Fjca.21338" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Cancer&amp;title=The+PARP-1+inhibitor+olaparib+suppresses+BRCA1+protein+levels,+increases+apoptosis+and+causes+radiation+hypersensitivity+in+BRCA1(+/-)+lymphoblastoid+cells&amp;author=EC+Bourton&amp;author=PA+Ahorner&amp;author=PN+Plowman&amp;author=SA+Zahir&amp;author=H+Al-Ali&amp;volume=8&amp;issue=19&amp;publication_year=2017&amp;doi=10.7150/jca.21338&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B187">187. <span class="mixed-citation">
Ryu H, Kim HJ, Song JY, Hwang SG, Kim JS, Kim J, et al.. <span class="ref-title">A small compound KJ-28d enhances the sensitivity of non-small cell lung cancer to radio- and chemotherapy</span>. <span class="ref-journal">Int J Mol Sci</span> (2019) <span class="ref-vol">20</span>(<span class="ref-iss">23</span>):6026. doi: 10.3390/ijms20236026
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6928747/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31795418" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fijms20236026" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Mol+Sci&amp;title=A+small+compound+KJ-28d+enhances+the+sensitivity+of+non-small+cell+lung+cancer+to+radio-+and+chemotherapy&amp;author=H+Ryu&amp;author=HJ+Kim&amp;author=JY+Song&amp;author=SG+Hwang&amp;author=JS+Kim&amp;volume=20&amp;issue=23&amp;publication_year=2019&amp;pages=6026&amp;doi=10.3390/ijms20236026&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B188">188. <span class="mixed-citation">
Guillot C, Favaudon V, Herceg Z, Sagne C, Sauvaigo S, Merle P, et al.. <span class="ref-title">PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models</span>. <span class="ref-journal">BMC Cancer</span> (2014) <span class="ref-vol">14</span>:603. doi: 10.1186/1471-2407-14-603
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4153905/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25139788" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2F1471-2407-14-603" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMC+Cancer&amp;title=PARP+inhibition+and+the+radiosensitizing+effects+of+the+PARP+inhibitor+ABT-888+in+in+vitro+hepatocellular+carcinoma+models&amp;author=C+Guillot&amp;author=V+Favaudon&amp;author=Z+Herceg&amp;author=C+Sagne&amp;author=S+Sauvaigo&amp;volume=14&amp;publication_year=2014&amp;pages=603&amp;pmid=25139788&amp;doi=10.1186/1471-2407-14-603&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B189">189. <span class="mixed-citation">
Wang L, Mason KA, Ang KK, Buchholz T, Valdecanas D, Mathur A, et al.. <span class="ref-title">MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation</span>. <span class="ref-journal">Invest N Drugs</span> (2012) <span class="ref-vol">30</span>(<span class="ref-iss">6</span>):2113&#x02013;20. doi: 10.1007/s10637-011-9770-x
 [<a href="https://pubmed.ncbi.nlm.nih.gov/22127459" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs10637-011-9770-x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Invest+N+Drugs&amp;title=MK-4827,+a+PARP-1/-2+inhibitor,+strongly+enhances+response+of+human+lung+and+breast+cancer+xenografts+to+radiation&amp;author=L+Wang&amp;author=KA+Mason&amp;author=KK+Ang&amp;author=T+Buchholz&amp;author=D+Valdecanas&amp;volume=30&amp;issue=6&amp;publication_year=2012&amp;doi=10.1007/s10637-011-9770-x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B190">190. <span class="mixed-citation">
Pernin V, M&#x000e9;gnin-Chanet F, Pennaneach V, Fourquet A, Kirova Y, Hall J. <span class="ref-title">[PARP inhibitors and radiotherapy: rational and prospects for a clinical use]</span>. <span class="ref-journal">Cancer Radiother</span> (2014) <span class="ref-vol">18</span>(<span class="ref-iss">8</span>):790&#x02013;8; quiz 799-802. doi:&#x000a0; 10.1016/j.canrad.2014.05.012
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25441760" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.canrad.2014.05.012" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Radiother&amp;title=[PARP+inhibitors+and+radiotherapy:+rational+and+prospects+for+a+clinical+use]&amp;author=V+Pernin&amp;author=F+M&#x000e9;gnin-Chanet&amp;author=V+Pennaneach&amp;author=A+Fourquet&amp;author=Y+Kirova&amp;volume=18&amp;issue=8&amp;publication_year=2014&amp;pages=790-8;+quiz+799-802&amp;pmid=25441760&amp;doi=10.1016/j.canrad.2014.05.012&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B191">191. <span class="mixed-citation">
Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, et al.. <span class="ref-title">Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer</span>. <span class="ref-journal">Nat Cancer</span> (2021) <span class="ref-vol">2</span>(<span class="ref-iss">1</span>):66&#x02013;82. doi: 10.1038/s43018-020-00148-7
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7963404/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33738458" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs43018-020-00148-7" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Cancer&amp;title=Targeting+immunosuppressive+macrophages+overcomes+PARP+inhibitor+resistance+in+BRCA1-associated+triple-negative+breast+cancer&amp;author=AK+Mehta&amp;author=EM+Cheney&amp;author=CA+Hartl&amp;author=C+Pantelidou&amp;author=M+Oliwa&amp;volume=2&amp;issue=1&amp;publication_year=2021&amp;pages=66-82&amp;pmid=33738458&amp;doi=10.1038/s43018-020-00148-7&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B192">192. <span class="mixed-citation">
Qiu L, Wang JJ, Ying SH, Feng MG. <span class="ref-title">Wee1 and Cdc25 control morphogenesis, virulence and multistress tolerance of beauveria bassiana by balancing cell cycle-required cyclin-dependent kinase 1 activity</span>. <span class="ref-journal">Environ Microbiol</span> (2015) <span class="ref-vol">17</span>(<span class="ref-iss">4</span>):1119&#x02013;33. doi: 10.1111/1462-2920.12530
 [<a href="https://pubmed.ncbi.nlm.nih.gov/24910927" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2F1462-2920.12530" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Environ+Microbiol&amp;title=Wee1+and+Cdc25+control+morphogenesis,+virulence+and+multistress+tolerance+of+beauveria+bassiana+by+balancing+cell+cycle-required+cyclin-dependent+kinase+1+activity&amp;author=L+Qiu&amp;author=JJ+Wang&amp;author=SH+Ying&amp;author=MG+Feng&amp;volume=17&amp;issue=4&amp;publication_year=2015&amp;doi=10.1111/1462-2920.12530&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B193">193. <span class="mixed-citation">
Koh SB. <span class="ref-title">The expanding role of WEE1</span>. <span class="ref-journal">Cell Signal</span> (2022) <span class="ref-vol">94</span>:110310. doi: 10.1016/j.cellsig.2022.110310
 [<a href="https://pubmed.ncbi.nlm.nih.gov/35304285" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cellsig.2022.110310" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Signal&amp;title=The+expanding+role+of+WEE1&amp;author=SB+Koh&amp;volume=94&amp;publication_year=2022&amp;pages=110310&amp;pmid=35304285&amp;doi=10.1016/j.cellsig.2022.110310&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B194">194. <span class="mixed-citation">
Hamilton DH, Huang B, Fernando RI, Tsang KY, Palena C. <span class="ref-title">WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition</span>. <span class="ref-journal">Cancer Res</span> (2014) <span class="ref-vol">74</span>(<span class="ref-iss">9</span>):2510&#x02013;9. doi: 10.1158/0008-5472.CAN-13-1894
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4011139/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24626094" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-13-1894" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=WEE1+inhibition+alleviates+resistance+to+immune+attack+of+tumor+cells+undergoing+epithelial-mesenchymal+transition&amp;author=DH+Hamilton&amp;author=B+Huang&amp;author=RI+Fernando&amp;author=KY+Tsang&amp;author=C+Palena&amp;volume=74&amp;issue=9&amp;publication_year=2014&amp;doi=10.1158/0008-5472.CAN-13-1894&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B195">195. <span class="mixed-citation">
Li C, Shen Q, Zhang P, Wang T, Liu W, Li R, et al.. <span class="ref-title">Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy <em>via</em> activating cGAS/STING signaling in gastric cancer cells</span>. <span class="ref-journal">J Exp Clin Cancer Res</span> (2021) <span class="ref-vol">40</span>(<span class="ref-iss">1</span>):315. doi: 10.1186/s13046-021-02120-4
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8501558/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34625086" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs13046-021-02120-4" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Exp+Clin+Cancer+Res&amp;title=Targeting+MUS81+promotes+the+anticancer+effect+of+WEE1+inhibitor+and+immune+checkpoint+blocking+combination+therapy+via+activating+cGAS/STING+signaling+in+gastric+cancer+cells&amp;author=C+Li&amp;author=Q+Shen&amp;author=P+Zhang&amp;author=T+Wang&amp;author=W+Liu&amp;volume=40&amp;issue=1&amp;publication_year=2021&amp;pages=315&amp;pmid=34625086&amp;doi=10.1186/s13046-021-02120-4&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B196">196. <span class="mixed-citation">
Wu X, Kang X, Zhang X, Xie W, Su Y, Liu X, et al.. <span class="ref-title">WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade</span>. <span class="ref-journal">Cancer Sci</span> (2021) <span class="ref-vol">112</span>(<span class="ref-iss">11</span>):4444&#x02013;56. doi: 10.1111/cas.15108
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8586668/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34382294" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fcas.15108" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Sci&amp;title=WEE1+inhibitor+and+ataxia+telangiectasia+and+RAD3-related+inhibitor+trigger+stimulator+of+interferon+gene-dependent+immune+response+and+enhance+tumor+treatment+efficacy+through+programmed+death-ligand+1+blockade&amp;author=X+Wu&amp;author=X+Kang&amp;author=X+Zhang&amp;author=W+Xie&amp;author=Y+Su&amp;volume=112&amp;issue=11&amp;publication_year=2021&amp;doi=10.1111/cas.15108&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B197">197. <span class="mixed-citation">
Hai J, Zhang H, Zhou J, Wu Z, Chen T, Papadopoulos E, et al.. <span class="ref-title">Generation of genetically engineered mouse lung organoid models for squamous cell lung cancers allows for the study of combinatorial immunotherapy</span>. <span class="ref-journal">Clin Cancer Res</span> (2020) <span class="ref-vol">26</span>(<span class="ref-iss">13</span>):3431&#x02013;42. doi: 10.1158/1078-0432.CCR-19-1627
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7334092/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32209571" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-19-1627" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Generation+of+genetically+engineered+mouse+lung+organoid+models+for+squamous+cell+lung+cancers+allows+for+the+study+of+combinatorial+immunotherapy&amp;author=J+Hai&amp;author=H+Zhang&amp;author=J+Zhou&amp;author=Z+Wu&amp;author=T+Chen&amp;volume=26&amp;issue=13&amp;publication_year=2020&amp;doi=10.1158/1078-0432.CCR-19-1627&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B198">198. <span class="mixed-citation">
Guo E, Xiao R, Wu Y, Lu F, Liu C, Yang B, et al.. <span class="ref-title">WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway</span>. <span class="ref-journal">J Exp Med</span> (2022) <span class="ref-vol">219</span>(<span class="ref-iss">1</span>):e20210789. doi: 10.1084/jem.20210789
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8628262/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34825915" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1084%2Fjem.20210789" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Exp+Med&amp;title=WEE1+inhibition+induces+anti-tumor+immunity+by+activating+ERV+and+the+dsRNA+pathway&amp;author=E+Guo&amp;author=R+Xiao&amp;author=Y+Wu&amp;author=F+Lu&amp;author=C+Liu&amp;volume=219&amp;issue=1&amp;publication_year=2022&amp;pages=e20210789&amp;pmid=34825915&amp;doi=10.1084/jem.20210789&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B199">199. <span class="mixed-citation">
Lee YY, Cho YJ, Shin SW, Choi C, Ryu JY, Jeon HK, et al.. <span class="ref-title">Anti-tumor effects of Wee1 kinase inhibitor with radiotherapy in human cervical cancer</span>. <span class="ref-journal">Sci Rep</span> (2019) <span class="ref-vol">9</span>(<span class="ref-iss">1</span>):15394. doi: 10.1038/s41598-019-51959-3
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6817901/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31659268" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41598-019-51959-3" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Rep&amp;title=Anti-tumor+effects+of+Wee1+kinase+inhibitor+with+radiotherapy+in+human+cervical+cancer&amp;author=YY+Lee&amp;author=YJ+Cho&amp;author=SW+Shin&amp;author=C+Choi&amp;author=JY+Ryu&amp;volume=9&amp;issue=1&amp;publication_year=2019&amp;pages=15394&amp;pmid=31659268&amp;doi=10.1038/s41598-019-51959-3&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B200">200. <span class="mixed-citation">
Lescarbeau RS, Lei L, Bakken KK, Sims PA, Sarkaria JN, Canoll P, et al.. <span class="ref-title">Quantitative phosphoproteomics reveals Wee1 kinase as a therapeutic target in a model of proneural glioblastoma</span>. <span class="ref-journal">Mol Cancer Ther</span> (2016) <span class="ref-vol">15</span>(<span class="ref-iss">6</span>):1332&#x02013;43. doi: 10.1158/1535-7163.MCT-15-0692
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4893926/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27196784" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.MCT-15-0692" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Quantitative+phosphoproteomics+reveals+Wee1+kinase+as+a+therapeutic+target+in+a+model+of+proneural+glioblastoma&amp;author=RS+Lescarbeau&amp;author=L+Lei&amp;author=KK+Bakken&amp;author=PA+Sims&amp;author=JN+Sarkaria&amp;volume=15&amp;issue=6&amp;publication_year=2016&amp;doi=10.1158/1535-7163.MCT-15-0692&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B201">201. <span class="mixed-citation">
Matheson CJ, Venkataraman S, Amani V, Harris PS, Backos DS, Donson AM, et al.. <span class="ref-title">A WEE1 inhibitor analog of AZD1775 maintains synergy with cisplatin and demonstrates reduced single-agent cytotoxicity in medulloblastoma cells</span>. <span class="ref-journal">ACS Chem Biol</span> (2016) <span class="ref-vol">11</span>(<span class="ref-iss">4</span>):921&#x02013;30. doi: 10.1021/acschembio.5b00725
 [<a href="https://pubmed.ncbi.nlm.nih.gov/26745241" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1021%2Facschembio.5b00725" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=ACS+Chem+Biol&amp;title=A+WEE1+inhibitor+analog+of+AZD1775+maintains+synergy+with+cisplatin+and+demonstrates+reduced+single-agent+cytotoxicity+in+medulloblastoma+cells&amp;author=CJ+Matheson&amp;author=S+Venkataraman&amp;author=V+Amani&amp;author=PS+Harris&amp;author=DS+Backos&amp;volume=11&amp;issue=4&amp;publication_year=2016&amp;doi=10.1021/acschembio.5b00725&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B202">202. <span class="mixed-citation">
Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, et al.. <span class="ref-title">Sensitization of pancreatic cancers to gemcitabine chemoradiation by WEE1 kinase inhibition depends on homologous recombination repair</span>. <span class="ref-journal">Neoplasia</span> (2015) <span class="ref-vol">17</span>(<span class="ref-iss">10</span>):757&#x02013;66. doi: 10.1016/j.neo.2015.09.006
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4656803/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26585231" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.neo.2015.09.006" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neoplasia&amp;title=Sensitization+of+pancreatic+cancers+to+gemcitabine+chemoradiation+by+WEE1+kinase+inhibition+depends+on+homologous+recombination+repair&amp;author=T+Kausar&amp;author=JS+Schreiber&amp;author=D+Karnak&amp;author=LA+Parsels&amp;author=JD+Parsels&amp;volume=17&amp;issue=10&amp;publication_year=2015&amp;doi=10.1016/j.neo.2015.09.006&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B203">203. <span class="mixed-citation">
Havelek R, Cmielova J, Kralovec K, Bruckova L, Bilkova Z, Fousova I, et al.. <span class="ref-title">Specific inhibition of Wee1 kinase and Rad51 recombinase: a strategy to enhance the sensitivity of leukemic T-cells to ionizing radiation-induced DNA double-strand breaks</span>. <span class="ref-journal">Biochem Biophys Res Commun</span> (2014) <span class="ref-vol">453</span>(<span class="ref-iss">3</span>):569&#x02013;75. doi: 10.1016/j.bbrc.2014.09.123
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25285634" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.bbrc.2014.09.123" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Commun&amp;title=Specific+inhibition+of+Wee1+kinase+and+Rad51+recombinase:+a+strategy+to+enhance+the+sensitivity+of+leukemic+T-cells+to+ionizing+radiation-induced+DNA+double-strand+breaks&amp;author=R+Havelek&amp;author=J+Cmielova&amp;author=K+Kralovec&amp;author=L+Bruckova&amp;author=Z+Bilkova&amp;volume=453&amp;issue=3&amp;publication_year=2014&amp;doi=10.1016/j.bbrc.2014.09.123&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B204">204. <span class="mixed-citation">
PosthumaDeBoer J, W&#x000fc;rdinger T, Graat HC, van Beusechem VW, Helder MN, van Royen BJ, et al.. <span class="ref-title">WEE1 inhibition sensitizes osteosarcoma to radiotherapy</span>. <span class="ref-journal">BMC Cancer</span> (2011) <span class="ref-vol">11</span>:156. doi: 10.1186/1471-2407-11-156
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3103478/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21529352" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2F1471-2407-11-156" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMC+Cancer&amp;title=WEE1+inhibition+sensitizes+osteosarcoma+to+radiotherapy&amp;author=J+PosthumaDeBoer&amp;author=T+W&#x000fc;rdinger&amp;author=HC+Graat&amp;author=VW+van+Beusechem&amp;author=MN+Helder&amp;volume=11&amp;publication_year=2011&amp;pages=156&amp;pmid=21529352&amp;doi=10.1186/1471-2407-11-156&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B205">205. <span class="mixed-citation">
Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, et al.. <span class="ref-title">MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells</span>. <span class="ref-journal">Clin Cancer Res</span> (2011) <span class="ref-vol">17</span>(<span class="ref-iss">17</span>):5638&#x02013;48. doi: 10.1158/1078-0432.CCR-11-0650
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3167033/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21799033" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-11-0650" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=MK-1775,+a+novel+Wee1+kinase+inhibitor,+radiosensitizes+p53-defective+human+tumor+cells&amp;author=KA+Bridges&amp;author=H+Hirai&amp;author=CA+Buser&amp;author=C+Brooks&amp;author=H+Liu&amp;volume=17&amp;issue=17&amp;publication_year=2011&amp;doi=10.1158/1078-0432.CCR-11-0650&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B206">206. <span class="mixed-citation">
Fu S, Wang Y, Keyomarsi K, Meric-Bernstam F, Meric-Bernstein F. <span class="ref-title">Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy</span>. <span class="ref-journal">Expert Opin Investig Drugs</span> (2018) <span class="ref-vol">27</span>(<span class="ref-iss">9</span>):741&#x02013;51. doi: 10.1080/13543784.2018.1511700
 [<a href="https://pubmed.ncbi.nlm.nih.gov/30102076" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F13543784.2018.1511700" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Opin+Investig+Drugs&amp;title=Strategic+development+of+AZD1775,+a+Wee1+kinase+inhibitor,+for+cancer+therapy&amp;author=S+Fu&amp;author=Y+Wang&amp;author=K+Keyomarsi&amp;author=F+Meric-Bernstam&amp;author=F+Meric-Bernstein&amp;volume=27&amp;issue=9&amp;publication_year=2018&amp;doi=10.1080/13543784.2018.1511700&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B207">207. <span class="mixed-citation">
Chen G, Zhang B, Xu H, Sun Y, Shi Y, Luo Y, et al.. <span class="ref-title">Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis</span>. <span class="ref-journal">Oncogene</span> (2017) <span class="ref-vol">36</span>(<span class="ref-iss">50</span>):6863&#x02013;72. doi: 10.1038/onc.2017.297
 [<a href="https://pubmed.ncbi.nlm.nih.gov/28869605" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fonc.2017.297" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Suppression+of+Sirt1+sensitizes+lung+cancer+cells+to+WEE1+inhibitor+MK-1775-induced+DNA+damage+and+apoptosis&amp;author=G+Chen&amp;author=B+Zhang&amp;author=H+Xu&amp;author=Y+Sun&amp;author=Y+Shi&amp;volume=36&amp;issue=50&amp;publication_year=2017&amp;doi=10.1038/onc.2017.297&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B208">208. <span class="mixed-citation">
Abe T, Harashima A, Xia T, Konno H, Konno K, Morales A, et al.. <span class="ref-title">STING recognition of cytoplasmic DNA instigates cellular defense</span>. <span class="ref-journal">Mol Cell</span> (2013) <span class="ref-vol">50</span>(<span class="ref-iss">1</span>):5&#x02013;15. doi: 10.1016/j.molcel.2013.01.039
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3881179/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23478444" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.molcel.2013.01.039" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell&amp;title=STING+recognition+of+cytoplasmic+DNA+instigates+cellular+defense&amp;author=T+Abe&amp;author=A+Harashima&amp;author=T+Xia&amp;author=H+Konno&amp;author=K+Konno&amp;volume=50&amp;issue=1&amp;publication_year=2013&amp;pages=5-15&amp;pmid=23478444&amp;doi=10.1016/j.molcel.2013.01.039&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B209">209. <span class="mixed-citation">
Sun L, Wu J, Du F, Chen X, Chen ZJ. <span class="ref-title">Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway</span>. <span class="ref-journal">Science</span> (2013) <span class="ref-vol">339</span>(<span class="ref-iss">6121</span>):786&#x02013;91. doi: 10.1126/science.1232458
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3863629/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23258413" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fscience.1232458" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Cyclic+GMP-AMP+synthase+is+a+cytosolic+DNA+sensor+that+activates+the+type+I+interferon+pathway&amp;author=L+Sun&amp;author=J+Wu&amp;author=F+Du&amp;author=X+Chen&amp;author=ZJ+Chen&amp;volume=339&amp;issue=6121&amp;publication_year=2013&amp;doi=10.1126/science.1232458&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B210">210. <span class="mixed-citation">
Sun W, Li Y, Chen L, Chen H, You F, Zhou X, et al.. <span class="ref-title">ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization</span>. <span class="ref-journal">Proc Natl Acad Sci U.S.A.</span> (2009) <span class="ref-vol">106</span>(<span class="ref-iss">21</span>):8653&#x02013;8. doi: 10.1073/pnas.0900850106
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2689030/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19433799" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.0900850106" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U.S.A.&amp;title=ERIS,+an+endoplasmic+reticulum+IFN+stimulator,+activates+innate+immune+signaling+through+dimerization&amp;author=W+Sun&amp;author=Y+Li&amp;author=L+Chen&amp;author=H+Chen&amp;author=F+You&amp;volume=106&amp;issue=21&amp;publication_year=2009&amp;doi=10.1073/pnas.0900850106&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B211">211. <span class="mixed-citation">
Ishikawa H, Barber GN. <span class="ref-title">STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling</span>. <span class="ref-journal">Nature</span> (2008) <span class="ref-vol">455</span>(<span class="ref-iss">7213</span>):674&#x02013;8. doi: 10.1038/nature07317
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2804933/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18724357" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnature07317" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=STING+is+an+endoplasmic+reticulum+adaptor+that+facilitates+innate+immune+signalling&amp;author=H+Ishikawa&amp;author=GN+Barber&amp;volume=455&amp;issue=7213&amp;publication_year=2008&amp;doi=10.1038/nature07317&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B212">212. <span class="mixed-citation">
Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, et al.. <span class="ref-title">STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors</span>. <span class="ref-journal">Immunity</span> (2014) <span class="ref-vol">41</span>(<span class="ref-iss">5</span>):830&#x02013;42. doi: 10.1016/j.immuni.2014.10.017
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4384884/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25517615" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.immuni.2014.10.017" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=STING-dependent+cytosolic+DNA+sensing+mediates+innate+immune+recognition+of+immunogenic+tumors&amp;author=SR+Woo&amp;author=MB+Fuertes&amp;author=L+Corrales&amp;author=S+Spranger&amp;author=MJ+Furdyna&amp;volume=41&amp;issue=5&amp;publication_year=2014&amp;doi=10.1016/j.immuni.2014.10.017&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B213">213. <span class="mixed-citation">
Ahn J, Gutman D, Saijo S, Barber GN. <span class="ref-title">STING manifests self DNA-dependent inflammatory disease</span>. <span class="ref-journal">Proc Natl Acad Sci U.S.A.</span> (2012) <span class="ref-vol">109</span>(<span class="ref-iss">47</span>):19386&#x02013;91. doi: 10.1073/pnas.1215006109
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3511090/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23132945" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.1215006109" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U.S.A.&amp;title=STING+manifests+self+DNA-dependent+inflammatory+disease&amp;author=J+Ahn&amp;author=D+Gutman&amp;author=S+Saijo&amp;author=GN+Barber&amp;volume=109&amp;issue=47&amp;publication_year=2012&amp;doi=10.1073/pnas.1215006109&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B214">214. <span class="mixed-citation">
Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al.. <span class="ref-title">STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors</span>. <span class="ref-journal">Immunity</span> (2014) <span class="ref-vol">41</span>(<span class="ref-iss">5</span>):843&#x02013;52. doi: 10.1016/j.immuni.2014.10.019
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5155593/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25517616" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.immuni.2014.10.019" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=STING-dependent+cytosolic+DNA+sensing+promotes+radiation-induced+type+I+interferon-dependent+antitumor+immunity+in+immunogenic+tumors&amp;author=L+Deng&amp;author=H+Liang&amp;author=M+Xu&amp;author=X+Yang&amp;author=B+Burnette&amp;volume=41&amp;issue=5&amp;publication_year=2014&amp;doi=10.1016/j.immuni.2014.10.019&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B215">215. <span class="mixed-citation">
Cheng H, Xu Q, Lu X, Yuan H, Li T, Zhang Y, et al.. <span class="ref-title">Activation of STING by cGAMP regulates MDSCs to suppress tumor metastasis <em>via</em> reversing epithelial-mesenchymal transition</span>. <span class="ref-journal">Front Oncol</span> (2020) <span class="ref-vol">10</span>:896. doi: 10.3389/fonc.2020.00896
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7300176/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32596152" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffonc.2020.00896" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Oncol&amp;title=Activation+of+STING+by+cGAMP+regulates+MDSCs+to+suppress+tumor+metastasis+via+reversing+epithelial-mesenchymal+transition&amp;author=H+Cheng&amp;author=Q+Xu&amp;author=X+Lu&amp;author=H+Yuan&amp;author=T+Li&amp;volume=10&amp;publication_year=2020&amp;pages=896&amp;pmid=32596152&amp;doi=10.3389/fonc.2020.00896&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B216">216. <span class="mixed-citation">
Zhang CX, Ye SB, Ni JJ, Cai TT, Liu YN, Huang DJ, et al.. <span class="ref-title">STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion</span>. <span class="ref-journal">Cell Death Differ</span> (2019) <span class="ref-vol">26</span>(<span class="ref-iss">11</span>):2314&#x02013;28. doi: 10.1038/s41418-019-0302-0
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6889506/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30816302" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41418-019-0302-0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Death+Differ&amp;title=STING+signaling+remodels+the+tumor+microenvironment+by+antagonizing+myeloid-derived+suppressor+cell+expansion&amp;author=CX+Zhang&amp;author=SB+Ye&amp;author=JJ+Ni&amp;author=TT+Cai&amp;author=YN+Liu&amp;volume=26&amp;issue=11&amp;publication_year=2019&amp;doi=10.1038/s41418-019-0302-0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B217">217. <span class="mixed-citation">
Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al.. <span class="ref-title">DNA Exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity</span>. <span class="ref-journal">Nat Commun</span> (2017) <span class="ref-vol">8</span>:15618. doi: 10.1038/ncomms15618
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5472757/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28598415" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fncomms15618" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Commun&amp;title=DNA+Exonuclease+Trex1+regulates+radiotherapy-induced+tumour+immunogenicity&amp;author=C+Vanpouille-Box&amp;author=A+Alard&amp;author=MJ+Aryankalayil&amp;author=Y+Sarfraz&amp;author=JM+Diamond&amp;volume=8&amp;publication_year=2017&amp;pages=15618&amp;pmid=28598415&amp;doi=10.1038/ncomms15618&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B218">218. <span class="mixed-citation">
Baguley BC. <span class="ref-title">Antivascular therapy of cancer: DMXAA</span>. <span class="ref-journal">Lancet Oncol</span> (2003) <span class="ref-vol">4</span>(<span class="ref-iss">3</span>):141&#x02013;8. doi: 10.1016/S1470-2045(03)01018-0
 [<a href="https://pubmed.ncbi.nlm.nih.gov/12623359" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS1470-2045(03)01018-0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Oncol&amp;title=Antivascular+therapy+of+cancer:+DMXAA&amp;author=BC+Baguley&amp;volume=4&amp;issue=3&amp;publication_year=2003&amp;doi=10.1016/S1470-2045(03)01018-0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B219">219. <span class="mixed-citation">
Baguley BC, Siemann DW. <span class="ref-title">Temporal aspects of the action of ASA404 (vadimezan; DMXAA)</span>. <span class="ref-journal">Expert Opin Investig Drugs</span> (2010) <span class="ref-vol">19</span>(<span class="ref-iss">11</span>):1413&#x02013;25. doi: 10.1517/13543784.2010.529128
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3583340/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20964495" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1517%2F13543784.2010.529128" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Opin+Investig+Drugs&amp;title=Temporal+aspects+of+the+action+of+ASA404+(vadimezan;+DMXAA)&amp;author=BC+Baguley&amp;author=DW+Siemann&amp;volume=19&amp;issue=11&amp;publication_year=2010&amp;doi=10.1517/13543784.2010.529128&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B220">220. <span class="mixed-citation">
Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC. <span class="ref-title">Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid</span>. <span class="ref-journal">Br J Cancer</span> (2002) <span class="ref-vol">86</span>(<span class="ref-iss">12</span>):1937&#x02013;42. doi: 10.1038/sj.bjc.6600368
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2375421/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12085190" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fsj.bjc.6600368" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Cancer&amp;title=Induction+of+endothelial+cell+apoptosis+by+the+antivascular+agent+5,6-Dimethylxanthenone-4-acetic+acid&amp;author=LM+Ching&amp;author=Z+Cao&amp;author=C+Kieda&amp;author=S+Zwain&amp;author=MB+Jameson&amp;volume=86&amp;issue=12&amp;publication_year=2002&amp;doi=10.1038/sj.bjc.6600368&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B221">221. <span class="mixed-citation">
Wilson WR, Li AE, Cowan DS, Siim BG. <span class="ref-title">Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid</span>. <span class="ref-journal">Int J Radiat Oncol Biol Phys</span> (1998) <span class="ref-vol">42</span>(<span class="ref-iss">4</span>):905&#x02013;8. doi: 10.1016/S0360-3016(98)00358-7
 [<a href="https://pubmed.ncbi.nlm.nih.gov/9845119" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS0360-3016(98)00358-7" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Radiat+Oncol+Biol+Phys&amp;title=Enhancement+of+tumor+radiation+response+by+the+antivascular+agent+5,6-dimethylxanthenone-4-acetic+acid&amp;author=WR+Wilson&amp;author=AE+Li&amp;author=DS+Cowan&amp;author=BG+Siim&amp;volume=42&amp;issue=4&amp;publication_year=1998&amp;doi=10.1016/S0360-3016(98)00358-7&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B222">222. <span class="mixed-citation">
Matthews KE, Hermans IF, Roberts JM, Ching LM, Ronchese F. <span class="ref-title">5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy</span>. <span class="ref-journal">Immunol Cell Biol</span> (2006) <span class="ref-vol">84</span>(<span class="ref-iss">4</span>):383&#x02013;9. doi: 10.1111/j.1440-1711.2006.01448.x
 [<a href="https://pubmed.ncbi.nlm.nih.gov/16834573" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fj.1440-1711.2006.01448.x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunol+Cell+Biol&amp;title=5,6-Dimethylxanthenone-4-acetic+acid+treatment+of+a+non-immunogenic+tumour+does+not+synergize+with+active+or+passive+CD8++T-cell+immunotherapy&amp;author=KE+Matthews&amp;author=IF+Hermans&amp;author=JM+Roberts&amp;author=LM+Ching&amp;author=F+Ronchese&amp;volume=84&amp;issue=4&amp;publication_year=2006&amp;doi=10.1111/j.1440-1711.2006.01448.x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B223">223. <span class="mixed-citation">
Lemos H, Mohamed E, Huang L, Ou R, Pacholczyk G, Arbab AS, et al.. <span class="ref-title">STING promotes the growth of tumors characterized by low antigenicity <em>via</em> IDO activation</span>. <span class="ref-journal">Cancer Res</span> (2016) <span class="ref-vol">76</span>(<span class="ref-iss">8</span>):2076&#x02013;81. doi: 10.1158/0008-5472.CAN-15-1456
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4873329/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26964621" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-15-1456" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=STING+promotes+the+growth+of+tumors+characterized+by+low+antigenicity+via+IDO+activation&amp;author=H+Lemos&amp;author=E+Mohamed&amp;author=L+Huang&amp;author=R+Ou&amp;author=G+Pacholczyk&amp;volume=76&amp;issue=8&amp;publication_year=2016&amp;doi=10.1158/0008-5472.CAN-15-1456&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B224">224. <span class="mixed-citation">
Gulen MF, Koch U, Haag SM, Schuler F, Apetoh L, Villunger A, et al.. <span class="ref-title">Signalling strength determines proapoptotic functions of STING</span>. <span class="ref-journal">Nat Commun</span> (2017) <span class="ref-vol">8</span>(<span class="ref-iss">1</span>):427. doi: 10.1038/s41467-017-00573-w
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5585373/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28874664" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41467-017-00573-w" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Commun&amp;title=Signalling+strength+determines+proapoptotic+functions+of+STING&amp;author=MF+Gulen&amp;author=U+Koch&amp;author=SM+Haag&amp;author=F+Schuler&amp;author=L+Apetoh&amp;volume=8&amp;issue=1&amp;publication_year=2017&amp;pages=427&amp;pmid=28874664&amp;doi=10.1038/s41467-017-00573-w&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B225">225. <span class="mixed-citation">
Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. <span class="ref-title">Vascular normalization as an emerging strategy to enhance cancer immunotherapy</span>. <span class="ref-journal">Cancer Res</span> (2013) <span class="ref-vol">73</span>(<span class="ref-iss">10</span>):2943&#x02013;8. doi: 10.1158/0008-5472.CAN-12-4354
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3655127/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23440426" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-12-4354" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Vascular+normalization+as+an+emerging+strategy+to+enhance+cancer+immunotherapy&amp;author=Y+Huang&amp;author=S+Goel&amp;author=DG+Duda&amp;author=D+Fukumura&amp;author=RK+Jain&amp;volume=73&amp;issue=10&amp;publication_year=2013&amp;doi=10.1158/0008-5472.CAN-12-4354&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B226">226. <span class="mixed-citation">
Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Chang SK, et al.. <span class="ref-title">STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade</span>. <span class="ref-journal">J Clin Invest</span> (2019) <span class="ref-vol">129</span>(<span class="ref-iss">10</span>):4350&#x02013;64. doi: 10.1172/JCI125413
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6763266/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31343989" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1172%2FJCI125413" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Invest&amp;title=STING+activation+reprograms+tumor+vasculatures+and+synergizes+with+VEGFR2+blockade&amp;author=H+Yang&amp;author=WS+Lee&amp;author=SJ+Kong&amp;author=CG+Kim&amp;author=JH+Kim&amp;volume=129&amp;issue=10&amp;publication_year=2019&amp;doi=10.1172/JCI125413&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B227">227. <span class="mixed-citation">
Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ. <span class="ref-title">STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment</span>. <span class="ref-journal">J Immunother Cancer</span> (2021) <span class="ref-vol">9</span>(<span class="ref-iss">2</span>):e001906. doi: 10.1136/jitc-2020-001906
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7852948/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33526609" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1136%2Fjitc-2020-001906" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunother+Cancer&amp;title=STING+agonist-based+treatment+promotes+vascular+normalization+and+tertiary+lymphoid+structure+formation+in+the+therapeutic+melanoma+microenvironment&amp;author=M+Chelvanambi&amp;author=RJ+Fecek&amp;author=JL+Taylor&amp;author=WJ+Storkus&amp;volume=9&amp;issue=2&amp;publication_year=2021&amp;pages=e001906&amp;pmid=33526609&amp;doi=10.1136/jitc-2020-001906&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B228">228. <span class="mixed-citation">
Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. <span class="ref-title">STING agonists as cancer therapeutics</span>. <span class="ref-journal">Cancers (Basel)</span> (2021) <span class="ref-vol">13</span>(<span class="ref-iss">11</span>):2695. doi: 10.3390/cancers13112695
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8198217/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34070756" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fcancers13112695" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancers+(Basel)&amp;title=STING+agonists+as+cancer+therapeutics&amp;author=A+Amouzegar&amp;author=M+Chelvanambi&amp;author=JN+Filderman&amp;author=WJ+Storkus&amp;author=JJ+Luke&amp;volume=13&amp;issue=11&amp;publication_year=2021&amp;pages=2695&amp;pmid=34070756&amp;doi=10.3390/cancers13112695&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B229">229. <span class="mixed-citation">
Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, et al.. <span class="ref-title">Design of amidobenzimidazole STING receptor agonists with systemic activity</span>. <span class="ref-journal">Nature</span> (2018) <span class="ref-vol">564</span>(<span class="ref-iss">7736</span>):439&#x02013;43. doi: 10.1038/s41586-018-0705-y
 [<a href="https://pubmed.ncbi.nlm.nih.gov/30405246" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41586-018-0705-y" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Design+of+amidobenzimidazole+STING+receptor+agonists+with+systemic+activity&amp;author=JM+Ramanjulu&amp;author=GS+Pesiridis&amp;author=J+Yang&amp;author=N+Concha&amp;author=R+Singhaus&amp;volume=564&amp;issue=7736&amp;publication_year=2018&amp;doi=10.1038/s41586-018-0705-y&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B230">230. <span class="mixed-citation">
Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, et al.. <span class="ref-title">An orally available non-nucleotide STING agonist with antitumor activity</span>. <span class="ref-journal">Science</span> (2020) <span class="ref-vol">369</span>(<span class="ref-iss">6506</span>):eaba6098. doi: 10.1126/science.aba6098
 [<a href="https://pubmed.ncbi.nlm.nih.gov/32820094" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fscience.aba6098" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=An+orally+available+non-nucleotide+STING+agonist+with+antitumor+activity&amp;author=BS+Pan&amp;author=SA+Perera&amp;author=JA+Piesvaux&amp;author=JP+Presland&amp;author=GK+Schroeder&amp;volume=369&amp;issue=6506&amp;publication_year=2020&amp;pages=eaba6098&amp;pmid=32820094&amp;doi=10.1126/science.aba6098&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B231">231. <span class="mixed-citation">
Liu Y, Crowe WN, Wang L, Lu Y, Petty WJ, Habib AA, et al.. <span class="ref-title">An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases</span>. <span class="ref-journal">Nat Commun</span> (2019) <span class="ref-vol">10</span>(<span class="ref-iss">1</span>):5108. doi: 10.1038/s41467-019-13094-5
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6841721/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31704921" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41467-019-13094-5" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Commun&amp;title=An+inhalable+nanoparticulate+STING+agonist+synergizes+with+radiotherapy+to+confer+long-term+control+of+lung+metastases&amp;author=Y+Liu&amp;author=WN+Crowe&amp;author=L+Wang&amp;author=Y+Lu&amp;author=WJ+Petty&amp;volume=10&amp;issue=1&amp;publication_year=2019&amp;pages=5108&amp;pmid=31704921&amp;doi=10.1038/s41467-019-13094-5&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B232">232. <span class="mixed-citation">
Raghida A, Bukhalid JRD, Naniye Malli C, Catcott KC, Avocetien K, Bentley KW, et al.. <span class="ref-title">Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines</span>. <span class="ref-journal">Cancer Res</span> (2020) <span class="ref-vol">. 80</span>(<span class="ref-iss">16_Supplement</span>):6706. doi:&#x000a0; 10.1158/1538-7445.AM2020-6706
 [<a href="//doi.org/10.1158%2F1538-7445.AM2020-6706" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Abstract+6706:+Systemic+administration+of+STING+agonist+antibody-drug+conjugates+elicit+potent+anti-tumor+immune+responses+with+minimal+induction+of+circulating+cytokines&amp;author=A+Raghida&amp;author=JRD+Bukhalid&amp;author=C+Naniye+Malli&amp;author=KC+Catcott&amp;author=K+Avocetien&amp;volume=.+80&amp;issue=16_Supplement&amp;publication_year=2020&amp;pages=6706&amp;doi=10.1158/1538-7445.AM2020-6706&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B233">233. <span class="mixed-citation">
Le Naour J, Zitvogel L, Galluzzi L, Vacchelli E, Kroemer G. <span class="ref-title">Trial watch: STING agonists in cancer therapy</span>. <span class="ref-journal">Oncoimmunology</span> (2020) <span class="ref-vol">9</span>(<span class="ref-iss">1</span>):1777624. doi: 10.1080/2162402X.2020.1777624
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7466854/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32934881" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F2162402X.2020.1777624" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=Trial+watch:+STING+agonists+in+cancer+therapy&amp;author=J+Le+Naour&amp;author=L+Zitvogel&amp;author=L+Galluzzi&amp;author=E+Vacchelli&amp;author=G+Kroemer&amp;volume=9&amp;issue=1&amp;publication_year=2020&amp;pages=1777624&amp;pmid=32934881&amp;doi=10.1080/2162402X.2020.1777624&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B234">234. <span class="mixed-citation">
Harberts E, Gaspari AA. <span class="ref-title">TLR signaling and DNA repair: are they associated</span>? <span class="ref-journal">J Invest Dermatol</span> (2013) <span class="ref-vol">133</span>(<span class="ref-iss">2</span>):296&#x02013;302. doi: 10.1038/jid.2012.288
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8381358/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22931928" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fjid.2012.288" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Invest+Dermatol&amp;title=TLR+signaling+and+DNA+repair:+are+they+associated&amp;author=E+Harberts&amp;author=AA+Gaspari&amp;volume=133&amp;issue=2&amp;publication_year=2013&amp;pages=296-302&amp;pmid=22931928&amp;doi=10.1038/jid.2012.288&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B235">235. <span class="mixed-citation">
Menendez D, Shatz M, Azzam K, Garantziotis S, Fessler MB, Resnick MA. <span class="ref-title">The toll-like receptor gene family is integrated into human DNA damage and p53 networks</span>. <span class="ref-journal">PloS Genet</span> (2011) <span class="ref-vol">7</span>(<span class="ref-iss">3</span>):e1001360. doi: 10.1371/journal.pgen.1001360
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3069118/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21483755" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1371%2Fjournal.pgen.1001360" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PloS+Genet&amp;title=The+toll-like+receptor+gene+family+is+integrated+into+human+DNA+damage+and+p53+networks&amp;author=D+Menendez&amp;author=M+Shatz&amp;author=K+Azzam&amp;author=S+Garantziotis&amp;author=MB+Fessler&amp;volume=7&amp;issue=3&amp;publication_year=2011&amp;pages=e1001360&amp;pmid=21483755&amp;doi=10.1371/journal.pgen.1001360&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B236">236. <span class="mixed-citation">
Walshaw RC, Honeychurch J, Choudhury A, Illidge TM. <span class="ref-title">Toll-like receptor agonists and radiation therapy combinations: An untapped opportunity to induce anticancer immunity and improve tumor control</span>. <span class="ref-journal">Int J Radiat Oncol Biol Phys</span> (2020) <span class="ref-vol">108</span>(<span class="ref-iss">1</span>):27&#x02013;37. doi: 10.1016/j.ijrobp.2020.04.020
 [<a href="https://pubmed.ncbi.nlm.nih.gov/32339645" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ijrobp.2020.04.020" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Radiat+Oncol+Biol+Phys&amp;title=Toll-like+receptor+agonists+and+radiation+therapy+combinations:+An+untapped+opportunity+to+induce+anticancer+immunity+and+improve+tumor+control&amp;author=RC+Walshaw&amp;author=J+Honeychurch&amp;author=A+Choudhury&amp;author=TM+Illidge&amp;volume=108&amp;issue=1&amp;publication_year=2020&amp;pages=27-37&amp;pmid=32339645&amp;doi=10.1016/j.ijrobp.2020.04.020&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B237">237. <span class="mixed-citation">
Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, A&#x000ef;t-Yahia S, et al.. <span class="ref-title">Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites</span>. <span class="ref-journal">J Exp Med</span> (1998) <span class="ref-vol">188</span>(<span class="ref-iss">2</span>):373&#x02013;86. doi: 10.1084/jem.188.2.373
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2212459/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9670049" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1084%2Fjem.188.2.373" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Exp+Med&amp;title=Selective+recruitment+of+immature+and+mature+dendritic+cells+by+distinct+chemokines+expressed+in+different+anatomic+sites&amp;author=MC+Dieu&amp;author=B+Vanbervliet&amp;author=A+Vicari&amp;author=JM+Bridon&amp;author=E+Oldham&amp;volume=188&amp;issue=2&amp;publication_year=1998&amp;doi=10.1084/jem.188.2.373&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B238">238. <span class="mixed-citation">
F&#x000f6;rster R, Schubel A, Breitfeld D, Kremmer E, Renner-M&#x000fc;ller I, Wolf E, et al.. <span class="ref-title">CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs</span>. <span class="ref-journal">Cell</span> (1999) <span class="ref-vol">99</span>(<span class="ref-iss">1</span>):23&#x02013;33. doi: 10.1016/S0092-8674(00)80059-8
 [<a href="https://pubmed.ncbi.nlm.nih.gov/10520991" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS0092-8674(00)80059-8" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=CCR7+coordinates+the+primary+immune+response+by+establishing+functional+microenvironments+in+secondary+lymphoid+organs&amp;author=R+F&#x000f6;rster&amp;author=A+Schubel&amp;author=D+Breitfeld&amp;author=E+Kremmer&amp;author=I+Renner-M&#x000fc;ller&amp;volume=99&amp;issue=1&amp;publication_year=1999&amp;pages=23-33&amp;pmid=10520991&amp;doi=10.1016/S0092-8674(00)80059-8&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B239">239. <span class="mixed-citation">
Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, et al.. <span class="ref-title">Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation</span>. <span class="ref-journal">Eur J Immunol</span> (1998) <span class="ref-vol">28</span>(<span class="ref-iss">9</span>):2760&#x02013;9. doi: 10.1002/(SICI)1521-4141(199809)28:09&#x0003c;2760::AID-IMMU2760&#x0003e;3.0.CO;2-N
 [<a href="https://pubmed.ncbi.nlm.nih.gov/9754563" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2F(SICI)1521-4141(199809)28%3A09%3C2760%3A%3AAID-IMMU2760%3E3.0.CO%3B2-N" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Immunol&amp;title=Rapid+and+coordinated+switch+in+chemokine+receptor+expression+during+dendritic+cell+maturation&amp;author=F+Sallusto&amp;author=P+Schaerli&amp;author=P+Loetscher&amp;author=C+Schaniel&amp;author=D+Lenig&amp;volume=28&amp;issue=9&amp;publication_year=1998&amp;doi=10.1002/(SICI)1521-4141(199809)28:09&#x0003c;2760::AID-IMMU2760&#x0003e;3.0.CO;2-N&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B240">240. <span class="mixed-citation">
Janeway CA, Jr, Travers P, Walport M, Shlomchik MJ. <span class="ref-journal">Immunobiology: The immune system in health and disease</span>. 5th ed. New York: Garland Science;  (2001). <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Immunobiology:+The+immune+system+in+health+and+disease&amp;author=CA+Janeway&amp;author=P+Travers&amp;author=M+Walport&amp;author=MJ+Shlomchik&amp;publication_year=2001&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B241">241. <span class="mixed-citation">
Pasare C, Medzhitov R. <span class="ref-title">Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells</span>. <span class="ref-journal">Science</span> (2003) <span class="ref-vol">299</span>(<span class="ref-iss">5609</span>):1033&#x02013;6. doi: 10.1126/science.1078231
 [<a href="https://pubmed.ncbi.nlm.nih.gov/12532024" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fscience.1078231" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Toll+pathway-dependent+blockade+of+CD4+CD25++T+cell-mediated+suppression+by+dendritic+cells&amp;author=C+Pasare&amp;author=R+Medzhitov&amp;volume=299&amp;issue=5609&amp;publication_year=2003&amp;doi=10.1126/science.1078231&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B242">242. <span class="mixed-citation">
Durand V, Wong SY, Tough DF, Le Bon A. <span class="ref-title">IFN-alpha/beta-dependent cross-priming induced by specific toll-like receptor agonists</span>. <span class="ref-journal">Vaccine</span> (2006) <span class="ref-vol">24 Suppl 2</span>:S2&#x02013;22-3. doi:&#x000a0; 10.1016/j.vaccine.2005.01.115
 [<a href="https://pubmed.ncbi.nlm.nih.gov/16823911" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.vaccine.2005.01.115" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=IFN-alpha/beta-dependent+cross-priming+induced+by+specific+toll-like+receptor+agonists&amp;author=V+Durand&amp;author=SY+Wong&amp;author=DF+Tough&amp;author=A+Le+Bon&amp;volume=24+Suppl+2&amp;publication_year=2006&amp;pages=S2-22-3&amp;doi=10.1016/j.vaccine.2005.01.115&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B243">243. <span class="mixed-citation">
McBride S, Hoebe K, Georgel P, Janssen E. <span class="ref-title">Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN</span>. <span class="ref-journal">J Immunol</span> (2006) <span class="ref-vol">177</span>(<span class="ref-iss">9</span>):6122&#x02013;8. doi: 10.4049/jimmunol.177.9.6122
 [<a href="https://pubmed.ncbi.nlm.nih.gov/17056539" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.177.9.6122" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Cell-associated+double-stranded+RNA+enhances+antitumor+activity+through+the+production+of+type+I+IFN&amp;author=S+McBride&amp;author=K+Hoebe&amp;author=P+Georgel&amp;author=E+Janssen&amp;volume=177&amp;issue=9&amp;publication_year=2006&amp;doi=10.4049/jimmunol.177.9.6122&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B244">244. <span class="mixed-citation">
Datta SK, Redecke V, Prilliman KR, Takabayashi K, Corr M, Tallant T, et al.. <span class="ref-title">A subset of toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells</span>. <span class="ref-journal">J Immunol</span> (2003) <span class="ref-vol">170</span>(<span class="ref-iss">8</span>):4102&#x02013;10. doi: 10.4049/jimmunol.170.8.4102
 [<a href="https://pubmed.ncbi.nlm.nih.gov/12682240" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.170.8.4102" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=A+subset+of+toll-like+receptor+ligands+induces+cross-presentation+by+bone+marrow-derived+dendritic+cells&amp;author=SK+Datta&amp;author=V+Redecke&amp;author=KR+Prilliman&amp;author=K+Takabayashi&amp;author=M+Corr&amp;volume=170&amp;issue=8&amp;publication_year=2003&amp;doi=10.4049/jimmunol.170.8.4102&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B245">245. <span class="mixed-citation">
Schulz O, Diebold SS, Chen M, N&#x000e4;slund TI, Nolte MA, Alexopoulou L, et al.. <span class="ref-title">Toll-like receptor 3 promotes cross-priming to virus-infected cells</span>. <span class="ref-journal">Nature</span> (2005) <span class="ref-vol">433</span>(<span class="ref-iss">7028</span>):887&#x02013;92. doi: 10.1038/nature03326
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15711573" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnature03326" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Toll-like+receptor+3+promotes+cross-priming+to+virus-infected+cells&amp;author=O+Schulz&amp;author=SS+Diebold&amp;author=M+Chen&amp;author=TI+N&#x000e4;slund&amp;author=MA+Nolte&amp;volume=433&amp;issue=7028&amp;publication_year=2005&amp;doi=10.1038/nature03326&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B246">246. <span class="mixed-citation">
Benwell RK, Hruska JE, Fritsche KL, Lee DR. <span class="ref-title">Double stranded RNA- relative to other TLR ligand-activated dendritic cells induce extremely polarized human Th1 responses</span>. <span class="ref-journal">Cell Immunol</span> (2010) <span class="ref-vol">264</span>(<span class="ref-iss">2</span>):119&#x02013;26. doi: 10.1016/j.cellimm.2010.05.008
 [<a href="https://pubmed.ncbi.nlm.nih.gov/20547386" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cellimm.2010.05.008" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Immunol&amp;title=Double+stranded+RNA-+relative+to+other+TLR+ligand-activated+dendritic+cells+induce+extremely+polarized+human+Th1+responses&amp;author=RK+Benwell&amp;author=JE+Hruska&amp;author=KL+Fritsche&amp;author=DR+Lee&amp;volume=264&amp;issue=2&amp;publication_year=2010&amp;doi=10.1016/j.cellimm.2010.05.008&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B247">247. <span class="mixed-citation">
Smits EL, Ponsaerts P, Van de Velde AL, Van Driessche A, Cools N, Lenjou M, et al.. <span class="ref-title">Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells</span>. <span class="ref-journal">Leukemia</span> (2007) <span class="ref-vol">21</span>(<span class="ref-iss">8</span>):1691&#x02013;9. doi: 10.1038/sj.leu.2404763
 [<a href="https://pubmed.ncbi.nlm.nih.gov/17525722" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fsj.leu.2404763" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Proinflammatory+response+of+human+leukemic+cells+to+dsRNA+transfection+linked+to+activation+of+dendritic+cells&amp;author=EL+Smits&amp;author=P+Ponsaerts&amp;author=AL+Van+de+Velde&amp;author=A+Van+Driessche&amp;author=N+Cools&amp;volume=21&amp;issue=8&amp;publication_year=2007&amp;doi=10.1038/sj.leu.2404763&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B248">248. <span class="mixed-citation">
Verdijk RM, Mutis T, Esendam B, Kamp J, Melief CJ, Brand A, et al.. <span class="ref-title">Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells</span>. <span class="ref-journal">J Immunol</span> (1999) <span class="ref-vol">163</span>(<span class="ref-iss">1</span>):57&#x02013;61. [<a href="https://pubmed.ncbi.nlm.nih.gov/10384099" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Polyriboinosinic+polyribocytidylic+acid+(poly(I:C))+induces+stable+maturation+of+functionally+active+human+dendritic+cells&amp;author=RM+Verdijk&amp;author=T+Mutis&amp;author=B+Esendam&amp;author=J+Kamp&amp;author=CJ+Melief&amp;volume=163&amp;issue=1&amp;publication_year=1999&amp;pages=57-61&amp;pmid=10384099&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B249">249. <span class="mixed-citation">
Salem ML, Diaz-Montero CM, El-Naggar SA, Chen Y, Moussa O, Cole DJ. <span class="ref-title">The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into na&#x000ef;ve recipient mice</span>. <span class="ref-journal">Vaccine</span> (2009) <span class="ref-vol">27</span>(<span class="ref-iss">4</span>):549&#x02013;57. doi: 10.1016/j.vaccine.2008.11.013
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3072892/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19027047" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.vaccine.2008.11.013" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=The+TLR3+agonist+poly(I:C)+targets+CD8++T+cells+and+augments+their+antigen-specific+responses+upon+their+adoptive+transfer+into+na&#x000ef;ve+recipient+mice&amp;author=ML+Salem&amp;author=CM+Diaz-Montero&amp;author=SA+El-Naggar&amp;author=Y+Chen&amp;author=O+Moussa&amp;volume=27&amp;issue=4&amp;publication_year=2009&amp;doi=10.1016/j.vaccine.2008.11.013&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B250">250. <span class="mixed-citation">
Currie AJ, van der Most RG, Broomfield SA, Prosser AC, Tovey MG, Robinson BW. <span class="ref-title">Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors</span>. <span class="ref-journal">J Immunol</span> (2008) <span class="ref-vol">180</span>(<span class="ref-iss">3</span>):1535&#x02013;44. doi: 10.4049/jimmunol.180.3.1535
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18209049" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.180.3.1535" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Targeting+the+effector+site+with+IFN-alphabeta-inducing+TLR+ligands+reactivates+tumor-resident+CD8+T+cell+responses+to+eradicate+established+solid+tumors&amp;author=AJ+Currie&amp;author=RG+van+der+Most&amp;author=SA+Broomfield&amp;author=AC+Prosser&amp;author=MG+Tovey&amp;volume=180&amp;issue=3&amp;publication_year=2008&amp;doi=10.4049/jimmunol.180.3.1535&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B251">251. <span class="mixed-citation">
Lauzon NM, Mian F, MacKenzie R, Ashkar AA. <span class="ref-title">The direct effects of toll-like receptor ligands on human NK cell cytokine production and cytotoxicity</span>. <span class="ref-journal">Cell Immunol</span> (2006) <span class="ref-vol">241</span>(<span class="ref-iss">2</span>):102&#x02013;12. doi: 10.1016/j.cellimm.2006.08.004
 [<a href="https://pubmed.ncbi.nlm.nih.gov/17049504" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cellimm.2006.08.004" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Immunol&amp;title=The+direct+effects+of+toll-like+receptor+ligands+on+human+NK+cell+cytokine+production+and+cytotoxicity&amp;author=NM+Lauzon&amp;author=F+Mian&amp;author=R+MacKenzie&amp;author=AA+Ashkar&amp;volume=241&amp;issue=2&amp;publication_year=2006&amp;doi=10.1016/j.cellimm.2006.08.004&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B252">252. <span class="mixed-citation">
Schmidt KN, Leung B, Kwong M, Zarember KA, Satyal S, Navas TA, et al.. <span class="ref-title">APC-independent activation of NK cells by the toll-like receptor 3 agonist double-stranded RNA</span>. <span class="ref-journal">J Immunol</span> (2004) <span class="ref-vol">172</span>(<span class="ref-iss">1</span>):138&#x02013;43. doi: 10.4049/jimmunol.172.1.138
 [<a href="https://pubmed.ncbi.nlm.nih.gov/14688319" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.172.1.138" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=APC-independent+activation+of+NK+cells+by+the+toll-like+receptor+3+agonist+double-stranded+RNA&amp;author=KN+Schmidt&amp;author=B+Leung&amp;author=M+Kwong&amp;author=KA+Zarember&amp;author=S+Satyal&amp;volume=172&amp;issue=1&amp;publication_year=2004&amp;doi=10.4049/jimmunol.172.1.138&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B253">253. <span class="mixed-citation">
Miyake T, Kumagai Y, Kato H, Guo Z, Matsushita K, Satoh T, et al.. <span class="ref-title">Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells <em>via</em> the IPS-1 and TRIF-dependent pathways</span>. <span class="ref-journal">J Immunol</span> (2009) <span class="ref-vol">183</span>(<span class="ref-iss">4</span>):2522&#x02013;8. doi: 10.4049/jimmunol.0901500
 [<a href="https://pubmed.ncbi.nlm.nih.gov/19635904" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.0901500" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Poly+I:C-induced+activation+of+NK+cells+by+CD8+alpha++dendritic+cells+via+the+IPS-1+and+TRIF-dependent+pathways&amp;author=T+Miyake&amp;author=Y+Kumagai&amp;author=H+Kato&amp;author=Z+Guo&amp;author=K+Matsushita&amp;volume=183&amp;issue=4&amp;publication_year=2009&amp;doi=10.4049/jimmunol.0901500&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B254">254. <span class="mixed-citation">
Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, et al.. <span class="ref-title">Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors</span>. <span class="ref-journal">Proc Natl Acad Sci U.S.A.</span> (2012) <span class="ref-vol">109</span>(<span class="ref-iss">6</span>):2066&#x02013;71. doi: 10.1073/pnas.1113099109
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3277567/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22308357" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.1113099109" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U.S.A.&amp;title=Toll-like+receptor+3+signaling+converts+tumor-supporting+myeloid+cells+to+tumoricidal+effectors&amp;author=H+Shime&amp;author=M+Matsumoto&amp;author=H+Oshiumi&amp;author=S+Tanaka&amp;author=A+Nakane&amp;volume=109&amp;issue=6&amp;publication_year=2012&amp;doi=10.1073/pnas.1113099109&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B255">255. <span class="mixed-citation">
Vidyarthi A, Khan N, Agnihotri T, Negi S, Das DK, Aqdas M, et al.. <span class="ref-title">TLR-3 stimulation skews M2 macrophages to M1 through IFN-&#x003b1;&#x003b2; signaling and restricts tumor progression</span>. <span class="ref-journal">Front Immunol</span> (2018) <span class="ref-vol">9</span>:1650. doi: 10.3389/fimmu.2018.01650
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6060442/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30072995" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffimmu.2018.01650" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Immunol&amp;title=TLR-3+stimulation+skews+M2+macrophages+to+M1+through+IFN-&#x003b1;&#x003b2;+signaling+and+restricts+tumor+progression&amp;author=A+Vidyarthi&amp;author=N+Khan&amp;author=T+Agnihotri&amp;author=S+Negi&amp;author=DK+Das&amp;volume=9&amp;publication_year=2018&amp;pages=1650&amp;pmid=30072995&amp;doi=10.3389/fimmu.2018.01650&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B256">256. <span class="mixed-citation">
Yoshida S, Shime H, Takeda Y, Nam JM, Takashima K, Matsumoto M, et al.. <span class="ref-title">Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model</span>. <span class="ref-journal">Cancer Sci</span> (2018) <span class="ref-vol">109</span>(<span class="ref-iss">4</span>):956&#x02013;65. doi: 10.1111/cas.13543
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5891207/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29465830" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fcas.13543" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Sci&amp;title=Toll-like+receptor+3+signal+augments+radiation-induced+tumor+growth+retardation+in+a+murine+model&amp;author=S+Yoshida&amp;author=H+Shime&amp;author=Y+Takeda&amp;author=JM+Nam&amp;author=K+Takashima&amp;volume=109&amp;issue=4&amp;publication_year=2018&amp;doi=10.1111/cas.13543&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B257">257. <span class="mixed-citation">
Levine AS, Sivulich M, Wiernik PH, Levy HB. <span class="ref-title">Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-l-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer</span>. <span class="ref-journal">Cancer Res</span> (1979) <span class="ref-vol">39</span>(<span class="ref-iss">5</span>):1645&#x02013;50. [<a href="https://pubmed.ncbi.nlm.nih.gov/371793" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Initial+clinical+trials+in+cancer+patients+of+polyriboinosinic-polyribocytidylic+acid+stabilized+with+poly-l-lysine,+in+carboxymethylcellulose+[poly(ICLC)],+a+highly+effective+interferon+inducer&amp;author=AS+Levine&amp;author=M+Sivulich&amp;author=PH+Wiernik&amp;author=HB+Levy&amp;volume=39&amp;issue=5&amp;publication_year=1979&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B258">258. <span class="mixed-citation">
Hammerich L, Marron TU, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S, et al.. <span class="ref-title">Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination</span>. <span class="ref-journal">Nat Med</span> (2019) <span class="ref-vol">25</span>(<span class="ref-iss">5</span>):814&#x02013;24. doi: 10.1038/s41591-019-0410-x
 [<a href="https://pubmed.ncbi.nlm.nih.gov/30962585" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41591-019-0410-x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Med&amp;title=Systemic+clinical+tumor+regressions+and+potentiation+of+PD1+blockade+with+in+situ+vaccination&amp;author=L+Hammerich&amp;author=TU+Marron&amp;author=R+Upadhyay&amp;author=J+Svensson-Arvelund&amp;author=M+Dhainaut&amp;volume=25&amp;issue=5&amp;publication_year=2019&amp;doi=10.1038/s41591-019-0410-x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B259">259. <span class="mixed-citation">
Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H, et al.. <span class="ref-title">HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses</span>. <span class="ref-journal">Nature</span> (2009) <span class="ref-vol">462</span>(<span class="ref-iss">7269</span>):99&#x02013;103. doi: 10.1038/nature08512
 [<a href="https://pubmed.ncbi.nlm.nih.gov/19890330" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnature08512" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=HMGB+proteins+function+as+universal+sentinels+for+nucleic-acid-mediated+innate+immune+responses&amp;author=H+Yanai&amp;author=T+Ban&amp;author=Z+Wang&amp;author=MK+Choi&amp;author=T+Kawamura&amp;volume=462&amp;issue=7269&amp;publication_year=2009&amp;pages=99-103&amp;pmid=19890330&amp;doi=10.1038/nature08512&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B260">260. <span class="mixed-citation">
Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, et al.. <span class="ref-title">A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma</span>. <span class="ref-journal">Neuro Oncol</span> (2010) <span class="ref-vol">12</span>(<span class="ref-iss">10</span>):1071&#x02013;7. doi: 10.1093/neuonc/noq071
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3018929/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20615924" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fneuonc%2Fnoq071" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neuro+Oncol&amp;title=A+multi-institution+phase+II+study+of+poly-ICLC+and+radiotherapy+with+concurrent+and+adjuvant+temozolomide+in+adults+with+newly+diagnosed+glioblastoma&amp;author=MR+Rosenfeld&amp;author=MC+Chamberlain&amp;author=SA+Grossman&amp;author=DM+Peereboom&amp;author=GJ+Lesser&amp;volume=12&amp;issue=10&amp;publication_year=2010&amp;doi=10.1093/neuonc/noq071&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B261">261. <span class="mixed-citation">
Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, et al.. <span class="ref-title">A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a north American brain tumor consortium (NABTC01-05)</span>. <span class="ref-journal">J Neurooncol</span> (2009) <span class="ref-vol">91</span>(<span class="ref-iss">2</span>):175&#x02013;82. doi: 10.1007/s11060-008-9693-3
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4779120/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18797818" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs11060-008-9693-3" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurooncol&amp;title=A+phase+II+clinical+trial+of+poly-ICLC+with+radiation+for+adult+patients+with+newly+diagnosed+supratentorial+glioblastoma:+a+north+American+brain+tumor+consortium+(NABTC01-05)&amp;author=N+Butowski&amp;author=SM+Chang&amp;author=L+Junck&amp;author=LM+DeAngelis&amp;author=L+Abrey&amp;volume=91&amp;issue=2&amp;publication_year=2009&amp;doi=10.1007/s11060-008-9693-3&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B262">262. <span class="mixed-citation">
Spinetti T, Spagnuolo L, Mottas I, Secondini C, Treinies M, R&#x000fc;egg C, et al.. <span class="ref-title">TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function</span>. <span class="ref-journal">Oncoimmunology</span> (2016) <span class="ref-vol">5</span>(<span class="ref-iss">11</span>):e1230578. doi: 10.1080/2162402X.2016.1230578
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5139641/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27999739" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F2162402X.2016.1230578" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=TLR7-based+cancer+immunotherapy+decreases+intratumoral+myeloid-derived+suppressor+cells+and+blocks+their+immunosuppressive+function&amp;author=T+Spinetti&amp;author=L+Spagnuolo&amp;author=I+Mottas&amp;author=C+Secondini&amp;author=M+Treinies&amp;volume=5&amp;issue=11&amp;publication_year=2016&amp;pages=e1230578&amp;pmid=27999739&amp;doi=10.1080/2162402X.2016.1230578&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B263">263. <span class="mixed-citation">
Wang J, Shirota Y, Bayik D, Shirota H, Tross D, Gulley JL, et al.. <span class="ref-title">Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells</span>. <span class="ref-journal">J Immunol</span> (2015) <span class="ref-vol">194</span>(<span class="ref-iss">9</span>):4215&#x02013;21. doi: 10.4049/jimmunol.1402004
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4402268/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25825448" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.1402004" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Effect+of+TLR+agonists+on+the+differentiation+and+function+of+human+monocytic+myeloid-derived+suppressor+cells&amp;author=J+Wang&amp;author=Y+Shirota&amp;author=D+Bayik&amp;author=H+Shirota&amp;author=D+Tross&amp;volume=194&amp;issue=9&amp;publication_year=2015&amp;doi=10.4049/jimmunol.1402004&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B264">264. <span class="mixed-citation">
Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. <span class="ref-title">Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod</span>. <span class="ref-journal">J Immunol</span> (2005) <span class="ref-vol">174</span>(<span class="ref-iss">5</span>):2476&#x02013;80. doi: 10.4049/jimmunol.174.5.2476
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15728450" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.174.5.2476" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Cutting+edge:+priming+of+CTL+by+transcutaneous+peptide+immunization+with+imiquimod&amp;author=G+Rechtsteiner&amp;author=T+Warger&amp;author=P+Osterloh&amp;author=H+Schild&amp;author=MP+Radsak&amp;volume=174&amp;issue=5&amp;publication_year=2005&amp;doi=10.4049/jimmunol.174.5.2476&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B265">265. <span class="mixed-citation">
Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, et al.. <span class="ref-title">The impact of imiquimod, a toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand</span>. <span class="ref-journal">Cancer Immun</span> (2004) <span class="ref-vol">4</span>:9. [<a href="https://pubmed.ncbi.nlm.nih.gov/15384929" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Immun&amp;title=The+impact+of+imiquimod,+a+toll-like+receptor-7+ligand+(TLR7L),+on+the+immunogenicity+of+melanoma+peptide+vaccination+with+adjuvant+Flt3+ligand&amp;author=M+Shackleton&amp;author=ID+Davis&amp;author=W+Hopkins&amp;author=H+Jackson&amp;author=N+Dimopoulos&amp;volume=4&amp;publication_year=2004&amp;pages=9&amp;pmid=15384929&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B266">266. <span class="mixed-citation">
Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, et al.. <span class="ref-title">Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists</span>. <span class="ref-journal">Int Immunol</span> (2006) <span class="ref-vol">18</span>(<span class="ref-iss">7</span>):1115&#x02013;26. doi: 10.1093/intimm/dxl046
 [<a href="https://pubmed.ncbi.nlm.nih.gov/16728430" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fintimm%2Fdxl046" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+Immunol&amp;title=Distinct+indirect+pathways+govern+human+NK-cell+activation+by+TLR-7+and+TLR-8+agonists&amp;author=KS+Gorski&amp;author=EL+Waller&amp;author=J+Bjornton-Severson&amp;author=JA+Hanten&amp;author=CL+Riter&amp;volume=18&amp;issue=7&amp;publication_year=2006&amp;doi=10.1093/intimm/dxl046&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B267">267. <span class="mixed-citation">
Navi D, Huntley A. <span class="ref-title">Imiquimod 5 percent cream and the treatment of cutaneous malignancy</span>. <span class="ref-journal">Dermatol Online J</span> (2004) <span class="ref-vol">10</span>(<span class="ref-iss">1</span>):4. doi: 10.5070/D34VW339W4
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15347486" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.5070%2FD34VW339W4" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Dermatol+Online+J&amp;title=Imiquimod+5+percent+cream+and+the+treatment+of+cutaneous+malignancy&amp;author=D+Navi&amp;author=A+Huntley&amp;volume=10&amp;issue=1&amp;publication_year=2004&amp;pages=4&amp;doi=10.5070/D34VW339W4&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B268">268. <span class="mixed-citation">
Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, et al.. <span class="ref-title">Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function</span>. <span class="ref-journal">Science</span> (2005) <span class="ref-vol">309</span>(<span class="ref-iss">5739</span>):1380&#x02013;4. doi: 10.1126/science.1113401
 [<a href="https://pubmed.ncbi.nlm.nih.gov/16123302" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fscience.1113401" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Toll-like+receptor+8-mediated+reversal+of+CD4++regulatory+T+cell+function&amp;author=G+Peng&amp;author=Z+Guo&amp;author=Y+Kiniwa&amp;author=KS+Voo&amp;author=W+Peng&amp;volume=309&amp;issue=5739&amp;publication_year=2005&amp;doi=10.1126/science.1113401&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B269">269. <span class="mixed-citation">
Panelli MC, Stashower ME, Slade HB, Smith K, Norwood C, Abati A, et al.. <span class="ref-title">Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection</span>. <span class="ref-journal">Genome Biol</span> (2007) <span class="ref-vol">8</span>(<span class="ref-iss">1</span>):R8. doi:&#x000a0; 10.1186/gb-2007-8-1-r8
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1839129/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17222352" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fgb-2007-8-1-r8" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Genome+Biol&amp;title=Sequential+gene+profiling+of+basal+cell+carcinomas+treated+with+imiquimod+in+a+placebo-controlled+study+defines+the+requirements+for+tissue+rejection&amp;author=MC+Panelli&amp;author=ME+Stashower&amp;author=HB+Slade&amp;author=K+Smith&amp;author=C+Norwood&amp;volume=8&amp;issue=1&amp;publication_year=2007&amp;pages=R8&amp;pmid=17222352&amp;doi=10.1186/gb-2007-8-1-r8&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B270">270. <span class="mixed-citation">
Xiang AX, Webber SE, Kerr BM, Rueden EJ, Lennox JR, Haley GJ, et al.. <span class="ref-title">Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine</span>. <span class="ref-journal">Nucleosides Nucleotides Nucleic Acids</span> (2007) <span class="ref-vol">26</span>(<span class="ref-iss">6-7</span>):635&#x02013;40. doi: 10.1080/15257770701490472
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18066870" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F15257770701490472" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleosides+Nucleotides+Nucleic+Acids&amp;title=Discovery+of+ANA975:+an+oral+prodrug+of+the+TLR-7+agonist+isatoribine&amp;author=AX+Xiang&amp;author=SE+Webber&amp;author=BM+Kerr&amp;author=EJ+Rueden&amp;author=JR+Lennox&amp;volume=26&amp;issue=6-7&amp;publication_year=2007&amp;doi=10.1080/15257770701490472&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B271">271. <span class="mixed-citation">
PRESS RELEASE . <span class="ref-journal">Anadys Pharmaceuticals Discontinues Development of Hepatitis C Drug [press release]</span>. San Diego, CA: Fierce Biotech, (2007). <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Anadys+Pharmaceuticals+Discontinues+Development+of+Hepatitis+C+Drug+[press+release]&amp;publication_year=2007&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B272">272. <span class="mixed-citation">
Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al.. <span class="ref-title">A toll-like receptor recognizes bacterial DNA</span>. <span class="ref-journal">Nature</span> (2000) <span class="ref-vol">408</span>(<span class="ref-iss">6813</span>):740&#x02013;5. doi: 10.1038/35047123
 [<a href="https://pubmed.ncbi.nlm.nih.gov/11130078" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2F35047123" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=A+toll-like+receptor+recognizes+bacterial+DNA&amp;author=H+Hemmi&amp;author=O+Takeuchi&amp;author=T+Kawai&amp;author=T+Kaisho&amp;author=S+Sato&amp;volume=408&amp;issue=6813&amp;publication_year=2000&amp;doi=10.1038/35047123&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B273">273. <span class="mixed-citation">
Kawai T, Akira S. <span class="ref-title">The role of pattern-recognition receptors in innate immunity: update on toll-like receptors</span>. <span class="ref-journal">Nat Immunol</span> (2010) <span class="ref-vol">11</span>(<span class="ref-iss">5</span>):373&#x02013;84. doi: 10.1038/ni.1863
 [<a href="https://pubmed.ncbi.nlm.nih.gov/20404851" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fni.1863" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Immunol&amp;title=The+role+of+pattern-recognition+receptors+in+innate+immunity:+update+on+toll-like+receptors&amp;author=T+Kawai&amp;author=S+Akira&amp;volume=11&amp;issue=5&amp;publication_year=2010&amp;doi=10.1038/ni.1863&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B274">274. <span class="mixed-citation">
Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al.. <span class="ref-title">CpG motifs in bacterial DNA trigger direct b-cell activation</span>. <span class="ref-journal">Nature</span> (1995) <span class="ref-vol">374</span>(<span class="ref-iss">6522</span>):546&#x02013;9. doi: 10.1038/374546a0
 [<a href="https://pubmed.ncbi.nlm.nih.gov/7700380" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2F374546a0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=CpG+motifs+in+bacterial+DNA+trigger+direct+b-cell+activation&amp;author=AM+Krieg&amp;author=AK+Yi&amp;author=S+Matson&amp;author=TJ+Waldschmidt&amp;author=GA+Bishop&amp;volume=374&amp;issue=6522&amp;publication_year=1995&amp;doi=10.1038/374546a0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B275">275. <span class="mixed-citation">
H&#x000e4;cker H, Mischak H, H&#x000e4;cker G, Eser S, Prenzel N, Ullrich A, et al.. <span class="ref-title">Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells</span>. <span class="ref-journal">EMBO J</span> (1999) <span class="ref-vol">18</span>(<span class="ref-iss">24</span>):6973&#x02013;82. doi: 10.1093/emboj/18.24.6973
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1171760/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10601019" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Femboj%2F18.24.6973" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=EMBO+J&amp;title=Cell+type-specific+activation+of+mitogen-activated+protein+kinases+by+CpG-DNA+controls+interleukin-12+release+from+antigen-presenting+cells&amp;author=H+H&#x000e4;cker&amp;author=H+Mischak&amp;author=G+H&#x000e4;cker&amp;author=S+Eser&amp;author=N+Prenzel&amp;volume=18&amp;issue=24&amp;publication_year=1999&amp;doi=10.1093/emboj/18.24.6973&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B276">276. <span class="mixed-citation">
Hartmann G, Weiner GJ, Krieg AM. <span class="ref-title">CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells</span>. <span class="ref-journal">Proc Natl Acad Sci U.S.A.</span> (1999) <span class="ref-vol">96</span>(<span class="ref-iss">16</span>):9305&#x02013;10. doi: 10.1073/pnas.96.16.9305
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC17777/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10430938" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.96.16.9305" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U.S.A.&amp;title=CpG+DNA:+a+potent+signal+for+growth,+activation,+and+maturation+of+human+dendritic+cells&amp;author=G+Hartmann&amp;author=GJ+Weiner&amp;author=AM+Krieg&amp;volume=96&amp;issue=16&amp;publication_year=1999&amp;doi=10.1073/pnas.96.16.9305&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B277">277. <span class="mixed-citation">
Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC. <span class="ref-title">Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA</span>. <span class="ref-journal">J Immunol</span> (1998) <span class="ref-vol">161</span>(<span class="ref-iss">6</span>):3042&#x02013;9. [<a href="https://pubmed.ncbi.nlm.nih.gov/9743369" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Activation+of+cutaneous+dendritic+cells+by+CpG-containing+oligodeoxynucleotides:+a+role+for+dendritic+cells+in+the+augmentation+of+Th1+responses+by+immunostimulatory+DNA&amp;author=T+Jakob&amp;author=PS+Walker&amp;author=AM+Krieg&amp;author=MC+Udey&amp;author=JC+Vogel&amp;volume=161&amp;issue=6&amp;publication_year=1998&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B278">278. <span class="mixed-citation">
Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW, et al.. <span class="ref-title">Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells</span>. <span class="ref-journal">Eur J Immunol</span> (1998) <span class="ref-vol">28</span>(<span class="ref-iss">6</span>):2045&#x02013;54. doi: 10.1002/(SICI)1521-4141(199806)28:06&#x0003c;2045::AID-IMMU2045&#x0003e;3.0.CO;2-8
 [<a href="https://pubmed.ncbi.nlm.nih.gov/9645386" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2F(SICI)1521-4141(199806)28%3A06%3C2045%3A%3AAID-IMMU2045%3E3.0.CO%3B2-8" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Immunol&amp;title=Bacterial+DNA+and+immunostimulatory+CpG+oligonucleotides+trigger+maturation+and+activation+of+murine+dendritic+cells&amp;author=T+Sparwasser&amp;author=ES+Koch&amp;author=RM+Vabulas&amp;author=K+Heeg&amp;author=GB+Lipford&amp;volume=28&amp;issue=6&amp;publication_year=1998&amp;doi=10.1002/(SICI)1521-4141(199806)28:06&#x0003c;2045::AID-IMMU2045&#x0003e;3.0.CO;2-8&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B279">279. <span class="mixed-citation">
Shirota Y, Shirota H, Klinman DM. <span class="ref-title">Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells</span>. <span class="ref-journal">J Immunol</span> (2012) <span class="ref-vol">188</span>(<span class="ref-iss">4</span>):1592&#x02013;9. doi: 10.4049/jimmunol.1101304
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3273593/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22231700" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.1101304" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Intratumoral+injection+of+CpG+oligonucleotides+induces+the+differentiation+and+reduces+the+immunosuppressive+activity+of+myeloid-derived+suppressor+cells&amp;author=Y+Shirota&amp;author=H+Shirota&amp;author=DM+Klinman&amp;volume=188&amp;issue=4&amp;publication_year=2012&amp;doi=10.4049/jimmunol.1101304&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B280">280. <span class="mixed-citation">
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. <span class="ref-title">Regulatory T cells and immune tolerance</span>. <span class="ref-journal">Cell</span> (2008) <span class="ref-vol">133</span>(<span class="ref-iss">5</span>):775&#x02013;87. doi: 10.1016/j.cell.2008.05.009
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18510923" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cell.2008.05.009" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Regulatory+T+cells+and+immune+tolerance&amp;author=S+Sakaguchi&amp;author=T+Yamaguchi&amp;author=T+Nomura&amp;author=M+Ono&amp;volume=133&amp;issue=5&amp;publication_year=2008&amp;doi=10.1016/j.cell.2008.05.009&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B281">281. <span class="mixed-citation">
Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S, et al.. <span class="ref-title">Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of toll-like receptor 9</span>. <span class="ref-journal">Clin Cancer Res</span> (2009) <span class="ref-vol">15</span>(<span class="ref-iss">5</span>):1575&#x02013;84. doi: 10.1158/1078-0432.CCR-08-2628
 [<a href="https://pubmed.ncbi.nlm.nih.gov/19240169" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-08-2628" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Treatment+of+mammary+carcinomas+in+HER-2+transgenic+mice+through+combination+of+genetic+vaccine+and+an+agonist+of+toll-like+receptor+9&amp;author=L+Aurisicchio&amp;author=D+Peruzzi&amp;author=A+Conforti&amp;author=S+Dharmapuri&amp;author=A+Biondo&amp;volume=15&amp;issue=5&amp;publication_year=2009&amp;doi=10.1158/1078-0432.CCR-08-2628&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B282">282. <span class="mixed-citation">
Baines J, Celis E. <span class="ref-title">Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides</span>. <span class="ref-journal">Clin Cancer Res</span> (2003) <span class="ref-vol">9</span>(<span class="ref-iss">7</span>):2693&#x02013;700. [<a href="https://pubmed.ncbi.nlm.nih.gov/12855649" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Immune-mediated+tumor+regression+induced+by+CpG-containing+oligodeoxynucleotides&amp;author=J+Baines&amp;author=E+Celis&amp;volume=9&amp;issue=7&amp;publication_year=2003&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B283">283. <span class="mixed-citation">
Blazar BR, Krieg AM, Taylor PA. <span class="ref-title">Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients</span>. <span class="ref-journal">Blood</span> (2001) <span class="ref-vol">98</span>(<span class="ref-iss">4</span>):1217&#x02013;25. doi: 10.1182/blood.V98.4.1217
 [<a href="https://pubmed.ncbi.nlm.nih.gov/11493473" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1182%2Fblood.V98.4.1217" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Synthetic+unmethylated+cytosine-phosphate-guanosine+oligodeoxynucleotides+are+potent+stimulators+of+antileukemia+responses+in+naive+and+bone+marrow+transplant+recipients&amp;author=BR+Blazar&amp;author=AM+Krieg&amp;author=PA+Taylor&amp;volume=98&amp;issue=4&amp;publication_year=2001&amp;doi=10.1182/blood.V98.4.1217&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B284">284. <span class="mixed-citation">
Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann PV, Tary-Lehmann M. <span class="ref-title">Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity</span>. <span class="ref-journal">J Immunol</span> (2003) <span class="ref-vol">171</span>(<span class="ref-iss">8</span>):3941&#x02013;6. doi: 10.4049/jimmunol.171.8.3941
 [<a href="https://pubmed.ncbi.nlm.nih.gov/14530311" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.171.8.3941" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Intratumor+CpG-oligodeoxynucleotide+injection+induces+protective+antitumor+T+cell+immunity&amp;author=AS+Lonsdorf&amp;author=H+Kuekrek&amp;author=BV+Stern&amp;author=BO+Boehm&amp;author=PV+Lehmann&amp;volume=171&amp;issue=8&amp;publication_year=2003&amp;doi=10.4049/jimmunol.171.8.3941&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B285">285. <span class="mixed-citation">
Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, H&#x000e4;mmerling GJ. <span class="ref-title">NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides</span>. <span class="ref-journal">J Immunol</span> (2001) <span class="ref-vol">167</span>(<span class="ref-iss">9</span>):5247&#x02013;53. doi: 10.4049/jimmunol.167.9.5247
 [<a href="https://pubmed.ncbi.nlm.nih.gov/11673539" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.167.9.5247" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=NK-+and+CD8(+)+T+cell-mediated+eradication+of+established+tumors+by+peritumoral+injection+of+CpG-containing+oligodeoxynucleotides&amp;author=Y+Kawarada&amp;author=R+Ganss&amp;author=N+Garbi&amp;author=T+Sacher&amp;author=B+Arnold&amp;volume=167&amp;issue=9&amp;publication_year=2001&amp;doi=10.4049/jimmunol.167.9.5247&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B286">286. <span class="mixed-citation">
Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al.. <span class="ref-title">In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study</span>. <span class="ref-journal">J Clin Oncol</span> (2010) <span class="ref-vol">28</span>(<span class="ref-iss">28</span>):4324&#x02013;32. doi: 10.1200/JCO.2010.28.9793
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2954133/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20697067" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1200%2FJCO.2010.28.9793" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=In+situ+vaccination+with+a+TLR9+agonist+induces+systemic+lymphoma+regression:+a+phase+I/II+study&amp;author=JD+Brody&amp;author=WZ+Ai&amp;author=DK+Czerwinski&amp;author=JA+Torchia&amp;author=M+Levy&amp;volume=28&amp;issue=28&amp;publication_year=2010&amp;doi=10.1200/JCO.2010.28.9793&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B287">287. <span class="mixed-citation">
Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al.. <span class="ref-title">The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses</span>. <span class="ref-journal">Nat Immunol</span> (2004) <span class="ref-vol">5</span>(<span class="ref-iss">7</span>):730&#x02013;7. doi: 10.1038/ni1087
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15208624" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fni1087" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Immunol&amp;title=The+RNA+helicase+RIG-I+has+an+essential+function+in+double-stranded+RNA-induced+innate+antiviral+responses&amp;author=M+Yoneyama&amp;author=M+Kikuchi&amp;author=T+Natsukawa&amp;author=N+Shinobu&amp;author=T+Imaizumi&amp;volume=5&amp;issue=7&amp;publication_year=2004&amp;doi=10.1038/ni1087&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B288">288. <span class="mixed-citation">
Fitzgerald ME, Rawling DC, Vela A, Pyle AM. <span class="ref-title">An evolving arsenal: viral RNA detection by RIG-i-like receptors</span>. <span class="ref-journal">Curr Opin Microbiol</span> (2014) <span class="ref-vol">20</span>:76&#x02013;81. doi: 10.1016/j.mib.2014.05.004
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7108371/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24912143" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.mib.2014.05.004" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+Opin+Microbiol&amp;title=An+evolving+arsenal:+viral+RNA+detection+by+RIG-i-like+receptors&amp;author=ME+Fitzgerald&amp;author=DC+Rawling&amp;author=A+Vela&amp;author=AM+Pyle&amp;volume=20&amp;publication_year=2014&amp;pages=76-81&amp;pmid=24912143&amp;doi=10.1016/j.mib.2014.05.004&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B289">289. <span class="mixed-citation">
Feng Q, Hato SV, Langereis MA, Zoll J, Virgen-Slane R, Peisley A, et al.. <span class="ref-title">MDA5 detects the double-stranded RNA replicative form in picornavirus-infected cells</span>. <span class="ref-journal">Cell Rep</span> (2012) <span class="ref-vol">2</span>(<span class="ref-iss">5</span>):1187&#x02013;96. doi: 10.1016/j.celrep.2012.10.005
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7103987/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23142662" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.celrep.2012.10.005" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Rep&amp;title=MDA5+detects+the+double-stranded+RNA+replicative+form+in+picornavirus-infected+cells&amp;author=Q+Feng&amp;author=SV+Hato&amp;author=MA+Langereis&amp;author=J+Zoll&amp;author=R+Virgen-Slane&amp;volume=2&amp;issue=5&amp;publication_year=2012&amp;doi=10.1016/j.celrep.2012.10.005&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B290">290. <span class="mixed-citation">
Guo G, Gao M, Gao X, Zhu B, Huang J, Tu X, et al.. <span class="ref-title">Reciprocal regulation of RIG-I and XRCC4 connects DNA repair with RIG-I immune signaling</span>. <span class="ref-journal">Nat Commun</span> (2021) <span class="ref-vol">12</span>(<span class="ref-iss">1</span>):2187. doi: 10.1038/s41467-021-22484-7
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8041803/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33846346" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41467-021-22484-7" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Commun&amp;title=Reciprocal+regulation+of+RIG-I+and+XRCC4+connects+DNA+repair+with+RIG-I+immune+signaling&amp;author=G+Guo&amp;author=M+Gao&amp;author=X+Gao&amp;author=B+Zhu&amp;author=J+Huang&amp;volume=12&amp;issue=1&amp;publication_year=2021&amp;pages=2187&amp;pmid=33846346&amp;doi=10.1038/s41467-021-22484-7&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B291">291. <span class="mixed-citation">
Poeck H, Wintges A, Dahl S, Bassermann F, Haas T, Heidegger S. <span class="ref-title">Tumor cell-intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in mice</span>. <span class="ref-journal">Eur J Immunol</span> (2021) <span class="ref-vol">51</span>(<span class="ref-iss">6</span>):1531&#x02013;4. doi: 10.1002/eji.202049158
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33733474" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Feji.202049158" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Immunol&amp;title=Tumor+cell-intrinsic+RIG-I+signaling+governs+synergistic+effects+of+immunogenic+cancer+therapies+and+checkpoint+inhibitors+in+mice&amp;author=H+Poeck&amp;author=A+Wintges&amp;author=S+Dahl&amp;author=F+Bassermann&amp;author=T+Haas&amp;volume=51&amp;issue=6&amp;publication_year=2021&amp;doi=10.1002/eji.202049158&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B292">292. <span class="mixed-citation">
Besch R, Poeck H, Hohenauer T, Senft D, H&#x000e4;cker G, Berking C, et al.. <span class="ref-title">Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells</span>. <span class="ref-journal">J Clin Invest</span> (2009) <span class="ref-vol">119</span>(<span class="ref-iss">8</span>):2399&#x02013;411. doi: 10.1172/JCI37155
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2719920/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19620789" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1172%2FJCI37155" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Invest&amp;title=Proapoptotic+signaling+induced+by+RIG-I+and+MDA-5+results+in+type+I+interferon-independent+apoptosis+in+human+melanoma+cells&amp;author=R+Besch&amp;author=H+Poeck&amp;author=T+Hohenauer&amp;author=D+Senft&amp;author=G+H&#x000e4;cker&amp;volume=119&amp;issue=8&amp;publication_year=2009&amp;doi=10.1172/JCI37155&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B293">293. <span class="mixed-citation">
Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al.. <span class="ref-title">DNA-Demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts</span>. <span class="ref-journal">Cell</span> (2015) <span class="ref-vol">162</span>(<span class="ref-iss">5</span>):961&#x02013;73. doi: 10.1016/j.cell.2015.07.056
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4843502/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26317465" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cell.2015.07.056" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=DNA-Demethylating+agents+target+colorectal+cancer+cells+by+inducing+viral+mimicry+by+endogenous+transcripts&amp;author=D+Roulois&amp;author=H+Loo+Yau&amp;author=R+Singhania&amp;author=Y+Wang&amp;author=A+Danesh&amp;volume=162&amp;issue=5&amp;publication_year=2015&amp;doi=10.1016/j.cell.2015.07.056&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B294">294. <span class="mixed-citation">
Ellermeier J, Wei J, Duewell P, Hoves S, Stieg MR, Adunka T, et al.. <span class="ref-title">Therapeutic efficacy of bifunctional siRNA combining TGF-&#x003b2;1 silencing with RIG-I activation in pancreatic cancer</span>. <span class="ref-journal">Cancer Res</span> (2013) <span class="ref-vol">73</span>(<span class="ref-iss">6</span>):1709&#x02013;20. doi: 10.1158/0008-5472.CAN-11-3850
 [<a href="https://pubmed.ncbi.nlm.nih.gov/23338611" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-11-3850" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Therapeutic+efficacy+of+bifunctional+siRNA+combining+TGF-&#x003b2;1+silencing+with+RIG-I+activation+in+pancreatic+cancer&amp;author=J+Ellermeier&amp;author=J+Wei&amp;author=P+Duewell&amp;author=S+Hoves&amp;author=MR+Stieg&amp;volume=73&amp;issue=6&amp;publication_year=2013&amp;doi=10.1158/0008-5472.CAN-11-3850&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B295">295. <span class="mixed-citation">
K&#x000fc;bler K, Gehrke N, Riemann S, B&#x000f6;hnert V, Zillinger T, Hartmann E, et al.. <span class="ref-title">Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells</span>. <span class="ref-journal">Cancer Res</span> (2010) <span class="ref-vol">70</span>(<span class="ref-iss">13</span>):5293&#x02013;304. doi: 10.1158/0008-5472.CAN-10-0825
 [<a href="https://pubmed.ncbi.nlm.nih.gov/20551064" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-10-0825" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Targeted+activation+of+RNA+helicase+retinoic+acid-inducible+gene-I+induces+proimmunogenic+apoptosis+of+human+ovarian+cancer+cells&amp;author=K+K&#x000fc;bler&amp;author=N+Gehrke&amp;author=S+Riemann&amp;author=V+B&#x000f6;hnert&amp;author=T+Zillinger&amp;volume=70&amp;issue=13&amp;publication_year=2010&amp;doi=10.1158/0008-5472.CAN-10-0825&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B296">296. <span class="mixed-citation">
Duewell P, Steger A, Lohr H, Bourhis H, Hoelz H, Kirchleitner SV, et al.. <span class="ref-title">RIG-i-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells</span>. <span class="ref-journal">Cell Death Differ</span> (2014) <span class="ref-vol">21</span>(<span class="ref-iss">12</span>):1825&#x02013;37. doi: 10.1038/cdd.2014.96
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4227156/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25012502" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fcdd.2014.96" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Death+Differ&amp;title=RIG-i-like+helicases+induce+immunogenic+cell+death+of+pancreatic+cancer+cells+and+sensitize+tumors+toward+killing+by+CD8(+)+T+cells&amp;author=P+Duewell&amp;author=A+Steger&amp;author=H+Lohr&amp;author=H+Bourhis&amp;author=H+Hoelz&amp;volume=21&amp;issue=12&amp;publication_year=2014&amp;doi=10.1038/cdd.2014.96&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B297">297. <span class="mixed-citation">
Engel C, Br&#x000fc;gmann G, Lambing S, M&#x000fc;hlenbeck LH, Marx S, Hagen C, et al.. <span class="ref-title">RIG-I resists hypoxia-induced immunosuppression and dedifferentiation</span>. <span class="ref-journal">Cancer Immunol Res</span> (2017) <span class="ref-vol">5</span>(<span class="ref-iss">6</span>):455&#x02013;67. doi: 10.1158/2326-6066.CIR-16-0129-T
 [<a href="https://pubmed.ncbi.nlm.nih.gov/28468914" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F2326-6066.CIR-16-0129-T" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Immunol+Res&amp;title=RIG-I+resists+hypoxia-induced+immunosuppression+and+dedifferentiation&amp;author=C+Engel&amp;author=G+Br&#x000fc;gmann&amp;author=S+Lambing&amp;author=LH+M&#x000fc;hlenbeck&amp;author=S+Marx&amp;volume=5&amp;issue=6&amp;publication_year=2017&amp;doi=10.1158/2326-6066.CIR-16-0129-T&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B298">298. <span class="mixed-citation">
Zhu H, Xu WY, Hu Z, Zhang H, Shen Y, Lu S, et al.. <span class="ref-title">RNA Virus receptor rig-I monitors gut microbiota and inhibits colitis-associated colorectal cancer</span>. <span class="ref-journal">J Exp Clin Cancer Res</span> (2017) <span class="ref-vol">36</span>(<span class="ref-iss">1</span>):2. doi: 10.1186/s13046-016-0471-3
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5217425/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28057020" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs13046-016-0471-3" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Exp+Clin+Cancer+Res&amp;title=RNA+Virus+receptor+rig-I+monitors+gut+microbiota+and+inhibits+colitis-associated+colorectal+cancer&amp;author=H+Zhu&amp;author=WY+Xu&amp;author=Z+Hu&amp;author=H+Zhang&amp;author=Y+Shen&amp;volume=36&amp;issue=1&amp;publication_year=2017&amp;pages=2&amp;pmid=28057020&amp;doi=10.1186/s13046-016-0471-3&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B299">299. <span class="mixed-citation">
Ranoa DR, Parekh AD, Pitroda SP, Huang X, Darga T, Wong AC, et al.. <span class="ref-title">Cancer therapies activate RIG-i-like receptor pathway through endogenous non-coding RNAs</span>. <span class="ref-journal">Oncotarget</span> (2016) <span class="ref-vol">7</span>(<span class="ref-iss">18</span>):26496&#x02013;515. doi: 10.18632/oncotarget.8420
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5041995/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27034163" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.18632%2Foncotarget.8420" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Cancer+therapies+activate+RIG-i-like+receptor+pathway+through+endogenous+non-coding+RNAs&amp;author=DR+Ranoa&amp;author=AD+Parekh&amp;author=SP+Pitroda&amp;author=X+Huang&amp;author=T+Darga&amp;volume=7&amp;issue=18&amp;publication_year=2016&amp;doi=10.18632/oncotarget.8420&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B300">300. <span class="mixed-citation">
Jiang X, Muthusamy V, Fedorova O, Kong Y, Kim DJ, Bosenberg M, et al.. <span class="ref-title">Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses</span>. <span class="ref-journal">J Exp Med</span> (2019) <span class="ref-vol">216</span>(<span class="ref-iss">12</span>):2854&#x02013;68. doi: 10.1084/jem.20190801
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6888973/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31601678" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1084%2Fjem.20190801" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Exp+Med&amp;title=Intratumoral+delivery+of+RIG-I+agonist+SLR14+induces+robust+antitumor+responses&amp;author=X+Jiang&amp;author=V+Muthusamy&amp;author=O+Fedorova&amp;author=Y+Kong&amp;author=DJ+Kim&amp;volume=216&amp;issue=12&amp;publication_year=2019&amp;doi=10.1084/jem.20190801&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B301">301. <span class="mixed-citation">
Sato Y, Yoshino H, Tsuruga E, Kashiwakura I. <span class="ref-title">Fas ligand enhances apoptosis of human lung cancer cells cotreated with RIG-i-like receptor agonist and radiation</span>. <span class="ref-journal">Curr Cancer Drug Targets</span> (2020) <span class="ref-vol">20</span>(<span class="ref-iss">5</span>):372&#x02013;81. doi: 10.2174/1568009620666200115161717
 [<a href="https://pubmed.ncbi.nlm.nih.gov/31951181" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2174%2F1568009620666200115161717" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+Cancer+Drug+Targets&amp;title=Fas+ligand+enhances+apoptosis+of+human+lung+cancer+cells+cotreated+with+RIG-i-like+receptor+agonist+and+radiation&amp;author=Y+Sato&amp;author=H+Yoshino&amp;author=E+Tsuruga&amp;author=I+Kashiwakura&amp;volume=20&amp;issue=5&amp;publication_year=2020&amp;doi=10.2174/1568009620666200115161717&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B302">302. <span class="mixed-citation">
Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. <span class="ref-title">Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance</span>. <span class="ref-journal">Immunity</span> (2013) <span class="ref-vol">39</span>(<span class="ref-iss">1</span>):74&#x02013;88. doi: 10.1016/j.immuni.2013.06.014
 [<a href="https://pubmed.ncbi.nlm.nih.gov/23890065" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.immuni.2013.06.014" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=Mechanism+of+action+of+conventional+and+targeted+anticancer+therapies:+reinstating+immunosurveillance&amp;author=L+Zitvogel&amp;author=L+Galluzzi&amp;author=MJ+Smyth&amp;author=G+Kroemer&amp;volume=39&amp;issue=1&amp;publication_year=2013&amp;pages=74-88&amp;pmid=23890065&amp;doi=10.1016/j.immuni.2013.06.014&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B303">303. <span class="mixed-citation">
Barber GN. <span class="ref-title">STING: infection, inflammation and cancer</span>. <span class="ref-journal">Nat Rev Immunol</span> (2015) <span class="ref-vol">15</span>(<span class="ref-iss">12</span>):760&#x02013;70. doi: 10.1038/nri3921
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5004891/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26603901" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnri3921" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Immunol&amp;title=STING:+infection,+inflammation+and+cancer&amp;author=GN+Barber&amp;volume=15&amp;issue=12&amp;publication_year=2015&amp;doi=10.1038/nri3921&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B304">304. <span class="mixed-citation">
Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, et al.. <span class="ref-title">Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer</span>. <span class="ref-journal">Breast Cancer Res</span> (2016) <span class="ref-vol">18</span>(<span class="ref-iss">1</span>):10. doi: 10.1186/s13058-015-0669-x
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4727393/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26810608" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs13058-015-0669-x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res&amp;title=Lymphocyte+depletion+and+repopulation+after+chemotherapy+for+primary+breast+cancer&amp;author=R+Verma&amp;author=RE+Foster&amp;author=K+Horgan&amp;author=K+Mounsey&amp;author=H+Nixon&amp;volume=18&amp;issue=1&amp;publication_year=2016&amp;pages=10&amp;pmid=26810608&amp;doi=10.1186/s13058-015-0669-x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B305">305. <span class="mixed-citation">
Matiello J, Dal Pra A, Zardo L, Silva R, Berton DC. <span class="ref-title">Impacts of post-radiotherapy lymphocyte count on progression-free and overall survival in patients with stage III lung cancer</span>. <span class="ref-journal">Thorac Cancer</span> (2020) <span class="ref-vol">11</span>(<span class="ref-iss">11</span>):3139&#x02013;44. doi: 10.1111/1759-7714.13621
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7606004/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32956564" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2F1759-7714.13621" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Thorac+Cancer&amp;title=Impacts+of+post-radiotherapy+lymphocyte+count+on+progression-free+and+overall+survival+in+patients+with+stage+III+lung+cancer&amp;author=J+Matiello&amp;author=A+Dal+Pra&amp;author=L+Zardo&amp;author=R+Silva&amp;author=DC+Berton&amp;volume=11&amp;issue=11&amp;publication_year=2020&amp;doi=10.1111/1759-7714.13621&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B306">306. <span class="mixed-citation">
Ahn S, Park JS, Jang J, Ahn KJ, Hong YK, Yang SH, et al.. <span class="ref-title">The association between total lymphocyte count after concomitant chemoradiation and overall survival in patients with newly diagnosed glioblastoma</span>. <span class="ref-journal">J Clin Neurosci</span> (2020) <span class="ref-vol">71</span>:21&#x02013;5. doi: 10.1016/j.jocn.2019.11.017
 [<a href="https://pubmed.ncbi.nlm.nih.gov/31843432" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.jocn.2019.11.017" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Neurosci&amp;title=The+association+between+total+lymphocyte+count+after+concomitant+chemoradiation+and+overall+survival+in+patients+with+newly+diagnosed+glioblastoma&amp;author=S+Ahn&amp;author=JS+Park&amp;author=J+Jang&amp;author=KJ+Ahn&amp;author=YK+Hong&amp;volume=71&amp;publication_year=2020&amp;doi=10.1016/j.jocn.2019.11.017&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B307">307. <span class="mixed-citation">
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al.. <span class="ref-title">Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade</span>. <span class="ref-journal">Science</span> (2016) <span class="ref-vol">351</span>(<span class="ref-iss">6280</span>):1463&#x02013;9. doi: 10.1126/science.aaf1490
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4984254/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26940869" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fscience.aaf1490" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Clonal+neoantigens+elicit+T+cell+immunoreactivity+and+sensitivity+to+immune+checkpoint+blockade&amp;author=N+McGranahan&amp;author=AJ+Furness&amp;author=R+Rosenthal&amp;author=S+Ramskov&amp;author=R+Lyngaa&amp;volume=351&amp;issue=6280&amp;publication_year=2016&amp;doi=10.1126/science.aaf1490&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B308">308. <span class="mixed-citation">
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al.. <span class="ref-title">Genomic correlates of response to CTLA-4 blockade in metastatic melanoma</span>. <span class="ref-journal">Science</span> (2015) <span class="ref-vol">350</span>(<span class="ref-iss">6257</span>):207&#x02013;11. doi: 10.1126/science.aad0095
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5054517/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26359337" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fscience.aad0095" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Genomic+correlates+of+response+to+CTLA-4+blockade+in+metastatic+melanoma&amp;author=EM+Van+Allen&amp;author=D+Miao&amp;author=B+Schilling&amp;author=SA+Shukla&amp;author=C+Blank&amp;volume=350&amp;issue=6257&amp;publication_year=2015&amp;doi=10.1126/science.aad0095&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B309">309. <span class="mixed-citation">
Brown JM. <span class="ref-title">Beware of clinical trials of DNA repair inhibitors</span>. <span class="ref-journal">Int J Radiat Oncol Biol Phys</span> (2019) <span class="ref-vol">103</span>(<span class="ref-iss">5</span>):1182&#x02013;3. doi: 10.1016/j.ijrobp.2018.11.063
 [<a href="https://pubmed.ncbi.nlm.nih.gov/30529372" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ijrobp.2018.11.063" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Radiat+Oncol+Biol+Phys&amp;title=Beware+of+clinical+trials+of+DNA+repair+inhibitors&amp;author=JM+Brown&amp;volume=103&amp;issue=5&amp;publication_year=2019&amp;doi=10.1016/j.ijrobp.2018.11.063&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B310">310. <span class="mixed-citation">
Zenke FT, Zimmermann A, Sirrenberg C, Dahmen H, Kirkin V, Pehl U, et al.. <span class="ref-title">Pharmacologic inhibitor of DNA-PK, M3814, potentiates radiotherapy and regresses human tumors in mouse models</span>. <span class="ref-journal">Mol Cancer Ther</span> (2020) <span class="ref-vol">19</span>(<span class="ref-iss">5</span>):1091&#x02013;101. doi: 10.1158/1535-7163.MCT-19-0734
 [<a href="https://pubmed.ncbi.nlm.nih.gov/32220971" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.MCT-19-0734" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Pharmacologic+inhibitor+of+DNA-PK,+M3814,+potentiates+radiotherapy+and+regresses+human+tumors+in+mouse+models&amp;author=FT+Zenke&amp;author=A+Zimmermann&amp;author=C+Sirrenberg&amp;author=H+Dahmen&amp;author=V+Kirkin&amp;volume=19&amp;issue=5&amp;publication_year=2020&amp;doi=10.1158/1535-7163.MCT-19-0734&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B311">311. <span class="mixed-citation">
Mau-Sorensen M, Kuipers M, Nielsen DL, Verheul HM, Aftimos P, de Jonge MJA, et al.. <span class="ref-title">Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: results from two phase I trials, in ESMO 2017 congress. 2018</span>. <span class="ref-journal">Annals of Oncology</span> (2018) <span class="ref-vol">29</span>(<span class="ref-iss">suppl_8</span>):viii649&#x02013;viii669. doi:&#x000a0; 10.1093/annonc/mdy303.015
 [<a href="//doi.org/10.1093%2Fannonc%2Fmdy303.015" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annals+of+Oncology&amp;title=Safety,+clinical+activity+and+pharmacological+biomarker+evaluation+of+the+DNA-dependent+protein+kinase+(DNA-PK)+inhibitor+M3814:+results+from+two+phase+I+trials,+in+ESMO+2017+congress.+2018&amp;author=M+Mau-Sorensen&amp;author=M+Kuipers&amp;author=DL+Nielsen&amp;author=HM+Verheul&amp;author=P+Aftimos&amp;volume=29&amp;issue=suppl_8&amp;publication_year=2018&amp;pages=viii649-viii669&amp;doi=10.1093/annonc/mdy303.015&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B312">312. <span class="mixed-citation">
Wong WW, Jackson RK, Liew LP, Dickson BD, Cheng GJ, Lipert B, et al.. <span class="ref-title">Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361</span>. <span class="ref-journal">Biochem Pharmacol</span> (2019) <span class="ref-vol">169</span>:113641. doi: 10.1016/j.bcp.2019.113641
 [<a href="https://pubmed.ncbi.nlm.nih.gov/31541630" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.bcp.2019.113641" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Pharmacol&amp;title=Hypoxia-selective+radiosensitisation+by+SN38023,+a+bioreductive+prodrug+of+DNA-dependent+protein+kinase+inhibitor+IC87361&amp;author=WW+Wong&amp;author=RK+Jackson&amp;author=LP+Liew&amp;author=BD+Dickson&amp;author=GJ+Cheng&amp;volume=169&amp;publication_year=2019&amp;pages=113641&amp;pmid=31541630&amp;doi=10.1016/j.bcp.2019.113641&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B313">313. <span class="mixed-citation">
Alastair HK, Baker JHE, Fryer KH, Bana&#x000e1;th J, Wang T, Porres SS, et al.. <span class="ref-title">Hypoxia-selective DNA-PK inhibitor [abstract]</span>. In: <span class="ref-journal">AACR-NCI-EORTC international conference</span>. Philadelphia, PA: AACR; Mol Cancer Ther;  (2017). <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=AACR-NCI-EORTC+international+conference&amp;author=HK+Alastair&amp;author=JHE+Baker&amp;author=KH+Fryer&amp;author=J+Bana&#x000e1;th&amp;author=T+Wang&amp;publication_year=2017&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B314">314. <span class="mixed-citation">
Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al.. <span class="ref-title">Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated</span>. <span class="ref-journal">Int J Radiat Oncol Biol Phys</span> (2004) <span class="ref-vol">58</span>(<span class="ref-iss">3</span>):862&#x02013;70. doi: 10.1016/j.ijrobp.2003.09.012
 [<a href="https://pubmed.ncbi.nlm.nih.gov/14967443" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ijrobp.2003.09.012" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Radiat+Oncol+Biol+Phys&amp;title=Ionizing+radiation+inhibition+of+distant+untreated+tumors+(abscopal+effect)+is+immune+mediated&amp;author=S+Demaria&amp;author=B+Ng&amp;author=ML+Devitt&amp;author=JS+Babb&amp;author=N+Kawashima&amp;volume=58&amp;issue=3&amp;publication_year=2004&amp;doi=10.1016/j.ijrobp.2003.09.012&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B315">315. <span class="mixed-citation">
Ko EC, Benjamin KT, Formenti SC. <span class="ref-title">Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation</span>. <span class="ref-journal">Adv Radiat Oncol</span> (2018) <span class="ref-vol">3</span>(<span class="ref-iss">4</span>):486&#x02013;93. doi: 10.1016/j.adro.2018.08.021
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6200901/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30370347" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.adro.2018.08.021" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Adv+Radiat+Oncol&amp;title=Generating+antitumor+immunity+by+targeted+radiation+therapy:+Role+of+dose+and+fractionation&amp;author=EC+Ko&amp;author=KT+Benjamin&amp;author=SC+Formenti&amp;volume=3&amp;issue=4&amp;publication_year=2018&amp;doi=10.1016/j.adro.2018.08.021&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B316">316. <span class="mixed-citation">
Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, et al.. <span class="ref-title">Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy</span>. <span class="ref-journal">Clin Cancer Res</span> (2018) <span class="ref-vol">24</span>(<span class="ref-iss">20</span>):5058&#x02013;71. doi: 10.1158/1078-0432.CCR-17-3427
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6532976/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29898992" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-17-3427" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Elective+nodal+irradiation+attenuates+the+combinatorial+efficacy+of+stereotactic+radiation+therapy+and+immunotherapy&amp;author=AE+Marciscano&amp;author=A+Ghasemzadeh&amp;author=TR+Nirschl&amp;author=D+Theodros&amp;author=CM+Kochel&amp;volume=24&amp;issue=20&amp;publication_year=2018&amp;doi=10.1158/1078-0432.CCR-17-3427&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B317">317. <span class="mixed-citation">
Nikitaki Z, Velalopoulou A, Zanni V, Tremi I, Havaki S, Kokkoris M, et al.. <span class="ref-title">Key biological mechanisms involved in high-LET radiation therapies with a focus on DNA damage and repair</span>. <span class="ref-journal">Expert Rev Mol Med</span> (2022) <span class="ref-vol">24</span>:e15. doi: 10.1017/erm.2022.6
 [<a href="https://pubmed.ncbi.nlm.nih.gov/35357290" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1017%2Ferm.2022.6" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Rev+Mol+Med&amp;title=Key+biological+mechanisms+involved+in+high-LET+radiation+therapies+with+a+focus+on+DNA+damage+and+repair&amp;author=Z+Nikitaki&amp;author=A+Velalopoulou&amp;author=V+Zanni&amp;author=I+Tremi&amp;author=S+Havaki&amp;volume=24&amp;publication_year=2022&amp;pages=e15&amp;pmid=35357290&amp;doi=10.1017/erm.2022.6&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B318">318. <span class="mixed-citation">
Averbeck D, Rodriguez-Lafrasse C. <span class="ref-title">Role of mitochondria in radiation responses: Epigenetic, metabolic, and signaling impacts</span>. <span class="ref-journal">Int J Mol Sci</span> (2021) <span class="ref-vol">22</span>(<span class="ref-iss">20</span>):11047. doi: 10.3390/ijms222011047
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8541263/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34681703" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fijms222011047" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Mol+Sci&amp;title=Role+of+mitochondria+in+radiation+responses:+Epigenetic,+metabolic,+and+signaling+impacts&amp;author=D+Averbeck&amp;author=C+Rodriguez-Lafrasse&amp;volume=22&amp;issue=20&amp;publication_year=2021&amp;pages=11047&amp;pmid=34681703&amp;doi=10.3390/ijms222011047&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B319">319. <span class="mixed-citation">
Tigano M, Vargas DC, Tremblay-Belzile S, Fu Y, Sfeir A. <span class="ref-title">Nuclear sensing of breaks in mitochondrial DNA enhances immune surveillance</span>. <span class="ref-journal">Nature</span> (2021) <span class="ref-vol">591</span>(<span class="ref-iss">7850</span>):477&#x02013;81. doi: 10.1038/s41586-021-03269-w
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33627873" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41586-021-03269-w" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Nuclear+sensing+of+breaks+in+mitochondrial+DNA+enhances+immune+surveillance&amp;author=M+Tigano&amp;author=DC+Vargas&amp;author=S+Tremblay-Belzile&amp;author=Y+Fu&amp;author=A+Sfeir&amp;volume=591&amp;issue=7850&amp;publication_year=2021&amp;doi=10.1038/s41586-021-03269-w&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B320">320. <span class="mixed-citation">
Yamazaki T, Kirchmair A, Sato A, Buqu&#x000e9; A, Rybstein M, Petroni G, et al.. <span class="ref-title">Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy</span>. <span class="ref-journal">Nat Immunol</span> (2020) <span class="ref-vol">21</span>(<span class="ref-iss">10</span>):1160&#x02013;71. doi: 10.1038/s41590-020-0751-0
 [<a href="https://pubmed.ncbi.nlm.nih.gov/32747819" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41590-020-0751-0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Immunol&amp;title=Mitochondrial+DNA+drives+abscopal+responses+to+radiation+that+are+inhibited+by+autophagy&amp;author=T+Yamazaki&amp;author=A+Kirchmair&amp;author=A+Sato&amp;author=A+Buqu&#x000e9;&amp;author=M+Rybstein&amp;volume=21&amp;issue=10&amp;publication_year=2020&amp;doi=10.1038/s41590-020-0751-0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B321">321. <span class="mixed-citation">
Banoth B, Cassel SL. <span class="ref-title">Mitochondria in innate immune signaling</span>. <span class="ref-journal">Transl Res</span> (2018) <span class="ref-vol">202</span>:52&#x02013;68. doi: 10.1016/j.trsl.2018.07.014
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6218307/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30165038" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.trsl.2018.07.014" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Transl+Res&amp;title=Mitochondria+in+innate+immune+signaling&amp;author=B+Banoth&amp;author=SL+Cassel&amp;volume=202&amp;publication_year=2018&amp;pages=52-68&amp;pmid=30165038&amp;doi=10.1016/j.trsl.2018.07.014&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B322">322. <span class="mixed-citation">
Chang MC, Chen YL, Lin HW, Chiang YC, Chang CF, Hsieh SF, et al.. <span class="ref-title">Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment</span>. <span class="ref-journal">Mol Ther</span> (2018) <span class="ref-vol">26</span>(<span class="ref-iss">2</span>):404&#x02013;19. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5835145/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29248428" ref="reftype=pubmed&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Ther&amp;title=Irradiation+Enhances+Abscopal+Anti-tumor+Effects+of+Antigen-Specific+Immunotherapy+through+Regulating+Tumor+Microenvironment&amp;author=MC+Chang&amp;author=YL+Chen&amp;author=HW+Lin&amp;author=YC+Chiang&amp;author=CF+Chang&amp;volume=26&amp;issue=2&amp;publication_year=2018&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9465159&amp;issue-id=400062&amp;journal-id=1755&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">Frontiers in Oncology</span> are provided here courtesy of <strong>Frontiers Media SA</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC9465159/pdf/fonc-12-971959.pdf" class="int-view">PDF (2.5M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/9465159/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/9465159/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="9465159" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9465159%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="LYlIQ5dV3TRlH4zixQgWtD8KSzD5GCdsYwbJfYbxf9MdKDSrv11i91y5mv3v6JNS">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9465159%2F&amp;text=Enhancing%20anti-tumour%20innate%20immunity%20by%20targeting%20the%20DNA%20damage%20response%20and%20pattern%20recognition%20receptors%20in%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9465159%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465159/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC9465159/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/36106115/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC9465159/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/36106115/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC9465159/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/9465159/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC9465159/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
